{"0b9249faf42463eb8673c8635f33c34c5d8a8bfb": [["IntroductionALI/ARDS is a common critical emergency in clinical practice (Xiong et al., 2016) and has become a major issue in public health due to outbreaks of severe acute respiratory syndrome (SARS) and bird flu. vascular leakage syndrome induced by increased microvascular permeability.", [["vascular", "ANATOMY", 215, 223], ["microvascular", "ANATOMY", 262, 275], ["ARDS", "DISEASE", 16, 20], ["acute respiratory syndrome", "DISEASE", 167, 193], ["SARS", "DISEASE", 195, 199], ["vascular leakage", "DISEASE", 215, 231], ["vascular", "MULTI-TISSUE_STRUCTURE", 215, 223], ["microvascular", "TISSUE", 262, 275], ["ARDS", "PROBLEM", 16, 20], ["severe acute respiratory syndrome", "PROBLEM", 160, 193], ["SARS", "PROBLEM", 195, 199], ["bird flu", "PROBLEM", 205, 213], ["vascular leakage syndrome", "PROBLEM", 215, 240], ["increased microvascular permeability", "PROBLEM", 252, 288], ["ARDS", "OBSERVATION", 16, 20], ["severe", "OBSERVATION_MODIFIER", 160, 166], ["acute", "OBSERVATION_MODIFIER", 167, 172], ["respiratory syndrome", "OBSERVATION", 173, 193], ["leakage syndrome", "OBSERVATION", 224, 240], ["increased", "OBSERVATION_MODIFIER", 252, 261], ["microvascular permeability", "OBSERVATION", 262, 288]]], ["The integrity of the cellular membrane is essential for maintaining the vital activities of cells (Lucas et al., 2009) .", [["cellular membrane", "ANATOMY", 21, 38], ["cells", "ANATOMY", 92, 97], ["cellular membrane", "CELLULAR_COMPONENT", 21, 38], ["cells", "CELL", 92, 97], ["integrity", "OBSERVATION_MODIFIER", 4, 13], ["cellular membrane", "OBSERVATION", 21, 38]]], ["The physiological function of damaged membranes can be recovered by repair, regeneration or reshaping.", [["membranes", "ANATOMY", 38, 47], ["membranes", "CELLULAR_COMPONENT", 38, 47], ["damaged membranes", "PROBLEM", 30, 47], ["repair", "TREATMENT", 68, 74], ["damaged membranes", "OBSERVATION", 30, 47], ["repair", "OBSERVATION", 68, 74]]], ["Phospholipids are the main component of cell membranes, and their degradation marks the start of cellular damage (De Luca et al., 2012; Elder et al., 2012) .", [["cell membranes", "ANATOMY", 40, 54], ["cellular", "ANATOMY", 97, 105], ["Phospholipids", "SIMPLE_CHEMICAL", 0, 13], ["cell membranes", "CELLULAR_COMPONENT", 40, 54], ["cellular", "CELL", 97, 105], ["Phospholipids", "TREATMENT", 0, 13], ["cell membranes", "PROBLEM", 40, 54], ["their degradation", "PROBLEM", 60, 77], ["cellular damage", "PROBLEM", 97, 112], ["main", "OBSERVATION_MODIFIER", 22, 26], ["component", "OBSERVATION_MODIFIER", 27, 36], ["cell membranes", "OBSERVATION", 40, 54], ["cellular damage", "OBSERVATION", 97, 112]]], ["PLA2, a phospholipase highly expressed on cellular membranes, catalyzes the hydrolysis of the sn-2 position of membrane glycerophospholipids to release lysolecithin, platelet activating factor (PAF) and arachidonic acid (AA), which process is a key link to induce lung injury (Kitsiouli et al., 2009; Shiyu et al., 2011) .", [["cellular membranes", "ANATOMY", 42, 60], ["membrane", "ANATOMY", 111, 119], ["lung", "ANATOMY", 264, 268], ["lysolecithin", "CHEMICAL", 152, 164], ["arachidonic acid", "CHEMICAL", 203, 219], ["AA", "CHEMICAL", 221, 223], ["lung injury", "DISEASE", 264, 275], ["glycerophospholipids", "CHEMICAL", 120, 140], ["lysolecithin", "CHEMICAL", 152, 164], ["arachidonic acid", "CHEMICAL", 203, 219], ["PLA2", "GENE_OR_GENE_PRODUCT", 0, 4], ["phospholipase", "GENE_OR_GENE_PRODUCT", 8, 21], ["cellular membranes", "CELLULAR_COMPONENT", 42, 60], ["membrane glycerophospholipids", "CELLULAR_COMPONENT", 111, 140], ["lysolecithin", "SIMPLE_CHEMICAL", 152, 164], ["platelet activating factor", "GENE_OR_GENE_PRODUCT", 166, 192], ["PAF", "GENE_OR_GENE_PRODUCT", 194, 197], ["arachidonic acid", "SIMPLE_CHEMICAL", 203, 219], ["AA", "SIMPLE_CHEMICAL", 221, 223], ["lung", "ORGAN", 264, 268], ["PLA2", "PROTEIN", 0, 4], ["phospholipase", "PROTEIN", 8, 21], ["platelet activating factor", "PROTEIN", 166, 192], ["PAF", "PROTEIN", 194, 197], ["PLA2", "TEST", 0, 4], ["a phospholipase", "TEST", 6, 21], ["cellular membranes", "TREATMENT", 42, 60], ["the sn-2 position of membrane glycerophospholipids", "TREATMENT", 90, 140], ["lysolecithin", "TREATMENT", 152, 164], ["platelet activating factor", "PROBLEM", 166, 192], ["PAF", "PROBLEM", 194, 197], ["arachidonic acid (AA)", "PROBLEM", 203, 224], ["lung injury", "PROBLEM", 264, 275], ["cellular membranes", "OBSERVATION", 42, 60], ["lung", "ANATOMY", 264, 268], ["injury", "OBSERVATION", 269, 275]]], ["CCSP is a major secretion of pulmonary clara cells, the nonciliated epithelial cells coving distal bronchiole (Jorens et al., 1995) .", [["pulmonary clara cells", "ANATOMY", 29, 50], ["epithelial cells", "ANATOMY", 68, 84], ["distal bronchiole", "ANATOMY", 92, 109], ["CCSP", "GENE_OR_GENE_PRODUCT", 0, 4], ["pulmonary clara cells", "CELL", 29, 50], ["epithelial cells", "CELL", 68, 84], ["bronchiole", "TISSUE", 99, 109], ["CCSP", "PROTEIN", 0, 4], ["pulmonary clara cells", "CELL_TYPE", 29, 50], ["nonciliated epithelial cells", "CELL_TYPE", 56, 84], ["a major secretion of pulmonary clara cells", "PROBLEM", 8, 50], ["pulmonary", "ANATOMY", 29, 38], ["clara cells", "OBSERVATION", 39, 50], ["nonciliated", "OBSERVATION_MODIFIER", 56, 67], ["epithelial cells", "OBSERVATION", 68, 84], ["distal", "ANATOMY_MODIFIER", 92, 98], ["bronchiole", "ANATOMY", 99, 109]]], ["As an endogenous PLA2 inhibitor, CCSP1 has potent immune inhibition and anti-inflammation activity (Rastogi and McHowat, 2009 ) and can increase self-defense of the membrane phospholipids (Magrioti and Kokotos, 2010) .", [["membrane phospholipids", "ANATOMY", 165, 187], ["CCSP1", "CHEMICAL", 33, 38], ["PLA2", "GENE_OR_GENE_PRODUCT", 17, 21], ["CCSP1", "GENE_OR_GENE_PRODUCT", 33, 38], ["membrane phospholipids", "CELLULAR_COMPONENT", 165, 187], ["an endogenous PLA2 inhibitor", "TREATMENT", 3, 31], ["CCSP1", "TEST", 33, 38], ["potent immune inhibition", "TREATMENT", 43, 67], ["anti-inflammation activity", "TEST", 72, 98], ["the membrane phospholipids", "TREATMENT", 161, 187]]], ["CCSP1 reduces the production of lysolecithin, blocks the abnormal deposition of integrins in fibroblasts, and inhibits the release of AA derivatives as inflammatory mediators, the chemotactic response of fibroblasts to PAF, and the production and action of multiple inflammatory mediators (Wong et al., 2009 ).", [["fibroblasts", "ANATOMY", 93, 104], ["fibroblasts", "ANATOMY", 204, 215], ["CCSP1", "CHEMICAL", 0, 5], ["lysolecithin", "CHEMICAL", 32, 44], ["AA", "CHEMICAL", 134, 136], ["PAF", "CHEMICAL", 219, 222], ["lysolecithin", "CHEMICAL", 32, 44], ["CCSP1", "GENE_OR_GENE_PRODUCT", 0, 5], ["lysolecithin", "SIMPLE_CHEMICAL", 32, 44], ["integrins", "GENE_OR_GENE_PRODUCT", 80, 89], ["fibroblasts", "CELL", 93, 104], ["AA derivatives", "SIMPLE_CHEMICAL", 134, 148], ["fibroblasts", "CELL", 204, 215], ["PAF", "GENE_OR_GENE_PRODUCT", 219, 222], ["CCSP1", "PROTEIN", 0, 5], ["integrins", "PROTEIN", 80, 89], ["fibroblasts", "CELL_TYPE", 93, 104], ["inflammatory mediators", "PROTEIN", 152, 174], ["fibroblasts", "CELL_TYPE", 204, 215], ["PAF", "PROTEIN", 219, 222], ["inflammatory mediators", "PROTEIN", 266, 288], ["CCSP1", "TREATMENT", 0, 5], ["lysolecithin", "TREATMENT", 32, 44], ["the abnormal deposition of integrins in fibroblasts", "PROBLEM", 53, 104], ["AA derivatives", "TREATMENT", 134, 148], ["inflammatory mediators", "PROBLEM", 152, 174], ["fibroblasts", "PROBLEM", 204, 215], ["PAF", "PROBLEM", 219, 222], ["multiple inflammatory mediators", "PROBLEM", 257, 288], ["production", "OBSERVATION_MODIFIER", 18, 28], ["lysolecithin", "OBSERVATION_MODIFIER", 32, 44], ["abnormal", "OBSERVATION_MODIFIER", 57, 65], ["deposition", "OBSERVATION_MODIFIER", 66, 76], ["integrins", "OBSERVATION_MODIFIER", 80, 89], ["fibroblasts", "OBSERVATION_MODIFIER", 93, 104], ["multiple", "OBSERVATION_MODIFIER", 257, 265], ["inflammatory", "OBSERVATION_MODIFIER", 266, 278]]], ["In our initial study stage, we found that the mRNA and protein of CCSP1 were reduced in the in vitro ALI model, BEAS-2B cells exposed to LPS (Shiyu et al., 2011) .", [["BEAS-2B cells", "ANATOMY", 112, 125], ["ALI", "DISEASE", 101, 104], ["LPS", "CHEMICAL", 137, 140], ["CCSP1", "GENE_OR_GENE_PRODUCT", 66, 71], ["BEAS-2B cells", "CELL", 112, 125], ["LPS", "SIMPLE_CHEMICAL", 137, 140], ["mRNA", "RNA", 46, 50], ["CCSP1", "PROTEIN", 66, 71], ["BEAS-2B cells", "CELL_LINE", 112, 125], ["the mRNA", "TEST", 42, 50], ["CCSP1", "TEST", 66, 71], ["BEAS", "TEST", 112, 116], ["ALI model", "OBSERVATION", 101, 110], ["2B cells", "OBSERVATION", 117, 125]]], ["Up-regulation of CCSP1 can therefore stabilize membrane phospholipids and maintain normal cellular function in response to external factors, particularly endotoxin, by inhibiting PLA2 activity and thus preventing lung injury.IntroductionC/EBPs, a type of transcriptional regulation factor, were identified by Graves in 1987 (Zahnow, 2009 ).", [["membrane phospholipids", "ANATOMY", 47, 69], ["cellular", "ANATOMY", 90, 98], ["lung", "ANATOMY", 213, 217], ["endotoxin", "CHEMICAL", 154, 163], ["lung injury", "DISEASE", 213, 224], ["CCSP1", "GENE_OR_GENE_PRODUCT", 17, 22], ["membrane phospholipids", "CELLULAR_COMPONENT", 47, 69], ["cellular", "CELL", 90, 98], ["endotoxin", "SIMPLE_CHEMICAL", 154, 163], ["PLA2", "GENE_OR_GENE_PRODUCT", 179, 183], ["lung", "ORGAN", 213, 217], ["EBPs", "GENE_OR_GENE_PRODUCT", 239, 243], ["CCSP1", "PROTEIN", 17, 22], ["PLA2", "PROTEIN", 179, 183], ["EBPs", "PROTEIN", 239, 243], ["transcriptional regulation factor", "PROTEIN", 255, 288], ["Up-regulation of CCSP1", "PROBLEM", 0, 22], ["membrane phospholipids", "TREATMENT", 47, 69], ["external factors", "PROBLEM", 123, 139], ["endotoxin", "TREATMENT", 154, 163], ["lung injury", "PROBLEM", 213, 224], ["normal cellular function", "OBSERVATION", 83, 107], ["lung", "ANATOMY", 213, 217], ["injury", "OBSERVATION", 218, 224]]], ["The C/EBP family of transcriptional regulation factors includes at least six members: C/EBP\u03b1, -\u03b2, -\u03b3, -\u03b4, -\u03b5 and -\u03b6.", [["C/EBP", "GENE_OR_GENE_PRODUCT", 4, 9], ["C", "GENE_OR_GENE_PRODUCT", 86, 87], ["EBP\u03b1", "GENE_OR_GENE_PRODUCT", 88, 92], ["-\u03b2", "GENE_OR_GENE_PRODUCT", 94, 96], ["-\u03b3", "GENE_OR_GENE_PRODUCT", 98, 100], ["-\u03b4", "GENE_OR_GENE_PRODUCT", 102, 104], ["-\u03b5", "GENE_OR_GENE_PRODUCT", 106, 108], ["-\u03b6.", "GENE_OR_GENE_PRODUCT", 113, 116], ["C/EBP family", "PROTEIN", 4, 16], ["transcriptional regulation factors", "PROTEIN", 20, 54], ["C", "PROTEIN", 86, 87], ["EBP\u03b1", "PROTEIN", 88, 92], ["-\u03b2", "PROTEIN", 94, 96], ["-\u03b3", "PROTEIN", 98, 100], ["-\u03b4", "PROTEIN", 102, 104], ["-\u03b5", "PROTEIN", 106, 108], ["-\u03b6.", "PROTEIN", 113, 116], ["transcriptional regulation factors", "PROBLEM", 20, 54], ["C/EBP\u03b1", "TEST", 86, 92]]], ["C/EBP proves to be closely associated with ALI (Okuma et al., 2015) .", [["ALI", "DISEASE", 43, 46], ["C/EBP", "GENE_OR_GENE_PRODUCT", 0, 5], ["EBP", "PROTEIN", 2, 5], ["ALI", "PROBLEM", 43, 46]]], ["Sugahara et al. demonstrated that C/EBP promotes the proliferation of alveolar endothelial cells in ALI (Sugahara et al., 1999) .", [["alveolar endothelial cells", "ANATOMY", 70, 96], ["ALI", "DISEASE", 100, 103], ["C/EBP", "GENE_OR_GENE_PRODUCT", 34, 39], ["alveolar endothelial cells", "CELL", 70, 96], ["EBP", "PROTEIN", 36, 39], ["alveolar endothelial cells", "CELL_TYPE", 70, 96], ["C/EBP", "TEST", 34, 39], ["alveolar endothelial cells", "PROBLEM", 70, 96], ["proliferation", "OBSERVATION_MODIFIER", 53, 66], ["alveolar endothelial cells", "OBSERVATION", 70, 96], ["ALI", "ANATOMY", 100, 103]]], ["Therefore, we think that the phosphorylation of C/EBP \u03b2 plays a crucial role in the regulation of LPS-induced cellular membrane damage in BEAS-2B cells.", [["cellular membrane", "ANATOMY", 110, 127], ["BEAS-2B cells", "ANATOMY", 138, 151], ["LPS", "CHEMICAL", 98, 101], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 48, 55], ["LPS", "SIMPLE_CHEMICAL", 98, 101], ["cellular membrane", "CELLULAR_COMPONENT", 110, 127], ["BEAS-2B cells", "CELL", 138, 151], ["C/EBP \u03b2", "PROTEIN", 48, 55], ["BEAS-2B cells", "CELL_LINE", 138, 151], ["the phosphorylation of C/EBP", "PROBLEM", 25, 53], ["LPS", "PROBLEM", 98, 101], ["cellular membrane damage", "PROBLEM", 110, 134], ["cellular membrane damage", "OBSERVATION", 110, 134], ["2B cells", "OBSERVATION", 143, 151]]], ["The major purposes of the study is to verify that (1) phosphorylation of C/EBP \u03b2 increases the activity of the transcription factor;Introduction(2) C/EBP \u03b2 can bind to the promoter of CCSP1 gene and positively regulates its transcription; (3) C/EBP \u03b2 regulates the expression of PLA2 protein through CCSP1 transcription and thus affects LPS-induced membrane damage; i.e., there is a C/EBP \u03b2/CCSP1/PLA2 pathway which regulates the cellular membrane damage in the ALI model.BEAS-2B cells (a gift from Professor Tianbao Zhang of PhysiologyDepartment, Second Military Medical University of China) are human normal lung/bronchial epithelia cells transformed by the SV40 T-antigen.", [["membrane", "ANATOMY", 349, 357], ["cellular membrane", "ANATOMY", 430, 447], ["BEAS-2B cells", "ANATOMY", 472, 485], ["lung/bronchial epithelia cells", "ANATOMY", 610, 640], ["LPS", "CHEMICAL", 337, 340], ["ALI", "DISEASE", 462, 465], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 73, 80], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 148, 155], ["CCSP1", "GENE_OR_GENE_PRODUCT", 184, 189], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 243, 250], ["PLA2", "GENE_OR_GENE_PRODUCT", 279, 283], ["CCSP1", "GENE_OR_GENE_PRODUCT", 300, 305], ["LPS", "SIMPLE_CHEMICAL", 337, 340], ["membrane", "CELLULAR_COMPONENT", 349, 357], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 383, 390], ["CCSP1", "GENE_OR_GENE_PRODUCT", 391, 396], ["PLA2", "GENE_OR_GENE_PRODUCT", 397, 401], ["cellular membrane", "CELLULAR_COMPONENT", 430, 447], ["BEAS-2B cells", "CELL", 472, 485], ["human", "ORGANISM", 597, 602], ["lung", "ORGAN", 610, 614], ["bronchial epithelia cells", "CELL", 615, 640], ["SV40", "ORGANISM", 660, 664], ["T-antigen", "GENE_OR_GENE_PRODUCT", 665, 674], ["C/EBP \u03b2", "PROTEIN", 73, 80], ["transcription factor", "PROTEIN", 111, 131], ["EBP \u03b2", "PROTEIN", 150, 155], ["promoter", "DNA", 172, 180], ["CCSP1 gene", "DNA", 184, 194], ["EBP \u03b2", "PROTEIN", 245, 250], ["PLA2 protein", "PROTEIN", 279, 291], ["CCSP1", "PROTEIN", 300, 305], ["CCSP1", "PROTEIN", 391, 396], ["PLA2", "PROTEIN", 397, 401], ["BEAS-2B cells", "CELL_LINE", 472, 485], ["human normal lung/bronchial epithelia cells", "CELL_TYPE", 597, 640], ["SV40 T-antigen", "PROTEIN", 660, 674], ["human", "SPECIES", 597, 602], ["human", "SPECIES", 597, 602], ["the study", "TEST", 22, 31], ["C/EBP", "TEST", 73, 78], ["Introduction(2) C/EBP", "TREATMENT", 132, 153], ["C/EBP", "TEST", 243, 248], ["PLA2 protein", "TREATMENT", 279, 291], ["CCSP1 transcription", "TREATMENT", 300, 319], ["LPS", "PROBLEM", 337, 340], ["membrane damage", "PROBLEM", 349, 364], ["a C/EBP", "TEST", 381, 388], ["CCSP1/PLA2 pathway", "TREATMENT", 391, 409], ["the cellular membrane damage", "PROBLEM", 426, 454], ["BEAS", "TEST", 472, 476], ["bronchial epithelia cells", "PROBLEM", 615, 640], ["the SV40 T", "TEST", 656, 666], ["membrane damage", "OBSERVATION", 349, 364], ["cellular membrane damage", "OBSERVATION", 430, 454], ["ALI model", "OBSERVATION", 462, 471], ["2B cells", "OBSERVATION", 477, 485], ["lung", "ANATOMY", 610, 614], ["bronchial epithelia", "ANATOMY", 615, 634]]], ["BEAS-2B cells were cultured in LHC-8 medium (Invitrogen, CA, USA).", [["BEAS-2B cells", "ANATOMY", 0, 13], ["BEAS-2B cells", "CELL", 0, 13], ["BEAS-2B cells", "CELL_LINE", 0, 13], ["BEAS", "TEST", 0, 4], ["LHC", "TEST", 31, 34], ["2B cells", "OBSERVATION", 5, 13]]], ["Virus producing cell line 293 T (Systermbio, CA, USA) maintained in DMEM supplemented with 10% FBS were used for lentiviral packaging, in the luciferase reporter experiments, 293 T were used as a tool cell line.", [["cell line 293", "ANATOMY", 16, 29], ["FBS", "ANATOMY", 95, 98], ["cell line", "ANATOMY", 201, 210], ["Virus", "ORGANISM", 0, 5], ["cell line 293 T", "CELL", 16, 31], ["Systermbio, CA, USA", "CELL", 33, 52], ["FBS", "ORGANISM_SUBSTANCE", 95, 98], ["lentiviral", "ORGANISM", 113, 123], ["luciferase", "GENE_OR_GENE_PRODUCT", 142, 152], ["293 T", "CELL", 175, 180], ["cell line", "CELL", 201, 210], ["Virus producing cell line 293 T", "CELL_LINE", 0, 31], ["Systermbio, CA, USA", "CELL_LINE", 33, 52], ["293 T", "CELL_LINE", 175, 180], ["tool cell line", "CELL_LINE", 196, 210], ["Virus", "PROBLEM", 0, 5], ["cell line", "TEST", 16, 25], ["T", "TEST", 30, 31], ["Systermbio", "TEST", 33, 43], ["CA", "TEST", 45, 47], ["10% FBS", "TREATMENT", 91, 98], ["lentiviral packaging", "TREATMENT", 113, 133], ["a tool cell line", "TREATMENT", 194, 210], ["cell line", "OBSERVATION", 16, 25], ["cell line", "OBSERVATION", 201, 210]]], ["All these adherent cells were passaged by 0.25% trypsin digestion (Invitrogen) and incubated in an atmosphere of 5% CO 2 at 37\u00b0C.Construction of gene expression vectorThe CDS of human C/EBP \u03b2 (NM_005194.3) was amplified using the primers 5\u2032-GCTCTAGAGCCACCATGCAACGCCTGG-3\u2032 and 5\u2032-CGGGATCCCTAGCAGT GGCCGGAGGA-3\u2032, which contain an XbaI restriction site(5\u2032-TCTAGA-3\u2032) and Kozaksequence(5\u2032-CCACC-3\u2032) and a BamHI restriction site(5\u2032-GATCC-3\u2032), respectively, and cDNA was prepared by reverse transcription of RNA isolated from BEAS-2B cells.", [["cells", "ANATOMY", 19, 24], ["BEAS-2B cells", "ANATOMY", 520, 533], ["CO 2", "CHEMICAL", 116, 120], ["cells", "CELL", 19, 24], ["human", "ORGANISM", 178, 183], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 184, 191], ["NM_005194.3", "GENE_OR_GENE_PRODUCT", 193, 204], ["XbaI", "GENE_OR_GENE_PRODUCT", 328, 332], ["BamHI", "GENE_OR_GENE_PRODUCT", 401, 406], ["BEAS-2B cells", "CELL", 520, 533], ["adherent cells", "CELL_TYPE", 10, 24], ["trypsin", "PROTEIN", 48, 55], ["CDS", "DNA", 171, 174], ["human C/EBP \u03b2", "DNA", 178, 191], ["NM_005194.3", "DNA", 193, 204], ["XbaI restriction site", "DNA", 328, 349], ["Kozaksequence", "DNA", 368, 381], ["CCACC", "DNA", 385, 390], ["BamHI restriction site", "DNA", 401, 423], ["5\u2032", "DNA", 424, 426], ["GATCC", "DNA", 427, 432], ["cDNA", "DNA", 456, 460], ["BEAS-2B cells", "CELL_LINE", 520, 533], ["human", "SPECIES", 178, 183], ["human", "SPECIES", 178, 183], ["human C/EBP", "TEST", 178, 189], ["the primers", "TEST", 226, 237], ["GCTCTAGAGCCACCATGCAACGCCTGG", "TEST", 241, 268], ["GGCCGGAGGA", "TEST", 296, 306], ["an XbaI restriction site", "TREATMENT", 325, 349], ["TCTAGA", "TEST", 353, 359], ["Kozaksequence", "TREATMENT", 368, 381], ["a BamHI restriction site", "TREATMENT", 399, 423], ["adherent cells", "OBSERVATION", 10, 24], ["2B cells", "OBSERVATION", 525, 533]]], ["The PCR product was digested and cloned into the pcDH1-CMV expression vector (Systermbio); the recombinant vector was named pcDH1-C/EBP \u03b2.", [["pcDH1", "GENE_OR_GENE_PRODUCT", 49, 54], ["CMV", "ORGANISM", 55, 58], ["pcDH1-C", "GENE_OR_GENE_PRODUCT", 124, 131], ["pcDH1-CMV expression vector", "DNA", 49, 76], ["Systermbio", "DNA", 78, 88], ["recombinant vector", "DNA", 95, 113], ["pcDH1", "PROTEIN", 124, 129], ["The PCR product", "TREATMENT", 0, 15], ["CMV expression vector", "TREATMENT", 55, 76], ["the recombinant vector", "TREATMENT", 91, 113]]], ["The expression vector for human CDK2 (NM_001798.4) pcDH1-CDK2 and the expression vector for the CCSP1 gene (NM_003357.4) pcDH1-CCSP1 were similarly constructed using the primers 5\u2032-GCTCTAGAGCCACCATGGAGAACTTCCAA-3\u2032 and 5\u2032-CGGGATCC TCAGAGTCGAAG ATGGGGTA-3\u2032 for CDK2 and 5\u2032-GCTCTAGAGCCACCATGGGAGCTGCTG GGA-3\u2032and 5\u2032-ATAAGAATG CGGCCGCTCACAACTTCTTCTTC-3\u2032 for CCSP1.Construction of shRNA vectorAn siRNA sequence targeting the CDS of C/EBP \u03b2 was designed, and corresponding DNA hairpin structure (5\u2032-GATCCGAG CAAGGCCAAGAAGACCCTTCCTGTCAGAGGTCTTCTTGGCCTTGCTC TTTTTG-3\u2032) sequences were synthesized, annealed and cloned into the pshRNA-H1 expression vector (Systermbio); the resulting vector was named pshRNA-C/EBP \u03b2.", [["human", "ORGANISM", 26, 31], ["CDK2", "GENE_OR_GENE_PRODUCT", 32, 36], ["pcDH1-CDK2", "GENE_OR_GENE_PRODUCT", 51, 61], ["CCSP1", "GENE_OR_GENE_PRODUCT", 96, 101], ["pcDH1-CCSP1", "GENE_OR_GENE_PRODUCT", 121, 132], ["CDK2", "GENE_OR_GENE_PRODUCT", 259, 263], ["CCSP1", "GENE_OR_GENE_PRODUCT", 353, 358], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 426, 433], ["DNA", "CELLULAR_COMPONENT", 466, 469], ["pshRNA-H1", "GENE_OR_GENE_PRODUCT", 617, 626], ["pshRNA-C", "GENE_OR_GENE_PRODUCT", 690, 698], ["human CDK2 (NM_001798.4) pcDH1-CDK2 and the expression vector", "DNA", 26, 87], ["CCSP1 gene", "DNA", 96, 106], ["NM_003357.4", "DNA", 108, 119], ["pcDH1", "DNA", 121, 126], ["CCSP1", "DNA", 127, 132], ["CDK2", "DNA", 259, 263], ["CCSP1", "DNA", 353, 358], ["shRNA vectorAn siRNA sequence", "DNA", 375, 404], ["CDS", "DNA", 419, 422], ["C/EBP \u03b2", "DNA", 426, 433], ["DNA hairpin structure", "DNA", 466, 487], ["pshRNA-H1 expression vector", "DNA", 617, 644], ["Systermbio", "DNA", 646, 656], ["pshRNA", "DNA", 690, 696], ["EBP", "DNA", 699, 702], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 26, 31], ["human CDK2", "TEST", 26, 36], ["NM_", "TEST", 38, 41], ["pcDH1", "TEST", 51, 56], ["the expression vector", "TREATMENT", 66, 87], ["pcDH1", "TEST", 121, 126], ["the primers", "TEST", 166, 177], ["GCTCTAGAGCCACCATGGAGAACTTCCAA", "TEST", 181, 210], ["ATGGGGTA", "TEST", 243, 251], ["CDK2", "TEST", 259, 263], ["GGA", "TEST", 299, 302], ["CGGCCGCTCACAACTTCTTCTTC", "TEST", 322, 345], ["CCSP1", "TREATMENT", 353, 358], ["shRNA vectorAn siRNA sequence", "TREATMENT", 375, 404], ["the CDS of C/EBP", "TEST", 415, 431], ["corresponding DNA hairpin structure", "PROBLEM", 452, 487]]], ["The shRNA expression vectors targeting CCSP1 and CDK2, pshRNA-CCSP1 and pshRNA-CDK2, which contained the sequences 5\u2032-GGAGCTTAACCATCCTAAT-3\u2032 and 5\u2032-GGAGCTTAACCATCCTAAT-3\u2032, respectively, and the control vector pshRNA-NC (Negative Control), which contained the sequence 5\u2032-GTGACGAGCGAGTCAAGAT-3\u2032, were constructed in a similar manner.Construction of CCSP1 gene expression vector with specific promoterNext, we extracted human genomic DNA from BEAS-2B cells by QIAamp DNA Mini Kit(QIAGEN, Germany) and amplified the promoter of CCSP1 using the primers 5\u2032-GACTAGTAGGCCAGGTT AGGTGCTATGA-3\u2032 and 5\u2032-GACTAGTGTGAGGGTGACAGCGA GTTTCAT-3\u2032, which each contain a SpeI restriction site(5\u2032-GACTAGT-3\u2032).", [["BEAS-2B cells", "ANATOMY", 441, 454], ["CCSP1", "GENE_OR_GENE_PRODUCT", 39, 44], ["CDK2", "GENE_OR_GENE_PRODUCT", 49, 53], ["pshRNA-CCSP1", "GENE_OR_GENE_PRODUCT", 55, 67], ["pshRNA-CDK2", "GENE_OR_GENE_PRODUCT", 72, 83], ["pshRNA-NC", "GENE_OR_GENE_PRODUCT", 209, 218], ["CCSP1", "GENE_OR_GENE_PRODUCT", 348, 353], ["human", "ORGANISM", 418, 423], ["DNA", "CELLULAR_COMPONENT", 432, 435], ["BEAS-2B cells", "CELL", 441, 454], ["CCSP1", "GENE_OR_GENE_PRODUCT", 525, 530], ["SpeI", "GENE_OR_GENE_PRODUCT", 649, 653], ["shRNA expression vectors", "DNA", 4, 28], ["CCSP1", "PROTEIN", 39, 44], ["CDK2", "PROTEIN", 49, 53], ["pshRNA-CCSP1", "PROTEIN", 55, 67], ["pshRNA", "PROTEIN", 72, 78], ["CDK2", "PROTEIN", 79, 83], ["pshRNA", "DNA", 209, 215], ["NC", "DNA", 216, 218], ["CCSP1 gene expression vector", "DNA", 348, 376], ["promoterNext", "DNA", 391, 403], ["human genomic DNA", "DNA", 418, 435], ["BEAS-2B cells", "CELL_LINE", 441, 454], ["promoter", "DNA", 513, 521], ["CCSP1", "DNA", 525, 530], ["primers 5", "DNA", 541, 550], ["SpeI restriction site", "DNA", 649, 670], ["human", "SPECIES", 418, 423], ["human", "SPECIES", 418, 423], ["The shRNA expression vectors", "TREATMENT", 0, 28], ["CCSP1", "TEST", 39, 44], ["CDK2", "TEST", 49, 53], ["pshRNA-CCSP1", "TEST", 55, 67], ["pshRNA", "TEST", 72, 78], ["the sequences", "TEST", 101, 114], ["GGAGCTTAACCATCCTAAT", "TEST", 118, 137], ["GGAGCTTAACCATCCTAAT", "TEST", 148, 167], ["the sequence", "TEST", 255, 267], ["Construction of CCSP1 gene expression vector", "TREATMENT", 332, 376], ["specific promoterNext", "TREATMENT", 382, 403], ["BEAS", "TEST", 441, 445], ["the primers", "TREATMENT", 537, 548], ["AGGTGCTATGA", "TEST", 570, 581], ["GTTTCAT", "TEST", 616, 623], ["a SpeI restriction site", "TREATMENT", 647, 670]]], ["The PCR product was digested and cloned into the pcDH1-CCSP1 expression vector to replace the CMV promoter; the recombinant vector was named pcDH1-wPro-CCSP1 (wPro means vector with wild type CCSP1 promoter).", [["pcDH1", "GENE_OR_GENE_PRODUCT", 49, 54], ["CCSP1", "GENE_OR_GENE_PRODUCT", 55, 60], ["CMV", "ORGANISM", 94, 97], ["pcDH1-wPro-CCSP1", "GENE_OR_GENE_PRODUCT", 141, 157], ["CCSP1", "GENE_OR_GENE_PRODUCT", 192, 197], ["pcDH1-CCSP1 expression vector", "DNA", 49, 78], ["CMV promoter", "DNA", 94, 106], ["recombinant vector", "DNA", 112, 130], ["pcDH1", "DNA", 141, 146], ["wPro-CCSP1", "DNA", 147, 157], ["wPro means vector", "DNA", 159, 176], ["wild type CCSP1 promoter", "DNA", 182, 206], ["The PCR product", "TREATMENT", 0, 15], ["CCSP1 expression vector", "TREATMENT", 55, 78], ["the CMV promoter", "TREATMENT", 90, 106], ["the recombinant vector", "TREATMENT", 108, 130], ["wild type CCSP1 promoter", "TREATMENT", 182, 206], ["CMV promoter", "OBSERVATION", 94, 106]]], ["Bioinformatics analysis (TRANSFAC) revealed a potential C/EBP \u03b2 binding site, 5\u2032-CTTGAGAAAA-3\u2032, in the CCSP1 promoter.", [["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 56, 63], ["CTTGAGAAAA-3", "GENE_OR_GENE_PRODUCT", 81, 93], ["CCSP1", "GENE_OR_GENE_PRODUCT", 103, 108], ["C/EBP \u03b2 binding site", "DNA", 56, 76], ["5\u2032-CTTGAGAAAA-3\u2032", "DNA", 78, 94], ["CCSP1 promoter", "DNA", 103, 117], ["Bioinformatics analysis", "TEST", 0, 23], ["a potential C/EBP \u03b2 binding site", "PROBLEM", 44, 76], ["CTTGAGAAAA", "TEST", 81, 91]]], ["We mutated the sequence to 5\u2032-CTTGCGGAAG-3\u2032 to generate a CCSP1 expression vector carrying a mutant promoter, pcDH1-mPro-CCSP1 (mPro means vector with wild mutant CCSP1 promoter).Construction of luciferase reporter gene expression vectorThe promoters were amplified by using pcDH1-wPro-CCSP1 and pcDH1-mPro-CCSP1 plasmids as template, and cloned to a luciferase reporter vector, pGL3-Enkancer (Promega, WI, USA), to construct the wild-type and mutant-type reporter vectors, pGL3-wPro-CCSP1 and pGL3-mPro-CCSP1.", [["CCSP1", "GENE_OR_GENE_PRODUCT", 58, 63], ["pcDH1-mPro-CCSP1", "GENE_OR_GENE_PRODUCT", 110, 126], ["CCSP1", "GENE_OR_GENE_PRODUCT", 163, 168], ["luciferase", "GENE_OR_GENE_PRODUCT", 195, 205], ["pcDH1-wPro-CCSP1", "GENE_OR_GENE_PRODUCT", 275, 291], ["pcDH1-mPro-CCSP1", "GENE_OR_GENE_PRODUCT", 296, 312], ["luciferase", "GENE_OR_GENE_PRODUCT", 351, 361], ["pGL3", "GENE_OR_GENE_PRODUCT", 379, 383], ["pGL3-wPro-CCSP1", "GENE_OR_GENE_PRODUCT", 474, 489], ["pGL3-mPro-CCSP1", "GENE_OR_GENE_PRODUCT", 494, 509], ["5\u2032-CTTGCGGAAG-3\u2032", "DNA", 27, 43], ["CCSP1 expression vector", "DNA", 58, 81], ["mutant promoter", "DNA", 93, 108], ["pcDH1", "DNA", 110, 115], ["mPro-CCSP1", "DNA", 116, 126], ["mPro means vector", "DNA", 128, 145], ["wild mutant CCSP1 promoter", "DNA", 151, 177], ["luciferase reporter gene expression vector", "DNA", 195, 237], ["promoters", "DNA", 241, 250], ["pcDH1-wPro-CCSP1 and pcDH1-mPro-CCSP1 plasmids", "DNA", 275, 321], ["luciferase reporter vector", "DNA", 351, 377], ["pGL3", "DNA", 379, 383], ["wild-type and mutant-type reporter vectors", "DNA", 430, 472], ["pGL3-wPro-CCSP1 and pGL3-mPro-CCSP1", "DNA", 474, 509], ["CTTGCGGAAG", "TEST", 30, 40], ["a CCSP1 expression vector", "TREATMENT", 56, 81], ["a mutant promoter", "TREATMENT", 91, 108], ["pcDH1", "TEST", 110, 115], ["mPro-CCSP1 (mPro means vector", "TREATMENT", 116, 145], ["wild mutant CCSP1 promoter", "TREATMENT", 151, 177], ["pcDH1-wPro-CCSP1", "TREATMENT", 275, 291], ["pcDH1", "TREATMENT", 296, 301], ["mPro-CCSP1 plasmids", "TREATMENT", 302, 321], ["pGL3", "TEST", 379, 383], ["pGL3", "TEST", 474, 478], ["pGL3-mPro-CCSP1", "TREATMENT", 494, 509]]], ["The PCR primers used are: forward, 5\u2032-GGGTACCAGGCCAGGTTAGGTGCTATGA-3\u2032 and backward, 5\u2032-CCAAGCTTGTGAGGGTGACAGCGAGTTTCAT-3\u2032, including KpnI (5\u2032-GGGTACC-3\u2032) and HidIII (5\u2032-CCCAAGCTT-3\u2032) digestion sites and protective bases.Packaging of recombinant lentivirus and infection of BEAS-2B cells with lentivirusThe sequence-validated recombinant vectors were amplified in bacteria, and endotoxin-free DNA was prepared by EndoFree Plasmid Mini Kit (Qiagen).", [["BEAS-2B cells", "ANATOMY", 273, 286], ["infection", "DISEASE", 260, 269], ["endotoxin", "CHEMICAL", 377, 386], ["KpnI", "GENE_OR_GENE_PRODUCT", 133, 137], ["lentivirus", "ORGANISM", 245, 255], ["BEAS-2B cells", "CELL", 273, 286], ["lentivirus", "ORGANISM", 292, 302], ["endotoxin", "SIMPLE_CHEMICAL", 377, 386], ["DNA", "CELLULAR_COMPONENT", 392, 395], ["PCR primers", "DNA", 4, 15], ["digestion sites", "DNA", 183, 198], ["BEAS-2B cells", "CELL_LINE", 273, 286], ["recombinant vectors", "DNA", 325, 344], ["endotoxin-free DNA", "DNA", 377, 395], ["lentivirus", "SPECIES", 245, 255], ["lentivirus", "SPECIES", 292, 302], ["The PCR primers", "TEST", 0, 15], ["GGGTACCAGGCCAGGTTAGGTGCTATGA", "TEST", 38, 66], ["CCAAGCTTGTGAGGGTGACAGCGAGTTTCAT", "TEST", 87, 118], ["KpnI", "TEST", 133, 137], ["GGGTACC", "TEST", 142, 149], ["HidIII", "TEST", 158, 164], ["CCCAAGCTT", "TEST", 169, 178], ["recombinant lentivirus", "PROBLEM", 233, 255], ["infection", "PROBLEM", 260, 269], ["BEAS", "TEST", 273, 277], ["lentivirus", "TREATMENT", 292, 302], ["The sequence", "TEST", 302, 314], ["validated recombinant vectors", "TREATMENT", 315, 344], ["bacteria", "PROBLEM", 363, 371], ["endotoxin-free DNA", "TREATMENT", 377, 395], ["bases", "ANATOMY_MODIFIER", 214, 219], ["recombinant lentivirus", "OBSERVATION", 233, 255], ["infection", "OBSERVATION", 260, 269], ["2B cells", "OBSERVATION", 278, 286], ["lentivirus", "OBSERVATION", 292, 302]]], ["The expression vector or shRNA vector and Lentivirus Package plasmids mix(Systermbio) were co-transfected into 293 T producer cells using Lipofectamine\u2122 2000 (Invitrogen)as instructed by the manufacturer.", [["293 T producer cells", "ANATOMY", 111, 131], ["Lipofectamine\u2122", "CHEMICAL", 138, 152], ["Lentivirus", "ORGANISM", 42, 52], ["293 T producer cells", "CELL", 111, 131], ["expression vector", "DNA", 4, 21], ["shRNA vector", "DNA", 25, 37], ["Lentivirus Package plasmids mix", "DNA", 42, 73], ["Systermbio", "DNA", 74, 84], ["293 T producer cells", "CELL_LINE", 111, 131], ["Lentivirus", "SPECIES", 42, 52], ["The expression vector", "TREATMENT", 0, 21], ["shRNA vector", "TREATMENT", 25, 37], ["Lentivirus Package plasmids mix(Systermbio)", "TREATMENT", 42, 85], ["Lipofectamine\u2122", "TREATMENT", 138, 152]]], ["After 48 h, the supernatants were collected, centrifuged and filtered using 0.45-\u03bcm polyvinylidene fluoride membranes (Millipore, MI, USA).", [["supernatants", "ANATOMY", 16, 28], ["polyvinylidene fluoride", "CHEMICAL", 84, 107], ["polyvinylidene fluoride membranes", "SIMPLE_CHEMICAL", 84, 117], ["0.45-\u03bcm polyvinylidene fluoride membranes", "TREATMENT", 76, 117], ["MI", "PROBLEM", 130, 132]]], ["The viral titer was evaluated by gradient dilution.", [["The viral titer", "TEST", 0, 15], ["viral titer", "OBSERVATION", 4, 15]]], ["The packaged lentiviruses were named Lv-CDK2, Lv-C/EBP \u03b2, Lv-CCSP1, Lv-wPro-CCSP1, Lv-mPro-CCSP1, Lv-shRNA-C/ EBP \u03b2, Lv-shRNA-CCSP1, Lv-shRNA-CDK2 and Lv-NC.Packaging of recombinant lentivirus and infection of BEAS-2B cells with lentivirusTo examine the gene delivery efficiency and gene intervention effect of the recombinant viruses, we infected BEAS-2B cells with the overexpression and silencing viruses of CDK2, C/EBP \u03b2 and CCSP1.", [["BEAS-2B cells", "ANATOMY", 210, 223], ["BEAS-2B cells", "ANATOMY", 348, 361], ["infection", "DISEASE", 197, 206], ["lentiviruses", "ORGANISM", 13, 25], ["Lv-CDK2", "GENE_OR_GENE_PRODUCT", 37, 44], ["Lv-C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 46, 56], ["Lv-CCSP1", "GENE_OR_GENE_PRODUCT", 58, 66], ["Lv-wPro-CCSP1", "GENE_OR_GENE_PRODUCT", 68, 81], ["Lv-mPro-CCSP1", "GENE_OR_GENE_PRODUCT", 83, 96], ["Lv-shRNA-C/ EBP \u03b2", "GENE_OR_GENE_PRODUCT", 98, 115], ["Lv-shRNA-CCSP1", "GENE_OR_GENE_PRODUCT", 117, 131], ["Lv-shRNA-CDK2", "GENE_OR_GENE_PRODUCT", 133, 146], ["lentivirus", "ORGANISM", 182, 192], ["BEAS-2B cells", "CELL", 210, 223], ["lentivirus", "ORGANISM", 229, 239], ["BEAS-2B cells", "CELL", 348, 361], ["CDK2", "GENE_OR_GENE_PRODUCT", 411, 415], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 417, 424], ["CCSP1", "GENE_OR_GENE_PRODUCT", 429, 434], ["Lv-CDK2", "PROTEIN", 37, 44], ["Lv", "PROTEIN", 46, 48], ["C", "PROTEIN", 49, 50], ["EBP \u03b2", "PROTEIN", 51, 56], ["Lv-CCSP1", "DNA", 58, 66], ["Lv-wPro-CCSP1", "DNA", 68, 81], ["Lv-mPro-CCSP1", "DNA", 83, 96], ["Lv-shRNA", "DNA", 98, 106], ["C", "DNA", 107, 108], ["EBP \u03b2", "DNA", 110, 115], ["Lv-shRNA-CCSP1", "DNA", 117, 131], ["Lv-shRNA-CDK2", "DNA", 133, 146], ["Lv-NC", "DNA", 151, 156], ["BEAS-2B cells", "CELL_LINE", 210, 223], ["BEAS-2B cells", "CELL_LINE", 348, 361], ["CDK2", "PROTEIN", 411, 415], ["C/EBP \u03b2", "PROTEIN", 417, 424], ["CCSP1", "PROTEIN", 429, 434], ["lentivirus", "SPECIES", 182, 192], ["lentivirus", "SPECIES", 229, 239], ["Lv-CDK2", "TEST", 37, 44], ["Lv", "TEST", 46, 48], ["EBP", "TEST", 51, 54], ["Lv-CCSP1", "TEST", 58, 66], ["Lv-wPro-", "TEST", 68, 76], ["CCSP1", "TEST", 76, 81], ["Lv-mPro-", "TEST", 83, 91], ["CCSP1", "TEST", 91, 96], ["Lv-shRNA", "TEST", 98, 106], ["EBP", "TEST", 110, 113], ["Lv-shRNA-", "TEST", 117, 126], ["CCSP1", "TEST", 126, 131], ["recombinant lentivirus", "PROBLEM", 170, 192], ["infection", "PROBLEM", 197, 206], ["BEAS", "TEST", 210, 214], ["lentivirus", "TREATMENT", 229, 239], ["the gene delivery efficiency", "TREATMENT", 250, 278], ["gene intervention", "TREATMENT", 283, 300], ["the recombinant viruses", "PROBLEM", 311, 334], ["the overexpression", "PROBLEM", 367, 385], ["silencing viruses of CDK2", "PROBLEM", 390, 415], ["C/EBP", "TEST", 417, 422], ["CCSP1", "TEST", 429, 434], ["lentiviruses", "OBSERVATION", 13, 25], ["Lv", "ANATOMY", 46, 48], ["CDK2", "OBSERVATION", 142, 146], ["recombinant lentivirus", "OBSERVATION", 170, 192], ["infection", "OBSERVATION", 197, 206], ["2B cells", "OBSERVATION", 215, 223], ["lentivirus", "OBSERVATION", 229, 239]]], ["The cells were divided into five groups: BEASe2B, BEAS-2B + Lv-Control, BEAS-2B + Lv-CDK2, BEAS-2B + Lv-NC and BEAS-2B + Lv-shRNA-CDK2; the grouping for C/EBP \u03b2 and CCSP1 gene intervention was similar.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["BEASe2B", "CELL", 41, 48], ["BEAS-2B", "CELL", 50, 57], ["BEAS-2B", "CELL", 72, 79], ["BEAS-2B", "GENE_OR_GENE_PRODUCT", 91, 98], ["BEAS-2B", "GENE_OR_GENE_PRODUCT", 111, 118], ["Lv-shRNA-CDK2", "GENE_OR_GENE_PRODUCT", 121, 134], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 153, 160], ["CCSP1", "GENE_OR_GENE_PRODUCT", 165, 170], ["BEAS", "PROTEIN", 72, 76], ["Lv-CDK2", "PROTEIN", 82, 89], ["BEAS", "PROTEIN", 91, 95], ["Lv-NC", "CELL_LINE", 101, 106], ["BEAS", "PROTEIN", 111, 115], ["Lv-shRNA", "PROTEIN", 121, 129], ["CDK2", "PROTEIN", 130, 134], ["CCSP1 gene", "DNA", 165, 175], ["BEASe2B", "TEST", 41, 48], ["BEAS", "TEST", 50, 54], ["Lv-Control", "TEST", 60, 70], ["BEAS", "TEST", 72, 76], ["Lv-CDK2", "TEST", 82, 89], ["BEAS", "TEST", 91, 95], ["Lv-NC", "TEST", 101, 106], ["BEAS", "TEST", 111, 115], ["Lv-shRNA", "TEST", 121, 129], ["CDK2", "PROBLEM", 130, 134], ["C/EBP", "TEST", 153, 158], ["CCSP1 gene intervention", "TREATMENT", 165, 188]]], ["One day before viral infection, BEAS-2B cells in logarithmic phase were made into suspension by trypsin digestion, and the number of viable cells was counted by using trypan blue staining.", [["BEAS-2B cells", "ANATOMY", 32, 45], ["cells", "ANATOMY", 140, 145], ["viral infection", "DISEASE", 15, 30], ["trypan blue", "CHEMICAL", 167, 178], ["trypan blue", "CHEMICAL", 167, 178], ["BEAS-2B cells", "CELL", 32, 45], ["trypsin", "GENE_OR_GENE_PRODUCT", 96, 103], ["cells", "CELL", 140, 145], ["BEAS-2B cells", "CELL_LINE", 32, 45], ["trypsin", "PROTEIN", 96, 103], ["viral infection", "PROBLEM", 15, 30], ["BEAS", "TEST", 32, 36], ["trypsin digestion", "PROBLEM", 96, 113], ["viable cells", "PROBLEM", 133, 145], ["trypan blue staining", "TEST", 167, 187], ["viral", "OBSERVATION_MODIFIER", 15, 20], ["infection", "OBSERVATION", 21, 30], ["2B cells", "OBSERVATION", 37, 45], ["viable cells", "OBSERVATION", 133, 145]]], ["Cells were collected by 1000 \u00d7 g centrifugation and re-suspended in LHC-8 medium to a concentration of 5 \u00d7 10 5 cells/ml.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 112, 117], ["Cells", "CELL", 0, 5]]], ["Cells were seeded on 6-well plates, 2 ml/well, and cultured overnight under normal conditions.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["normal conditions", "OBSERVATION", 76, 93]]], ["One day after seeding, BEAS-2B cells were infected with lentiviruses diluted by LHC-8 at a MOI of 10, and the medium was refreshed after 24 h.", [["BEAS-2B cells", "ANATOMY", 23, 36], ["LHC-8", "CHEMICAL", 80, 85], ["BEAS-2B cells", "CELL", 23, 36], ["lentiviruses", "ORGANISM", 56, 68], ["BEAS-2B cells", "CELL_LINE", 23, 36], ["LHC", "PROTEIN", 80, 83], ["seeding", "PROBLEM", 14, 21], ["BEAS", "TEST", 23, 27], ["2B cells", "PROBLEM", 28, 36], ["lentiviruses", "PROBLEM", 56, 68], ["LHC", "TEST", 80, 83], ["2B cells", "OBSERVATION", 28, 36]]], ["The infection efficiency was assessed by fluorescence microscopy 72 h after infection.", [["infection", "DISEASE", 4, 13], ["infection", "DISEASE", 76, 85], ["The infection efficiency", "PROBLEM", 0, 24], ["fluorescence microscopy", "TEST", 41, 64], ["infection", "PROBLEM", 76, 85], ["infection efficiency", "OBSERVATION", 4, 24]]], ["Total protein were extracted from the cells by a M-PER Mammalian Protein Extraction Reagent Kit (Thermo, USA) and subjected to western blotting to measure the levels of CDK2, C/EBP \u03b2 and CCSP1.Development of in vitro ALI modelWe developed an in vitro ALI model using LPS to induce BEAS-2B cells.", [["cells", "ANATOMY", 38, 43], ["BEAS-2B cells", "ANATOMY", 281, 294], ["ALI", "DISEASE", 251, 254], ["LPS", "CHEMICAL", 267, 270], ["cells", "CELL", 38, 43], ["CDK2", "GENE_OR_GENE_PRODUCT", 169, 173], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 175, 182], ["CCSP1", "GENE_OR_GENE_PRODUCT", 187, 192], ["LPS", "SIMPLE_CHEMICAL", 267, 270], ["BEAS-2B cells", "CELL", 281, 294], ["CDK2", "PROTEIN", 169, 173], ["C/EBP \u03b2", "PROTEIN", 175, 182], ["CCSP1", "PROTEIN", 187, 192], ["BEAS-2B cells", "CELL_LINE", 281, 294], ["Total protein", "TEST", 0, 13], ["CDK2", "TEST", 169, 173], ["C/EBP", "TEST", 175, 180], ["CCSP1", "TEST", 187, 192], ["vitro ALI modelWe", "TREATMENT", 211, 228], ["an in vitro ALI model", "TREATMENT", 239, 260], ["LPS", "TREATMENT", 267, 270], ["BEAS", "TEST", 281, 285], ["vitro ALI modelWe", "OBSERVATION", 211, 228], ["2B cells", "OBSERVATION", 286, 294]]], ["Suspension of BEAS-2B cells in logarithmic phase was prepared by trypsin digestion, and the number of viable cells was counted with a hemocytometer by trypan blue staining.", [["BEAS-2B cells", "ANATOMY", 14, 27], ["cells", "ANATOMY", 109, 114], ["trypan blue", "CHEMICAL", 151, 162], ["trypan blue", "CHEMICAL", 151, 162], ["BEAS-2B cells", "CELL", 14, 27], ["trypsin", "GENE_OR_GENE_PRODUCT", 65, 72], ["cells", "CELL", 109, 114], ["BEAS-2B cells", "CELL_LINE", 14, 27], ["trypsin", "PROTEIN", 65, 72], ["BEAS", "TEST", 14, 18], ["a hemocytometer", "TEST", 132, 147], ["2B cells", "OBSERVATION", 19, 27], ["logarithmic phase", "OBSERVATION_MODIFIER", 31, 48], ["viable cells", "OBSERVATION", 102, 114]]], ["Cells were suspended in LHC-8 medium and seeded to 6-well plates at 2 \u00d7 10 5 /well and cultured for 16 h and then the medium was replaced with the LHC-8 medium.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["LHC", "TEST", 24, 27], ["the LHC", "TEST", 143, 150], ["8 medium", "OBSERVATION_MODIFIER", 28, 36]]], ["8 h after the medium replacement, LPS was added to a final concentration of 10 mg/ml, and the cells were cultured for 12, 24 or 48 h more.", [["cells", "ANATOMY", 94, 99], ["LPS", "CHEMICAL", 34, 37], ["LPS", "SIMPLE_CHEMICAL", 34, 37], ["cells", "CELL", 94, 99], ["the medium replacement", "TREATMENT", 10, 32], ["LPS", "TREATMENT", 34, 37], ["the cells", "TEST", 90, 99]]], ["Cells were collected and total protein was extracted and quantified by the method of BCA; intracellular inflammatory factors such as TNF-\u03b1, IL-1\u03b2 and 1 L-10, as well as PAF and AA, were measured by ELISA, which were used to determine whether the model was established.", [["Cells", "ANATOMY", 0, 5], ["intracellular", "ANATOMY", 90, 103], ["Cells", "CELL", 0, 5], ["BCA", "SIMPLE_CHEMICAL", 85, 88], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 90, 103], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 133, 138], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 140, 145], ["1 L-10", "GENE_OR_GENE_PRODUCT", 150, 156], ["PAF", "SIMPLE_CHEMICAL", 169, 172], ["AA", "SIMPLE_CHEMICAL", 177, 179], ["intracellular inflammatory factors", "PROTEIN", 90, 124], ["TNF", "PROTEIN", 133, 136], ["IL-1\u03b2", "PROTEIN", 140, 145], ["PAF", "PROTEIN", 169, 172], ["Cells", "TEST", 0, 5], ["total protein", "TEST", 25, 38], ["intracellular inflammatory factors", "PROBLEM", 90, 124], ["TNF", "TEST", 133, 136], ["IL", "TEST", 140, 142], ["PAF", "PROBLEM", 169, 172], ["AA", "TEST", 177, 179], ["ELISA", "TEST", 198, 203], ["inflammatory", "OBSERVATION_MODIFIER", 104, 116], ["PAF", "OBSERVATION", 169, 172]]], ["We then assessed the expression of CDK2, CCSP1 and PLA2, and phosphorylation of C/EBP \u03b2 in the cells by western blotting.Overexpression and silencing of CDK2 and CCSP1 and their effects on phosphorylation of C/EBP \u03b2Since it is reported that overexpression of CDK2 can regulate the phosphorylation of C/EBP \u03b2 (Li et al., 2007) , we overexpressed and knocked down CDK2 via a lentiviral approach in BEAS-2B cells and examined the phosphorylation of C/EBP \u03b2.", [["cells", "ANATOMY", 95, 100], ["BEAS-2B cells", "ANATOMY", 396, 409], ["CDK2", "GENE_OR_GENE_PRODUCT", 35, 39], ["CCSP1", "GENE_OR_GENE_PRODUCT", 41, 46], ["PLA2", "GENE_OR_GENE_PRODUCT", 51, 55], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 80, 87], ["cells", "CELL", 95, 100], ["CDK2", "GENE_OR_GENE_PRODUCT", 153, 157], ["CCSP1", "GENE_OR_GENE_PRODUCT", 162, 167], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 208, 215], ["CDK2", "GENE_OR_GENE_PRODUCT", 259, 263], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 300, 307], ["CDK2", "GENE_OR_GENE_PRODUCT", 362, 366], ["BEAS-2B cells", "CELL", 396, 409], ["C/EBP", "GENE_OR_GENE_PRODUCT", 446, 451], ["CDK2", "PROTEIN", 35, 39], ["CCSP1", "PROTEIN", 41, 46], ["PLA2", "PROTEIN", 51, 55], ["C/EBP \u03b2", "PROTEIN", 80, 87], ["CDK2", "PROTEIN", 153, 157], ["CCSP1", "PROTEIN", 162, 167], ["C/EBP \u03b2", "PROTEIN", 208, 215], ["CDK2", "PROTEIN", 259, 263], ["C/EBP \u03b2", "PROTEIN", 300, 307], ["CDK2", "PROTEIN", 362, 366], ["BEAS-2B cells", "CELL_LINE", 396, 409], ["CDK2", "TEST", 35, 39], ["CCSP1", "TEST", 41, 46], ["PLA2", "TEST", 51, 55], ["phosphorylation of C/EBP", "PROBLEM", 61, 85], ["Overexpression and silencing of CDK2", "PROBLEM", 121, 157], ["CCSP1", "TEST", 162, 167], ["phosphorylation of C/EBP", "TREATMENT", 189, 213], ["overexpression of CDK2", "PROBLEM", 241, 263], ["CDK2", "PROBLEM", 362, 366], ["a lentiviral approach", "TREATMENT", 371, 392], ["2B cells", "OBSERVATION", 401, 409]]], ["At the same time, we predicted C/EBP \u03b2 as a regulator of CCSP1 transcription, so we also overexpressed and silenced CCSP1 in BEAS-2B cells, and observed the effect on the phosphorylation of C/EBP \u03b2.", [["BEAS-2B cells", "ANATOMY", 125, 138], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 31, 38], ["CCSP1", "GENE_OR_GENE_PRODUCT", 57, 62], ["CCSP1", "GENE_OR_GENE_PRODUCT", 116, 121], ["BEAS-2B cells", "CELL", 125, 138], ["C/EBP", "GENE_OR_GENE_PRODUCT", 190, 195], ["C/EBP \u03b2", "PROTEIN", 31, 38], ["CCSP1", "PROTEIN", 57, 62], ["CCSP1", "PROTEIN", 116, 121], ["BEAS-2B cells", "CELL_LINE", 125, 138], ["EBP", "PROTEIN", 192, 195], ["C/EBP", "TEST", 31, 36], ["2B cells", "OBSERVATION", 130, 138]]], ["BEAS-2B cells in logarithmic phase were seeded to 6-well plates and recombinant viral solution was added at an MOI of 10.", [["BEAS-2B cells", "ANATOMY", 0, 13], ["BEAS-2B cells", "CELL", 0, 13], ["BEAS-2B cells", "CELL_LINE", 0, 13], ["BEAS", "TEST", 0, 4], ["logarithmic phase", "TEST", 17, 34], ["recombinant viral solution", "TREATMENT", 68, 94], ["2B cells", "OBSERVATION", 5, 13], ["logarithmic phase", "OBSERVATION_MODIFIER", 17, 34]]], ["72 h later, cells were collected and total protein was isolated and subjected to western blotting for measuring the phosphorylation of C/EBP \u03b2.", [["cells", "ANATOMY", 12, 17], ["cells", "CELL", 12, 17], ["C/EBP", "GENE_OR_GENE_PRODUCT", 135, 140], ["EBP", "PROTEIN", 137, 140], ["total protein", "TEST", 37, 50]]], ["The cells were divided into five groups: cell control, the cells infected with Lv-NC, Lv-CDK2, Lv-shRNA-CDK2, Lv-CCSP1, or Lv-shRNA-CCSP1.Effect of C/EBP \u03b2 phosphorylation on CCSP1 transcriptionAccording to bioinformatics, we found a possible binding site of C/ EBP \u03b2 in CCSP1 promoter, 5\u2032-CTTGAGAAAA-3\u2032.", [["cells", "ANATOMY", 4, 9], ["cell", "ANATOMY", 41, 45], ["cells", "ANATOMY", 59, 64], ["cells", "CELL", 4, 9], ["cell", "CELL", 41, 45], ["cells", "CELL", 59, 64], ["Lv-CDK2", "GENE_OR_GENE_PRODUCT", 86, 93], ["Lv-shRNA-CDK2", "GENE_OR_GENE_PRODUCT", 95, 108], ["Lv-CCSP1", "GENE_OR_GENE_PRODUCT", 110, 118], ["Lv-shRNA-CCSP1", "GENE_OR_GENE_PRODUCT", 123, 137], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 148, 155], ["CCSP1", "GENE_OR_GENE_PRODUCT", 175, 180], ["C/ EBP \u03b2", "GENE_OR_GENE_PRODUCT", 259, 267], ["CCSP1", "GENE_OR_GENE_PRODUCT", 271, 276], ["CDK2", "PROTEIN", 89, 93], ["Lv-shRNA", "PROTEIN", 95, 103], ["CDK2", "PROTEIN", 104, 108], ["Lv-CCSP1", "PROTEIN", 110, 118], ["Lv-shRNA", "PROTEIN", 123, 131], ["CCSP1", "PROTEIN", 132, 137], ["EBP \u03b2", "PROTEIN", 150, 155], ["CCSP1", "PROTEIN", 175, 180], ["C/ EBP \u03b2", "DNA", 259, 267], ["CCSP1 promoter", "DNA", 271, 285], ["5\u2032-CTTGAGAAAA-3\u2032", "DNA", 287, 303], ["The cells", "TREATMENT", 0, 9], ["cell control", "TREATMENT", 41, 53], ["Lv-NC", "TREATMENT", 79, 84], ["Lv-shRNA", "TEST", 95, 103], ["CDK2", "PROBLEM", 104, 108], ["Lv-CCSP1", "TEST", 110, 118], ["Lv-shRNA", "TEST", 123, 131], ["C/EBP", "TEST", 148, 153], ["phosphorylation", "PROBLEM", 156, 171], ["C/ EBP", "PROBLEM", 259, 265], ["CCSP1 promoter", "TREATMENT", 271, 285], ["CTTGAGAAAA", "TEST", 290, 300]]], ["We overexpressed Lv-wPro-CCSP1 or Lv-mPro-CCSP1 in BEAS-2B cells and then overexpressed or silenced CDK2 to find out the effects of overexpression and depletion of CDK2 and C/EBP \u03b2 phosphorylation on the mRNA level of CCSP1.", [["BEAS-2B cells", "ANATOMY", 51, 64], ["Lv-wPro-CCSP1", "GENE_OR_GENE_PRODUCT", 17, 30], ["Lv-mPro-CCSP1", "GENE_OR_GENE_PRODUCT", 34, 47], ["BEAS-2B cells", "CELL", 51, 64], ["CDK2", "GENE_OR_GENE_PRODUCT", 100, 104], ["CDK2", "GENE_OR_GENE_PRODUCT", 164, 168], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 173, 180], ["CCSP1", "GENE_OR_GENE_PRODUCT", 218, 223], ["Lv-wPro-CCSP1", "PROTEIN", 17, 30], ["Lv-mPro-CCSP1", "PROTEIN", 34, 47], ["BEAS-2B cells", "CELL_LINE", 51, 64], ["CDK2", "PROTEIN", 100, 104], ["CDK2", "PROTEIN", 164, 168], ["EBP \u03b2", "PROTEIN", 175, 180], ["CCSP1", "PROTEIN", 218, 223], ["overexpressed Lv-wPro-CCSP1", "PROBLEM", 3, 30], ["Lv-mPro-CCSP1", "PROBLEM", 34, 47], ["BEAS", "TEST", 51, 55], ["silenced CDK2", "PROBLEM", 91, 104], ["overexpression", "PROBLEM", 132, 146], ["CDK2", "PROBLEM", 164, 168], ["C/EBP", "TEST", 173, 178], ["phosphorylation", "PROBLEM", 181, 196], ["CCSP1", "TEST", 218, 223], ["2B cells", "OBSERVATION", 56, 64], ["overexpression", "OBSERVATION", 132, 146]]], ["By measuring CCSP1 transcription, we wanted to figure out the effect of C/EBP \u03b2 phosphorylation on CCSP1 transcription and whether C/EBP \u03b2 binds to CCSP1 promoter through the predicted site.", [["CCSP1", "GENE_OR_GENE_PRODUCT", 13, 18], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 72, 79], ["CCSP1", "GENE_OR_GENE_PRODUCT", 99, 104], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 131, 138], ["CCSP1", "GENE_OR_GENE_PRODUCT", 148, 153], ["CCSP1", "PROTEIN", 13, 18], ["EBP \u03b2", "PROTEIN", 74, 79], ["CCSP1", "PROTEIN", 99, 104], ["C/EBP \u03b2", "PROTEIN", 131, 138], ["CCSP1 promoter", "DNA", 148, 162], ["C/EBP", "TREATMENT", 72, 77], ["CCSP1 transcription", "TREATMENT", 99, 118], ["C/EBP", "PROBLEM", 131, 136]]], ["The cells were divided into nine groups: cell control, cells infected with Lv-wPro-Effect of C/EBP \u03b2 phosphorylation on CCSP1 transcription, Lv-wPro-CCSP1 + Lv-shRNA-CDK2, and Lv-mPro-CCSP1 + Lv-shRNA-CDK2.", [["cells", "ANATOMY", 4, 9], ["cell", "ANATOMY", 41, 45], ["cells", "ANATOMY", 55, 60], ["cells", "CELL", 4, 9], ["cell", "CELL", 41, 45], ["cells", "CELL", 55, 60], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 93, 100], ["CCSP1", "GENE_OR_GENE_PRODUCT", 120, 125], ["Lv-wPro-CCSP1 + Lv-shRNA-CDK2", "GENE_OR_GENE_PRODUCT", 141, 170], ["Lv-mPro-CCSP1 + Lv-shRNA-CDK2", "GENE_OR_GENE_PRODUCT", 176, 205], ["EBP \u03b2", "PROTEIN", 95, 100], ["CCSP1", "PROTEIN", 120, 125], ["Lv-wPro-CCSP1", "PROTEIN", 141, 154], ["Lv-shRNA-CDK2", "PROTEIN", 157, 170], ["Lv-mPro-CCSP1", "PROTEIN", 176, 189], ["Lv-shRNA-CDK2", "PROTEIN", 192, 205], ["The cells", "TREATMENT", 0, 9], ["cell control", "TREATMENT", 41, 53], ["C/EBP", "TREATMENT", 93, 98], ["phosphorylation", "PROBLEM", 101, 116], ["CCSP1 transcription", "TREATMENT", 120, 139], ["Lv-wPro-CCSP1", "TEST", 141, 154], ["CDK2", "PROBLEM", 166, 170], ["Lv-mPro-CCSP1", "TEST", 176, 189], ["Lv-shRNA-CDK2", "PROBLEM", 192, 205]]], ["The infection condition was the same as described above, and mRNA quantification was performed 72 h after infection.Verification of binding site of transcription factor in CCSP1 promoter by CHIP and luciferase assayTo verify the binding site of C/EBP \u03b2 in CCSP1 promoter, we conducted CHIP-PCR experiment.", [["infection", "DISEASE", 4, 13], ["infection", "DISEASE", 106, 115], ["CCSP1", "GENE_OR_GENE_PRODUCT", 172, 177], ["CHIP", "GENE_OR_GENE_PRODUCT", 190, 194], ["luciferase", "GENE_OR_GENE_PRODUCT", 199, 209], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 245, 252], ["CCSP1", "GENE_OR_GENE_PRODUCT", 256, 261], ["CHIP", "GENE_OR_GENE_PRODUCT", 285, 289], ["mRNA", "RNA", 61, 65], ["transcription factor", "PROTEIN", 148, 168], ["CCSP1 promoter", "DNA", 172, 186], ["CHIP", "PROTEIN", 190, 194], ["luciferase", "PROTEIN", 199, 209], ["binding site", "DNA", 229, 241], ["C/EBP \u03b2", "DNA", 245, 252], ["CCSP1 promoter", "DNA", 256, 270], ["CHIP", "PROTEIN", 285, 289], ["The infection condition", "PROBLEM", 0, 23], ["mRNA quantification", "TEST", 61, 80], ["infection", "PROBLEM", 106, 115], ["binding site", "PROBLEM", 132, 144], ["transcription factor in CCSP1 promoter", "TREATMENT", 148, 186], ["luciferase assay", "TEST", 199, 215], ["C/EBP", "PROBLEM", 245, 250], ["CCSP1 promoter", "TREATMENT", 256, 270], ["infection", "OBSERVATION", 4, 13]]], ["BEAS-2B cells in logarithmic phase were infected with Lv-wPro-CCSP1 or Lv-mPro-CCSP1 and then infected with Lv-C/EBP \u03b2.", [["BEAS-2B cells", "ANATOMY", 0, 13], ["BEAS-2B cells", "CELL", 0, 13], ["Lv-wPro-CCSP1", "GENE_OR_GENE_PRODUCT", 54, 67], ["Lv-mPro-CCSP1", "GENE_OR_GENE_PRODUCT", 71, 84], ["BEAS-2B cells", "CELL_LINE", 0, 13], ["Lv-wPro-CCSP1", "PROTEIN", 54, 67], ["Lv-mPro-CCSP1", "PROTEIN", 71, 84], ["BEAS", "TEST", 0, 4], ["logarithmic phase", "TEST", 17, 34], ["Lv-wPro-CCSP1", "PROBLEM", 54, 67], ["Lv-mPro-CCSP1", "TREATMENT", 71, 84], ["2B cells", "OBSERVATION", 5, 13], ["logarithmic phase", "OBSERVATION_MODIFIER", 17, 34]]], ["72 h later, cells were harvested and subjected to CHIP-PCR in accordance with the instruction of EZ CHIP KIT (Millipore, MI,USA),The experiment were carried out with reference (Yang et al., 2013) and in accordance with the manufacturer's protocol.", [["cells", "ANATOMY", 12, 17], ["cells", "CELL", 12, 17], ["CHIP", "GENE_OR_GENE_PRODUCT", 50, 54], ["CHIP", "PROTEIN", 50, 54], ["CHIP KIT", "PROTEIN", 100, 108], ["PCR", "TEST", 55, 58], ["MI", "PROBLEM", 121, 123], ["the manufacturer's protocol", "TREATMENT", 219, 246]]], ["The primers for real-time quantitative PCR were: 5\u2032-TTGTGTGAGCTCAGTTTCAG-3\u2032 and 5\u2032-GCTTGGTGGGATAGGTAA-3\u2032, producing a product of 72 bp, carrying the predicted C/EBP \u03b2 binding site \"5\u2032-CTTGAGAAAA-3\u2032\".Verification of binding site of transcription factor in CCSP1 promoter by CHIP and luciferase assayTo eliminate the interference of endogenous CCSP1 promoter on CHIP-PCR, we also performed luciferase reporter assays.", [["5\u2032-GCTTGGTGGGATAGGTAA-3", "GENE_OR_GENE_PRODUCT", 80, 103], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 159, 166], ["CCSP1", "GENE_OR_GENE_PRODUCT", 255, 260], ["CHIP", "GENE_OR_GENE_PRODUCT", 273, 277], ["luciferase", "GENE_OR_GENE_PRODUCT", 282, 292], ["CCSP1", "GENE_OR_GENE_PRODUCT", 342, 347], ["CHIP", "GENE_OR_GENE_PRODUCT", 360, 364], ["luciferase", "GENE_OR_GENE_PRODUCT", 388, 398], ["C/EBP \u03b2 binding site", "DNA", 159, 179], ["transcription factor", "PROTEIN", 231, 251], ["CCSP1 promoter", "DNA", 255, 269], ["CHIP", "PROTEIN", 273, 277], ["luciferase", "PROTEIN", 282, 292], ["CCSP1 promoter", "DNA", 342, 356], ["CHIP", "PROTEIN", 360, 364], ["luciferase", "PROTEIN", 388, 398], ["The primers", "TEST", 0, 11], ["quantitative PCR", "TEST", 26, 42], ["TTGTGTGAGCTCAGTTTCAG", "TEST", 52, 72], ["GCTTGGTGGGATAGGTAA", "TEST", 83, 101], ["binding site", "PROBLEM", 215, 227], ["transcription factor in CCSP1 promoter", "TREATMENT", 231, 269], ["luciferase assay", "TEST", 282, 298], ["endogenous CCSP1 promoter", "TREATMENT", 331, 356], ["CHIP-PCR", "TREATMENT", 360, 368], ["luciferase reporter assays", "TEST", 388, 414]]], ["293 cells were transfected with pcDH1-C/EBP \u03b2 and pGL3-wPro-CCSP1 or pGL3-mPro-CCSP1, and harvested for luciferase activity assay 48 h later.", [["293 cells", "ANATOMY", 0, 9], ["293 cells", "CELL", 0, 9], ["pcDH1-C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 32, 45], ["pGL3-wPro-CCSP1", "GENE_OR_GENE_PRODUCT", 50, 65], ["pGL3-mPro-CCSP1", "GENE_OR_GENE_PRODUCT", 69, 84], ["luciferase", "GENE_OR_GENE_PRODUCT", 104, 114], ["293 cells", "CELL_LINE", 0, 9], ["pcDH1", "PROTEIN", 32, 37], ["C/EBP \u03b2", "DNA", 38, 45], ["pGL3", "DNA", 50, 54], ["wPro-CCSP1", "DNA", 55, 65], ["pGL3", "DNA", 69, 73], ["mPro-CCSP1", "DNA", 74, 84], ["luciferase", "PROTEIN", 104, 114], ["pcDH1", "TEST", 32, 37], ["EBP", "TEST", 40, 43], ["pGL3", "TEST", 50, 54], ["wPro-CCSP1", "TEST", 55, 65], ["pGL3", "TEST", 69, 73], ["mPro-CCSP1", "TREATMENT", 74, 84], ["luciferase activity assay", "TEST", 104, 129]]], ["The transfection experiment was carried out in 24-well plates, following the instructions for Lipofectmaine2000.", [["Lipofectmaine2000", "CHEMICAL", 94, 111], ["Lipofectmaine2000", "SIMPLE_CHEMICAL", 94, 111], ["The transfection experiment", "TEST", 0, 27], ["Lipofectmaine2000", "TREATMENT", 94, 111]]], ["PGL-TK (100 ng) was transfected for each well as the internal reference for luciferase assay.Effect of C/EBP \u03b2 phosphorylation on C/EBP \u03b2/CCSP1/PLA2 pathwayTo verify the specificity of the C/EBP \u03b2/CCSP1/PLA2 pathway, we knocked down C/EBP \u03b2 and CCSP1 respectively, and overexpressed CDK2 in the in vitro ALI model established by LPS induction to observe the effect on the inhibition of PLA2 by CDK2 and analyze the specificity of the pathway.", [["PGL-TK", "CHEMICAL", 0, 6], ["ALI", "DISEASE", 304, 307], ["LPS", "CHEMICAL", 329, 332], ["PGL-TK", "GENE_OR_GENE_PRODUCT", 0, 6], ["luciferase", "GENE_OR_GENE_PRODUCT", 76, 86], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 103, 110], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 130, 137], ["CCSP1", "GENE_OR_GENE_PRODUCT", 138, 143], ["PLA2", "GENE_OR_GENE_PRODUCT", 144, 148], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 189, 196], ["CCSP1", "GENE_OR_GENE_PRODUCT", 197, 202], ["PLA2", "GENE_OR_GENE_PRODUCT", 203, 207], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 233, 240], ["CCSP1", "GENE_OR_GENE_PRODUCT", 245, 250], ["CDK2", "GENE_OR_GENE_PRODUCT", 283, 287], ["LPS", "SIMPLE_CHEMICAL", 329, 332], ["PLA2", "GENE_OR_GENE_PRODUCT", 386, 390], ["CDK2", "GENE_OR_GENE_PRODUCT", 394, 398], ["luciferase", "PROTEIN", 76, 86], ["EBP \u03b2", "PROTEIN", 105, 110], ["CCSP1", "PROTEIN", 138, 143], ["PLA2", "PROTEIN", 144, 148], ["EBP \u03b2", "PROTEIN", 191, 196], ["CCSP1", "PROTEIN", 197, 202], ["PLA2", "PROTEIN", 203, 207], ["C/EBP \u03b2", "PROTEIN", 233, 240], ["CCSP1", "PROTEIN", 245, 250], ["CDK2", "PROTEIN", 283, 287], ["PLA2", "PROTEIN", 386, 390], ["CDK2", "PROTEIN", 394, 398], ["PGL", "TEST", 0, 3], ["luciferase assay", "TEST", 76, 92], ["C/EBP", "TEST", 103, 108], ["phosphorylation", "TEST", 111, 126], ["C", "TEST", 130, 131], ["EBP", "TEST", 132, 135], ["PLA2 pathway", "TREATMENT", 144, 156], ["the C/EBP", "TEST", 185, 194], ["EBP", "TEST", 235, 238], ["CCSP1", "TEST", 245, 250], ["overexpressed CDK2", "PROBLEM", 269, 287], ["LPS induction", "TREATMENT", 329, 342], ["PLA2", "TREATMENT", 386, 390], ["TK", "ANATOMY", 4, 6], ["CDK2", "OBSERVATION", 283, 287]]], ["The infection condition and LPS induction condition were the same as described above; 48 h after infection, LPS induction was carried out.", [["infection", "DISEASE", 4, 13], ["LPS", "CHEMICAL", 28, 31], ["infection", "DISEASE", 97, 106], ["LPS", "CHEMICAL", 108, 111], ["LPS", "SIMPLE_CHEMICAL", 28, 31], ["LPS", "SIMPLE_CHEMICAL", 108, 111], ["The infection condition", "PROBLEM", 0, 23], ["LPS induction condition", "PROBLEM", 28, 51], ["infection", "PROBLEM", 97, 106], ["LPS induction", "TREATMENT", 108, 121], ["infection", "OBSERVATION", 4, 13]]], ["24 h after LPS treatment, cells were harvested and total protein was isolated for western blotting for measuring PLA2.Effect of C/EBP \u03b2 phosphorylation on C/EBP \u03b2/CCSP1/PLA2 pathway2.9.", [["cells", "ANATOMY", 26, 31], ["LPS", "CHEMICAL", 11, 14], ["LPS", "SIMPLE_CHEMICAL", 11, 14], ["cells", "CELL", 26, 31], ["PLA2", "GENE_OR_GENE_PRODUCT", 113, 117], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 128, 135], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 155, 162], ["CCSP1", "GENE_OR_GENE_PRODUCT", 163, 168], ["PLA2", "GENE_OR_GENE_PRODUCT", 169, 173], ["PLA2", "PROTEIN", 113, 117], ["EBP \u03b2", "PROTEIN", 130, 135], ["C/EBP \u03b2", "PROTEIN", 155, 162], ["CCSP1", "PROTEIN", 163, 168], ["PLA2 pathway2.9", "PROTEIN", 169, 184], ["LPS treatment", "TREATMENT", 11, 24], ["cells", "PROBLEM", 26, 31], ["total protein", "TEST", 51, 64], ["western blotting", "TEST", 82, 98], ["PLA2", "TEST", 113, 117], ["C/EBP", "TEST", 128, 133], ["phosphorylation", "TEST", 136, 151], ["C/EBP", "TEST", 155, 160], ["CCSP1", "TEST", 163, 168], ["PLA2", "TEST", 169, 173]]], ["Examination of effect of C/EBP \u03b2 phosphorylation on damage of phospholipid membrane in in vitro ALI modelEffect of C/EBP \u03b2 phosphorylation on C/EBP \u03b2/CCSP1/PLA2 pathwayThe cells were treated as in the experiment for verifying pathway specificity: LPS induction started 48 h after infection, and 24 h after induction, cells were collected and subjected to PAF and AA assessment.", [["phospholipid membrane", "ANATOMY", 62, 83], ["cells", "ANATOMY", 172, 177], ["cells", "ANATOMY", 317, 322], ["ALI", "DISEASE", 96, 99], ["LPS", "CHEMICAL", 247, 250], ["infection", "DISEASE", 280, 289], ["PAF", "CHEMICAL", 355, 358], ["AA", "CHEMICAL", 363, 365], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 25, 32], ["phospholipid membrane", "CELLULAR_COMPONENT", 62, 83], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 115, 122], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 142, 149], ["CCSP1", "GENE_OR_GENE_PRODUCT", 150, 155], ["PLA2", "GENE_OR_GENE_PRODUCT", 156, 160], ["cells", "CELL", 172, 177], ["LPS", "SIMPLE_CHEMICAL", 247, 250], ["cells", "CELL", 317, 322], ["EBP \u03b2", "PROTEIN", 27, 32], ["EBP \u03b2", "PROTEIN", 117, 122], ["CCSP1", "PROTEIN", 150, 155], ["PLA2", "PROTEIN", 156, 160], ["PAF", "PROTEIN", 355, 358], ["Examination", "TEST", 0, 11], ["C/EBP", "TEST", 25, 30], ["phosphorylation", "PROBLEM", 33, 48], ["phospholipid membrane", "TREATMENT", 62, 83], ["C/EBP", "TEST", 115, 120], ["phosphorylation", "TEST", 123, 138], ["C/EBP", "TREATMENT", 142, 147], ["CCSP1/PLA2 pathway", "TREATMENT", 150, 168], ["LPS induction", "TREATMENT", 247, 260], ["infection", "PROBLEM", 280, 289], ["PAF", "PROBLEM", 355, 358], ["AA assessment", "TEST", 363, 376]]], ["The inter-group difference of PAF and AA releases was used to determine the damage degree of membrane phospholipid.Measurement of relative mRNA by real-time PCRAfter removal of the culture medium, the cells were washed with pre-cooled dPBS, supplemented with pre-cooled trizol reagent, and pipetted until the lysate became viscous and clear.", [["membrane", "ANATOMY", 93, 101], ["cells", "ANATOMY", 201, 206], ["lysate", "ANATOMY", 309, 315], ["PAF", "CHEMICAL", 30, 33], ["AA", "CHEMICAL", 38, 40], ["dPBS", "CHEMICAL", 235, 239], ["trizol", "CHEMICAL", 270, 276], ["PAF", "SIMPLE_CHEMICAL", 30, 33], ["AA", "SIMPLE_CHEMICAL", 38, 40], ["membrane phospholipid", "CELLULAR_COMPONENT", 93, 114], ["cells", "CELL", 201, 206], ["dPBS", "SIMPLE_CHEMICAL", 235, 239], ["trizol", "SIMPLE_CHEMICAL", 270, 276], ["PAF", "PROTEIN", 30, 33], ["mRNA", "RNA", 139, 143], ["PAF", "PROBLEM", 30, 33], ["AA releases", "TREATMENT", 38, 49], ["the damage degree of membrane phospholipid", "PROBLEM", 72, 114], ["the culture medium", "TEST", 177, 195], ["pre-cooled dPBS", "TREATMENT", 224, 239], ["pre-cooled trizol reagent", "TREATMENT", 259, 284], ["viscous", "PROBLEM", 323, 330], ["PAF", "OBSERVATION", 30, 33], ["membrane phospholipid", "OBSERVATION", 93, 114], ["clear", "OBSERVATION", 335, 340]]], ["The lysate was transferred to a 1.5-ml centrifuge tube and extracted using the phenolchloroform method (Han et al., 2002) .", [["lysate", "ANATOMY", 4, 10], ["phenolchloroform", "CHEMICAL", 79, 95], ["lysate", "ORGANISM_SUBSTANCE", 4, 10], ["The lysate", "TREATMENT", 0, 10], ["a 1.5-ml centrifuge tube", "TREATMENT", 30, 54], ["the phenolchloroform method", "TREATMENT", 75, 102]]], ["The purity of the total RNA was determined by ultraviolet spectrophotometry, and the mRNA levels of CCSP1 were detected by real-time PCR.", [["CCSP1", "GENE_OR_GENE_PRODUCT", 100, 105], ["total RNA", "RNA", 18, 27], ["CCSP1", "PROTEIN", 100, 105], ["the total RNA", "TREATMENT", 14, 27], ["ultraviolet spectrophotometry", "TEST", 46, 75], ["the mRNA levels", "TEST", 81, 96], ["CCSP1", "TEST", 100, 105]]], ["Total RNA (2 \u03bcg) was used as the template to prepare cDNA by reverse transcription.", [["cDNA", "DNA", 53, 57], ["Total RNA", "TREATMENT", 0, 9]]], ["The product of reverse transcription (2 \u03bcl) was used as the template for real-time PCR.", [["reverse transcription", "TREATMENT", 15, 36], ["real-time PCR", "TEST", 73, 86]]], ["The results were analyzed using the2 \u0394\u0394Ct method with \u03b2-actin (NM_001101.3) as the internal reference (Livak and Schmittgen, 2001) .", [["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 54, 61], ["\u03b2-actin", "PROTEIN", 54, 61]]], ["The PCR primers were as follows: \u03b2 actin-forward,5\u2032-CCTGTACGCCA-ACACAGTGC-3\u2032, \u03b2 actin-reverse,5\u2032-ATACTCCTGCTT GCTGATCC-3\u2032; C-CSP1-forward,5\u2032-GCCGGCGCCCGAGCTCTGGCTC-3\u2032;CCSP1-reverse, 5\u2032-TGTCAGTTTGTCAAATACCCCA-3.Each PCR reaction contained 10 \u03bcl of SYBR Premix Ex Taq, 0.2 \u03bcl each of forward and reverse primers (20 \u03bcM), 2 \u03bcl of cDNA, and dH 2 O to a final volume of 20 \u03bcl.", [["\u03b2 actin", "GENE_OR_GENE_PRODUCT", 33, 40], ["PCR primers", "DNA", 4, 15], ["actin", "PROTEIN", 35, 40], ["CSP1", "DNA", 125, 129], ["CCSP1-reverse, 5\u2032-TGTCAGTTTGTCAAATACCCCA-3", "DNA", 167, 209], ["The PCR primers", "TEST", 0, 15], ["actin", "TEST", 35, 40], ["CCTGTACGCCA", "TEST", 52, 63], ["ACACAGTGC", "TEST", 64, 73], ["actin-reverse", "TEST", 80, 93], ["ATACTCCTGCTT", "TEST", 97, 109], ["GCTGATCC", "TEST", 110, 118], ["C", "TEST", 123, 124], ["CSP1", "TEST", 125, 129], ["GCCGGCGCCCGAGCTCTGGCTC", "TEST", 141, 163], ["CCSP1", "TEST", 167, 172], ["Each PCR reaction", "TEST", 210, 227], ["SYBR Premix Ex Taq", "TEST", 247, 265], ["reverse primers", "TREATMENT", 294, 309], ["a final volume", "TEST", 347, 361]]], ["The reaction parameters were 40 cycles of denaturation at 95\u00b0C for 10 s, annealing at 58\u00b0C for 10 s, and elongation at 72\u00b0C for 10 s.", [["The reaction parameters", "TEST", 0, 23], ["denaturation", "TREATMENT", 42, 54], ["elongation", "TEST", 105, 115]]], ["The experiment was carried out on Takara fluorescent quantitative TP800.Evaluation of protein levels by western blottingTotal protein was extracted, and proteins were detected by western blotting.", [["Takara fluorescent quantitative TP800", "PROTEIN", 34, 71], ["Evaluation of protein levels", "TEST", 72, 100], ["Total protein", "TEST", 120, 133]]], ["Cells were rinsed with 1 ml of cooled dPBS, and 1 ml of cell lysis buffer (50 mM pH 8.0 Tris, 1 mg/ml leupeptin,150 mMNaCl, 0.5% Nonidet P-40, 5 mM EDTA, 100 mMphenylmethylsulfonyl fluoride, 1 M dithiothreitol, and 1 mg/ml aprotinin) was added for protein extraction.", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 56, 60], ["Nonidet P-40", "CHEMICAL", 129, 141], ["mMphenylmethylsulfonyl fluoride", "CHEMICAL", 158, 189], ["dithiothreitol", "CHEMICAL", 195, 209], ["leupeptin", "CHEMICAL", 102, 111], ["Nonidet P-40", "CHEMICAL", 129, 141], ["EDTA", "CHEMICAL", 148, 152], ["mMphenylmethylsulfonyl fluoride", "CHEMICAL", 158, 189], ["dithiothreitol", "CHEMICAL", 195, 209], ["Cells", "CELL", 0, 5], ["dPBS", "SIMPLE_CHEMICAL", 38, 42], ["cell", "CELL", 56, 60], ["leupeptin", "SIMPLE_CHEMICAL", 102, 111], ["Nonidet P-40", "SIMPLE_CHEMICAL", 129, 141], ["EDTA", "SIMPLE_CHEMICAL", 148, 152], ["mMphenylmethylsulfonyl fluoride", "SIMPLE_CHEMICAL", 158, 189], ["dithiothreitol", "SIMPLE_CHEMICAL", 195, 209], ["aprotinin", "SIMPLE_CHEMICAL", 223, 232], ["Cells", "TEST", 0, 5], ["cooled dPBS", "TREATMENT", 31, 42], ["cell lysis buffer", "TREATMENT", 56, 73], ["pH", "TEST", 81, 83], ["Tris", "TEST", 88, 92], ["leupeptin", "TREATMENT", 102, 111], ["mMNaCl", "TEST", 116, 122], ["5 mM EDTA", "TREATMENT", 143, 152], ["100 mMphenylmethylsulfonyl fluoride", "TREATMENT", 154, 189], ["1 M dithiothreitol", "TREATMENT", 191, 209], ["aprotinin", "TREATMENT", 223, 232], ["protein extraction", "TREATMENT", 248, 266]]], ["Protein concentrations were determined using the bicinchoninic acid (BCA) assay.", [["bicinchoninic acid", "CHEMICAL", 49, 67], ["BCA", "CHEMICAL", 69, 72], ["bicinchoninic acid", "CHEMICAL", 49, 67], ["BCA", "CHEMICAL", 69, 72], ["bicinchoninic acid", "SIMPLE_CHEMICAL", 49, 67], ["BCA", "SIMPLE_CHEMICAL", 69, 72], ["Protein concentrations", "TEST", 0, 22], ["the bicinchoninic acid (BCA", "TREATMENT", 45, 72]]], ["Protein samples (10 \u03bcl/lane) were separated by 10% SDS-PAGE and transferred to PVDF membranes by wet transfer.", [["samples", "ANATOMY", 8, 15], ["PVDF membranes", "ANATOMY", 79, 93], ["SDS", "CHEMICAL", 51, 54], ["PVDF", "CHEMICAL", 79, 83], ["membranes", "CELLULAR_COMPONENT", 84, 93], ["Protein samples", "TEST", 0, 15]]], ["Blots were blocked in Tris-buffered saline containing Tween-20 (TBST) containing 5% nonfat milk at room temperature for 2 h and incubated with primary antibodies (anti-CDK2(sc-6248, santacruz),1:300;anti-CCSP1(07-623,millipore),1:500; anti-PLA2(sc-58,363,santacruz),1:500; anti-\u03b2 actin(sc-130,301,santacruz),1:800; anti-C/EBP \u03b2(ab32358,Abcam),1:400;anti-phosphorylation-C/EBP \u03b2(ab52194,Abcam),1:400) at 4\u00b0C overnight.", [["milk", "ANATOMY", 91, 95], ["Tween-20", "CHEMICAL", 54, 62], ["santacruz", "CHEMICAL", 182, 191], ["Tris", "CHEMICAL", 22, 26], ["Tween-20", "CHEMICAL", 54, 62], ["Tris-buffered saline", "SIMPLE_CHEMICAL", 22, 42], ["Tween-20", "SIMPLE_CHEMICAL", 54, 62], ["milk", "ORGANISM_SUBSTANCE", 91, 95], ["CDK2", "GENE_OR_GENE_PRODUCT", 168, 172], ["sc-6248", "SIMPLE_CHEMICAL", 173, 180], ["santacruz", "SIMPLE_CHEMICAL", 182, 191], ["millipore", "SIMPLE_CHEMICAL", 217, 226], ["anti-PLA2", "SIMPLE_CHEMICAL", 235, 244], ["sc-58,363", "SIMPLE_CHEMICAL", 245, 254], ["santacruz", "SIMPLE_CHEMICAL", 255, 264], ["1:", "SIMPLE_CHEMICAL", 266, 268], ["anti-\u03b2 actin", "SIMPLE_CHEMICAL", 273, 285], ["sc-130,301", "SIMPLE_CHEMICAL", 286, 296], ["santacruz", "SIMPLE_CHEMICAL", 297, 306], ["anti-C/EBP \u03b2", "SIMPLE_CHEMICAL", 315, 327], ["Abcam", "GENE_OR_GENE_PRODUCT", 336, 341], ["primary antibodies", "PROTEIN", 143, 161], ["CDK2", "PROTEIN", 168, 172], ["actin", "PROTEIN", 280, 285], ["EBP \u03b2", "PROTEIN", 322, 327], ["Abcam", "PROTEIN", 336, 341], ["anti-phosphorylation-C", "PROTEIN", 349, 371], ["EBP \u03b2", "PROTEIN", 372, 377], ["Blots", "TEST", 0, 5], ["Tris", "TREATMENT", 22, 26], ["buffered saline containing Tween", "TREATMENT", 27, 59], ["primary antibodies", "TEST", 143, 161], ["anti-PLA2", "TEST", 235, 244], ["anti-C/EBP", "TEST", 315, 325], ["ab", "TEST", 328, 330], ["Abcam", "TEST", 336, 341], ["anti", "TEST", 349, 353], ["Abcam", "TEST", 386, 391]]], ["The membranes were then rinsed with TBST and incubated with secondary antibodies for 2 h.", [["membranes", "ANATOMY", 4, 13], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["secondary antibodies", "PROTEIN", 60, 80], ["TBST", "TREATMENT", 36, 40], ["secondary antibodies", "TREATMENT", 60, 80]]], ["Enhanced chemiluminescence (ECL) substrates (Pierce, CA,USA) and Xray film were used to detect the bands, and the relative optical densities were analyzed using image processing software (Daniels et al., 2017) .Evaluation of protein levels by ELISATotal protein was extracted and quantified using the BCA method, and intracellular TNF\u03b1, IL-1\u03b2 and IL-10 were measured using Human TNF\u03b1-ELISA kit, Human IL-1\u03b2-ELISA kit and Human IL-10 ELISA kit (Invitrogen).Experiments for the PAF and AA level were performed using the Human arachidonic acid (AA) ELISA Kit (MBS703581, Cayman) and Human Platelet Activating Factor (PAF) ELISA Kit (MBS701223) according to the manufacturer's instructions.", [["intracellular", "ANATOMY", 317, 330], ["PAF", "CHEMICAL", 476, 479], ["AA", "CHEMICAL", 484, 486], ["arachidonic acid", "CHEMICAL", 524, 540], ["AA", "CHEMICAL", 542, 544], ["arachidonic acid", "CHEMICAL", 524, 540], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 317, 330], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 331, 335], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 337, 342], ["IL-10", "GENE_OR_GENE_PRODUCT", 347, 352], ["Human", "ORGANISM", 373, 378], ["TNF\u03b1-", "GENE_OR_GENE_PRODUCT", 379, 384], ["Human", "ORGANISM", 395, 400], ["IL-1\u03b2-", "GENE_OR_GENE_PRODUCT", 401, 407], ["Human", "ORGANISM", 421, 426], ["IL-10", "GENE_OR_GENE_PRODUCT", 427, 432], ["PAF", "SIMPLE_CHEMICAL", 476, 479], ["AA", "SIMPLE_CHEMICAL", 484, 486], ["Human", "ORGANISM", 518, 523], ["arachidonic acid", "SIMPLE_CHEMICAL", 524, 540], ["AA", "SIMPLE_CHEMICAL", 542, 544], ["MBS703581", "SIMPLE_CHEMICAL", 557, 566], ["Cayman", "SIMPLE_CHEMICAL", 568, 574], ["Human", "ORGANISM", 580, 585], ["Platelet Activating Factor", "GENE_OR_GENE_PRODUCT", 586, 612], ["ELISATotal protein", "PROTEIN", 243, 261], ["TNF\u03b1", "PROTEIN", 331, 335], ["IL-1\u03b2", "PROTEIN", 337, 342], ["TNF", "PROTEIN", 379, 382], ["Human IL-1\u03b2-ELISA kit", "PROTEIN", 395, 416], ["PAF", "PROTEIN", 476, 479], ["Human Platelet Activating Factor", "PROTEIN", 580, 612], ["PAF", "PROTEIN", 614, 617], ["Human", "SPECIES", 373, 378], ["Human", "SPECIES", 395, 400], ["Human", "SPECIES", 421, 426], ["Human", "SPECIES", 518, 523], ["Human", "SPECIES", 580, 585], ["Human", "SPECIES", 373, 378], ["Human", "SPECIES", 395, 400], ["Human", "SPECIES", 421, 426], ["Enhanced chemiluminescence", "TEST", 0, 26], ["Xray film", "TEST", 65, 74], ["the bands", "PROBLEM", 95, 104], ["Evaluation of protein levels", "TEST", 211, 239], ["ELISATotal protein", "TEST", 243, 261], ["the BCA method", "TEST", 297, 311], ["intracellular TNF", "TEST", 317, 334], ["IL", "TEST", 337, 339], ["IL", "TEST", 347, 349], ["Human IL", "TREATMENT", 395, 403], ["Human IL", "TREATMENT", 421, 429], ["the PAF", "PROBLEM", 472, 479], ["AA level", "TEST", 484, 492], ["the Human arachidonic acid", "TREATMENT", 514, 540], ["ELISA Kit", "TEST", 546, 555], ["Cayman", "TEST", 568, 574], ["Human Platelet Activating Factor (PAF", "TREATMENT", 580, 617]]], ["After the experiments, the value data of PAF and AA were calculated according to the A450.Statistical analysesAll data is expressed as mean \u00b1 SD, and analyzed by one way ANOVA.", [["PAF", "CHEMICAL", 41, 44], ["AA", "CHEMICAL", 49, 51], ["PAF", "SIMPLE_CHEMICAL", 41, 44], ["AA", "SIMPLE_CHEMICAL", 49, 51], ["PAF", "PROTEIN", 41, 44], ["the value data", "TEST", 23, 37], ["PAF", "PROBLEM", 41, 44], ["AA", "TEST", 49, 51], ["Statistical analyses", "TEST", 90, 110]]], ["Least Significant Difference (LSD) was used for multiple comparisons between any two means.", [["Significant", "OBSERVATION_MODIFIER", 6, 17], ["Difference", "OBSERVATION_MODIFIER", 18, 28]]], ["P-values < 0.05 were considered statistically significant.", [["P-values", "TEST", 0, 8]]], ["All statistical analysis was performed using SPSS 13.0 software.Lentiviral infection of BEAS-2B cells and determination of gene intervention efficiencyHighly efficient gene delivery is essential for effective interference.", [["BEAS-2B cells", "ANATOMY", 88, 101], ["infection", "DISEASE", 75, 84], ["Lentiviral", "ORGANISM", 64, 74], ["BEAS-2B cells", "CELL", 88, 101], ["BEAS-2B cells", "CELL_LINE", 88, 101], ["Lentiviral", "SPECIES", 64, 74], ["All statistical analysis", "TEST", 0, 24], ["SPSS", "TEST", 45, 49], ["Lentiviral infection of BEAS", "PROBLEM", 64, 92], ["2B cells", "PROBLEM", 93, 101], ["gene intervention efficiency", "TREATMENT", 123, 151], ["Highly efficient gene delivery", "TREATMENT", 151, 181], ["effective interference", "PROBLEM", 199, 221], ["infection", "OBSERVATION", 75, 84], ["2B cells", "OBSERVATION", 93, 101]]], ["We resolved the difficulty of transfecting BEAS-2B cells by using routine approaches with a lentiviral system (Fig. 1A) , resulting in GFP expression in more than 90% of cells.", [["BEAS-2B cells", "ANATOMY", 43, 56], ["cells", "ANATOMY", 170, 175], ["BEAS-2B cells", "CELL", 43, 56], ["GFP", "GENE_OR_GENE_PRODUCT", 135, 138], ["cells", "CELL", 170, 175], ["BEAS-2B cells", "CELL_LINE", 43, 56], ["GFP", "PROTEIN", 135, 138], ["a lentiviral system", "TREATMENT", 90, 109], ["GFP expression", "TEST", 135, 149], ["GFP expression", "OBSERVATION", 135, 149]]], ["The lentiviral approach produced good results for overexpression and knockdown of CDK2, C/EBP \u03b2 and CCSP1 in BEAS-2B cells: western blotting results show that the expression levels of CDK2, C/EBP \u03b2 and CCSP1 in the overexpression groups were 3.69 \u00b1 0.06, 4.18 \u00b1 0.04 and 3.06 \u00b1 0.07 times as high as that of the control groups respectively (Fig. 1B) , and CDK2, C/ EBP \u03b2 and CCSP1 in the knockdown groups were 0.12 \u00b1 0.01, 0.28 \u00b1 0.02 and 0.20 \u00b1 0.01 times as high as that of the control groups respectively (Fig. 1B) , with significant differences between the genetic intervention groups and the cell groups (P < 0.05); no significant differences were observed in CDK2, C/EBP \u03b2 and CCSP1 expression levels between the Lv-NC or Lv-control groups and the control groups (P > 0.05).", [["BEAS-2B cells", "ANATOMY", 109, 122], ["cell", "ANATOMY", 597, 601], ["Lv-NC", "ANATOMY", 719, 724], ["lentiviral", "ORGANISM", 4, 14], ["CDK2", "GENE_OR_GENE_PRODUCT", 82, 86], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 88, 95], ["CCSP1", "GENE_OR_GENE_PRODUCT", 100, 105], ["BEAS-2B cells", "CELL", 109, 122], ["CDK2", "GENE_OR_GENE_PRODUCT", 184, 188], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 190, 197], ["CCSP1", "GENE_OR_GENE_PRODUCT", 202, 207], ["CDK2", "GENE_OR_GENE_PRODUCT", 356, 360], ["C/ EBP \u03b2", "GENE_OR_GENE_PRODUCT", 362, 370], ["CCSP1", "GENE_OR_GENE_PRODUCT", 375, 380], ["cell", "CELL", 597, 601], ["CDK2", "GENE_OR_GENE_PRODUCT", 665, 669], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 671, 678], ["CCSP1", "GENE_OR_GENE_PRODUCT", 683, 688], ["CDK2", "PROTEIN", 82, 86], ["C/EBP \u03b2", "PROTEIN", 88, 95], ["CCSP1", "PROTEIN", 100, 105], ["BEAS-2B cells", "CELL_LINE", 109, 122], ["CDK2", "PROTEIN", 184, 188], ["C/EBP \u03b2", "PROTEIN", 190, 197], ["CCSP1", "PROTEIN", 202, 207], ["CDK2", "PROTEIN", 356, 360], ["C/ EBP \u03b2", "PROTEIN", 362, 370], ["CCSP1", "PROTEIN", 375, 380], ["CDK2", "PROTEIN", 665, 669], ["CCSP1", "PROTEIN", 683, 688], ["The lentiviral approach", "TREATMENT", 0, 23], ["CDK2", "TEST", 82, 86], ["C/EBP", "TEST", 88, 93], ["CCSP1", "TEST", 100, 105], ["BEAS", "TEST", 109, 113], ["western blotting", "TEST", 124, 140], ["CDK2", "TEST", 184, 188], ["C", "TEST", 190, 191], ["EBP", "TEST", 192, 195], ["CCSP1", "TEST", 202, 207], ["CDK2", "TEST", 356, 360], ["C", "TEST", 362, 363], ["EBP", "TEST", 365, 368], ["CCSP1", "TEST", 375, 380], ["the cell groups", "TEST", 593, 608], ["significant differences", "PROBLEM", 624, 647], ["CDK2", "TEST", 665, 669], ["C/EBP", "TEST", 671, 676], ["CCSP1 expression levels", "PROBLEM", 683, 706], ["Lv-control groups", "TREATMENT", 728, 745], ["2B cells", "OBSERVATION", 114, 122], ["significant", "OBSERVATION_MODIFIER", 525, 536]]], ["These data suggest that the lentiviral approach we used effectively expressed or knocked down CDK2, C/EBP \u03b2 and CCSP1 genes, and the viral system and hairpin structure themselves had little effect on these genes.Establishment of in intro ALI model and measurement of relevant proteinsWe employed LPS to induce BEAS-2B cells to develop an in vitro ALI model, and examined TNF\u03b1, IL-1\u03b2, and IL-10, as well as PAF and AA, in the cells to determine whether the model was established.", [["BEAS-2B cells", "ANATOMY", 310, 323], ["cells", "ANATOMY", 425, 430], ["LPS", "CHEMICAL", 296, 299], ["ALI", "DISEASE", 347, 350], ["PAF", "CHEMICAL", 406, 409], ["AA", "CHEMICAL", 414, 416], ["lentiviral", "ORGANISM", 28, 38], ["CDK2", "GENE_OR_GENE_PRODUCT", 94, 98], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 100, 107], ["CCSP1", "GENE_OR_GENE_PRODUCT", 112, 117], ["LPS", "SIMPLE_CHEMICAL", 296, 299], ["BEAS-2B cells", "CELL", 310, 323], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 371, 375], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 377, 382], ["IL-10", "GENE_OR_GENE_PRODUCT", 388, 393], ["PAF", "SIMPLE_CHEMICAL", 406, 409], ["AA", "SIMPLE_CHEMICAL", 414, 416], ["cells", "CELL", 425, 430], ["CDK2, C/EBP \u03b2 and CCSP1 genes", "DNA", 94, 123], ["BEAS-2B cells", "CELL_LINE", 310, 323], ["TNF\u03b1", "PROTEIN", 371, 375], ["IL-1\u03b2", "PROTEIN", 377, 382], ["IL", "PROTEIN", 388, 390], ["PAF", "PROTEIN", 406, 409], ["the lentiviral approach", "TREATMENT", 24, 47], ["CDK2", "TEST", 94, 98], ["C/EBP", "TEST", 100, 105], ["CCSP1 genes", "PROBLEM", 112, 123], ["the viral system and hairpin structure themselves", "PROBLEM", 129, 178], ["intro ALI model", "TREATMENT", 232, 247], ["relevant proteins", "PROBLEM", 267, 284], ["LPS", "TREATMENT", 296, 299], ["BEAS", "TEST", 310, 314], ["2B cells", "PROBLEM", 315, 323], ["an in vitro ALI model", "TEST", 335, 356], ["TNF", "TEST", 371, 374], ["IL", "TEST", 377, 379], ["IL", "TEST", 388, 390], ["PAF", "PROBLEM", 406, 409], ["AA", "TREATMENT", 414, 416], ["hairpin structure", "OBSERVATION", 150, 167]]], ["ELISA results ( Fig. 2A) show that TNF\u03b1, IL-1\u03b2, and IL-10 were increased in BEAS-2B cells induced with LPS for 12 h, 24 h or 48 h, with significant difference in the three inflammatory factors between the LPS group and the cell group at 24 and 48 h (P < 0.05).", [["BEAS-2B cells", "ANATOMY", 76, 89], ["cell", "ANATOMY", 223, 227], ["LPS", "CHEMICAL", 103, 106], ["LPS", "CHEMICAL", 205, 208], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 35, 39], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 41, 46], ["IL-10", "GENE_OR_GENE_PRODUCT", 52, 57], ["BEAS-2B cells", "CELL", 76, 89], ["LPS", "SIMPLE_CHEMICAL", 103, 106], ["LPS", "SIMPLE_CHEMICAL", 205, 208], ["cell", "CELL", 223, 227], ["TNF\u03b1", "PROTEIN", 35, 39], ["BEAS-2B cells", "CELL_LINE", 76, 89], ["inflammatory factors", "PROTEIN", 172, 192], ["ELISA results", "TEST", 0, 13], ["TNF\u03b1", "TEST", 35, 39], ["IL", "TEST", 41, 43], ["IL", "TEST", 52, 54], ["BEAS", "TEST", 76, 80], ["LPS", "TEST", 103, 106], ["significant difference", "PROBLEM", 136, 158], ["the three inflammatory factors", "PROBLEM", 162, 192], ["significant", "OBSERVATION_MODIFIER", 136, 147], ["difference", "OBSERVATION", 148, 158], ["inflammatory", "OBSERVATION_MODIFIER", 172, 184]]], ["Measurements of PAF and AA demonstrate that induction of 10 mg/ml LPS for 12, 24, or 48 h increased PAF and AA, both of which peaked at 48 h.", [["PAF", "CHEMICAL", 16, 19], ["AA", "CHEMICAL", 24, 26], ["LPS", "CHEMICAL", 66, 69], ["PAF", "CHEMICAL", 100, 103], ["AA", "CHEMICAL", 108, 110], ["PAF", "SIMPLE_CHEMICAL", 16, 19], ["AA", "SIMPLE_CHEMICAL", 24, 26], ["LPS", "SIMPLE_CHEMICAL", 66, 69], ["PAF", "SIMPLE_CHEMICAL", 100, 103], ["AA", "SIMPLE_CHEMICAL", 108, 110], ["PAF", "PROTEIN", 16, 19], ["PAF", "PROTEIN", 100, 103], ["PAF", "PROBLEM", 16, 19], ["increased PAF", "PROBLEM", 90, 103], ["AA", "TEST", 108, 110], ["PAF", "OBSERVATION", 16, 19], ["increased", "OBSERVATION_MODIFIER", 90, 99], ["PAF", "OBSERVATION", 100, 103]]], ["The inflammatory indicators and membrane metabolic indices suggested that BEAS-2B cells displayed an obvious inflammatory response after being induced by 10 mg/ml LPS and released PAF and AA, indicating the successful establishment of the in-vitro ALI model.", [["membrane", "ANATOMY", 32, 40], ["BEAS-2B cells", "ANATOMY", 74, 87], ["LPS", "CHEMICAL", 163, 166], ["PAF", "CHEMICAL", 180, 183], ["AA", "CHEMICAL", 188, 190], ["ALI", "DISEASE", 248, 251], ["membrane", "CELLULAR_COMPONENT", 32, 40], ["BEAS-2B cells", "CELL", 74, 87], ["LPS", "SIMPLE_CHEMICAL", 163, 166], ["PAF", "SIMPLE_CHEMICAL", 180, 183], ["AA", "SIMPLE_CHEMICAL", 188, 190], ["BEAS-2B cells", "CELL_LINE", 74, 87], ["PAF", "PROTEIN", 180, 183], ["The inflammatory indicators", "TEST", 0, 27], ["membrane metabolic indices", "TEST", 32, 58], ["BEAS", "TEST", 74, 78], ["2B cells", "PROBLEM", 79, 87], ["inflammatory response", "PROBLEM", 109, 130], ["LPS", "TREATMENT", 163, 166], ["PAF", "PROBLEM", 180, 183], ["the in-vitro ALI model", "TREATMENT", 235, 257], ["inflammatory", "OBSERVATION_MODIFIER", 4, 16], ["2B cells", "OBSERVATION", 79, 87], ["obvious", "OBSERVATION_MODIFIER", 101, 108], ["inflammatory", "OBSERVATION", 109, 121]]], ["Based on the model, we assessed CDK2, CCSP1 and PLA2 levels and C/EBP \u03b2 phosphorylation in the cells (Fig. 2C) , and found the expression of CDK2 and CCSP1 and C/EBP \u03b2 phosphorylation displayed similar changes-a decrease after treatment of LPS, with significant differences between the LPS treated groups and the cell groups (P < 0.05); PLA2 was increased by LPS treatment, significant difference found at 24 and 48 h (P < 0.05).", [["cells", "ANATOMY", 95, 100], ["cell", "ANATOMY", 313, 317], ["LPS", "CHEMICAL", 240, 243], ["LPS", "CHEMICAL", 286, 289], ["LPS", "CHEMICAL", 359, 362], ["CDK2", "GENE_OR_GENE_PRODUCT", 32, 36], ["CCSP1", "GENE_OR_GENE_PRODUCT", 38, 43], ["PLA2", "GENE_OR_GENE_PRODUCT", 48, 52], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 64, 71], ["cells", "CELL", 95, 100], ["Fig. 2C", "CELL", 102, 109], ["CDK2", "GENE_OR_GENE_PRODUCT", 141, 145], ["CCSP1", "GENE_OR_GENE_PRODUCT", 150, 155], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 160, 167], ["LPS", "SIMPLE_CHEMICAL", 240, 243], ["LPS", "SIMPLE_CHEMICAL", 286, 289], ["cell", "CELL", 313, 317], ["PLA2", "GENE_OR_GENE_PRODUCT", 337, 341], ["LPS", "SIMPLE_CHEMICAL", 359, 362], ["CDK2", "PROTEIN", 32, 36], ["CCSP1", "PROTEIN", 38, 43], ["PLA2", "PROTEIN", 48, 52], ["EBP \u03b2", "PROTEIN", 66, 71], ["CDK2", "PROTEIN", 141, 145], ["CCSP1", "PROTEIN", 150, 155], ["EBP \u03b2", "PROTEIN", 162, 167], ["PLA2", "PROTEIN", 337, 341], ["CDK2", "TEST", 32, 36], ["CCSP1", "TEST", 38, 43], ["PLA2 levels", "TEST", 48, 59], ["C/EBP", "TEST", 64, 69], ["CDK2", "TEST", 141, 145], ["CCSP1", "TEST", 150, 155], ["C/EBP \u03b2 phosphorylation", "TEST", 160, 183], ["LPS", "PROBLEM", 240, 243], ["the LPS treated groups", "TREATMENT", 282, 304], ["the cell groups", "TEST", 309, 324], ["PLA2", "TEST", 337, 341], ["LPS treatment", "TREATMENT", 359, 372], ["CDK2", "OBSERVATION", 141, 145], ["decrease", "OBSERVATION_MODIFIER", 212, 220], ["significant", "OBSERVATION_MODIFIER", 250, 261], ["significant", "OBSERVATION_MODIFIER", 374, 385]]], ["Analyzing the change of four proteins in different groups, we found that in the ALI model, CDK2, CCSP1 and phosphorylation of C/EBP \u03b2 were decreased, with obvious correlation between each other.", [["ALI", "DISEASE", 80, 83], ["CDK2", "GENE_OR_GENE_PRODUCT", 91, 95], ["CCSP1", "GENE_OR_GENE_PRODUCT", 97, 102], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 126, 133], ["CDK2", "PROTEIN", 91, 95], ["CCSP1", "PROTEIN", 97, 102], ["C/EBP \u03b2", "PROTEIN", 126, 133], ["the ALI model", "TEST", 76, 89], ["CDK2", "TEST", 91, 95], ["CCSP1", "TEST", 97, 102], ["phosphorylation of C/EBP", "TEST", 107, 131], ["change", "OBSERVATION_MODIFIER", 14, 20], ["four proteins", "OBSERVATION_MODIFIER", 24, 37], ["ALI", "ANATOMY", 80, 83]]], ["In addition, the expression of PLA2 was significantly increased in the ALI model, which was negatively correlated with the expression of CDK2 and CCSP1, and the phosphorylation of C/EBP \u03b2.These findings hinted that the increase in the expression of CDK2, and CCSP1, and the phosphorylation of C/EBP \u03b2, and the decrease in PLA2 may have a positive impact on ALI.Overexpression and knockdown of CDK2 and CCSP1 and their effects on C/EBP \u03b2 phosphorylationXi Le et al. reported that CDK2 can phosphorylate C/EBP \u03b2 through Thr188 (Xi Li et al., 2007) , so in the study, we used CDK2 to regulate the phosphorylation and dephosphorylation of C/EBP \u03b2 by overexpressing and knocking down CDK2 in BEAS-2B cells.", [["BEAS-2B cells", "ANATOMY", 687, 700], ["ALI", "DISEASE", 71, 74], ["ALI", "DISEASE", 357, 360], ["Thr188", "CHEMICAL", 518, 524], ["Thr", "CHEMICAL", 518, 521], ["PLA2", "GENE_OR_GENE_PRODUCT", 31, 35], ["CDK2", "GENE_OR_GENE_PRODUCT", 137, 141], ["CCSP1", "GENE_OR_GENE_PRODUCT", 146, 151], ["C/EBP", "GENE_OR_GENE_PRODUCT", 180, 185], ["CDK2", "GENE_OR_GENE_PRODUCT", 249, 253], ["CCSP1", "GENE_OR_GENE_PRODUCT", 259, 264], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 293, 300], ["PLA2", "GENE_OR_GENE_PRODUCT", 322, 326], ["CDK2", "GENE_OR_GENE_PRODUCT", 393, 397], ["CCSP1", "GENE_OR_GENE_PRODUCT", 402, 407], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 429, 436], ["CDK2", "GENE_OR_GENE_PRODUCT", 479, 483], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 502, 509], ["Thr188", "AMINO_ACID", 518, 524], ["CDK2", "GENE_OR_GENE_PRODUCT", 573, 577], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 635, 642], ["CDK2", "GENE_OR_GENE_PRODUCT", 679, 683], ["BEAS-2B cells", "CELL", 687, 700], ["PLA2", "PROTEIN", 31, 35], ["CDK2", "PROTEIN", 137, 141], ["CCSP1", "PROTEIN", 146, 151], ["EBP", "PROTEIN", 182, 185], ["CDK2", "PROTEIN", 249, 253], ["CCSP1", "PROTEIN", 259, 264], ["C/EBP \u03b2", "PROTEIN", 293, 300], ["PLA2", "PROTEIN", 322, 326], ["CDK2", "PROTEIN", 393, 397], ["CCSP1", "PROTEIN", 402, 407], ["C/EBP \u03b2", "PROTEIN", 429, 436], ["CDK2", "PROTEIN", 479, 483], ["C/EBP \u03b2", "PROTEIN", 502, 509], ["CDK2", "PROTEIN", 573, 577], ["C/EBP \u03b2", "PROTEIN", 635, 642], ["CDK2", "PROTEIN", 679, 683], ["BEAS-2B cells", "CELL_LINE", 687, 700], ["PLA2", "TEST", 31, 35], ["the ALI model", "TEST", 67, 80], ["CDK2", "TEST", 137, 141], ["CCSP1", "TEST", 146, 151], ["the phosphorylation of C/EBP", "PROBLEM", 157, 185], ["CDK2", "TEST", 249, 253], ["CCSP1", "TEST", 259, 264], ["the phosphorylation of C/EBP", "PROBLEM", 270, 298], ["the decrease in PLA2", "PROBLEM", 306, 326], ["ALI", "PROBLEM", 357, 360], ["CDK2", "PROBLEM", 393, 397], ["CCSP1", "TEST", 402, 407], ["C/EBP", "TREATMENT", 429, 434], ["phosphorylationXi", "TREATMENT", 437, 454], ["phosphorylate C", "TEST", 488, 503], ["EBP", "TEST", 504, 507], ["Thr", "TEST", 518, 521], ["the study", "TEST", 554, 563], ["CDK2", "TREATMENT", 573, 577], ["the phosphorylation", "TREATMENT", 590, 609], ["dephosphorylation of C/EBP", "TREATMENT", 614, 640], ["knocking down CDK2", "PROBLEM", 665, 683], ["BEAS", "TEST", 687, 691], ["increased", "OBSERVATION_MODIFIER", 54, 63], ["ALI model", "OBSERVATION", 71, 80], ["increase", "OBSERVATION_MODIFIER", 219, 227], ["CDK2", "OBSERVATION", 249, 253], ["decrease", "OBSERVATION_MODIFIER", 310, 318], ["positive", "OBSERVATION_MODIFIER", 338, 346], ["impact", "OBSERVATION_MODIFIER", 347, 353], ["ALI", "OBSERVATION", 357, 360], ["CDK2", "OBSERVATION", 393, 397], ["et al", "OBSERVATION", 458, 463], ["2B cells", "OBSERVATION", 692, 700]]], ["At the same time, we also overexpressed and depleted CCSP1 to observe the effect on C/EBP \u03b2 phosphorylation, which would help us to ascertain the relation between C/EBP \u03b2 and CCSP1.", [["CCSP1", "GENE_OR_GENE_PRODUCT", 53, 58], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 84, 91], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 163, 170], ["CCSP1", "GENE_OR_GENE_PRODUCT", 175, 180], ["CCSP1", "PROTEIN", 53, 58], ["EBP \u03b2", "PROTEIN", 86, 91], ["C/EBP \u03b2", "PROTEIN", 163, 170], ["CCSP1", "PROTEIN", 175, 180], ["C/EBP \u03b2 phosphorylation", "TREATMENT", 84, 107], ["C/EBP", "TEST", 163, 168], ["CCSP1", "TEST", 175, 180], ["depleted", "OBSERVATION", 44, 52]]], ["The results (Fig. 3) indicate that CDK2 overexpression increased both C/EBP \u03b2 phosphorylation and C-CSP1 expression (P < 0.05 vs cell control) while CDK2 knockdown suppressed both C/EBP \u03b2 phosphorylation and CCSP1 expression (P < 0.05 vs cell control).", [["cell", "ANATOMY", 129, 133], ["cell", "ANATOMY", 238, 242], ["CDK2", "GENE_OR_GENE_PRODUCT", 35, 39], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 70, 77], ["C-CSP1", "GENE_OR_GENE_PRODUCT", 98, 104], ["cell", "CELL", 129, 133], ["CDK2", "GENE_OR_GENE_PRODUCT", 149, 153], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 180, 187], ["CCSP1", "GENE_OR_GENE_PRODUCT", 208, 213], ["cell", "CELL", 238, 242], ["CDK2", "PROTEIN", 35, 39], ["EBP \u03b2", "PROTEIN", 72, 77], ["CSP1", "PROTEIN", 100, 104], ["CDK2", "PROTEIN", 149, 153], ["CCSP1", "PROTEIN", 208, 213], ["CDK2 overexpression", "PROBLEM", 35, 54], ["EBP", "TEST", 72, 75], ["phosphorylation", "TEST", 78, 93], ["C", "TEST", 98, 99], ["P", "TEST", 117, 118], ["cell control", "TEST", 129, 141], ["CDK2 knockdown", "TEST", 149, 163], ["C/EBP", "TEST", 180, 185], ["phosphorylation", "TEST", 188, 203], ["CCSP1 expression", "TEST", 208, 224], ["P", "TEST", 226, 227], ["cell control", "TREATMENT", 238, 250]]], ["For C/EBP \u03b2 phosphorylation or CCSP1 expression, there was no significant difference between the Lv-NC group and the control group (P > 0.05).", [["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 4, 11], ["CCSP1", "GENE_OR_GENE_PRODUCT", 31, 36], ["Lv-NC", "CANCER", 97, 102], ["CCSP1", "PROTEIN", 31, 36], ["C/EBP", "TEST", 4, 9], ["no", "UNCERTAINTY", 59, 61], ["significant", "OBSERVATION_MODIFIER", 62, 73], ["difference", "OBSERVATION", 74, 84]]], ["In addition, the overexpression and silencing of CCSP1 had no obvious effect on the expression of CDK2 or the phosphorylation of C/EBP \u03b2 (P > 0.05 vs cell control).", [["cell", "ANATOMY", 150, 154], ["CCSP1", "GENE_OR_GENE_PRODUCT", 49, 54], ["CDK2", "GENE_OR_GENE_PRODUCT", 98, 102], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 129, 136], ["cell", "CELL", 150, 154], ["CCSP1", "PROTEIN", 49, 54], ["CDK2", "PROTEIN", 98, 102], ["C/EBP \u03b2", "PROTEIN", 129, 136], ["the overexpression and silencing of CCSP1", "PROBLEM", 13, 54], ["CDK2", "PROBLEM", 98, 102], ["the phosphorylation of C/EBP", "PROBLEM", 106, 134], ["P", "TEST", 138, 139], ["no obvious", "UNCERTAINTY", 59, 69]]], ["Based on the analysis of these data, we speculated that CDK2 is an upstream mediator of C/EBP \u03b2 and CCSP1 is a downstream element of C/EBP \u03b2.", [["CDK2", "GENE_OR_GENE_PRODUCT", 56, 60], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 88, 95], ["CCSP1", "GENE_OR_GENE_PRODUCT", 100, 105], ["C/EBP", "GENE_OR_GENE_PRODUCT", 133, 138], ["CDK2", "PROTEIN", 56, 60], ["C/EBP \u03b2", "PROTEIN", 88, 95], ["CCSP1", "PROTEIN", 100, 105], ["downstream element", "DNA", 111, 129], ["the analysis", "TEST", 9, 21], ["these data", "TEST", 25, 35], ["CDK2", "PROBLEM", 56, 60], ["C/EBP", "TEST", 88, 93], ["a downstream element of C/EBP", "PROBLEM", 109, 138]]], ["The regulation of C/EBP \u03b2 by CDK2 has been reported, but is it possible for C/EBP \u03b2 to regulate the expression of C-CSP1?", [["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 18, 25], ["CDK2", "GENE_OR_GENE_PRODUCT", 29, 33], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 76, 83], ["C-CSP1", "GENE_OR_GENE_PRODUCT", 114, 120], ["C/EBP \u03b2", "PROTEIN", 18, 25], ["CDK2", "PROTEIN", 29, 33], ["C/EBP \u03b2", "PROTEIN", 76, 83], ["C-CSP1", "PROTEIN", 114, 120], ["C/EBP", "TEST", 18, 23], ["CDK2", "PROBLEM", 29, 33], ["C/EBP", "PROBLEM", 76, 81]]], ["We next investigated the problem by using subsequent experiments.Verification of C/EBP \u03b2 binding site on CCSP1 promoterAccording to the prediction of bioinformatics, we constructed a recombinant lentivirus with the wild CCSP1 promoter, Lv-wPro-CCSP1, and a lentivirus carrying a mutant CCSP1 promoter, Lv-mPro-CCSP1.", [["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 81, 88], ["CCSP1", "GENE_OR_GENE_PRODUCT", 105, 110], ["lentivirus", "ORGANISM", 195, 205], ["CCSP1", "GENE_OR_GENE_PRODUCT", 220, 225], ["Lv-wPro-CCSP1", "GENE_OR_GENE_PRODUCT", 236, 249], ["lentivirus", "ORGANISM", 257, 267], ["CCSP1", "GENE_OR_GENE_PRODUCT", 286, 291], ["Lv-mPro-CCSP1", "GENE_OR_GENE_PRODUCT", 302, 315], ["C/EBP \u03b2 binding site", "DNA", 81, 101], ["CCSP1 promoterAccording", "DNA", 105, 128], ["wild CCSP1 promoter", "DNA", 215, 234], ["Lv-wPro-CCSP1", "DNA", 236, 249], ["mutant CCSP1 promoter", "DNA", 279, 300], ["Lv-mPro-CCSP1", "DNA", 302, 315], ["C/EBP \u03b2 binding site", "PROBLEM", 81, 101], ["CCSP1 promoterAccording", "TREATMENT", 105, 128], ["a recombinant lentivirus", "TREATMENT", 181, 205], ["the wild CCSP1 promoter", "TREATMENT", 211, 234], ["Lv-wPro-CCSP1", "TREATMENT", 236, 249], ["a mutant CCSP1 promoter", "TREATMENT", 277, 300]]], ["We infected BEAS-2B cells with these lentiviruses and overexpressed CDK2, and then qualified CCSP1 mRNA to verify the predicted binding site of C/EBP \u03b2.", [["BEAS-2B cells", "ANATOMY", 12, 25], ["BEAS-2B cells", "CELL", 12, 25], ["lentiviruses", "ORGANISM", 37, 49], ["CDK2", "GENE_OR_GENE_PRODUCT", 68, 72], ["CCSP1", "GENE_OR_GENE_PRODUCT", 93, 98], ["BEAS-2B cells", "CELL_LINE", 12, 25], ["CDK2", "PROTEIN", 68, 72], ["CCSP1 mRNA", "RNA", 93, 103], ["BEAS-2B", "SPECIES", 12, 19], ["these lentiviruses", "PROBLEM", 31, 49], ["overexpressed CDK2", "PROBLEM", 54, 72], ["2B cells", "OBSERVATION", 17, 25], ["lentiviruses", "OBSERVATION", 37, 49], ["CDK2", "OBSERVATION", 68, 72]]], ["The results (Fig. 4A) show that infection of Lv-wPro-CCSP1 or Lv-mPro-CCSP1 increased CCSP1 mRNA (P < 0.05 vs control).", [["infection", "DISEASE", 32, 41], ["Lv-wPro-CCSP1", "GENE_OR_GENE_PRODUCT", 45, 58], ["Lv-mPro-CCSP1", "GENE_OR_GENE_PRODUCT", 62, 75], ["CCSP1", "GENE_OR_GENE_PRODUCT", 86, 91], ["Lv-wPro-CCSP1", "PROTEIN", 45, 58], ["Lv-mPro-CCSP1", "PROTEIN", 62, 75], ["CCSP1 mRNA", "RNA", 86, 96], ["infection of Lv-wPro-CCSP1", "PROBLEM", 32, 58], ["Lv-mPro-CCSP1", "PROBLEM", 62, 75], ["infection", "OBSERVATION", 32, 41]]], ["In comparison with infection of Lv-wPro-CCSP1 alone, co-infection with Lv-CDK2 increased CCSP1 mRNA, and co-infection with Lv-shRNA-CDK2 impaired the increase (P < 0.05).", [["infection", "DISEASE", 19, 28], ["Lv-wPro-CCSP1", "CHEMICAL", 32, 45], ["Lv-wPro-CCSP1", "GENE_OR_GENE_PRODUCT", 32, 45], ["Lv-CDK2", "GENE_OR_GENE_PRODUCT", 71, 78], ["CCSP1", "GENE_OR_GENE_PRODUCT", 89, 94], ["Lv-shRNA-CDK2", "GENE_OR_GENE_PRODUCT", 123, 136], ["Lv-wPro-CCSP1", "PROTEIN", 32, 45], ["Lv-CDK2", "PROTEIN", 71, 78], ["CCSP1 mRNA", "RNA", 89, 99], ["Lv-shRNA-CDK2", "PROTEIN", 123, 136], ["Lv-wPro-CCSP1", "TREATMENT", 32, 45], ["co-infection", "PROBLEM", 53, 65], ["Lv-CDK2 increased CCSP1 mRNA", "PROBLEM", 71, 99], ["co-infection", "PROBLEM", 105, 117], ["Lv-shRNA-CDK2", "PROBLEM", 123, 136], ["co-infection", "OBSERVATION", 53, 65], ["increased", "OBSERVATION_MODIFIER", 79, 88], ["CCSP1 mRNA", "OBSERVATION", 89, 99], ["co-infection", "OBSERVATION", 105, 117], ["increase", "OBSERVATION_MODIFIER", 150, 158]]], ["The co-infection with Lv-CDK2 or Lv-shRNA-CDK2 did not change CCSP1 mRNA in the cells infected with Lv-mPro-CCSP1 (P > 0.05).", [["cells", "ANATOMY", 80, 85], ["Lv-CDK2", "GENE_OR_GENE_PRODUCT", 22, 29], ["Lv-shRNA-CDK2", "GENE_OR_GENE_PRODUCT", 33, 46], ["CCSP1", "GENE_OR_GENE_PRODUCT", 62, 67], ["cells", "CELL", 80, 85], ["Lv-mPro-CCSP1", "GENE_OR_GENE_PRODUCT", 100, 113], ["Lv-CDK2", "PROTEIN", 22, 29], ["Lv-shRNA-CDK2", "PROTEIN", 33, 46], ["CCSP1 mRNA", "RNA", 62, 72], ["Lv-mPro-CCSP1", "PROTEIN", 100, 113], ["The co-infection", "PROBLEM", 0, 16], ["Lv-CDK2", "PROBLEM", 22, 29], ["Lv-shRNA-CDK2", "PROBLEM", 33, 46], ["Lv-mPro-CCSP1", "TEST", 100, 113], ["co-infection", "OBSERVATION", 4, 16], ["cells", "ANATOMY", 80, 85], ["infected", "OBSERVATION_MODIFIER", 86, 94]]], ["All these data suggest that C/EBP \u03b2 regulates the transcription of CCSP1 through the predicted binding site.", [["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 28, 35], ["CCSP1", "GENE_OR_GENE_PRODUCT", 67, 72], ["C/EBP \u03b2", "PROTEIN", 28, 35], ["CCSP1", "PROTEIN", 67, 72], ["predicted binding site", "DNA", 85, 107], ["C/EBP", "TEST", 28, 33], ["binding site", "OBSERVATION", 95, 107]]], ["We further verified the binding by using CHIP-PCR (Fig. 4B ).", [["CHIP", "GENE_OR_GENE_PRODUCT", 41, 45], ["CHIP", "PROTEIN", 41, 45], ["CHIP-PCR", "TEST", 41, 49]]], ["In the BEAS-2B cells infected with Lv-wPro-CCSP1, C/EBP \u03b2 bound to more DNA fragments around the binding site in CCSP1 promoter (P < 0.05 vs Lv-control), and in the cells infected with Lv-mPro-CCSP1, no difference was observed (P > 0.05).", [["BEAS-2B cells", "ANATOMY", 7, 20], ["cells", "ANATOMY", 165, 170], ["BEAS-2B cells", "CELL", 7, 20], ["Lv-wPro-CCSP1", "GENE_OR_GENE_PRODUCT", 35, 48], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 50, 57], ["DNA", "CELLULAR_COMPONENT", 72, 75], ["CCSP1", "GENE_OR_GENE_PRODUCT", 113, 118], ["cells", "CELL", 165, 170], ["Lv-mPro-CCSP1", "GENE_OR_GENE_PRODUCT", 185, 198], ["BEAS-2B cells", "CELL_LINE", 7, 20], ["CCSP1", "PROTEIN", 43, 48], ["C/EBP \u03b2", "PROTEIN", 50, 57], ["DNA fragments", "DNA", 72, 85], ["binding site", "DNA", 97, 109], ["CCSP1 promoter", "DNA", 113, 127], ["Lv-mPro-CCSP1", "PROTEIN", 185, 198], ["BEAS-2B", "SPECIES", 7, 14], ["Lv-wPro-CCSP1", "TEST", 35, 48], ["C/EBP \u03b2 bound", "PROBLEM", 50, 63], ["DNA fragments", "PROBLEM", 72, 85], ["Lv-control", "TEST", 141, 151], ["Lv-mPro-CCSP1", "TEST", 185, 198], ["P", "TEST", 228, 229], ["2B cells", "OBSERVATION", 12, 20], ["infected", "OBSERVATION_MODIFIER", 21, 29], ["DNA fragments", "OBSERVATION", 72, 85], ["binding site", "OBSERVATION", 97, 109], ["cells", "ANATOMY", 165, 170], ["infected", "OBSERVATION", 171, 179], ["no", "UNCERTAINTY", 200, 202]]], ["The luciferase activity assay data (Fig. 4C ) demonstrated that the luciferase activity in the groups transfected with pcDH1-C/EBP \u03b2 alone or pshRNA-C/EBP \u03b2 and pGL3-wPro-CCSP1 was significantly higher or lower than in the group transfected with pGL3-wPro-CCSP1 alone (P < 0.05), but there was no significant difference in luciferase activity between the group transfected with pcDH1-C/EBP \u03b2, or pshRNA-C/EBP \u03b2 and pGL3-mPro-CCSP1, and the group transfected with pGL3-mPro-CCSP1 alone (P > 0.05).", [["luciferase", "GENE_OR_GENE_PRODUCT", 4, 14], ["luciferase", "GENE_OR_GENE_PRODUCT", 68, 78], ["pcDH1-C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 119, 132], ["pshRNA-C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 142, 156], ["pGL3-wPro-CCSP1", "GENE_OR_GENE_PRODUCT", 161, 176], ["pGL3-wPro-CCSP1", "GENE_OR_GENE_PRODUCT", 246, 261], ["luciferase", "GENE_OR_GENE_PRODUCT", 323, 333], ["pcDH1-C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 378, 391], ["pshRNA-C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 396, 410], ["pGL3-mPro-CCSP1", "GENE_OR_GENE_PRODUCT", 415, 430], ["pGL3-mPro-CCSP1", "GENE_OR_GENE_PRODUCT", 463, 478], ["luciferase", "PROTEIN", 4, 14], ["luciferase", "PROTEIN", 68, 78], ["pcDH1", "PROTEIN", 119, 124], ["C/EBP \u03b2", "DNA", 125, 132], ["pshRNA-C/EBP \u03b2", "DNA", 142, 156], ["pGL3", "DNA", 161, 165], ["wPro-CCSP1", "DNA", 166, 176], ["pGL3", "PROTEIN", 246, 250], ["CCSP1", "PROTEIN", 256, 261], ["luciferase", "PROTEIN", 323, 333], ["pcDH1", "PROTEIN", 378, 383], ["C/EBP \u03b2", "DNA", 384, 391], ["pshRNA", "DNA", 396, 402], ["EBP \u03b2", "DNA", 405, 410], ["pGL3", "DNA", 415, 419], ["mPro-CCSP1", "DNA", 420, 430], ["pGL3-mPro-CCSP1", "DNA", 463, 478], ["The luciferase activity assay data", "TEST", 0, 34], ["the luciferase activity", "PROBLEM", 64, 87], ["pcDH1", "TEST", 119, 124], ["EBP", "TEST", 127, 130], ["pshRNA", "TEST", 142, 148], ["EBP", "TEST", 151, 154], ["pGL3", "TEST", 161, 165], ["pGL3", "TEST", 246, 250], ["significant difference in luciferase activity", "PROBLEM", 297, 342], ["pcDH1", "TEST", 378, 383], ["EBP", "TEST", 386, 389], ["pshRNA", "TEST", 396, 402], ["EBP", "TEST", 405, 408], ["pGL3", "TEST", 415, 419], ["CCSP1", "TEST", 425, 430], ["pGL3", "TEST", 463, 467], ["lower", "OBSERVATION_MODIFIER", 205, 210], ["no", "UNCERTAINTY", 294, 296], ["significant", "OBSERVATION_MODIFIER", 297, 308], ["luciferase activity", "OBSERVATION", 323, 342]]], ["No difference was observed in the groups transfected with pshRNA-NC with pGL3-wPro-CCSP1 or pGL3-mPro-CCSP1, compared with the groups transfected with pGL3-wPro-CCSP1 or pGL3-mPro-CCSP1 alone (P > 0.05).Effect of CDK2 on C/EBP \u03b2/CCSP1/PLA2 pathway and effect of C/ EBP \u03b2 phosphorylation on membrane phospholipid damage in the in vitro ALI modelTo verify the critical role of C/EBP \u03b2 phosphorylation in the C/EBP \u03b2/CCSP1/PLA2 pathway and the specificity of the pathway, we overexpressed CDK2 in the in vitro ALI model to phosphorylate C/EBP \u03b2 and then observed the change in PLA2; In addition, we also knocked down C/EBP \u03b2 or CCSP1 in the ALI model with CDK2 overexpression and examined PLA2 protein levels in these groups.", [["membrane", "ANATOMY", 290, 298], ["ALI", "DISEASE", 335, 338], ["ALI", "DISEASE", 638, 641], ["pshRNA-NC", "GENE_OR_GENE_PRODUCT", 58, 67], ["pGL3-wPro-CCSP1", "GENE_OR_GENE_PRODUCT", 73, 88], ["pGL3-mPro-CCSP1", "GENE_OR_GENE_PRODUCT", 92, 107], ["pGL3-wPro-CCSP1", "GENE_OR_GENE_PRODUCT", 151, 166], ["pGL3-mPro-CCSP1", "GENE_OR_GENE_PRODUCT", 170, 185], ["CDK2", "GENE_OR_GENE_PRODUCT", 213, 217], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 221, 228], ["CCSP1", "GENE_OR_GENE_PRODUCT", 229, 234], ["PLA2", "GENE_OR_GENE_PRODUCT", 235, 239], ["C/ EBP \u03b2", "GENE_OR_GENE_PRODUCT", 262, 270], ["membrane phospholipid", "SIMPLE_CHEMICAL", 290, 311], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 375, 382], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 406, 413], ["CCSP1", "GENE_OR_GENE_PRODUCT", 414, 419], ["PLA2", "GENE_OR_GENE_PRODUCT", 420, 424], ["CDK2", "GENE_OR_GENE_PRODUCT", 486, 490], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 534, 541], ["PLA2", "GENE_OR_GENE_PRODUCT", 574, 578], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 614, 621], ["CCSP1", "GENE_OR_GENE_PRODUCT", 625, 630], ["CDK2", "GENE_OR_GENE_PRODUCT", 653, 657], ["PLA2", "GENE_OR_GENE_PRODUCT", 686, 690], ["pshRNA", "PROTEIN", 58, 64], ["pGL3-wPro-CCSP1 or pGL3-mPro-CCSP1", "DNA", 73, 107], ["pGL3-wPro-CCSP1 or pGL3-mPro-CCSP1", "DNA", 151, 185], ["CDK2", "PROTEIN", 213, 217], ["CCSP1", "PROTEIN", 229, 234], ["PLA2", "PROTEIN", 235, 239], ["EBP \u03b2", "PROTEIN", 265, 270], ["EBP \u03b2", "PROTEIN", 377, 382], ["EBP \u03b2", "PROTEIN", 408, 413], ["CCSP1", "PROTEIN", 414, 419], ["PLA2", "PROTEIN", 420, 424], ["CDK2", "PROTEIN", 486, 490], ["C/EBP \u03b2", "PROTEIN", 534, 541], ["PLA2", "PROTEIN", 574, 578], ["C/EBP \u03b2", "PROTEIN", 614, 621], ["CCSP1", "PROTEIN", 625, 630], ["CDK2", "PROTEIN", 653, 657], ["PLA2", "PROTEIN", 686, 690], ["pshRNA", "TEST", 58, 64], ["pGL3", "TEST", 73, 77], ["pGL3", "TEST", 92, 96], ["pGL3", "TEST", 151, 155], ["pGL3", "TEST", 170, 174], ["CDK2", "TEST", 213, 217], ["C", "TEST", 221, 222], ["EBP", "TEST", 223, 226], ["CCSP1", "TEST", 229, 234], ["PLA2 pathway", "TREATMENT", 235, 247], ["C/ EBP", "PROBLEM", 262, 268], ["phosphorylation", "PROBLEM", 271, 286], ["membrane phospholipid damage", "PROBLEM", 290, 318], ["the in vitro ALI model", "TREATMENT", 322, 344], ["C/EBP", "TEST", 375, 380], ["the C/EBP", "TEST", 402, 411], ["phosphorylate C/EBP", "TEST", 520, 539], ["the change in PLA2", "PROBLEM", 560, 578], ["CCSP1", "PROBLEM", 625, 630], ["CDK2 overexpression", "PROBLEM", 653, 672], ["PLA2 protein levels", "TEST", 686, 705], ["difference", "OBSERVATION_MODIFIER", 3, 13], ["ALI model", "OBSERVATION", 335, 344], ["ALI", "ANATOMY", 638, 641], ["CDK2 overexpression", "OBSERVATION", 653, 672]]], ["The results (Fig. 5A) show that CDK2 overexpression attenuated LPS-induced increase of PLA2 protein (P < 0.05 vs LPS group), indicating that overexpression of CDK2, or C/EBP \u03b2 phosphorylation, could significantly inhibit PLA2 expression in the in vitro ALI model.", [["LPS", "CHEMICAL", 63, 66], ["ALI", "DISEASE", 253, 256], ["CDK2", "GENE_OR_GENE_PRODUCT", 32, 36], ["LPS", "SIMPLE_CHEMICAL", 63, 66], ["PLA2", "GENE_OR_GENE_PRODUCT", 87, 91], ["LPS", "SIMPLE_CHEMICAL", 113, 116], ["CDK2", "GENE_OR_GENE_PRODUCT", 159, 163], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 168, 175], ["PLA2", "GENE_OR_GENE_PRODUCT", 221, 225], ["CDK2", "PROTEIN", 32, 36], ["PLA2 protein", "PROTEIN", 87, 99], ["CDK2", "PROTEIN", 159, 163], ["EBP \u03b2", "PROTEIN", 170, 175], ["PLA2", "PROTEIN", 221, 225], ["CDK2 overexpression attenuated LPS", "PROBLEM", 32, 66], ["PLA2 protein", "TEST", 87, 99], ["P", "TEST", 101, 102], ["LPS group", "TEST", 113, 122], ["overexpression of CDK2", "PROBLEM", 141, 163], ["C/EBP \u03b2 phosphorylation", "PROBLEM", 168, 191], ["PLA2 expression", "PROBLEM", 221, 236], ["increase", "OBSERVATION_MODIFIER", 75, 83]]], ["Knockdown of C/EBP \u03b2 or CCSP1 impaired the inhibition of PLA2 expression by CDK2 overexpression (P < 0.05 vs LPS + Lv-CDK2), indicating in the in vitro ALI model, there was a specific C/EBP \u03b2/CCSP1/PLA2 pathway.", [["ALI", "DISEASE", 152, 155], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 13, 20], ["CCSP1", "GENE_OR_GENE_PRODUCT", 24, 29], ["PLA2", "GENE_OR_GENE_PRODUCT", 57, 61], ["CDK2", "GENE_OR_GENE_PRODUCT", 76, 80], ["LPS + Lv-CDK2", "GENE_OR_GENE_PRODUCT", 109, 122], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 184, 191], ["CCSP1", "GENE_OR_GENE_PRODUCT", 192, 197], ["PLA2", "GENE_OR_GENE_PRODUCT", 198, 202], ["C/EBP \u03b2", "PROTEIN", 13, 20], ["CCSP1", "PROTEIN", 24, 29], ["PLA2", "PROTEIN", 57, 61], ["CDK2", "PROTEIN", 76, 80], ["Lv-CDK2", "PROTEIN", 115, 122], ["EBP \u03b2", "PROTEIN", 186, 191], ["CCSP1", "PROTEIN", 192, 197], ["PLA2", "PROTEIN", 198, 202], ["C/EBP", "TEST", 13, 18], ["CCSP1", "PROBLEM", 24, 29], ["PLA2 expression", "PROBLEM", 57, 72], ["CDK2 overexpression", "TEST", 76, 95], ["P", "TEST", 97, 98], ["LPS", "TEST", 109, 112], ["PLA2 pathway", "TREATMENT", 198, 210], ["ALI model", "OBSERVATION", 152, 161]]], ["To illustrate the effect of C/EBP \u03b2 phosphorylation on membrane phospholipid damage in the in vitro ALI model, we treated BEAS-2B cells which overexpressed or were depleted with CDK2 with LPS for 48 h and assessed PAF and AA by ELISA.", [["membrane", "ANATOMY", 55, 63], ["BEAS-2B cells", "ANATOMY", 122, 135], ["ALI", "DISEASE", 100, 103], ["LPS", "CHEMICAL", 188, 191], ["PAF", "CHEMICAL", 214, 217], ["AA", "CHEMICAL", 222, 224], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 28, 35], ["membrane", "CELLULAR_COMPONENT", 55, 63], ["phospholipid", "SIMPLE_CHEMICAL", 64, 76], ["BEAS-2B cells", "CELL", 122, 135], ["CDK2", "GENE_OR_GENE_PRODUCT", 178, 182], ["LPS", "SIMPLE_CHEMICAL", 188, 191], ["PAF", "SIMPLE_CHEMICAL", 214, 217], ["AA", "SIMPLE_CHEMICAL", 222, 224], ["EBP \u03b2", "PROTEIN", 30, 35], ["BEAS-2B cells", "CELL_LINE", 122, 135], ["CDK2", "PROTEIN", 178, 182], ["PAF", "PROTEIN", 214, 217], ["C/EBP \u03b2 phosphorylation", "TREATMENT", 28, 51], ["membrane phospholipid damage", "PROBLEM", 55, 83], ["LPS", "TREATMENT", 188, 191], ["PAF", "PROBLEM", 214, 217], ["membrane phospholipid damage", "OBSERVATION", 55, 83], ["2B cells", "OBSERVATION", 127, 135]]], ["The data (Fig. 5B) show that CDK2 overexpression inhibited the release of PAF and AA induced by LPS (P < 0.05), while the contents of PAF and AA in the group of CDK silencing and LPS induction were slightly higher than that in the LPS group (P > 0.05).", [["PAF", "CHEMICAL", 74, 77], ["AA", "CHEMICAL", 82, 84], ["LPS", "CHEMICAL", 96, 99], ["PAF", "CHEMICAL", 134, 137], ["AA", "CHEMICAL", 142, 144], ["LPS", "CHEMICAL", 179, 182], ["LPS", "CHEMICAL", 231, 234], ["CDK2", "GENE_OR_GENE_PRODUCT", 29, 33], ["PAF", "SIMPLE_CHEMICAL", 74, 77], ["AA", "SIMPLE_CHEMICAL", 82, 84], ["LPS", "SIMPLE_CHEMICAL", 96, 99], ["PAF", "SIMPLE_CHEMICAL", 134, 137], ["AA", "SIMPLE_CHEMICAL", 142, 144], ["CDK", "GENE_OR_GENE_PRODUCT", 161, 164], ["LPS", "SIMPLE_CHEMICAL", 179, 182], ["LPS", "SIMPLE_CHEMICAL", 231, 234], ["CDK2", "PROTEIN", 29, 33], ["PAF", "PROTEIN", 74, 77], ["PAF", "PROTEIN", 134, 137], ["CDK", "PROTEIN", 161, 164], ["The data (Fig. 5B)", "TEST", 0, 18], ["CDK2 overexpression", "PROBLEM", 29, 48], ["PAF", "PROBLEM", 74, 77], ["LPS", "TEST", 96, 99], ["PAF", "PROBLEM", 134, 137], ["AA", "PROBLEM", 142, 144], ["CDK silencing", "TREATMENT", 161, 174], ["LPS induction", "TREATMENT", 179, 192], ["P", "TEST", 242, 243], ["PAF", "OBSERVATION", 74, 77], ["PAF", "OBSERVATION", 134, 137], ["CDK silencing", "OBSERVATION", 161, 174], ["slightly", "OBSERVATION_MODIFIER", 198, 206], ["higher", "OBSERVATION_MODIFIER", 207, 213]]], ["No change in PAF or AA was found in the Lv-NC group (P > 0.05 vs LPS group).", [["Lv-NC", "ANATOMY", 40, 45], ["PAF", "CHEMICAL", 13, 16], ["AA", "CHEMICAL", 20, 22], ["PAF", "SIMPLE_CHEMICAL", 13, 16], ["AA", "SIMPLE_CHEMICAL", 20, 22], ["Lv-NC", "SIMPLE_CHEMICAL", 40, 45], ["PAF", "PROTEIN", 13, 16], ["PAF", "PROBLEM", 13, 16], ["AA", "PROBLEM", 20, 22], ["P", "TEST", 53, 54], ["change", "OBSERVATION_MODIFIER", 3, 9], ["PAF", "OBSERVATION", 13, 16]]], ["In conclusion, we believe that the phosphorylation of C/EBP \u03b2 can promote the transcription of CCSP1 and subsequently inhibit the expression of PLA2 and then resist the disruption of phospholipids caused by ALI.DiscussionC/EBP family members have a basic DNA-binding domain and a leucine zipper domain, which bind to the enhancer 5\u2032-RTTGCGYAAY-3 (\u2032R = A or G, Y]C or T) or variants to positively or negatively regulate transcription, thus playing important roles in energy metabolism, cell growth, differentiation and tumorigenesis, hematogenesis and the immune response (Sayeed et al., 2015; Shimizu et al., 2015) .", [["cell", "ANATOMY", 485, 489], ["ALI", "DISEASE", 207, 210], ["hematogenesis", "DISEASE", 533, 546], ["leucine", "CHEMICAL", 280, 287], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 54, 61], ["CCSP1", "GENE_OR_GENE_PRODUCT", 95, 100], ["PLA2", "GENE_OR_GENE_PRODUCT", 144, 148], ["phospholipids", "SIMPLE_CHEMICAL", 183, 196], ["EBP", "GENE_OR_GENE_PRODUCT", 223, 226], ["DNA", "CELLULAR_COMPONENT", 255, 258], ["RTTGCGYAAY-3", "GENE_OR_GENE_PRODUCT", 333, 345], ["\u2032R = A", "GENE_OR_GENE_PRODUCT", 347, 353], ["G, Y]C", "GENE_OR_GENE_PRODUCT", 357, 363], ["T", "GENE_OR_GENE_PRODUCT", 367, 368], ["cell", "CELL", 485, 489], ["C/EBP \u03b2", "PROTEIN", 54, 61], ["CCSP1", "PROTEIN", 95, 100], ["PLA2", "PROTEIN", 144, 148], ["DiscussionC/EBP family members", "PROTEIN", 211, 241], ["basic DNA-binding domain", "PROTEIN", 249, 273], ["leucine zipper domain", "PROTEIN", 280, 301], ["enhancer 5\u2032-RTTGCGYAAY-3", "DNA", 321, 345], ["the phosphorylation of C/EBP", "PROBLEM", 31, 59], ["CCSP1", "TREATMENT", 95, 100], ["PLA2", "TREATMENT", 144, 148], ["the disruption of phospholipids", "TREATMENT", 165, 196], ["ALI", "PROBLEM", 207, 210], ["a leucine zipper domain", "TREATMENT", 278, 301], ["RTTGCGYAAY", "TEST", 333, 343], ["variants", "PROBLEM", 373, 381], ["tumorigenesis", "PROBLEM", 518, 531], ["hematogenesis", "PROBLEM", 533, 546], ["ALI", "OBSERVATION", 207, 210]]], ["C/EBP \u03b2 expression varies in porcine liver during prenatal and postnatal development and sharply increases after birth, according to Tang et al. (Tang et al., 2015) .", [["liver", "ANATOMY", 37, 42], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 0, 7], ["porcine", "ORGANISM", 29, 36], ["liver", "ORGAN", 37, 42], ["EBP \u03b2", "PROTEIN", 2, 7], ["porcine", "SPECIES", 29, 36], ["porcine", "SPECIES", 29, 36], ["porcine", "ANATOMY_MODIFIER", 29, 36], ["liver", "ANATOMY", 37, 42], ["sharply", "OBSERVATION_MODIFIER", 89, 96], ["increases", "OBSERVATION_MODIFIER", 97, 106]]], ["C/EBP \u03b2 can activate the transcription of the IGF1 gene by A. TNF\u03b1, IL-1\u03b2, and IL-10 in BEAS-2B cells were examined using ELISA 12 h, 24 h or 48 h after treatment of 10 mg/ml LPS.", [["BEAS-2B cells", "ANATOMY", 88, 101], ["LPS", "CHEMICAL", 175, 178], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 0, 7], ["IGF1", "GENE_OR_GENE_PRODUCT", 46, 50], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 62, 66], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 68, 73], ["IL-10", "GENE_OR_GENE_PRODUCT", 79, 84], ["BEAS-2B cells", "CELL", 88, 101], ["LPS", "SIMPLE_CHEMICAL", 175, 178], ["C/EBP \u03b2", "PROTEIN", 0, 7], ["IGF1 gene", "DNA", 46, 55], ["TNF\u03b1", "PROTEIN", 62, 66], ["BEAS-2B cells", "CELL_LINE", 88, 101], ["IL", "TEST", 68, 70], ["IL", "TEST", 79, 81], ["BEAS", "TEST", 88, 92], ["ELISA", "TEST", 122, 127], ["treatment", "TREATMENT", 153, 162]]], ["The vertical coordinate indicates the concentration of target protein, and the horizontal coordinate indicates the experiment group.", [["target protein", "PROTEIN", 55, 69], ["vertical", "OBSERVATION_MODIFIER", 4, 12]]], ["B. PAF and AA contents in BEAS-2B cells were measured using ELISA 12 h, 24 h or 48 h after treatment of 10 mg/ml LPS.", [["BEAS-2B cells", "ANATOMY", 26, 39], ["PAF", "CHEMICAL", 3, 6], ["AA", "CHEMICAL", 11, 13], ["LPS", "CHEMICAL", 113, 116], ["AA", "SIMPLE_CHEMICAL", 11, 13], ["BEAS-2B cells", "CELL", 26, 39], ["LPS", "SIMPLE_CHEMICAL", 113, 116], ["PAF", "PROTEIN", 3, 6], ["BEAS-2B cells", "CELL_LINE", 26, 39], ["B. PAF", "PROBLEM", 0, 6], ["AA contents", "PROBLEM", 11, 22], ["BEAS", "TEST", 26, 30], ["ELISA", "TEST", 60, 65], ["treatment", "TREATMENT", 91, 100], ["PAF", "OBSERVATION", 3, 6], ["AA contents", "OBSERVATION", 11, 22], ["2B cells", "OBSERVATION", 31, 39]]], ["The vertical coordinate indicates the concentration of target protein, and the horizontal coordinate indicates the experiment group.", [["target protein", "PROTEIN", 55, 69], ["vertical", "OBSERVATION_MODIFIER", 4, 12]]], ["C. CDK2, CCSP1 and PLA2 expression levels, as well as C/EBP \u03b2 phosphorylation, were assessed by western blotting 12 h, 24 h or 48 h after treatment of 10 mg/ml LPS.", [["LPS", "CHEMICAL", 160, 163], ["CDK2", "GENE_OR_GENE_PRODUCT", 3, 7], ["CCSP1", "GENE_OR_GENE_PRODUCT", 9, 14], ["PLA2", "GENE_OR_GENE_PRODUCT", 19, 23], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 54, 61], ["LPS", "SIMPLE_CHEMICAL", 160, 163], ["CDK2", "PROTEIN", 3, 7], ["CCSP1", "PROTEIN", 9, 14], ["PLA2", "PROTEIN", 19, 23], ["EBP \u03b2", "PROTEIN", 56, 61], ["C. CDK2", "TEST", 0, 7], ["CCSP1", "TEST", 9, 14], ["PLA2 expression levels", "TEST", 19, 41], ["C/EBP \u03b2 phosphorylation", "TEST", 54, 77], ["treatment", "TREATMENT", 138, 147], ["CDK2", "OBSERVATION", 3, 7]]], ["Lower: image of target blots, upper: analysis on the optical density of three proteins, \u03b2 actin serving as the reference, and for the phosphorylated protein, the total protein of itself serving as the reference.", [["\u03b2 actin", "GENE_OR_GENE_PRODUCT", 88, 95], ["\u03b2 actin", "PROTEIN", 88, 95], ["phosphorylated protein", "PROTEIN", 134, 156], ["target blots", "TEST", 16, 28], ["the phosphorylated protein", "TEST", 130, 156], ["upper", "ANATOMY_MODIFIER", 30, 35]]], ["Data are means \u00b1 SD from at least three separate replicates.*, p < 0.05; **, p < 0.01. vs cell group.Discussionbinding to two sites of the IGF1 gene promoter.", [["cell", "ANATOMY", 90, 94], ["cell", "CELL", 90, 94], ["IGF1", "GENE_OR_GENE_PRODUCT", 139, 143], ["IGF1 gene promoter", "DNA", 139, 157], ["the IGF1 gene promoter", "TREATMENT", 135, 157]]], ["ATP-dependent P2X7 receptor activation is also dependent on the transcriptional regulation of C/EBP \u03b2 (Bilodeau et al., 2015) .", [["ATP", "CHEMICAL", 0, 3], ["ATP", "CHEMICAL", 0, 3], ["ATP", "SIMPLE_CHEMICAL", 0, 3], ["P2X7 receptor", "GENE_OR_GENE_PRODUCT", 14, 27], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 94, 101], ["P2X7 receptor", "PROTEIN", 14, 27], ["C/EBP \u03b2", "PROTEIN", 94, 101], ["ATP", "TEST", 0, 3], ["dependent", "OBSERVATION_MODIFIER", 4, 13], ["P2X7 receptor activation", "OBSERVATION", 14, 38], ["dependent", "OBSERVATION_MODIFIER", 47, 56]]], ["The above studies clearly indicate that C/EBP \u03b2 mainly plays its transcriptional regulatory role as a nuclear transcription factor.DiscussionCassel et al. identified two binding sites for C/EBP\u03b1 and C/EBP\u03b4 in the sequence between \u2212 100 bp and \u221262 bp of the CCSP promoter through which C/EBP\u03b4 and C/EBP\u03b1 enhance CCSP expression via a complex response element in A549 cells which are adenocarcinomic human alveolar basal epithelial cells (Cassel et al., 2000) .", [["nuclear", "ANATOMY", 102, 109], ["A549 cells", "ANATOMY", 361, 371], ["alveolar basal epithelial cells", "ANATOMY", 404, 435], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 40, 47], ["nuclear", "CELLULAR_COMPONENT", 102, 109], ["C/EBP\u03b1", "GENE_OR_GENE_PRODUCT", 188, 194], ["C/EBP\u03b4", "GENE_OR_GENE_PRODUCT", 199, 205], ["CCSP", "GENE_OR_GENE_PRODUCT", 257, 261], ["C/EBP\u03b4", "GENE_OR_GENE_PRODUCT", 285, 291], ["C/EBP\u03b1", "GENE_OR_GENE_PRODUCT", 296, 302], ["CCSP", "GENE_OR_GENE_PRODUCT", 311, 315], ["A549 cells", "CELL", 361, 371], ["human", "ORGANISM", 398, 403], ["alveolar basal epithelial cells", "CELL", 404, 435], ["C/EBP \u03b2", "PROTEIN", 40, 47], ["nuclear transcription factor", "PROTEIN", 102, 130], ["binding sites", "DNA", 170, 183], ["C/EBP\u03b1", "DNA", 188, 194], ["C/EBP\u03b4", "DNA", 199, 205], ["CCSP promoter", "DNA", 257, 270], ["C/EBP\u03b4", "PROTEIN", 285, 291], ["C/EBP\u03b1", "DNA", 296, 302], ["CCSP", "PROTEIN", 311, 315], ["complex response element", "DNA", 333, 357], ["A549 cells", "CELL_LINE", 361, 371], ["adenocarcinomic human alveolar basal epithelial cells", "CELL_TYPE", 382, 435], ["human", "SPECIES", 398, 403], ["human", "SPECIES", 398, 403], ["The above studies", "TEST", 0, 17], ["C/EBP", "TEST", 40, 45], ["two binding sites", "PROBLEM", 166, 183], ["C/EBP", "TEST", 188, 193], ["C/EBP", "PROBLEM", 199, 204], ["bp", "TEST", 236, 238], ["bp", "TEST", 247, 249], ["C/EBP", "TEST", 285, 290], ["C/EBP", "TEST", 296, 301], ["CCSP expression", "PROBLEM", 311, 326], ["a complex response element in A549 cells", "PROBLEM", 331, 371], ["adenocarcinomic human alveolar basal epithelial cells", "PROBLEM", 382, 435], ["binding sites", "OBSERVATION", 170, 183], ["A549 cells", "OBSERVATION", 361, 371], ["alveolar", "ANATOMY_MODIFIER", 404, 412], ["basal", "ANATOMY_MODIFIER", 413, 418], ["epithelial cells", "OBSERVATION", 419, 435]]], ["Massaad et al. (Massaad et al., 2000) suggested that IL-1\u03b2 can enhance the transcription of PLA2 through the promoter (\u2212 1614:+20 nt) by 6-7-fold, and the region (\u2212 210:\u2212176 nt) is crucial to the process.", [["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 53, 58], ["PLA2", "GENE_OR_GENE_PRODUCT", 92, 96], ["IL-1\u03b2", "PROTEIN", 53, 58], ["PLA2", "PROTEIN", 92, 96], ["promoter", "DNA", 109, 117]]], ["C/EBP \u03b2 and C/EBP\u03b4 can bind to this region, indicating that C/EBP may block IL-1\u03b2induced PLA2 transcription.", [["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 0, 7], ["C/EBP\u03b4", "GENE_OR_GENE_PRODUCT", 12, 18], ["C/EBP", "GENE_OR_GENE_PRODUCT", 60, 65], ["IL-1\u03b2induced PLA2", "GENE_OR_GENE_PRODUCT", 76, 93], ["C/EBP \u03b2", "PROTEIN", 0, 7], ["C/EBP\u03b4", "PROTEIN", 12, 18], ["EBP", "PROTEIN", 62, 65], ["PLA2", "PROTEIN", 89, 93], ["C/EBP", "TEST", 0, 5], ["C/EBP", "PROBLEM", 12, 17], ["C/EBP", "PROBLEM", 60, 65], ["block IL", "TREATMENT", 70, 78], ["PLA2 transcription", "TREATMENT", 89, 107]]], ["These studies may suggest that there are some potential relationships between C/EBP and CCSP/PLA2; however, the specific pathway remains unclear.DiscussionThe transcriptional activity of C/EBP \u03b2 depends on its phosphorylation: phosphorylation of specific amino acids allows the protein to be translocated into the nucleus and bind to the promoter of genes regulated by it, so as to regulate the transcription of downstream genes (Zhou et al., 2015) .Therefore, our research objectives are to prevent the damage of membrane by effective intervention in the in vitro ALI model through the C/EBP \u03b2/CCSP1/PLA2 pathway based on C/EBP \u03b2 phosphorylation.", [["nucleus", "ANATOMY", 314, 321], ["membrane", "ANATOMY", 514, 522], ["amino acids", "CHEMICAL", 255, 266], ["ALI", "DISEASE", 565, 568], ["amino acids", "CHEMICAL", 255, 266], ["C/EBP", "GENE_OR_GENE_PRODUCT", 78, 83], ["CCSP", "GENE_OR_GENE_PRODUCT", 88, 92], ["PLA2", "GENE_OR_GENE_PRODUCT", 93, 97], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 187, 194], ["amino acids", "AMINO_ACID", 255, 266], ["nucleus", "CELLULAR_COMPONENT", 314, 321], ["membrane", "CELLULAR_COMPONENT", 514, 522], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 587, 594], ["CCSP1", "GENE_OR_GENE_PRODUCT", 595, 600], ["PLA2", "GENE_OR_GENE_PRODUCT", 601, 605], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 623, 630], ["EBP", "PROTEIN", 80, 83], ["CCSP", "PROTEIN", 88, 92], ["PLA2", "PROTEIN", 93, 97], ["C/EBP \u03b2", "PROTEIN", 187, 194], ["downstream genes", "DNA", 412, 428], ["EBP \u03b2", "PROTEIN", 589, 594], ["CCSP1", "PROTEIN", 595, 600], ["PLA2", "PROTEIN", 601, 605], ["EBP \u03b2", "PROTEIN", 625, 630], ["These studies", "TEST", 0, 13], ["C/EBP", "TEST", 78, 83], ["CCSP/PLA2", "TEST", 88, 97], ["C/EBP", "TEST", 187, 192], ["phosphorylation of specific amino acids", "TREATMENT", 227, 266], ["the protein", "TREATMENT", 274, 285], ["the damage of membrane", "PROBLEM", 500, 522], ["effective intervention", "TREATMENT", 526, 548], ["the C/EBP", "TEST", 583, 592], ["CCSP1/PLA2 pathway", "TREATMENT", 595, 613], ["C/EBP", "TEST", 623, 628], ["PLA2", "ANATOMY", 93, 97]]], ["If C/EBP \u03b2 inhibits PLA2 by upregulating CCSP1, we may seek an approach to repair membrane phospholipids damaged by acute inflammation based on the C/EBP \u03b2/CCSP1/PLA2 pathway.", [["membrane phospholipids", "ANATOMY", 82, 104], ["inflammation", "DISEASE", 122, 134], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 3, 10], ["PLA2", "GENE_OR_GENE_PRODUCT", 20, 24], ["CCSP1", "GENE_OR_GENE_PRODUCT", 41, 46], ["membrane phospholipids", "CELLULAR_COMPONENT", 82, 104], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 148, 155], ["CCSP1", "GENE_OR_GENE_PRODUCT", 156, 161], ["PLA2", "GENE_OR_GENE_PRODUCT", 162, 166], ["C/EBP \u03b2", "PROTEIN", 3, 10], ["PLA2", "PROTEIN", 20, 24], ["CCSP1", "PROTEIN", 41, 46], ["EBP \u03b2", "PROTEIN", 150, 155], ["CCSP1", "PROTEIN", 156, 161], ["PLA2", "PROTEIN", 162, 166], ["C/EBP", "TEST", 3, 8], ["PLA2", "PROBLEM", 20, 24], ["repair membrane phospholipids", "TREATMENT", 75, 104], ["acute inflammation", "PROBLEM", 116, 134], ["the C/EBP", "TEST", 144, 153], ["CCSP1/PLA2 pathway", "TREATMENT", 156, 174], ["acute", "OBSERVATION_MODIFIER", 116, 121], ["inflammation", "OBSERVATION", 122, 134]]], ["Having confirmed the existence of the C/EBP \u03b2/CCSP/PLA2 pathway, we attempted to suppress the phosphorylation of C/EBP \u03b2 to inhibit the pathway and reduce the LPS-induced breakdown of membrane phospholipids.DiscussionOur data show that in an in vitro ALI model established by LPS induction, phosphorylation of C/EBP \u03b2 was decreased and bioinformatics analysis discovered a putative binding site of C/EBP \u03b2 in CCSP1 promoter, so we wondered whether C/EBP \u03b2 phosphorylation regulates the transcription of CCSP1.", [["membrane phospholipids", "ANATOMY", 184, 206], ["LPS", "CHEMICAL", 159, 162], ["ALI", "DISEASE", 251, 254], ["LPS", "CHEMICAL", 276, 279], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 38, 45], ["CCSP", "GENE_OR_GENE_PRODUCT", 46, 50], ["PLA2", "GENE_OR_GENE_PRODUCT", 51, 55], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 113, 120], ["LPS", "SIMPLE_CHEMICAL", 159, 162], ["membrane phospholipids", "CELLULAR_COMPONENT", 184, 206], ["LPS", "SIMPLE_CHEMICAL", 276, 279], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 310, 317], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 398, 405], ["CCSP1", "GENE_OR_GENE_PRODUCT", 409, 414], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 448, 455], ["CCSP1", "GENE_OR_GENE_PRODUCT", 503, 508], ["EBP \u03b2", "PROTEIN", 40, 45], ["CCSP", "PROTEIN", 46, 50], ["PLA2", "PROTEIN", 51, 55], ["C/EBP \u03b2", "PROTEIN", 113, 120], ["C/EBP \u03b2", "PROTEIN", 310, 317], ["putative binding site", "DNA", 373, 394], ["C/EBP \u03b2", "DNA", 398, 405], ["CCSP1 promoter", "DNA", 409, 423], ["EBP \u03b2", "PROTEIN", 450, 455], ["CCSP1", "PROTEIN", 503, 508], ["the C/EBP", "TEST", 34, 43], ["CCSP/PLA2 pathway", "TREATMENT", 46, 63], ["C/EBP", "TREATMENT", 113, 118], ["the LPS", "TREATMENT", 155, 162], ["membrane phospholipids", "TREATMENT", 184, 206], ["DiscussionOur data", "TEST", 207, 225], ["LPS induction", "TREATMENT", 276, 289], ["phosphorylation of C/EBP \u03b2", "TEST", 291, 317], ["bioinformatics analysis", "TEST", 336, 359], ["C/EBP", "PROBLEM", 398, 403], ["C/EBP", "TEST", 448, 453], ["membrane phospholipids", "OBSERVATION", 184, 206]]], ["We, using CHIP-PCR and luciferase reporter assay, demonstrated that C/EBP \u03b2 binds to CCSP1 promoter and positively regulates CCSP1 transcription, and its phosphorylation increases its transcriptional activity.", [["CHIP", "GENE_OR_GENE_PRODUCT", 10, 14], ["luciferase", "GENE_OR_GENE_PRODUCT", 23, 33], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 68, 75], ["CCSP1", "GENE_OR_GENE_PRODUCT", 85, 90], ["CCSP1", "GENE_OR_GENE_PRODUCT", 125, 130], ["CHIP", "PROTEIN", 10, 14], ["C/EBP \u03b2", "PROTEIN", 68, 75], ["CCSP1 promoter", "DNA", 85, 99], ["CCSP1", "PROTEIN", 125, 130], ["luciferase reporter assay", "TEST", 23, 48], ["C/EBP", "TEST", 68, 73], ["transcriptional activity", "OBSERVATION", 184, 208]]], ["Based on the validation of the specificity of C/EBP \u03b2/CCSP/PLA2 pathway, we overexpressed CDK2 to enhance the phosphorylation of C/EBP \u03b2 on Thr188 (Li et al., 2007) , so as to inhibit the expression of PLA2 via the C/EBP \u03b2/CCSP/PLA2 pathway, and to control LPS-induced cellular membrane injury.", [["cellular membrane", "ANATOMY", 269, 286], ["LPS", "CHEMICAL", 257, 260], ["Thr", "CHEMICAL", 140, 143], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 46, 53], ["CCSP", "GENE_OR_GENE_PRODUCT", 54, 58], ["PLA2", "GENE_OR_GENE_PRODUCT", 59, 63], ["CDK2", "GENE_OR_GENE_PRODUCT", 90, 94], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 129, 136], ["Thr188", "AMINO_ACID", 140, 146], ["PLA2", "GENE_OR_GENE_PRODUCT", 202, 206], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 215, 222], ["CCSP", "GENE_OR_GENE_PRODUCT", 223, 227], ["PLA2", "GENE_OR_GENE_PRODUCT", 228, 232], ["LPS", "SIMPLE_CHEMICAL", 257, 260], ["cellular membrane", "MULTI-TISSUE_STRUCTURE", 269, 286], ["EBP \u03b2", "PROTEIN", 48, 53], ["CCSP", "PROTEIN", 54, 58], ["PLA2", "PROTEIN", 59, 63], ["CDK2", "PROTEIN", 90, 94], ["C/EBP \u03b2", "PROTEIN", 129, 136], ["PLA2", "PROTEIN", 202, 206], ["CCSP", "PROTEIN", 223, 227], ["PLA2", "PROTEIN", 228, 232], ["C/EBP", "TEST", 46, 51], ["CCSP/PLA2 pathway", "TREATMENT", 54, 71], ["overexpressed CDK2", "PROBLEM", 76, 94], ["the phosphorylation", "TEST", 106, 125], ["C/EBP", "TEST", 129, 134], ["Thr", "TEST", 140, 143], ["PLA2", "TEST", 202, 206], ["the C/EBP", "TEST", 211, 220], ["CCSP/PLA2 pathway", "TREATMENT", 223, 240], ["LPS", "PROBLEM", 257, 260], ["cellular membrane injury", "PROBLEM", 269, 293], ["cellular membrane injury", "OBSERVATION", 269, 293]]], ["The findings corroborate that overexpression of CDK2 inhibited the production of PAF and AA in the ALI model, i.e., overexpression of CDK2 attenuated the damage of membrane phospholipids.", [["membrane phospholipids", "ANATOMY", 164, 186], ["PAF", "CHEMICAL", 81, 84], ["AA", "CHEMICAL", 89, 91], ["ALI", "DISEASE", 99, 102], ["CDK2", "GENE_OR_GENE_PRODUCT", 48, 52], ["PAF", "SIMPLE_CHEMICAL", 81, 84], ["AA", "SIMPLE_CHEMICAL", 89, 91], ["CDK2", "GENE_OR_GENE_PRODUCT", 134, 138], ["membrane phospholipids", "CELLULAR_COMPONENT", 164, 186], ["CDK2", "PROTEIN", 48, 52], ["PAF", "PROTEIN", 81, 84], ["CDK2", "PROTEIN", 134, 138], ["overexpression of CDK2", "PROBLEM", 30, 52], ["PAF", "PROBLEM", 81, 84], ["AA in the ALI model", "TREATMENT", 89, 108], ["CDK2", "PROBLEM", 134, 138], ["membrane phospholipids", "TREATMENT", 164, 186], ["PAF", "OBSERVATION", 81, 84], ["ALI model", "OBSERVATION", 99, 108], ["membrane phospholipids", "OBSERVATION", 164, 186]]], ["The study sheds light on the underlying signal transduction for repair of membrane phospholipids and provides a novel target for treatment of ALI.DiscussionWe employed LPS to induce BEAS-2B cells, and found out the optimal condition for building the in vitro ALI model, 10 mg/ml LPS induction for 24 h by examining TNF\u03b1, IL-1\u03b2 and IL-10 expression levels and the release of PAF and AA.", [["membrane", "ANATOMY", 74, 82], ["BEAS-2B cells", "ANATOMY", 182, 195], ["ALI", "DISEASE", 142, 145], ["LPS", "CHEMICAL", 168, 171], ["ALI", "DISEASE", 259, 262], ["LPS", "CHEMICAL", 279, 282], ["PAF", "CHEMICAL", 374, 377], ["AA", "CHEMICAL", 382, 384], ["membrane phospholipids", "CELLULAR_COMPONENT", 74, 96], ["LPS", "SIMPLE_CHEMICAL", 168, 171], ["BEAS-2B cells", "CELL", 182, 195], ["LPS", "SIMPLE_CHEMICAL", 279, 282], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 315, 319], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 321, 326], ["IL-10", "GENE_OR_GENE_PRODUCT", 331, 336], ["PAF", "SIMPLE_CHEMICAL", 374, 377], ["AA", "SIMPLE_CHEMICAL", 382, 384], ["BEAS-2B cells", "CELL_LINE", 182, 195], ["TNF", "PROTEIN", 315, 318], ["PAF", "PROTEIN", 374, 377], ["The study", "TEST", 0, 9], ["repair of membrane phospholipids", "TREATMENT", 64, 96], ["ALI", "PROBLEM", 142, 145], ["BEAS", "TEST", 182, 186], ["vitro ALI model", "TREATMENT", 253, 268], ["TNF", "TEST", 315, 318], ["IL", "TEST", 321, 323], ["IL", "TEST", 331, 333], ["expression levels", "TEST", 337, 354], ["PAF", "PROBLEM", 374, 377], ["AA", "PROBLEM", 382, 384], ["ALI", "OBSERVATION", 142, 145], ["PAF", "OBSERVATION", 374, 377]]], ["Based on the model, we assessed CDK2, Fig. 3 .", [["CDK2", "GENE_OR_GENE_PRODUCT", 32, 36], ["CDK2", "PROTEIN", 32, 36], ["CDK2", "TEST", 32, 36]]], ["Overexpression and knockdown of CDK2 and CCSP1 and their effects on C/EBP \u03b2 phosphorylation.", [["CDK2", "GENE_OR_GENE_PRODUCT", 32, 36], ["CCSP1", "GENE_OR_GENE_PRODUCT", 41, 46], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 68, 75], ["CDK2", "PROTEIN", 32, 36], ["CCSP1", "PROTEIN", 41, 46], ["EBP \u03b2", "PROTEIN", 70, 75], ["CDK2", "PROBLEM", 32, 36], ["CCSP1", "TEST", 41, 46], ["C/EBP \u03b2 phosphorylation", "TREATMENT", 68, 91], ["CDK2", "OBSERVATION", 32, 36]]], ["BEAS-2B cells were infected with the indicated lentivirus, and CDK2, CCSP1 and phosphorylated C/EBP \u03b2 and total C/EBP \u03b2 were measured by western blotting 72 h later.", [["BEAS-2B cells", "ANATOMY", 0, 13], ["BEAS-2B cells", "CELL", 0, 13], ["lentivirus", "ORGANISM", 47, 57], ["CDK2", "GENE_OR_GENE_PRODUCT", 63, 67], ["CCSP1", "GENE_OR_GENE_PRODUCT", 69, 74], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 94, 101], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 112, 119], ["BEAS-2B cells", "CELL_LINE", 0, 13], ["CDK2", "PROTEIN", 63, 67], ["CCSP1", "PROTEIN", 69, 74], ["phosphorylated C/EBP \u03b2", "PROTEIN", 79, 101], ["C/EBP \u03b2", "PROTEIN", 112, 119], ["lentivirus", "SPECIES", 47, 57], ["BEAS", "TEST", 0, 4], ["lentivirus", "TEST", 47, 57], ["CDK2", "TEST", 63, 67], ["CCSP1", "TEST", 69, 74], ["phosphorylated C", "TEST", 79, 95], ["EBP", "TEST", 96, 99], ["total C/EBP \u03b2", "TEST", 106, 119], ["2B cells", "OBSERVATION", 5, 13], ["lentivirus", "OBSERVATION", 47, 57]]], ["Upper: representative blots of CDK2, CCSP1 and phosphorylated C/EBP \u03b2 and total C/EBP \u03b2 and \u03b2-actin are shown.", [["CDK2", "GENE_OR_GENE_PRODUCT", 31, 35], ["CCSP1", "GENE_OR_GENE_PRODUCT", 37, 42], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 62, 69], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 80, 87], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 92, 99], ["CDK2", "PROTEIN", 31, 35], ["CCSP1", "PROTEIN", 37, 42], ["phosphorylated C/EBP \u03b2", "PROTEIN", 47, 69], ["total C/EBP \u03b2", "PROTEIN", 74, 87], ["\u03b2-actin", "PROTEIN", 92, 99], ["CDK2", "TEST", 31, 35], ["CCSP1", "TEST", 37, 42], ["phosphorylated C", "TEST", 47, 63], ["EBP", "TEST", 64, 67], ["total C/EBP", "TEST", 74, 85], ["\u03b2-actin", "TREATMENT", 92, 99]]], ["Lower: the optical density of the target band divided by the optical density of the \u03b2actin band.", [["\u03b2actin", "GENE_OR_GENE_PRODUCT", 84, 90], ["\u03b2actin band", "PROTEIN", 84, 95], ["the target band", "TREATMENT", 30, 45], ["optical density", "OBSERVATION_MODIFIER", 11, 26], ["optical density", "OBSERVATION", 61, 76], ["\u03b2actin band", "OBSERVATION", 84, 95]]], ["Data are means \u00b1 SD from at least three separate replicates.*, p < 0.05; **, p < 0.01 vs cell group or cell + Lv-NC group.", [["cell", "ANATOMY", 89, 93], ["cell", "ANATOMY", 103, 107], ["Lv-NC", "ANATOMY", 110, 115], ["cell", "CELL", 89, 93], ["cell", "CELL", 103, 107], ["Lv-NC", "CELL", 110, 115], ["cell + Lv-NC group", "TREATMENT", 103, 121]]], ["Verification of C/EBP \u03b2 binding site on CCSP1 promoter.", [["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 16, 23], ["CCSP1", "GENE_OR_GENE_PRODUCT", 40, 45], ["C/EBP \u03b2 binding site", "DNA", 16, 36], ["CCSP1 promoter", "DNA", 40, 54], ["C/EBP", "PROBLEM", 16, 21], ["binding site", "PROBLEM", 24, 36], ["CCSP1 promoter", "TREATMENT", 40, 54]]], ["A. BEAS-2B cells were infected with the indicated lentivirus, and CCSP1 mRNA was measured by real time quantitative PCR 72 h later.", [["BEAS-2B cells", "ANATOMY", 3, 16], ["BEAS-2B cells", "CELL", 3, 16], ["lentivirus", "ORGANISM", 50, 60], ["CCSP1", "GENE_OR_GENE_PRODUCT", 66, 71], ["BEAS-2B cells", "CELL_LINE", 3, 16], ["CCSP1 mRNA", "RNA", 66, 76], ["A. BEAS-2B", "SPECIES", 0, 10], ["lentivirus", "SPECIES", 50, 60], ["2B cells", "PROBLEM", 8, 16], ["lentivirus", "PROBLEM", 50, 60], ["CCSP1 mRNA", "TEST", 66, 76], ["quantitative PCR", "TEST", 103, 119], ["2B cells", "OBSERVATION", 8, 16], ["lentivirus", "OBSERVATION", 50, 60]]], ["The vertical coordinate indicates the relative amount of CCSP1 mRNA and the horizontal coordinate indicates the experiment group, \u03b2 actin serving as the reference.", [["CCSP1", "GENE_OR_GENE_PRODUCT", 57, 62], ["\u03b2 actin", "GENE_OR_GENE_PRODUCT", 130, 137], ["CCSP1 mRNA", "RNA", 57, 67], ["\u03b2 actin", "PROTEIN", 130, 137], ["CCSP1 mRNA", "PROBLEM", 57, 67], ["vertical", "OBSERVATION_MODIFIER", 4, 12], ["relative", "OBSERVATION_MODIFIER", 38, 46], ["amount", "OBSERVATION_MODIFIER", 47, 53], ["CCSP1 mRNA", "OBSERVATION", 57, 67]]], ["B. Verification of C/ EBP \u03b2 binding site on CCSP1 promoter by CHIP-PCR.", [["C/ EBP \u03b2", "GENE_OR_GENE_PRODUCT", 19, 27], ["CCSP1", "GENE_OR_GENE_PRODUCT", 44, 49], ["CHIP", "GENE_OR_GENE_PRODUCT", 62, 66], ["C/ EBP \u03b2 binding site", "DNA", 19, 40], ["CCSP1 promoter", "DNA", 44, 58], ["CHIP", "PROTEIN", 62, 66], ["C/ EBP", "PROBLEM", 19, 25], ["binding site", "PROBLEM", 28, 40], ["CCSP1 promoter", "TREATMENT", 44, 58]]], ["Upper: relatively quantitative analysis on DNA segments, the vertical coordinate being the ratio of gene copy number of the sample to the control gene copy number of Input, and the horizontal coordinate being experiment group.", [["DNA", "CELLULAR_COMPONENT", 43, 46], ["DNA segments", "DNA", 43, 55], ["DNA segments", "TREATMENT", 43, 55], ["vertical", "OBSERVATION_MODIFIER", 61, 69]]], ["Lower: western blotting results of C/EBP \u03b2 protein, Input is the negative control without antibody, and IgG is the control group with a primary antibody against GAPDH.", [["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 35, 42], ["IgG", "GENE_OR_GENE_PRODUCT", 104, 107], ["GAPDH", "GENE_OR_GENE_PRODUCT", 161, 166], ["C/EBP \u03b2 protein", "PROTEIN", 35, 50], ["IgG", "PROTEIN", 104, 107], ["primary antibody", "PROTEIN", 136, 152], ["GAPDH", "PROTEIN", 161, 166], ["C/EBP \u03b2 protein", "TEST", 35, 50], ["antibody", "PROBLEM", 90, 98], ["IgG", "TREATMENT", 104, 107], ["GAPDH", "PROBLEM", 161, 166]]], ["C. Measurements of luciferase activity.", [["luciferase", "GENE_OR_GENE_PRODUCT", 19, 29], ["luciferase", "PROTEIN", 19, 29], ["luciferase activity", "OBSERVATION", 19, 38]]], ["The vertical coordinate indicates the luciferase activity expressed as the firefly luciferase/ Renilla luciferase, and the horizontal coordinate indicates the experiment group.", [["luciferase", "GENE_OR_GENE_PRODUCT", 38, 48], ["luciferase", "GENE_OR_GENE_PRODUCT", 83, 93], ["Renilla", "GENE_OR_GENE_PRODUCT", 95, 102], ["luciferase", "GENE_OR_GENE_PRODUCT", 103, 113], ["luciferase", "PROTEIN", 38, 48], ["firefly luciferase/ Renilla luciferase", "DNA", 75, 113], ["the luciferase activity", "PROBLEM", 34, 57], ["the firefly luciferase/ Renilla luciferase", "PROBLEM", 71, 113], ["vertical", "OBSERVATION_MODIFIER", 4, 12], ["luciferase activity", "OBSERVATION", 38, 57], ["Renilla luciferase", "OBSERVATION", 95, 113]]], ["The determination of the luciferase activity was made 48 h after transfection of 293 cells.", [["293 cells", "ANATOMY", 81, 90], ["luciferase", "GENE_OR_GENE_PRODUCT", 25, 35], ["293 cells", "CELL", 81, 90], ["luciferase", "PROTEIN", 25, 35], ["293 cells", "CELL_LINE", 81, 90]]], ["CCSP1 and PLA2 protein levels, and the results revealed that in the model, CDK2 and CCSP1 were decreased, and PLA2 was increased.", [["CCSP1", "GENE_OR_GENE_PRODUCT", 0, 5], ["PLA2", "GENE_OR_GENE_PRODUCT", 10, 14], ["CDK2", "GENE_OR_GENE_PRODUCT", 75, 79], ["CCSP1", "GENE_OR_GENE_PRODUCT", 84, 89], ["PLA2", "GENE_OR_GENE_PRODUCT", 110, 114], ["CCSP1", "PROTEIN", 0, 5], ["PLA2", "PROTEIN", 10, 14], ["CDK2", "PROTEIN", 75, 79], ["CCSP1", "PROTEIN", 84, 89], ["PLA2", "PROTEIN", 110, 114], ["CCSP1", "TEST", 0, 5], ["PLA2 protein levels", "TEST", 10, 29], ["CDK2", "TEST", 75, 79], ["CCSP1", "TEST", 84, 89], ["PLA2", "TEST", 110, 114], ["decreased", "OBSERVATION_MODIFIER", 95, 104], ["increased", "OBSERVATION_MODIFIER", 119, 128]]], ["In addition, measurement of protein phosphorylation showed that LPS induction significantly suppressed C/EBP \u03b2 phosphorylation.", [["LPS", "CHEMICAL", 64, 67], ["LPS", "SIMPLE_CHEMICAL", 64, 67], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 103, 110], ["EBP \u03b2", "PROTEIN", 105, 110], ["measurement of protein phosphorylation", "TEST", 13, 51], ["LPS induction", "PROBLEM", 64, 77]]], ["To verify the existence of C/EBP \u03b2/CCSP1/PLA2 pathway, we analyzed the relation between C/EBP \u03b2 and CCSP1 gene.", [["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 27, 34], ["CCSP1", "GENE_OR_GENE_PRODUCT", 35, 40], ["PLA2", "GENE_OR_GENE_PRODUCT", 41, 45], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 88, 95], ["CCSP1", "GENE_OR_GENE_PRODUCT", 100, 105], ["EBP \u03b2", "PROTEIN", 29, 34], ["CCSP1", "PROTEIN", 35, 40], ["PLA2", "PROTEIN", 41, 45], ["C/EBP \u03b2 and CCSP1 gene", "DNA", 88, 110], ["C/EBP", "TEST", 27, 32], ["CCSP1/PLA2 pathway", "TREATMENT", 35, 53], ["C/EBP", "TEST", 88, 93]]], ["The experiment revealed that C/EBP \u03b2 phosphorylation or dephosphorylation could enhance or suppress CCSP1 transcription but overexpression or knockdown of CCSP1 had no effect on C/EBP \u03b2 phosphorylation, hinting at CCSP1 being downstream C/EBP \u03b2.", [["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 29, 36], ["CCSP1", "GENE_OR_GENE_PRODUCT", 100, 105], ["CCSP1", "GENE_OR_GENE_PRODUCT", 155, 160], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 178, 185], ["CCSP1", "GENE_OR_GENE_PRODUCT", 214, 219], ["EBP \u03b2", "PROTEIN", 31, 36], ["CCSP1", "PROTEIN", 100, 105], ["CCSP1", "PROTEIN", 155, 160], ["EBP \u03b2", "PROTEIN", 180, 185], ["CCSP1", "PROTEIN", 214, 219], ["The experiment", "TEST", 0, 14], ["C/EBP", "TEST", 29, 34], ["phosphorylation", "PROBLEM", 37, 52], ["dephosphorylation", "PROBLEM", 56, 73], ["CCSP1", "TEST", 155, 160], ["C/EBP", "TEST", 178, 183], ["phosphorylation", "TREATMENT", 186, 201]]], ["We next employed co-infection and CHIP-PCR to verify the binding site of C/EBP \u03b2 in CCSP1 promoter predicted by bioinformatics.", [["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 73, 80], ["CCSP1", "GENE_OR_GENE_PRODUCT", 84, 89], ["binding site", "DNA", 57, 69], ["C/EBP \u03b2", "DNA", 73, 80], ["CCSP1 promoter", "DNA", 84, 98], ["CHIP-PCR", "TEST", 34, 42], ["the binding site", "PROBLEM", 53, 69], ["C/EBP", "PROBLEM", 73, 78], ["CCSP1 promoter", "TREATMENT", 84, 98]]], ["Quantitative determination of CCSP1 mRNA shows that C/EBP \u03b2 phosphorylation enhanced CCSP1 transcription controlled by the wild promoter but not that controlled by the promoter with binding site mutation, and dephosphorylation of C/EBP \u03b2 only inhibited CCSP1 transcription controlled by the wild promoter.", [["CCSP1", "GENE_OR_GENE_PRODUCT", 30, 35], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 52, 59], ["CCSP1", "GENE_OR_GENE_PRODUCT", 85, 90], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 230, 237], ["CCSP1", "GENE_OR_GENE_PRODUCT", 253, 258], ["CCSP1 mRNA", "RNA", 30, 40], ["EBP \u03b2", "PROTEIN", 54, 59], ["CCSP1", "PROTEIN", 85, 90], ["wild promoter", "DNA", 123, 136], ["C/EBP \u03b2", "PROTEIN", 230, 237], ["CCSP1", "PROTEIN", 253, 258], ["wild promoter", "DNA", 291, 304], ["Quantitative determination of CCSP1 mRNA", "TEST", 0, 40], ["C/EBP", "TEST", 52, 57], ["phosphorylation enhanced CCSP1 transcription", "TREATMENT", 60, 104], ["binding site mutation", "PROBLEM", 182, 203], ["dephosphorylation of C/EBP", "PROBLEM", 209, 235], ["CCSP1 transcription", "TREATMENT", 253, 272]]], ["CHIP-PCR results show that C/EBP \u03b2 was capable of binding to the promoter DNA carrying the wild binding site but not the one carrying mutant binding site.", [["CHIP", "GENE_OR_GENE_PRODUCT", 0, 4], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 27, 34], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["CHIP", "PROTEIN", 0, 4], ["C/EBP \u03b2", "PROTEIN", 27, 34], ["promoter DNA", "DNA", 65, 77], ["wild binding site", "DNA", 91, 108], ["mutant binding site", "DNA", 134, 153], ["CHIP-PCR", "TEST", 0, 8], ["C/EBP", "PROBLEM", 27, 32], ["the promoter DNA", "TREATMENT", 61, 77]]], ["However, though endogenous CCSP1 promoter is at a low level in CHIP-PCR experiments, it may have a certain inference on the experimental data.", [["CCSP1", "GENE_OR_GENE_PRODUCT", 27, 32], ["CHIP", "GENE_OR_GENE_PRODUCT", 63, 67], ["CCSP1 promoter", "DNA", 27, 41], ["CHIP", "PROTEIN", 63, 67], ["endogenous CCSP1 promoter", "PROBLEM", 16, 41], ["endogenous", "OBSERVATION_MODIFIER", 16, 26], ["CCSP1", "OBSERVATION", 27, 32]]], ["Therefore, we employed the luciferase reporter assay to verify the results of CHIP-PCR.", [["luciferase", "GENE_OR_GENE_PRODUCT", 27, 37], ["CHIP", "GENE_OR_GENE_PRODUCT", 78, 82], ["CHIP", "PROTEIN", 78, 82]]], ["The results indicated that overexpression of C/EBP \u03b2 significantly increased the luciferase controlled by wild type CCSP1 promoter, but had no obvious effect on that controlled by the CCSP1 promoter with a mutant binding site.", [["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 45, 52], ["luciferase", "GENE_OR_GENE_PRODUCT", 81, 91], ["CCSP1", "GENE_OR_GENE_PRODUCT", 116, 121], ["CCSP1", "GENE_OR_GENE_PRODUCT", 184, 189], ["C/EBP \u03b2", "PROTEIN", 45, 52], ["luciferase", "PROTEIN", 81, 91], ["wild type CCSP1 promoter", "DNA", 106, 130], ["CCSP1 promoter", "DNA", 184, 198], ["mutant binding site", "DNA", 206, 225], ["overexpression of C/EBP", "PROBLEM", 27, 50], ["the luciferase", "PROBLEM", 77, 91], ["wild type CCSP1 promoter", "TREATMENT", 106, 130], ["the CCSP1 promoter", "TREATMENT", 180, 198], ["a mutant binding site", "PROBLEM", 204, 225], ["no obvious", "UNCERTAINTY", 140, 150]]], ["Eliminating the background impact, these data demonstrated that the transcription factor can bind to CCSP1 promoter through the predicted site and activate the transcription.DiscussionThese results clarified the regulatory sequence of the proteins in the C/EBP \u03b2/CCSP1/PLA2 pathway.", [["CCSP1", "GENE_OR_GENE_PRODUCT", 101, 106], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 255, 262], ["CCSP1", "GENE_OR_GENE_PRODUCT", 263, 268], ["PLA2", "GENE_OR_GENE_PRODUCT", 269, 273], ["transcription factor", "PROTEIN", 68, 88], ["CCSP1 promoter", "DNA", 101, 115], ["C/EBP \u03b2", "PROTEIN", 255, 262], ["CCSP1", "PROTEIN", 263, 268], ["PLA2", "PROTEIN", 269, 273], ["these data", "TEST", 35, 45], ["the transcription factor", "PROBLEM", 64, 88]]], ["In addition, we also investigated the specificity of the C/EBP \u03b2/CCSP1/PLA2 pathway by knocking down C/ EBP \u03b2 and CCSP1, and the results indicate that the inhibition of PLA2 by CDK2 was mediated by C/EBP \u03b2 phosphorylation and transcription of CCSP1.", [["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 57, 64], ["CCSP1", "GENE_OR_GENE_PRODUCT", 65, 70], ["PLA2", "GENE_OR_GENE_PRODUCT", 71, 75], ["C/ EBP \u03b2", "GENE_OR_GENE_PRODUCT", 101, 109], ["CCSP1", "GENE_OR_GENE_PRODUCT", 114, 119], ["PLA2", "GENE_OR_GENE_PRODUCT", 169, 173], ["CDK2", "GENE_OR_GENE_PRODUCT", 177, 181], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 198, 205], ["CCSP1", "GENE_OR_GENE_PRODUCT", 243, 248], ["EBP \u03b2", "PROTEIN", 59, 64], ["CCSP1", "PROTEIN", 65, 70], ["PLA2", "PROTEIN", 71, 75], ["C/ EBP \u03b2", "PROTEIN", 101, 109], ["CCSP1", "PROTEIN", 114, 119], ["PLA2", "PROTEIN", 169, 173], ["CDK2", "PROTEIN", 177, 181], ["EBP \u03b2", "PROTEIN", 200, 205], ["CCSP1", "PROTEIN", 243, 248], ["the C/EBP", "TEST", 53, 62], ["knocking down C/ EBP", "PROBLEM", 87, 107], ["CCSP1", "TEST", 114, 119], ["the inhibition of PLA2", "PROBLEM", 151, 173], ["C/EBP \u03b2 phosphorylation", "TREATMENT", 198, 221], ["transcription of CCSP1", "TREATMENT", 226, 248]]], ["LPS stimulation inhibits the phosphorylation of C/EBP \u03b2 in BEAS-2B cells, suppresses the C/EBP \u03b2/CCSP1/PLA2 pathway, and increases the expression of PLA2 protein, leading to membrane injury.", [["BEAS-2B cells", "ANATOMY", 59, 72], ["membrane", "ANATOMY", 174, 182], ["LPS", "CHEMICAL", 0, 3], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 48, 55], ["BEAS-2B cells", "CELL", 59, 72], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 89, 96], ["CCSP1", "GENE_OR_GENE_PRODUCT", 97, 102], ["PLA2", "GENE_OR_GENE_PRODUCT", 103, 107], ["PLA2", "GENE_OR_GENE_PRODUCT", 149, 153], ["membrane", "CELLULAR_COMPONENT", 174, 182], ["C/EBP \u03b2", "PROTEIN", 48, 55], ["BEAS-2B cells", "CELL_LINE", 59, 72], ["CCSP1", "PROTEIN", 97, 102], ["PLA2", "PROTEIN", 103, 107], ["PLA2 protein", "PROTEIN", 149, 161], ["LPS stimulation", "TEST", 0, 15], ["the phosphorylation", "TEST", 25, 44], ["C/EBP", "TEST", 48, 53], ["BEAS", "TEST", 59, 63], ["the C/EBP", "TEST", 85, 94], ["PLA2 pathway", "TEST", 103, 115], ["PLA2 protein", "PROBLEM", 149, 161], ["membrane injury", "PROBLEM", 174, 189], ["2B cells", "OBSERVATION", 64, 72], ["membrane injury", "OBSERVATION", 174, 189]]], ["Since CCSP1 is an endogenous inhibitor of PLA2, we tried to inhibit the damage of membrane in the in vitro ALI model through regulating PLA2 via C/EBP \u03b2 phosphorylation.", [["membrane", "ANATOMY", 82, 90], ["ALI", "DISEASE", 107, 110], ["CCSP1", "GENE_OR_GENE_PRODUCT", 6, 11], ["PLA2", "GENE_OR_GENE_PRODUCT", 42, 46], ["membrane", "CELLULAR_COMPONENT", 82, 90], ["PLA2", "GENE_OR_GENE_PRODUCT", 136, 140], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 145, 152], ["CCSP1", "PROTEIN", 6, 11], ["PLA2", "PROTEIN", 42, 46], ["PLA2", "PROTEIN", 136, 140], ["EBP \u03b2", "PROTEIN", 147, 152], ["an endogenous inhibitor of PLA2", "PROBLEM", 15, 46], ["the damage of membrane", "PROBLEM", 68, 90], ["C/EBP \u03b2 phosphorylation", "TREATMENT", 145, 168]]], ["To regulate phosphorylation and dephosphorylation of C/EBP \u03b2, we overexpressed or silenced its upstream kinase CDK2, which is proved to be an effective means to phosphorylate or dephosphorylate C/EBP \u03b2 by the experimental data.", [["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 53, 60], ["CDK2", "GENE_OR_GENE_PRODUCT", 111, 115], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 194, 201], ["C/EBP \u03b2", "PROTEIN", 53, 60], ["upstream kinase", "PROTEIN", 95, 110], ["CDK2", "PROTEIN", 111, 115], ["C/EBP \u03b2", "PROTEIN", 194, 201], ["dephosphorylation of C/EBP", "TREATMENT", 32, 58], ["silenced its upstream kinase CDK2", "PROBLEM", 82, 115], ["dephosphorylate C/EBP", "TREATMENT", 178, 199]]], ["The findings suggest that overexpression of CDK2 suppressed LPS-induced increase of PLA2 in the cells via the C/EBP \u03b2/CCSP1/PLA2 pathway, and inhibited the release of PAF and AA, a clear inhibition of membrane phospholipid damage in the in vitro ALI model.", [["cells", "ANATOMY", 96, 101], ["membrane", "ANATOMY", 201, 209], ["LPS", "CHEMICAL", 60, 63], ["PAF", "CHEMICAL", 167, 170], ["AA", "CHEMICAL", 175, 177], ["ALI", "DISEASE", 246, 249], ["CDK2", "GENE_OR_GENE_PRODUCT", 44, 48], ["LPS", "SIMPLE_CHEMICAL", 60, 63], ["PLA2", "GENE_OR_GENE_PRODUCT", 84, 88], ["cells", "CELL", 96, 101], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 110, 117], ["CCSP1", "GENE_OR_GENE_PRODUCT", 118, 123], ["PLA2", "GENE_OR_GENE_PRODUCT", 124, 128], ["PAF", "SIMPLE_CHEMICAL", 167, 170], ["AA", "SIMPLE_CHEMICAL", 175, 177], ["membrane", "CELLULAR_COMPONENT", 201, 209], ["phospholipid", "SIMPLE_CHEMICAL", 210, 222], ["CDK2", "PROTEIN", 44, 48], ["PLA2", "PROTEIN", 84, 88], ["CCSP1", "PROTEIN", 118, 123], ["PLA2", "PROTEIN", 124, 128], ["PAF", "PROTEIN", 167, 170], ["CDK2 suppressed LPS", "PROBLEM", 44, 63], ["PLA2 in the cells", "PROBLEM", 84, 101], ["the C/EBP", "TEST", 106, 115], ["PAF", "PROBLEM", 167, 170], ["AA", "PROBLEM", 175, 177], ["membrane phospholipid damage", "PROBLEM", 201, 229], ["CDK2 suppressed", "OBSERVATION", 44, 59], ["increase", "OBSERVATION_MODIFIER", 72, 80], ["PAF", "OBSERVATION", 167, 170], ["membrane phospholipid damage", "OBSERVATION", 201, 229], ["vitro ALI model", "OBSERVATION", 240, 255]]], ["These findings are promising, since it is of significance to the treatment of ALI that increase of C/EBP \u03b2 phosphorylation could inhibit PLA2 expression and membrane injury in ALI.", [["membrane", "ANATOMY", 157, 165], ["ALI", "DISEASE", 78, 81], ["ALI", "DISEASE", 176, 179], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 99, 106], ["PLA2", "GENE_OR_GENE_PRODUCT", 137, 141], ["membrane", "CELLULAR_COMPONENT", 157, 165], ["EBP \u03b2", "PROTEIN", 101, 106], ["PLA2", "PROTEIN", 137, 141], ["ALI", "PROBLEM", 78, 81], ["C/EBP \u03b2 phosphorylation", "TREATMENT", 99, 122], ["PLA2 expression", "PROBLEM", 137, 152], ["membrane injury in ALI", "PROBLEM", 157, 179], ["membrane injury", "OBSERVATION", 157, 172], ["ALI", "ANATOMY", 176, 179]]], ["The results indicate that C/EBP \u03b2 is a potential target for ALI treatment.", [["ALI", "DISEASE", 60, 63], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 26, 33], ["C/EBP \u03b2", "PROTEIN", 26, 33], ["C/EBP", "TEST", 26, 31], ["ALI treatment", "TREATMENT", 60, 73]]], ["For example, what is the mechanism by which LPS stimulation inhibits the phosphorylation of C/EBP \u03b2, and is there some approach that regulates the phosphorylation of C/EBP \u03b2 in a more effective, more direct and specific way?", [["LPS", "CHEMICAL", 44, 47], ["LPS", "GENE_OR_GENE_PRODUCT", 44, 47], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 92, 99], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 166, 173], ["C/EBP \u03b2", "PROTEIN", 92, 99], ["C/EBP \u03b2", "PROTEIN", 166, 173], ["LPS stimulation", "TEST", 44, 59], ["C/EBP", "TEST", 92, 97], ["C/EBP", "TEST", 166, 171]]], ["The experimental strategy of increasing C/EBP \u03b2 phosphorylation by CDK2 overexpression is obviously not suitable for clinical application.", [["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 40, 47], ["CDK2", "GENE_OR_GENE_PRODUCT", 67, 71], ["EBP \u03b2", "PROTEIN", 42, 47], ["CDK2", "PROTEIN", 67, 71], ["increasing C/EBP", "PROBLEM", 29, 45], ["CDK2 overexpression", "PROBLEM", 67, 86]]], ["For this reason, our future research will focus on the development of specific agonist for C/EBP \u03b2 phosphorylation, which may be used in the ALI treatment.DiscussionIn conclusion, our study shows that C/EBP \u03b2 phosphorylation could impair the increase in PLA2 in the in vitro ALI model through the C/ EBP \u03b2/CCSP1/PLA2 pathway and thus restrain the membrane injury caused by PLA2, which is of significance to maintaining normal function of epithelial cells in ALI disease.", [["membrane", "ANATOMY", 347, 355], ["epithelial cells", "ANATOMY", 438, 454], ["ALI", "DISEASE", 141, 144], ["ALI", "DISEASE", 275, 278], ["ALI", "DISEASE", 458, 461], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 91, 98], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 201, 208], ["PLA2", "GENE_OR_GENE_PRODUCT", 254, 258], ["C/ EBP \u03b2", "GENE_OR_GENE_PRODUCT", 297, 305], ["CCSP1", "GENE_OR_GENE_PRODUCT", 306, 311], ["PLA2", "GENE_OR_GENE_PRODUCT", 312, 316], ["membrane", "CELLULAR_COMPONENT", 347, 355], ["PLA2", "GENE_OR_GENE_PRODUCT", 373, 377], ["epithelial cells", "CELL", 438, 454], ["ALI disease", "CANCER", 458, 469], ["EBP \u03b2", "PROTEIN", 93, 98], ["EBP \u03b2", "PROTEIN", 203, 208], ["PLA2", "PROTEIN", 254, 258], ["CCSP1", "PROTEIN", 306, 311], ["PLA2", "PROTEIN", 312, 316], ["PLA2", "PROTEIN", 373, 377], ["epithelial cells", "CELL_TYPE", 438, 454], ["C/EBP \u03b2 phosphorylation", "TREATMENT", 91, 114], ["the ALI treatment", "TREATMENT", 137, 154], ["our study", "TEST", 180, 189], ["C/EBP", "TEST", 201, 206], ["the increase in PLA2", "PROBLEM", 238, 258], ["the C/ EBP", "TEST", 293, 303], ["CCSP1/PLA2 pathway", "TREATMENT", 306, 324], ["the membrane injury", "PROBLEM", 343, 362], ["PLA2", "TEST", 373, 377], ["ALI disease", "PROBLEM", 458, 469], ["increase", "OBSERVATION_MODIFIER", 242, 250], ["epithelial cells", "OBSERVATION", 438, 454], ["ALI disease", "OBSERVATION", 458, 469]]], ["It is also suggested that C/EBP \u03b2 be a potential target for targeted therapy of ALI and the development of Fig. 5 .", [["ALI", "DISEASE", 80, 83], ["C/EBP \u03b2", "GENE_OR_GENE_PRODUCT", 26, 33], ["C/EBP \u03b2", "PROTEIN", 26, 33], ["C/EBP", "TEST", 26, 31], ["targeted therapy", "TREATMENT", 60, 76], ["ALI", "TREATMENT", 80, 83]]], ["Verifying the specificity of the pathway and examining membrane damage A. BEAS-2B cells were infected with the indicated lentivirus, and PLA2 expression was measured by western blotting.", [["membrane", "ANATOMY", 55, 63], ["BEAS-2B cells", "ANATOMY", 74, 87], ["membrane", "CELLULAR_COMPONENT", 55, 63], ["BEAS-2B cells", "CELL", 74, 87], ["lentivirus", "ORGANISM", 121, 131], ["PLA2", "GENE_OR_GENE_PRODUCT", 137, 141], ["BEAS-2B cells", "CELL_LINE", 74, 87], ["PLA2", "PROTEIN", 137, 141], ["A. BEAS-2B", "SPECIES", 71, 81], ["lentivirus", "SPECIES", 121, 131], ["examining membrane damage", "TEST", 45, 70], ["BEAS", "TEST", 74, 78], ["2B cells", "PROBLEM", 79, 87], ["lentivirus", "PROBLEM", 121, 131], ["PLA2 expression", "TEST", 137, 152], ["2B cells", "OBSERVATION", 79, 87], ["lentivirus", "OBSERVATION", 121, 131]]], ["Upper: representative blots and lower: the optical density of the target band divided by the optical density of the \u03b2-actin band.", [["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 116, 123], ["\u03b2-actin band", "PROTEIN", 116, 128], ["lower", "ANATOMY_MODIFIER", 32, 37], ["optical density", "OBSERVATION", 93, 108], ["\u03b2-actin band", "OBSERVATION", 116, 128]]], ["B. BEAS-2B cells were infected with the indicated lentivirus, and treated with LPS 48 h later, and PAF and AA were measured using ELISA.", [["BEAS-2B cells", "ANATOMY", 3, 16], ["LPS", "CHEMICAL", 79, 82], ["PAF", "CHEMICAL", 99, 102], ["AA", "CHEMICAL", 107, 109], ["BEAS-2B cells", "CELL", 3, 16], ["lentivirus", "ORGANISM", 50, 60], ["PAF", "SIMPLE_CHEMICAL", 99, 102], ["AA", "SIMPLE_CHEMICAL", 107, 109], ["BEAS-2B cells", "CELL_LINE", 3, 16], ["PAF", "PROTEIN", 99, 102], ["lentivirus", "SPECIES", 50, 60], ["B. BEAS", "TEST", 0, 7], ["lentivirus", "PROBLEM", 50, 60], ["LPS", "TREATMENT", 79, 82], ["PAF", "PROBLEM", 99, 102], ["AA", "TEST", 107, 109], ["ELISA", "TEST", 130, 135], ["2B cells", "OBSERVATION", 8, 16], ["lentivirus", "OBSERVATION", 50, 60]]]], "bd305b9cef1342fd25f704778ad553ef5e89c54e": [["This analysis presents data from a new perspective offering key insights into the spread patterns of norovirus and influenza epidemic events.", [["norovirus", "DISEASE", 101, 110], ["influenza", "DISEASE", 115, 124], ["norovirus", "ORGANISM", 101, 110], ["This analysis", "TEST", 0, 13], ["norovirus", "PROBLEM", 101, 110], ["influenza epidemic events", "PROBLEM", 115, 140], ["norovirus", "OBSERVATION", 101, 110]]], ["We utilize optic flow analysis to gain an informed overview of a wealth of statistical epidemiological data and identify trends in movement of influenza waves throughout Germany on the NUTS 3 level (413 locations) which maps municipalities on European level.", [["optic", "ANATOMY", 11, 16], ["influenza", "DISEASE", 143, 152], ["optic flow analysis", "TEST", 11, 30], ["influenza waves", "PROBLEM", 143, 158], ["influenza", "OBSERVATION", 143, 152]]], ["We show that Influenza and norovirus seasonal outbreak events have a highly distinct pattern.We investigate the quantitative statistical properties of the epidemic patterns and find a shifted distribution in the time between influenza and norovirus seasonal peaks of reported infections over one decade.", [["Influenza", "DISEASE", 13, 22], ["influenza", "DISEASE", 225, 234], ["infections", "DISEASE", 276, 286], ["Influenza", "PROBLEM", 13, 22], ["norovirus seasonal outbreak events", "PROBLEM", 27, 61], ["influenza", "PROBLEM", 225, 234], ["norovirus", "PROBLEM", 239, 248], ["Influenza", "OBSERVATION", 13, 22], ["norovirus", "OBSERVATION", 27, 36], ["highly distinct", "OBSERVATION_MODIFIER", 69, 84], ["infections", "OBSERVATION", 276, 286]]], ["These findings align with key biological features of both pathogens as shown in the course of this analysis.This analysis presents data from a new perspective offering key insights into the spread patterns of norovirus and influenza epidemic events.", [["norovirus", "DISEASE", 209, 218], ["influenza", "DISEASE", 223, 232], ["norovirus", "ORGANISM", 209, 218], ["both pathogens", "PROBLEM", 53, 67], ["this analysis", "TEST", 94, 107], ["This analysis", "TEST", 108, 121], ["norovirus", "PROBLEM", 209, 218], ["influenza epidemic events", "PROBLEM", 223, 248], ["both", "OBSERVATION_MODIFIER", 53, 57], ["pathogens", "OBSERVATION", 58, 67], ["norovirus", "OBSERVATION", 209, 218]]], ["We utilize optic flow analysis to gain an informed overview of a wealth of statistical epidemiological data and identify trends in movement of influenza waves throughout Germany on the NUTS 3 level (413 locations) which maps municipalities on European level.", [["optic", "ANATOMY", 11, 16], ["influenza", "DISEASE", 143, 152], ["optic flow analysis", "TEST", 11, 30], ["influenza waves", "PROBLEM", 143, 158], ["influenza", "OBSERVATION", 143, 152]]], ["We show that Influenza and norovirus seasonal outbreak events have a highly distinct pattern.This work presents a novel perspective on the analysis of fine scale and high resolution epidemic datasets.", [["Influenza", "DISEASE", 13, 22], ["Influenza", "PROBLEM", 13, 22], ["norovirus seasonal outbreak events", "PROBLEM", 27, 61], ["the analysis", "TEST", 135, 147], ["fine scale", "TEST", 151, 161], ["Influenza", "OBSERVATION", 13, 22], ["norovirus", "OBSERVATION", 27, 36], ["highly distinct", "OBSERVATION_MODIFIER", 69, 84]]], ["We utilize optic flow, a method to observe and describe movement of patterns in videos, to analyze high resolution spatio-temporal epidemic patterns of noro and influenza seasons.", [["optic", "ANATOMY", 11, 16], ["influenza", "DISEASE", 161, 170], ["optic", "MULTI-TISSUE_STRUCTURE", 11, 16], ["optic flow", "TEST", 11, 21], ["high resolution spatio", "PROBLEM", 99, 121], ["noro", "PROBLEM", 152, 156], ["influenza seasons", "PROBLEM", 161, 178]]], ["Infectious diseases are widespread in our country and history.", [["Infectious diseases", "DISEASE", 0, 19]]], ["Depending on the capability of the agent as a pathogen, its environmental stability and infection rate, a disease's spread could result in an epidemic, limited to a community at a particular time or, in worst case, to a worldwide pandemic.", [["infection", "DISEASE", 88, 97], ["the agent", "TREATMENT", 31, 40], ["a pathogen", "PROBLEM", 44, 54], ["infection rate", "PROBLEM", 88, 102], ["a disease's spread", "PROBLEM", 104, 122]]], ["Past epidemics and pandemics, like the Influenza 1918, lead to a population apprehensive of possible dissemination of infectious diseases resulting in an increased effort in modelling and surveillance of known existing communicable diseases.", [["infectious diseases", "DISEASE", 118, 137], ["communicable diseases", "DISEASE", 219, 240], ["pandemics", "PROBLEM", 19, 28], ["the Influenza", "PROBLEM", 35, 48], ["infectious diseases", "PROBLEM", 118, 137], ["an increased effort", "PROBLEM", 151, 170], ["known existing communicable diseases", "PROBLEM", 204, 240], ["infectious", "OBSERVATION", 118, 128], ["increased", "OBSERVATION_MODIFIER", 154, 163], ["effort", "OBSERVATION_MODIFIER", 164, 170], ["communicable diseases", "OBSERVATION", 219, 240]]], ["In the present time, infectious diseases as noro or influenza occur in periodic epidemics and pandemics with worldwide deaths of 290.000-650.000 per year for influenza 1 .", [["infectious diseases", "DISEASE", 21, 40], ["noro", "CHEMICAL", 44, 48], ["influenza", "DISEASE", 52, 61], ["deaths", "DISEASE", 119, 125], ["influenza", "DISEASE", 158, 167], ["infectious diseases", "PROBLEM", 21, 40], ["noro", "PROBLEM", 44, 48], ["influenza", "PROBLEM", 52, 61], ["periodic epidemics", "PROBLEM", 71, 89], ["pandemics", "PROBLEM", 94, 103], ["influenza", "PROBLEM", 158, 167], ["infectious", "OBSERVATION", 21, 31]]], ["In comparison 1.45 million deaths caused by acute gastroenteritis and 18 % of these infections were triggered by viral infections 2 .", [["deaths", "DISEASE", 27, 33], ["gastroenteritis", "DISEASE", 50, 65], ["infections", "DISEASE", 84, 94], ["viral infections", "DISEASE", 113, 129], ["acute gastroenteritis", "PROBLEM", 44, 65], ["these infections", "PROBLEM", 78, 94], ["viral infections", "PROBLEM", 113, 129], ["acute", "OBSERVATION_MODIFIER", 44, 49], ["gastroenteritis", "OBSERVATION", 50, 65], ["infections", "OBSERVATION", 84, 94], ["viral", "OBSERVATION_MODIFIER", 113, 118], ["infections", "OBSERVATION", 119, 129]]], ["In Germany, influenza and noro infections are observed as the main communicable diseases 3 .", [["influenza", "DISEASE", 12, 21], ["noro infections", "DISEASE", 26, 41], ["influenza", "PROBLEM", 12, 21], ["noro infections", "PROBLEM", 26, 41], ["the main communicable diseases", "PROBLEM", 58, 88], ["influenza", "OBSERVATION", 12, 21], ["main", "OBSERVATION_MODIFIER", 62, 66], ["communicable diseases", "OBSERVATION", 67, 88]]], ["However, there is a big number of non-registered cases in both illnesses due to people not seeking medical attention and treating the symptoms at home.This analysis presents data from a new perspective offering key insights into the spread patterns of norovirus and influenza epidemic events.", [["norovirus", "DISEASE", 252, 261], ["influenza", "DISEASE", 266, 275], ["people", "ORGANISM", 80, 86], ["norovirus", "ORGANISM", 252, 261], ["people", "SPECIES", 80, 86], ["the symptoms", "PROBLEM", 130, 142], ["This analysis", "TEST", 151, 164], ["norovirus", "PROBLEM", 252, 261], ["influenza epidemic events", "PROBLEM", 266, 291], ["both", "OBSERVATION_MODIFIER", 58, 62], ["illnesses", "OBSERVATION", 63, 72], ["norovirus", "OBSERVATION", 252, 261]]], ["We utilize optic flow analysis to gain an informed overview of a wealth of statistical epidemiological data and identify trends in movement of influenza waves throughout Germany on the NUTS 3 level (413 locations) which maps municipalities on European level.", [["optic", "ANATOMY", 11, 16], ["influenza", "DISEASE", 143, 152], ["optic flow analysis", "TEST", 11, 30], ["influenza waves", "PROBLEM", 143, 158], ["influenza", "OBSERVATION", 143, 152]]], ["We show that Influenza and norovirus seasonal outbreak events have a highly distinct pattern.In the past there have been numerous views on influenza epidemic patterns 4, 5 and seasonality causes 6, 7 .", [["Influenza", "DISEASE", 13, 22], ["Influenza", "PROBLEM", 13, 22], ["norovirus seasonal outbreak events", "PROBLEM", 27, 61], ["influenza epidemic patterns", "PROBLEM", 139, 166], ["Influenza", "OBSERVATION", 13, 22], ["norovirus", "OBSERVATION", 27, 36], ["highly distinct", "OBSERVATION_MODIFIER", 69, 84], ["influenza", "OBSERVATION", 139, 148]]], ["Other studies have targeted single 8 or multiple regions 9 in time-domain with pattern analysis of the epidemic data of influenza using lab diagnostics.", [["influenza", "DISEASE", 120, 129], ["Other studies", "TEST", 0, 13], ["pattern analysis", "TEST", 79, 95], ["influenza", "PROBLEM", 120, 129], ["lab diagnostics", "TEST", 136, 151]]], ["Others have looked at regional influenza patterns utilizing the distribution of antiviral medication specific to influenza 10 .", [["influenza", "DISEASE", 113, 122], ["regional influenza patterns", "PROBLEM", 22, 49], ["antiviral medication", "TREATMENT", 80, 100], ["influenza", "PROBLEM", 113, 122], ["influenza", "OBSERVATION", 31, 40]]], ["Seasonality of influenza can be regarded as a well-established concept.", [["influenza", "DISEASE", 15, 24], ["influenza", "PROBLEM", 15, 24], ["influenza", "OBSERVATION", 15, 24]]], ["But is the spatial wave-like pattern of influenza outbreaks also well-established from historical data?", [["influenza", "DISEASE", 40, 49], ["influenza outbreaks", "PROBLEM", 40, 59], ["influenza", "OBSERVATION", 40, 49]]], ["And does the description of a wave hold true for another viral but profoundly different disease like norovirus infections?", [["norovirus infections", "DISEASE", 101, 121], ["norovirus", "ORGANISM", 101, 110], ["another viral", "PROBLEM", 49, 62], ["profoundly different disease", "PROBLEM", 67, 95], ["norovirus infections", "PROBLEM", 101, 121], ["norovirus", "OBSERVATION", 101, 110]]], ["In literature as well as in our calculations we observed a certain seasonality of norovirus and influenza cases in Germany.", [["norovirus", "DISEASE", 82, 91], ["influenza", "DISEASE", 96, 105], ["norovirus", "ORGANISM", 82, 91], ["norovirus", "PROBLEM", 82, 91], ["influenza cases", "PROBLEM", 96, 111], ["norovirus", "OBSERVATION", 82, 91]]], ["In comparison, norovirus infections are examined in the winter month (Dec./Jan.) whereas influenza is monitored at the beginning of the new year (Jan./Feb.) 11, 12 .", [["norovirus infections", "DISEASE", 15, 35], ["influenza", "DISEASE", 89, 98], ["norovirus", "ORGANISM", 15, 24], ["norovirus", "SPECIES", 15, 24], ["norovirus infections", "PROBLEM", 15, 35], ["influenza", "PROBLEM", 89, 98], ["norovirus", "OBSERVATION_MODIFIER", 15, 24], ["infections", "OBSERVATION", 25, 35]]], ["We found a pattern which could be observed as an alternating transition from norovirus infections to influenza.", [["norovirus infections", "DISEASE", 77, 97], ["influenza", "DISEASE", 101, 110], ["norovirus", "ORGANISM", 77, 86], ["an alternating transition", "PROBLEM", 46, 71], ["norovirus infections", "PROBLEM", 77, 97], ["influenza", "PROBLEM", 101, 110], ["norovirus infections", "OBSERVATION", 77, 97]]], ["Influenza occurs explosively in the population, www.nature.com/scientificreports/ we limited the maximum time of the season to 10% of the weeks per municipality.", [["Influenza", "DISEASE", 0, 9], ["Influenza", "PROBLEM", 0, 9]]], ["And in the third constraint we limited the season to the weeks 0-14 (See Fig. 4 and \"Methods\" for details).Overview of epidemic pattern of influenza and norovirus infections.In order to visualize the data and get an overview of the epidemic situation we created heatmaps (Fig. 1) .", [["influenza", "DISEASE", 139, 148], ["norovirus infections", "DISEASE", 153, 173], ["norovirus", "ORGANISM", 153, 162], ["influenza", "PROBLEM", 139, 148], ["norovirus infections", "PROBLEM", 153, 173], ["the data", "TEST", 196, 204], ["influenza", "OBSERVATION", 139, 148], ["norovirus", "OBSERVATION", 153, 162]]], ["These show the decade in horizontal axis and all German municipalities on the vertical axis (in no particular order) showing higher case counts of norovirus and influenza with brighter pixels (from blue over white to red) according to the legend.", [["norovirus", "DISEASE", 147, 156], ["influenza", "DISEASE", 161, 170], ["norovirus", "ORGANISM", 147, 156], ["norovirus", "PROBLEM", 147, 156], ["influenza", "PROBLEM", 161, 170], ["brighter pixels", "PROBLEM", 176, 191], ["blue", "PROBLEM", 198, 202], ["horizontal axis", "OBSERVATION_MODIFIER", 25, 40], ["vertical axis", "OBSERVATION_MODIFIER", 78, 91], ["norovirus", "OBSERVATION", 147, 156]]], ["Thus the (vertical) patterns in these particular heat maps are of no significance as there is no spatial correlation in the vertical placement.", [["these particular heat maps", "TEST", 32, 58], ["the vertical placement", "TREATMENT", 120, 142], ["no", "UNCERTAINTY", 94, 96], ["vertical placement", "OBSERVATION", 124, 142]]], ["While norovirus shows no week that exceeds 235 reported cases in this data source influenza exceeds 235 reported cases 3876 times out of 235,914 datapoints.", [["norovirus", "DISEASE", 6, 15], ["influenza", "DISEASE", 82, 91], ["norovirus", "ORGANISM", 6, 15], ["norovirus", "PROBLEM", 6, 15], ["influenza", "PROBLEM", 82, 91], ["no", "UNCERTAINTY", 22, 24]]], ["To preserve the integrity of the histogram this was also put into the 235+ bin.", [["the histogram", "TEST", 29, 42]]], ["For norovirus and influenza infections we see a wave pattern focusing on the winter months (Fig.7) .", [["norovirus", "DISEASE", 4, 13], ["influenza infections", "DISEASE", 18, 38], ["norovirus", "PROBLEM", 4, 13], ["influenza infections", "PROBLEM", 18, 38], ["norovirus", "OBSERVATION", 4, 13]]], ["For influenza this pattern is stronger pronounced than norovirus (see Fig. 2 for still picture and supplemental videos S1 and S2 for animation).Overview of epidemic pattern of influenza and norovirus infections.Tempo-spatial distribution and quantification of influenza and norovirus waves.", [["influenza", "DISEASE", 4, 13], ["norovirus", "DISEASE", 55, 64], ["influenza", "DISEASE", 176, 185], ["norovirus infections", "DISEASE", 190, 210], ["influenza", "DISEASE", 260, 269], ["norovirus", "DISEASE", 274, 283], ["norovirus", "ORGANISM", 190, 199], ["norovirus", "ORGANISM", 274, 283], ["S2", "PROTEIN", 126, 128], ["influenza", "PROBLEM", 4, 13], ["norovirus", "PROBLEM", 55, 64], ["still picture", "PROBLEM", 81, 94], ["influenza", "PROBLEM", 176, 185], ["norovirus infections", "PROBLEM", 190, 210], ["influenza", "PROBLEM", 260, 269], ["norovirus waves", "PROBLEM", 274, 289], ["influenza", "OBSERVATION", 176, 185], ["norovirus", "OBSERVATION", 190, 199], ["influenza", "OBSERVATION", 260, 269], ["norovirus waves", "OBSERVATION", 274, 289]]], ["In order to identify a wave-like incidence pattern that also applies to the spatial distribution, we needed to grasp the movement of case-report patterns.", [["a wave-like incidence pattern", "PROBLEM", 21, 50]]], ["For this we utilized the method of optical flow, an established concept from the field of computer vision (for details see Materials and methods-Optical flow) to identify moving objects or regions of similarity within an area.", [["optical flow", "TEST", 35, 47]]], ["This was done for the incidence maps of norovirus, influenza and MC controls constraint 1-3 for the whole decade 2008-2018.", [["norovirus", "DISEASE", 40, 49], ["influenza", "DISEASE", 51, 60], ["norovirus", "ORGANISM", 40, 49], ["norovirus", "PROBLEM", 40, 49], ["influenza", "PROBLEM", 51, 60], ["norovirus", "OBSERVATION", 40, 49]]], ["Videos of norovirus and influenza incidence and optical flow can be found in Supplementary Video S1 for the whole decade, for the season of 2009-2010 in detail in Supplementary Video S2.", [["norovirus", "DISEASE", 10, 19], ["influenza", "DISEASE", 24, 33], ["norovirus", "ORGANISM", 10, 19], ["norovirus", "PROBLEM", 10, 19], ["influenza incidence", "PROBLEM", 24, 43], ["optical flow", "TEST", 48, 60], ["norovirus", "OBSERVATION", 10, 19]]], ["2) showed a very high activity in incidence and optical flow probably due to the H1N1 epidemic occurring and serves as a prime example for the utility of the optical flow method as this particular season highlights the possible spatial paths of the epidemic wave very well.", [["H1N1", "DISEASE", 81, 85], ["a very high activity", "PROBLEM", 10, 30], ["optical flow", "TEST", 48, 60], ["the H1N1 epidemic", "PROBLEM", 77, 94], ["the optical flow method", "TREATMENT", 154, 177], ["very", "OBSERVATION_MODIFIER", 12, 16], ["high activity", "OBSERVATION", 17, 30], ["optical flow", "OBSERVATION", 48, 60], ["probably due to", "UNCERTAINTY", 61, 76], ["H1N1", "OBSERVATION", 81, 85]]], ["Looking at individual still frames the superior feature of the optical flow analysis versus pure incidence plot becomes evident (Fig. 3 ).", [["the optical flow analysis", "TEST", 59, 84], ["pure incidence plot", "PROBLEM", 92, 111], ["superior", "OBSERVATION_MODIFIER", 39, 47]]], ["For influenza we see a strong incidence in the south-east region while the optical flow clearly shows a strong transition from the city centers in the west to the north and south-east during this week indicated by the red and green markings stretching over the east.", [["influenza", "DISEASE", 4, 13], ["influenza", "PROBLEM", 4, 13], ["the optical flow", "TEST", 71, 87], ["the red and green markings stretching", "PROBLEM", 214, 251], ["strong", "OBSERVATION_MODIFIER", 104, 110], ["transition", "OBSERVATION_MODIFIER", 111, 121], ["red", "OBSERVATION", 218, 221], ["green markings", "OBSERVATION", 226, 240]]], ["Whereas the incidence in the western area is not as pronounced as in the south during the same time period.", [["not as", "UNCERTAINTY", 45, 51], ["pronounced", "OBSERVATION_MODIFIER", 52, 62]]], ["Optical flow captures the movement of incidence report, its direction and intensity in one image or video, without the need to look up all the corresponding values.", [["flow", "OBSERVATION", 8, 12], ["movement", "OBSERVATION_MODIFIER", 26, 34]]], ["For norovirus infections the still image shows a lower and more blanketed incident report situation.", [["norovirus infections", "DISEASE", 4, 24], ["norovirus", "ORGANISM", 4, 13], ["norovirus infections", "PROBLEM", 4, 24], ["infections", "OBSERVATION", 14, 24], ["lower", "OBSERVATION_MODIFIER", 49, 54]]], ["The optical flow activity is limited to individual metropolitan centers and slightly more spread in the east section.", [["The optical flow activity", "TEST", 0, 25], ["optical", "OBSERVATION_MODIFIER", 4, 11], ["flow activity", "OBSERVATION", 12, 25], ["slightly", "OBSERVATION_MODIFIER", 76, 84], ["more", "OBSERVATION_MODIFIER", 85, 89], ["spread", "OBSERVATION_MODIFIER", 90, 96]]], ["A different week was chosen to show norovirus peak activity as the two epidemic events' www.nature.com/scientificreports/ peaks do not occur at the same time.", [["norovirus", "ORGANISM", 36, 45], ["norovirus peak activity", "PROBLEM", 36, 59], ["norovirus", "OBSERVATION", 36, 45]]], ["The upper row (a) shows the summarized incidence over the decade revealing a difference in case numbers between influenza and norovirus infections with norovirus still showing strong incidence in certain high population density areas.", [["influenza", "DISEASE", 112, 121], ["norovirus infections", "DISEASE", 126, 146], ["norovirus", "DISEASE", 152, 161], ["norovirus", "ORGANISM", 126, 135], ["influenza", "PROBLEM", 112, 121], ["norovirus infections", "PROBLEM", 126, 146], ["norovirus", "PROBLEM", 152, 161], ["upper", "ANATOMY_MODIFIER", 4, 9], ["norovirus infections", "OBSERVATION", 126, 146], ["high", "OBSERVATION_MODIFIER", 204, 208], ["population", "OBSERVATION_MODIFIER", 209, 219], ["density", "OBSERVATION", 220, 227]]], ["The MC simulation shows a maximum incidence for all locations since the upper limit was the highest observed incidence count.", [["The MC simulation", "TEST", 0, 17], ["maximum", "OBSERVATION_MODIFIER", 26, 33], ["upper limit", "OBSERVATION_MODIFIER", 72, 83]]], ["The optical flow maximum projections (b) show that influenza waves cover the whole area over the decade, while norovirus optical flow activity is reserved to localized clusters with north-south movement as the dominant direction throughout and a west-bound tendency in the western part of Germany.", [["influenza", "DISEASE", 51, 60], ["influenza waves", "PROBLEM", 51, 66], ["norovirus optical flow activity", "TEST", 111, 142], ["influenza", "OBSERVATION", 51, 60], ["flow activity", "OBSERVATION", 129, 142], ["dominant", "OBSERVATION_MODIFIER", 210, 218], ["direction", "OBSERVATION_MODIFIER", 219, 228]]], ["Influenza is showing 339 no activity pixels and norovirus 10683.", [["Influenza", "DISEASE", 0, 9], ["norovirus 10683", "CHEMICAL", 48, 63], ["norovirus 10683", "SPECIES", 48, 63], ["Influenza", "TEST", 0, 9], ["activity pixels", "PROBLEM", 28, 43], ["norovirus", "PROBLEM", 48, 57], ["activity pixels", "OBSERVATION", 28, 43]]], ["The MC constraint 3 control displays maximum activity throughout the decade as there are no rules/effects in the simulation data governing the flow.", [["The MC constraint", "TREATMENT", 0, 17], ["the simulation data", "TEST", 109, 128], ["maximum", "OBSERVATION_MODIFIER", 37, 44], ["activity", "OBSERVATION_MODIFIER", 45, 53], ["no", "UNCERTAINTY", 89, 91]]], ["The simulation shows that by Monte-Carlo case-number distribution alone no pattern of movement can be extracted by optical flow (even more so in the videos).", [["The simulation", "TEST", 0, 14], ["optical flow", "TEST", 115, 127]]], ["The incidence sums and optical flow intensity was normalized and plotted ( Fig. 4a ).", [["optical flow intensity", "TEST", 23, 45], ["flow intensity", "OBSERVATION", 31, 45]]], ["We see a pronounced wave pattern of incidence for norovirus and influenza which translates into optical flow signals very well for influenza and less so for norovirus infections.", [["norovirus", "DISEASE", 50, 59], ["influenza", "DISEASE", 64, 73], ["influenza", "DISEASE", 131, 140], ["norovirus infections", "DISEASE", 157, 177], ["norovirus", "ORGANISM", 157, 166], ["a pronounced wave pattern", "PROBLEM", 7, 32], ["norovirus", "PROBLEM", 50, 59], ["influenza", "PROBLEM", 64, 73], ["optical flow signals", "TEST", 96, 116], ["influenza", "PROBLEM", 131, 140], ["norovirus infections", "PROBLEM", 157, 177], ["norovirus", "OBSERVATION", 50, 59]]], ["Influenza spreads in a globally pronounced pattern throughout the country whereas norovirus spreads in more geographically localized clusters showing no clear spread-receive patterns in the context of direct neighborhoods in the observed data.", [["Influenza", "DISEASE", 0, 9], ["norovirus", "DISEASE", 82, 91], ["Influenza spreads", "PROBLEM", 0, 17], ["a globally pronounced pattern", "PROBLEM", 21, 50], ["norovirus", "PROBLEM", 82, 91], ["clear spread", "PROBLEM", 153, 165], ["globally pronounced", "OBSERVATION_MODIFIER", 23, 42], ["no", "UNCERTAINTY", 150, 152], ["clear", "OBSERVATION_MODIFIER", 153, 158], ["spread", "OBSERVATION", 159, 165]]], ["While the intensity plot for norovirus shows a noisy peak formation in comparison to rather defined peaks of influenza cases the different spread patterns can be clearly discriminated in the maximum projection ( Fig. 3b ) with a spotty coverage amounting to more zero pixels for norovirus than for influenza.", [["norovirus", "DISEASE", 29, 38], ["influenza", "DISEASE", 109, 118], ["norovirus", "DISEASE", 279, 288], ["influenza", "DISEASE", 298, 307], ["the intensity plot", "TEST", 6, 24], ["norovirus", "PROBLEM", 29, 38], ["a noisy peak formation", "PROBLEM", 45, 67], ["influenza", "PROBLEM", 109, 118], ["a spotty coverage", "TREATMENT", 227, 244], ["norovirus", "PROBLEM", 279, 288], ["influenza", "PROBLEM", 298, 307], ["norovirus", "OBSERVATION", 29, 38], ["peak formation", "OBSERVATION", 53, 67], ["influenza", "OBSERVATION", 109, 118]]], ["For example, the city of Hamburg has six neighbors and shows a well identifiable pattern of disease spread and receive activity.", [["disease spread", "PROBLEM", 92, 106], ["disease", "OBSERVATION", 92, 99]]], ["For the city of Berlin having nine neighbors the spread pattern shows more fluctuations within one season.", [["more", "OBSERVATION_MODIFIER", 70, 74], ["fluctuations", "OBSERVATION_MODIFIER", 75, 87]]], ["In the control data-set both show very convoluted patterns as all municipalities get random MC data.Dynamic relation of norovirus and influenza waves.Regarding the distance of the seasonal peak between both infectious diseases for all municipalities together, we found, for the data available to us, a normal Gaussian distribution with an expectation of mu = \u22123(+ \u2212 0, 24958) and a sigma = 6, 724 (Fig. 5 ).", [["norovirus", "DISEASE", 120, 129], ["influenza", "DISEASE", 134, 143], ["infectious diseases", "DISEASE", 207, 226], ["norovirus", "ORGANISM", 120, 129], ["random MC data", "TEST", 85, 99], ["norovirus", "PROBLEM", 120, 129], ["influenza waves", "PROBLEM", 134, 149], ["both infectious diseases", "PROBLEM", 202, 226], ["the data", "TEST", 274, 282], ["a sigma", "TEST", 380, 387], ["norovirus", "OBSERVATION", 120, 129], ["influenza waves", "OBSERVATION", 134, 149], ["seasonal", "OBSERVATION_MODIFIER", 180, 188], ["peak", "OBSERVATION_MODIFIER", 189, 193], ["both", "OBSERVATION_MODIFIER", 202, 206], ["infectious", "OBSERVATION", 207, 217]]], ["This indicates that, based on our data set, there is a 3-week gap between the incidence maxima of reported norovirus and influenza infections.", [["norovirus", "DISEASE", 107, 116], ["influenza infections", "DISEASE", 121, 141], ["norovirus", "ORGANISM", 107, 116], ["reported norovirus", "PROBLEM", 98, 116], ["influenza infections", "PROBLEM", 121, 141], ["norovirus", "OBSERVATION", 107, 116], ["influenza infections", "OBSERVATION", 121, 141]]], ["Especially the constraint 3 data-set shows a strong difference between random peak data and real data. www.nature.com/scientificreports/ The application of optical flow analysis on complex epidemiological data-sets reveals infectious disease spreading patterns of two illnesses that are highly relevant for the public health sector in Germany.", [["the constraint 3 data", "TEST", 11, 32], ["random peak data", "TEST", 71, 87], ["optical flow analysis", "TEST", 156, 177], ["complex epidemiological data", "TEST", 181, 209], ["infectious disease spreading patterns of two illnesses", "PROBLEM", 223, 277], ["infectious", "OBSERVATION_MODIFIER", 223, 233]]], ["By using this method we could clearly show the wave-like spread pattern of influenza.", [["influenza", "DISEASE", 75, 84], ["this method", "TEST", 9, 20], ["influenza", "PROBLEM", 75, 84], ["influenza", "OBSERVATION", 75, 84]]], ["Furthermore, we could discover a statistical temporal connection to norovirus infection cases despite the different norovirus spread pattern.", [["norovirus infection", "DISEASE", 68, 87], ["norovirus", "ORGANISM", 68, 77], ["a statistical temporal connection to norovirus infection cases", "PROBLEM", 31, 93], ["the different norovirus spread pattern", "PROBLEM", 102, 140], ["norovirus", "OBSERVATION_MODIFIER", 68, 77], ["infection", "OBSERVATION", 78, 87], ["different", "OBSERVATION_MODIFIER", 106, 115], ["norovirus", "OBSERVATION", 116, 125]]], ["For doing so we analysed publicly available source data of very high resolution in the spatial and time domain (Fig. 1 ).", [["source data", "TEST", 44, 55]]], ["In the spatial domain the resolution scales down to municipalities and city states representing all 412 administrative regions of this level in Germany.", [["resolution", "OBSERVATION_MODIFIER", 26, 36], ["scales", "OBSERVATION_MODIFIER", 37, 43]]], ["In the time domain numbers for reported cases of confirmed norovirus and influenza infections are available for 573 weeks (with 2008, 2012 and 2016 being leap years).", [["norovirus", "DISEASE", 59, 68], ["influenza infections", "DISEASE", 73, 93], ["norovirus", "ORGANISM", 59, 68], ["norovirus", "PROBLEM", 59, 68], ["influenza infections", "PROBLEM", 73, 93], ["norovirus", "OBSERVATION", 59, 68]]], ["For the analysis we used reported norovirus infections and influenza cases.", [["norovirus infections", "DISEASE", 34, 54], ["influenza", "DISEASE", 59, 68], ["norovirus", "ORGANISM", 34, 43], ["the analysis", "TEST", 4, 16], ["norovirus infections", "PROBLEM", 34, 54], ["influenza cases", "PROBLEM", 59, 74], ["norovirus", "OBSERVATION", 34, 43]]], ["We excluded influenza-like illnesses (ILI), because we wanted to rely on infection disease cases confirmed by laboratory diagnostics.", [["influenza-like illnesses", "DISEASE", 12, 36], ["ILI", "DISEASE", 38, 41], ["infection disease", "DISEASE", 73, 90], ["influenza", "PROBLEM", 12, 21], ["illnesses", "PROBLEM", 27, 36], ["infection disease cases", "PROBLEM", 73, 96], ["laboratory diagnostics", "TEST", 110, 132], ["influenza", "OBSERVATION", 12, 21]]], ["The distribution of time between norovirus and influenza infection peaks (Fig. 5 ) may seem counter-intuitive at first.", [["infection", "DISEASE", 57, 66], ["norovirus", "ORGANISM", 33, 42], ["norovirus", "PROBLEM", 33, 42], ["influenza infection peaks", "PROBLEM", 47, 72]]], ["Especially the optical flow data show a wave-like spread pattern for influenza seasons (Fig. 4) and no wave pattern for norovirus outbreak seasons.", [["influenza", "DISEASE", 69, 78], ["norovirus", "DISEASE", 120, 129], ["the optical flow data", "TEST", 11, 32], ["a wave-like spread pattern", "PROBLEM", 38, 64], ["influenza seasons", "PROBLEM", 69, 86], ["wave pattern", "PROBLEM", 103, 115], ["norovirus", "PROBLEM", 120, 129], ["no", "UNCERTAINTY", 100, 102]]], ["This can be interpreted as evidence for the very different nature of spread-mechanics between these two illnesses.", [["these two illnesses", "PROBLEM", 94, 113]]], ["In the southern parts of Germany we see a lot of incidences but a rather low geographical movement of both infection diseases in the optic flow.", [["optic", "ANATOMY", 133, 138], ["infection diseases", "DISEASE", 107, 125], ["optic", "MULTI-TISSUE_STRUCTURE", 133, 138], ["both infection diseases", "PROBLEM", 102, 125], ["the optic flow", "TEST", 129, 143], ["both", "OBSERVATION_MODIFIER", 102, 106], ["infection", "OBSERVATION", 107, 116], ["optic flow", "OBSERVATION", 133, 143]]], ["This effect is more prominent for norovirus infections (see Fig.3b ) than for influenza.", [["norovirus infections", "DISEASE", 34, 54], ["influenza", "DISEASE", 78, 87], ["norovirus", "ORGANISM", 34, 43], ["norovirus infections", "PROBLEM", 34, 54], ["influenza", "PROBLEM", 78, 87], ["more prominent", "OBSERVATION_MODIFIER", 15, 29]]], ["Germany offers an interesting spatial dynamical insight in infectious disease spreading because the country has a high population density of 238.5 people per square-kilometer compared to the western European countries with 179.5 and the EU at large with 33.7 people per square-kilometer.", [["infectious disease", "DISEASE", 59, 77], ["people", "SPECIES", 147, 153], ["people", "SPECIES", 259, 265], ["infectious disease spreading", "PROBLEM", 59, 87], ["infectious", "OBSERVATION_MODIFIER", 59, 69], ["high population", "OBSERVATION_MODIFIER", 114, 129]]], ["Public transport is of high relevance for travelling to outskirts of cities and between smaller towns, whereas travelling by car is of importance for remote areas in Germany.", [["smaller", "OBSERVATION_MODIFIER", 88, 95]]], ["The possibility of contamination can be reduced to a minimum by thorough cleaning and disinfection because these viruses are transmitted via smear infections 45 .", [["infections", "DISEASE", 147, 157], ["contamination", "PROBLEM", 19, 32], ["thorough cleaning", "TREATMENT", 64, 81], ["disinfection", "TREATMENT", 86, 98], ["these viruses", "PROBLEM", 107, 120], ["smear infections", "PROBLEM", 141, 157], ["possibility of", "UNCERTAINTY", 4, 18], ["contamination", "OBSERVATION", 19, 32]]], ["Especially young children and elderly people are affected by the infections.", [["infections", "DISEASE", 65, 75], ["children", "ORGANISM", 17, 25], ["people", "ORGANISM", 38, 44], ["children", "SPECIES", 17, 25], ["people", "SPECIES", 38, 44], ["the infections", "PROBLEM", 61, 75], ["infections", "OBSERVATION", 65, 75]]], ["Because the immune system is not yet fully developed, children quickly become ill 46 .", [["immune system", "ANATOMY", 12, 25], ["children", "ORGANISM", 54, 62], ["children", "SPECIES", 54, 62]]], ["In elder people, the infection is often caused by contaminated food 47 .", [["infection", "DISEASE", 21, 30], ["people", "ORGANISM", 9, 15], ["people", "SPECIES", 9, 15], ["the infection", "PROBLEM", 17, 30], ["infection", "OBSERVATION", 21, 30]]], ["Due to the weakened immune system, they are particularly at risk here.", [["immune system", "ANATOMY", 20, 33], ["the weakened immune system", "PROBLEM", 7, 33], ["weakened", "OBSERVATION", 11, 19]]], ["Norovirus infections occur rather sporadically over the year: during the winter season increased numbers of infections are frequently reported.", [["Norovirus infections", "DISEASE", 0, 20], ["infections", "DISEASE", 108, 118], ["Norovirus", "ORGANISM", 0, 9], ["Norovirus infections", "PROBLEM", 0, 20], ["infections", "PROBLEM", 108, 118], ["infections", "OBSERVATION", 10, 20], ["infections", "OBSERVATION", 108, 118]]], ["People are getting closer together because of the weather and holiday season.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["Heated apartments may act as incubator for this virus and other infectious agents and the human immune system may get weakened due to vitamin deficiencies 6 .", [["vitamin", "CHEMICAL", 134, 141], ["vitamin", "CHEMICAL", 134, 141], ["human", "ORGANISM", 90, 95], ["vitamin", "SIMPLE_CHEMICAL", 134, 141], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 90, 95], ["Heated apartments", "TREATMENT", 0, 17], ["this virus", "PROBLEM", 43, 53], ["other infectious agents", "TREATMENT", 58, 81], ["the human immune system", "TREATMENT", 86, 109], ["vitamin deficiencies", "PROBLEM", 134, 154]]], ["Altogether, this increases the risk of infections and disease spreading.", [["infections", "DISEASE", 39, 49], ["infections", "PROBLEM", 39, 49], ["disease spreading", "PROBLEM", 54, 71], ["infections", "OBSERVATION", 39, 49], ["disease", "OBSERVATION", 54, 61]]], ["There are several circulating genotypes of human-pathogenic noroviruses known.", [["human-pathogenic noroviruses", "DISEASE", 43, 71], ["human", "ORGANISM", 43, 48], ["noroviruses", "ORGANISM", 60, 71], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 43, 48], ["pathogenic noroviruses", "PROBLEM", 49, 71], ["several", "OBSERVATION_MODIFIER", 10, 17], ["circulating", "OBSERVATION_MODIFIER", 18, 29], ["pathogenic noroviruses", "OBSERVATION", 49, 71]]], ["Currently, the genotype GII.4 is predominant, but recent studies show, that in children multiple genotypes co-circulate with low to high incidence.", [["children", "ORGANISM", 79, 87], ["children", "SPECIES", 79, 87], ["the genotype GII.4", "PROBLEM", 11, 29], ["recent studies", "TEST", 50, 64], ["GII.4", "OBSERVATION", 24, 29], ["predominant", "OBSERVATION_MODIFIER", 33, 44]]], ["Especially, genotypes GII.3, GII.6 and GII.2 together with GII.4 are able to cause norovirus infections in children under 5 years of age 35 .", [["norovirus infections", "DISEASE", 83, 103], ["GII.6", "GENE_OR_GENE_PRODUCT", 29, 34], ["GII.2", "GENE_OR_GENE_PRODUCT", 39, 44], ["norovirus", "ORGANISM", 83, 92], ["children", "ORGANISM", 107, 115], ["children", "SPECIES", 107, 115], ["GII.4", "PROBLEM", 59, 64], ["norovirus infections", "PROBLEM", 83, 103], ["norovirus", "OBSERVATION", 83, 92]]], ["This phenomenon might contribute to the very different outcomes of regional norovirus outbreaks.", [["norovirus", "DISEASE", 76, 85], ["norovirus", "ORGANISM", 76, 85], ["This phenomenon", "PROBLEM", 0, 15], ["regional norovirus outbreaks", "PROBLEM", 67, 95], ["very", "OBSERVATION_MODIFIER", 40, 44], ["different", "OBSERVATION_MODIFIER", 45, 54], ["regional", "OBSERVATION_MODIFIER", 67, 75], ["norovirus", "OBSERVATION", 76, 85]]], ["Depending on the capability of GII.4 sub-strains to get transmitted to adults which usually have a higher geospatial mobility than younger children, regional spreading of norovirus might increase.", [["norovirus", "DISEASE", 171, 180], ["adults", "ORGANISM", 71, 77], ["children", "ORGANISM", 139, 147], ["norovirus", "ORGANISM", 171, 180], ["children", "SPECIES", 139, 147], ["norovirus", "PROBLEM", 171, 180], ["norovirus", "OBSERVATION", 171, 180]]], ["For influenza, the impact of different circulating viral strains on the geospatial outbreak pattern is discussed below.", [["influenza", "DISEASE", 4, 13], ["influenza", "PROBLEM", 4, 13], ["different circulating viral strains", "PROBLEM", 29, 64], ["viral strains", "OBSERVATION", 51, 64]]], ["Influenza virus particles, on the other hand, do not have such high environmental stability, but are readily transmitted by droplet infection.", [["infection", "DISEASE", 132, 141], ["Influenza virus", "ORGANISM", 0, 15], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus particles", "PROBLEM", 0, 25], ["droplet infection", "PROBLEM", 124, 141], ["virus particles", "OBSERVATION", 10, 25], ["droplet infection", "OBSERVATION", 124, 141]]], ["Therefore, it may be sufficient enough just to be in the same room with an infected person to contract the disease.", [["person", "SPECIES", 84, 90], ["the disease", "PROBLEM", 103, 114], ["infected", "OBSERVATION", 75, 83], ["disease", "OBSERVATION", 107, 114]]], ["Due to the highly efficient aerogene transmission of influenza and the rather long time period of one week within an infected person may transmit the pathogen influenza spreading in human populations can increase exponentially with a high growth rate of infections.", [["influenza", "DISEASE", 53, 62], ["influenza", "DISEASE", 159, 168], ["infections", "DISEASE", 254, 264], ["human", "ORGANISM", 182, 187], ["person", "SPECIES", 126, 132], ["human", "SPECIES", 182, 187], ["human", "SPECIES", 182, 187], ["influenza", "PROBLEM", 53, 62], ["the pathogen influenza spreading in human populations", "PROBLEM", 146, 199], ["a high growth rate of infections", "PROBLEM", 232, 264], ["influenza", "OBSERVATION", 53, 62], ["infected", "OBSERVATION", 117, 125], ["pathogen", "OBSERVATION_MODIFIER", 150, 158], ["influenza", "OBSERVATION", 159, 168], ["high growth", "OBSERVATION_MODIFIER", 234, 245], ["infections", "OBSERVATION", 254, 264]]], ["This mainly affects age groups in the middle range (30-50 years).", [["middle", "ANATOMY_MODIFIER", 38, 44]]], ["Infected people may become symptomatic or even asymptomatic carriers for the disease and contribute to a wide spread of the infections over several days 48 .", [["infections", "DISEASE", 124, 134], ["people", "ORGANISM", 9, 15], ["people", "SPECIES", 9, 15], ["symptomatic", "PROBLEM", 27, 38], ["asymptomatic carriers", "PROBLEM", 47, 68], ["the disease", "PROBLEM", 73, 84], ["the infections", "PROBLEM", 120, 134], ["symptomatic", "OBSERVATION_MODIFIER", 27, 38], ["wide", "OBSERVATION_MODIFIER", 105, 109], ["spread", "OBSERVATION_MODIFIER", 110, 116], ["infections", "OBSERVATION", 124, 134]]], ["The increasing humidity and low temperatures in during the winter season promotes the transmission of influenza.Dynamic relation of norovirus and influenza waves.Spread pattern of different influenza virus strains dominating during flue season in Germany can be clearly discriminated by optical flow analysis.", [["influenza", "DISEASE", 102, 111], ["norovirus", "DISEASE", 132, 141], ["influenza", "DISEASE", 146, 155], ["norovirus", "ORGANISM", 132, 141], ["influenza virus", "ORGANISM", 190, 205], ["influenza virus", "SPECIES", 190, 205], ["The increasing humidity", "PROBLEM", 0, 23], ["low temperatures", "PROBLEM", 28, 44], ["influenza", "PROBLEM", 102, 111], ["norovirus", "PROBLEM", 132, 141], ["influenza waves", "PROBLEM", 146, 161], ["different influenza virus strains", "PROBLEM", 180, 213], ["optical flow analysis", "TEST", 287, 308], ["increasing", "OBSERVATION_MODIFIER", 4, 14], ["humidity", "OBSERVATION_MODIFIER", 15, 23], ["low temperatures", "OBSERVATION_MODIFIER", 28, 44], ["influenza", "OBSERVATION", 102, 111], ["norovirus", "OBSERVATION", 132, 141], ["influenza waves", "OBSERVATION", 146, 161], ["different", "OBSERVATION_MODIFIER", 180, 189], ["influenza virus strains", "OBSERVATION", 190, 213]]], ["In a recent report, the German national public health institute highlights four unusual influenza seasons in Germany: 2009/10, 2012/13, 2014/15 and 2017/18 [49] [50] [51] [52] .", [["influenza", "DISEASE", 88, 97]]], ["We analyzed the corresponding published data on reported cases by the optical flow method.", [["the optical flow method", "TEST", 66, 89]]], ["In 2009, a newly emerging pandemic influenza A strain H1N1 hit an immunological na\u00efve population in Germany (Fig. S4 (a-h) ).", [["influenza A strain H1N1", "ORGANISM", 35, 58], ["S4", "GENE_OR_GENE_PRODUCT", 114, 116], ["a-h", "GENE_OR_GENE_PRODUCT", 118, 121], ["influenza A strain H1N1", "SPECIES", 35, 58], ["a newly emerging pandemic influenza A strain H1N1", "PROBLEM", 9, 58]]], ["In the optical flow plots we observed a very distinct influenza spread pattern of this pandemic virus compared to other influenza seasons in Germany: high incidence values for influenza infections are going along with a wide spread of optical flow signals across Germany (Fig. S4 (d) and (h) ).", [["pandemic", "DISEASE", 87, 95], ["influenza", "DISEASE", 120, 129], ["influenza infections", "DISEASE", 176, 196], ["the optical flow plots", "TEST", 3, 25], ["a very distinct influenza spread pattern", "PROBLEM", 38, 78], ["this pandemic virus", "PROBLEM", 82, 101], ["other influenza seasons", "PROBLEM", 114, 137], ["high incidence values", "PROBLEM", 150, 171], ["influenza infections", "PROBLEM", 176, 196], ["flow plots", "OBSERVATION", 15, 25], ["very", "OBSERVATION_MODIFIER", 40, 44], ["distinct", "OBSERVATION_MODIFIER", 45, 53], ["influenza", "OBSERVATION", 54, 63]]], ["This pattern could be detected for the two distinct influenza A(H1N1) spreading events (2009, calendar weeks 24-30 and 35-53) described in the report by the German public health institute 49 , but was more prominent in the second outbreak wave during the winter season ( Fig. S4 (h) ).Dynamic relation of norovirus and influenza waves.The optical flow signals for influenza seasons 2012/13 and 2014/15 are characterized by less geographical spreading across Germany.", [["influenza", "DISEASE", 52, 61], ["norovirus", "DISEASE", 305, 314], ["influenza", "DISEASE", 319, 328], ["influenza A(H1N1", "ORGANISM", 52, 68], ["norovirus", "ORGANISM", 305, 314], ["the two distinct influenza A(H1N1) spreading events", "PROBLEM", 35, 86], ["norovirus", "PROBLEM", 305, 314], ["influenza waves", "PROBLEM", 319, 334], ["The optical flow signals", "TEST", 335, 359], ["influenza seasons", "TEST", 364, 381], ["distinct", "OBSERVATION_MODIFIER", 43, 51], ["influenza", "OBSERVATION", 52, 61], ["more prominent", "OBSERVATION_MODIFIER", 201, 215], ["norovirus", "OBSERVATION", 305, 314], ["influenza waves", "OBSERVATION", 319, 334], ["less", "OBSERVATION_MODIFIER", 423, 427], ["geographical", "OBSERVATION_MODIFIER", 428, 440], ["spreading", "OBSERVATION_MODIFIER", 441, 450]]], ["In 2012, an equal distribution of influenza A(H1N1)pdm09, influenza A(H3N2) and influenza B virus strains was observed ( Fig. S3 (a-d) ), whereas in season 2014/15 the influenza A(H3N2) strain dominated over influenza A(H1N1)pdm09 and influenza B (Fig. S2 (e-h) ) 50, 51 .", [["influenza", "DISEASE", 34, 43], ["influenza A", "DISEASE", 58, 69], ["influenza B", "DISEASE", 80, 91], ["influenza A(H1N1)pdm09", "DISEASE", 208, 230], ["influenza B", "DISEASE", 235, 246], ["influenza A(H1N1)pdm09", "ORGANISM", 34, 56], ["influenza A(H3N2)", "ORGANISM", 58, 75], ["influenza B virus", "ORGANISM", 80, 97], ["S3", "GENE_OR_GENE_PRODUCT", 126, 128], ["influenza A(H3N2) strain", "ORGANISM", 168, 192], ["influenza A(H1N1)pdm09", "ORGANISM", 208, 230], ["influenza B", "ORGANISM", 235, 246], ["influenza A(H1N1", "SPECIES", 34, 50], ["H3N2", "SPECIES", 70, 74], ["influenza B virus", "SPECIES", 80, 97], ["influenza A(H1N1", "SPECIES", 208, 224], ["influenza A(H1N1)pdm09", "SPECIES", 34, 56], ["influenza B virus", "SPECIES", 80, 97], ["influenza A(H1N1)pdm09", "SPECIES", 208, 230], ["influenza", "PROBLEM", 34, 43], ["H1N1", "PROBLEM", 46, 50], ["pdm09", "PROBLEM", 51, 56], ["influenza", "PROBLEM", 58, 67], ["H3N2", "PROBLEM", 70, 74], ["influenza B virus strains", "PROBLEM", 80, 105], ["the influenza A(H3N2) strain", "PROBLEM", 164, 192], ["influenza", "PROBLEM", 208, 217], ["pdm09", "PROBLEM", 225, 230], ["influenza B", "TEST", 235, 246], ["influenza", "OBSERVATION", 34, 43]]], ["A genetic drift in influenza A(H3N2) at the early beginning of the epidemic resulted in more infections most probably due to ineffectiveness of the vaccine used.", [["influenza A", "DISEASE", 19, 30], ["infections", "DISEASE", 93, 103], ["influenza A(H3N2", "ORGANISM", 19, 35], ["A genetic drift", "PROBLEM", 0, 15], ["influenza A", "PROBLEM", 19, 30], ["H3N2", "PROBLEM", 31, 35], ["more infections", "PROBLEM", 88, 103], ["the vaccine", "TREATMENT", 144, 155], ["genetic drift", "OBSERVATION", 2, 15], ["influenza", "OBSERVATION", 19, 28], ["infections", "OBSERVATION", 93, 103]]], ["Interestingly, the influenza season 2017/18 again showed high case numbers, but also an unusual age distribution among infected people in Germany 52 .", [["influenza", "DISEASE", 19, 28], ["people", "ORGANISM", 128, 134], ["people", "SPECIES", 128, 134], ["the influenza season", "TEST", 15, 35], ["high case numbers", "PROBLEM", 57, 74], ["infected", "OBSERVATION_MODIFIER", 119, 127]]], ["In relation to the previous influenza outbreaks shown here more infections of people in age groups with a presumably higher mobility were reported in 2017/18.", [["influenza", "DISEASE", 28, 37], ["infections", "DISEASE", 64, 74], ["people", "ORGANISM", 78, 84], ["people", "SPECIES", 78, 84], ["the previous influenza outbreaks", "PROBLEM", 15, 47], ["a presumably higher mobility", "PROBLEM", 104, 132], ["higher mobility", "OBSERVATION", 117, 132]]], ["In the optical flow analysis, this season is characterized by increased regional spread of reported influenza cases on the geospatial-temporal scale (Fig. S2 (a-d) ).", [["influenza", "DISEASE", 100, 109], ["S2", "GENE_OR_GENE_PRODUCT", 155, 157], ["the optical flow analysis", "TEST", 3, 28], ["reported influenza cases", "PROBLEM", 91, 115], ["increased", "OBSERVATION_MODIFIER", 62, 71], ["regional", "OBSERVATION_MODIFIER", 72, 80], ["spread", "OBSERVATION_MODIFIER", 81, 87], ["influenza", "OBSERVATION", 100, 109]]], ["Furthermore, optical flow activities run in front of reported maximum incidence values.", [["optical flow activities", "TEST", 13, 36], ["flow activities", "OBSERVATION", 21, 36], ["maximum", "OBSERVATION_MODIFIER", 62, 69]]], ["In maximum intensity projections of optical flow data of selected calendar weeks we could observe clearly distinct spread pattern for the different influenza outbreak seasons analyzed here: the pandemic influenza outbreak in 2009 is characterized by an optical flow pattern covering most parts of Germany (Fig. S4) , whereas the other seasons show a more fragmented pattern (Fig. S2 and S3 ).", [["influenza", "DISEASE", 148, 157], ["influenza", "DISEASE", 203, 212], ["S3", "GENE_OR_GENE_PRODUCT", 387, 389], ["S2", "PROTEIN", 380, 382], ["S3", "PROTEIN", 387, 389], ["optical flow data", "TEST", 36, 53], ["the different influenza outbreak seasons", "PROBLEM", 134, 174], ["the pandemic influenza outbreak", "PROBLEM", 190, 221], ["an optical flow pattern", "TEST", 250, 273], ["optical flow", "OBSERVATION", 253, 265], ["S3", "ANATOMY", 387, 389]]], ["Of note, the unusual influenza outbreak 2017/18 shows a broader coverage of some parts of Germany placing this optical flow pattern (Fig. S2 (c) ) closer to the pandemic event in season 2009/10 ( Fig. S4 (g) ).Dynamic relation of norovirus and influenza waves.While analysing both infectious disease spread pattern a question arose: Why is there an apparent connection between the spread pattern of norovirus and influenza infections on the time scale?", [["influenza", "DISEASE", 21, 30], ["norovirus", "DISEASE", 230, 239], ["influenza", "DISEASE", 244, 253], ["norovirus", "DISEASE", 399, 408], ["influenza infections", "DISEASE", 413, 433], ["norovirus", "ORGANISM", 230, 239], ["norovirus", "ORGANISM", 399, 408], ["S2 (c)", "PROTEIN", 138, 144], ["the unusual influenza outbreak", "PROBLEM", 9, 39], ["this optical flow pattern", "TEST", 106, 131], ["norovirus", "PROBLEM", 230, 239], ["influenza waves", "PROBLEM", 244, 259], ["norovirus", "PROBLEM", 399, 408], ["influenza infections", "PROBLEM", 413, 433], ["norovirus", "OBSERVATION", 230, 239], ["influenza waves", "OBSERVATION", 244, 259], ["infectious", "OBSERVATION", 281, 291], ["norovirus", "OBSERVATION", 399, 408], ["influenza", "OBSERVATION_MODIFIER", 413, 422], ["infections", "OBSERVATION", 423, 433]]], ["One explanation for this phenomenon might be a negative influence of subsequent infections by both pathogens on the human immune system.", [["immune system", "ANATOMY", 122, 135], ["infections", "DISEASE", 80, 90], ["human", "ORGANISM", 116, 121], ["immune system", "ANATOMICAL_SYSTEM", 122, 135], ["human", "SPECIES", 116, 121], ["human", "SPECIES", 116, 121], ["this phenomenon", "PROBLEM", 20, 35], ["subsequent infections", "PROBLEM", 69, 90], ["infections", "OBSERVATION", 80, 90]]], ["Norovirus infections could lead to nutrient deficiency by severe diarrhoea and dehydration.", [["Norovirus infections", "DISEASE", 0, 20], ["nutrient deficiency", "DISEASE", 35, 54], ["diarrhoea", "DISEASE", 65, 74], ["dehydration", "DISEASE", 79, 90], ["Norovirus", "ORGANISM", 0, 9], ["Norovirus infections", "PROBLEM", 0, 20], ["nutrient deficiency", "PROBLEM", 35, 54], ["severe diarrhoea", "PROBLEM", 58, 74], ["dehydration", "PROBLEM", 79, 90], ["infections", "OBSERVATION", 10, 20], ["nutrient deficiency", "OBSERVATION", 35, 54], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["diarrhoea", "OBSERVATION", 65, 74], ["dehydration", "OBSERVATION", 79, 90]]], ["Low light conditions and a poorer supply of nutrients cause, for example, a decreasing vitamin D level which leads to a weakened immune system 53 .", [["vitamin D", "CHEMICAL", 87, 96], ["vitamin D", "CHEMICAL", 87, 96], ["vitamin D", "SIMPLE_CHEMICAL", 87, 96], ["Low light conditions", "PROBLEM", 0, 20], ["a decreasing vitamin D level", "TEST", 74, 102], ["a weakened immune system", "PROBLEM", 118, 142], ["light conditions", "OBSERVATION_MODIFIER", 4, 20]]], ["Furthermore, norovirus infections mainly affect children and elderly people, because their immune system is not yet as good or not as well developed as a middle-aged person.", [["norovirus infections", "DISEASE", 13, 33], ["norovirus", "ORGANISM", 13, 22], ["children", "ORGANISM", 48, 56], ["people", "ORGANISM", 69, 75], ["person", "ORGANISM", 166, 172], ["children", "SPECIES", 48, 56], ["people", "SPECIES", 69, 75], ["person", "SPECIES", 166, 172], ["norovirus infections", "PROBLEM", 13, 33], ["norovirus", "OBSERVATION_MODIFIER", 13, 22], ["infections", "OBSERVATION", 23, 33]]], ["Due to the incubation period of influenza, the infection is not noticeable at first.", [["influenza", "DISEASE", 32, 41], ["infection", "DISEASE", 47, 56], ["influenza", "PROBLEM", 32, 41], ["the infection", "PROBLEM", 43, 56], ["influenza", "OBSERVATION", 32, 41], ["infection", "OBSERVATION", 47, 56]]], ["So many already infected people may still go to work and spread the disease 54 .", [["people", "ORGANISM", 25, 31], ["people", "SPECIES", 25, 31], ["infected", "OBSERVATION", 16, 24]]], ["In addition, the risk of getting infected persists even after the symptoms have subsided within a period of 7-10 days.", [["infected", "PROBLEM", 33, 41], ["the symptoms", "PROBLEM", 62, 74], ["infected", "OBSERVATION", 33, 41]]], ["This leads to the assumption that norovirus infections may support the spread of influenza.", [["norovirus infections", "DISEASE", 34, 54], ["influenza", "DISEASE", 81, 90], ["norovirus", "ORGANISM", 34, 43], ["norovirus infections", "PROBLEM", 34, 54], ["influenza", "PROBLEM", 81, 90], ["norovirus", "OBSERVATION", 34, 43], ["influenza", "OBSERVATION", 81, 90]]], ["First, the human body is weakened by a norovirus infection which result in fewer nutrients and Optical flow analysis of epidemiological data can be conveniently used to simplify complex disease spreading patterns as shown here.", [["body", "ANATOMY", 17, 21], ["norovirus infection", "DISEASE", 39, 58], ["human", "ORGANISM", 11, 16], ["body", "ORGANISM_SUBDIVISION", 17, 21], ["norovirus", "ORGANISM", 39, 48], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 11, 16], ["a norovirus infection", "PROBLEM", 37, 58], ["Optical flow analysis", "TEST", 95, 116], ["epidemiological data", "TEST", 120, 140], ["complex disease spreading patterns", "PROBLEM", 178, 212], ["human body", "ANATOMY", 11, 21], ["weakened", "OBSERVATION", 25, 33], ["norovirus", "OBSERVATION", 39, 48]]], ["This would also allow the detection of unusual infectious disease outbreaks, if signatures of such an event could be observed in the visualised data set 59 .", [["unusual infectious disease outbreaks", "PROBLEM", 39, 75], ["unusual", "OBSERVATION_MODIFIER", 39, 46], ["infectious", "OBSERVATION", 47, 57]]], ["Furthermore, the investigation of recent disease outbreaks by optical flow analysis could help to understand spatio-temporal disease spread patterns in relation to existing or vacant medical resource in a better way.", [["recent disease outbreaks", "PROBLEM", 34, 58], ["optical flow analysis", "TEST", 62, 83], ["temporal disease spread patterns", "PROBLEM", 116, 148], ["vacant medical resource", "TREATMENT", 176, 199], ["disease", "OBSERVATION", 41, 48], ["temporal", "ANATOMY", 116, 124], ["disease", "OBSERVATION", 125, 132]]], ["Both elements would contribute to strengthening of the public health system and would also enhance resilience of a society against unusual biological threats.", [["strengthening", "OBSERVATION", 34, 47]]], ["For the analysis presented here, we could have used a graph like other research groups did.", [["the analysis", "TEST", 4, 16]]], ["But the very high number of municipalities in combination with the dense neighborhood clusters and the timescale analyzed requires a lot computation time.", [["very", "OBSERVATION_MODIFIER", 8, 12], ["high", "OBSERVATION_MODIFIER", 13, 17], ["number", "OBSERVATION_MODIFIER", 18, 24], ["municipalities", "OBSERVATION", 28, 42], ["dense", "OBSERVATION_MODIFIER", 67, 72], ["neighborhood clusters", "OBSERVATION", 73, 94]]], ["Therefore, we decided to simplify the data into videos and take advantage of already established highly efficient image analysis algorithms to conduct our analysis.", [["our analysis", "TEST", 151, 163]]], ["By this approach, the comparison of results gained from methods that include these information to gain new insights in previously unknown infection spreading routes.", [["infection", "DISEASE", 138, 147], ["infection", "OBSERVATION", 138, 147]]], ["Advantage of the presented method is that it could be used to analyze spread patterns of any illness as long as coordinates and regularly timed incidence data for the locales is available (for example .", [["any illness", "PROBLEM", 89, 100]]], ["It requires no preconception of how an illness works.Dynamic relation of norovirus and influenza waves.In the cases analyzed here we see that norovirus infections clearly clusters around densely populated areas (compare Fig. 1 and Fig. 3 ) while the lower-density population areas are generally being left out by immediate neighborhood disease spreading waves.", [["norovirus", "DISEASE", 73, 82], ["influenza", "DISEASE", 87, 96], ["norovirus infections", "DISEASE", 142, 162], ["norovirus", "ORGANISM", 73, 82], ["norovirus", "ORGANISM", 142, 151], ["norovirus", "PROBLEM", 73, 82], ["influenza waves", "PROBLEM", 87, 102], ["norovirus infections", "PROBLEM", 142, 162], ["the lower-density population areas", "PROBLEM", 246, 280], ["immediate neighborhood disease spreading waves", "PROBLEM", 313, 359], ["no", "UNCERTAINTY", 12, 14], ["norovirus", "OBSERVATION", 73, 82], ["influenza waves", "OBSERVATION", 87, 102], ["norovirus", "OBSERVATION", 142, 151], ["densely", "OBSERVATION_MODIFIER", 187, 194], ["populated", "OBSERVATION_MODIFIER", 195, 204], ["lower", "OBSERVATION_MODIFIER", 250, 255], ["density", "OBSERVATION", 256, 263], ["neighborhood disease", "OBSERVATION", 323, 343], ["spreading", "OBSERVATION_MODIFIER", 344, 353], ["waves", "OBSERVATION_MODIFIER", 354, 359]]], ["Reported influenza cases however do roll over lower-population dense areas in most years (see Videos 60 ).", [["influenza", "DISEASE", 9, 18], ["influenza cases", "PROBLEM", 9, 24], ["influenza", "OBSERVATION", 9, 18], ["dense", "OBSERVATION_MODIFIER", 63, 68], ["areas", "OBSERVATION_MODIFIER", 69, 74]]], ["We need a more detailed picture, especially in the case of circulating norovirus genotypes to deal with potentially emerging epidemic situations.", [["norovirus", "ORGANISM", 71, 80], ["circulating norovirus genotypes", "PROBLEM", 59, 90], ["norovirus", "OBSERVATION", 71, 80]]], ["This includes an improved reporting of laboratory-confirmed cases in order to provide a better coverage of norovirus infections.", [["norovirus infections", "DISEASE", 107, 127], ["norovirus", "ORGANISM", 107, 116], ["norovirus infections", "PROBLEM", 107, 127], ["norovirus", "OBSERVATION", 107, 116]]], ["In the future, it might become possible that innovative data interpretation methods can be combined with anonymized movement profiles (e.g. derived from cell phones) to further elude low-level distribution of infectious diseases 61 .", [["cell", "ANATOMY", 153, 157], ["infectious diseases", "DISEASE", 209, 228], ["cell", "CELL", 153, 157], ["anonymized movement profiles", "TEST", 105, 133], ["infectious diseases", "PROBLEM", 209, 228], ["infectious", "OBSERVATION", 209, 219]]], ["A disadvantage of the method is the strong dependence on incidence data.", [["incidence data", "TEST", 57, 71]]], ["This post-event analysis cannot replace or visualize the tracking of individuals regarding infection chains during an epidemic.", [["infection", "DISEASE", 91, 100], ["infection chains", "PROBLEM", 91, 107], ["infection", "OBSERVATION", 91, 100]]], ["Ultimately, we show here that a better case-report system also www.nature.com/scientificreports/ enables a solid epidemiological pattern analysis by itself without the need for integrating individual movement profiles on a large scale.", [["a solid epidemiological pattern analysis", "TEST", 105, 145], ["a large scale", "TREATMENT", 221, 234]]], ["Optical flow activity proves to be a valuable tool for a condensed view of the spatial distribution (Fig. 3) of reported influenza and norovirus infections.ConclusionsOur study shows a clear temporal and spatial wave dynamic for influenza.", [["influenza", "DISEASE", 121, 130], ["norovirus infections", "DISEASE", 135, 155], ["influenza", "DISEASE", 229, 238], ["norovirus", "ORGANISM", 135, 144], ["Optical flow activity", "TEST", 0, 21], ["influenza", "PROBLEM", 121, 130], ["norovirus infections", "PROBLEM", 135, 155], ["Our study", "TEST", 167, 176], ["influenza", "PROBLEM", 229, 238], ["flow activity", "OBSERVATION", 8, 21], ["influenza", "OBSERVATION", 121, 130], ["norovirus infections", "OBSERVATION", 135, 155], ["clear", "OBSERVATION", 185, 190], ["influenza", "OBSERVATION", 229, 238]]], ["This is achieved by employing imaging-derived method of optical flow together with classic tools of quantitative epidemiology.", [["employing imaging", "TEST", 20, 37]]], ["Our findings allow for a better understanding of disease-spreading as optical flow manages to set a series of many events (reported cases) into a common context.", [["disease", "PROBLEM", 49, 56]]], ["We provide an intuitive insight into highly complex epidemiological dataset accessible to peers in the area of epidemic study and beyond.MethodsData sources.", [["epidemic study", "TEST", 111, 125]]], ["Incidence report data on norovirus and influenza infections was acquired from the public 67 ).We utilize optical flow analysis to detect the direction and intensity of possible shifts of case numbers of norovirus and influenza infections based on an intensity plot (done with Python MatplotLib).", [["norovirus", "DISEASE", 25, 34], ["influenza infections", "DISEASE", 39, 59], ["norovirus", "DISEASE", 203, 212], ["influenza infections", "DISEASE", 217, 237], ["norovirus", "ORGANISM", 25, 34], ["norovirus", "ORGANISM", 203, 212], ["norovirus", "PROBLEM", 25, 34], ["influenza infections", "PROBLEM", 39, 59], ["optical flow analysis", "TEST", 105, 126], ["norovirus", "PROBLEM", 203, 212], ["influenza infections", "PROBLEM", 217, 237], ["an intensity plot", "TEST", 247, 264], ["Python MatplotLib", "TREATMENT", 276, 293], ["norovirus", "OBSERVATION", 203, 212]]], ["An intensity plot for every week results in 570 frames that are analyzed as a stack in ImageJ Fiji with the Gaussian Window MSE Optic Flow plugin.", [["An intensity plot", "TEST", 0, 17], ["Flow plugin", "OBSERVATION", 134, 145]]], ["This plugin analyzes the stack of images by taking pairs of images and comparing each pixel within a Gaussian kernel.", [["images", "TEST", 60, 66]]], ["The resulting output are frames (see Fig. 2 ) that show a black silhouette (the search radii for each detected data point) of the German municipalities on a white background (no data).", [["a black silhouette", "PROBLEM", 56, 74], ["output", "OBSERVATION_MODIFIER", 14, 20], ["black", "OBSERVATION_MODIFIER", 58, 63], ["silhouette", "OBSERVATION", 64, 74]]], ["The vector of infectious disease spreading is indicated by the color of the trace according to the RGB color wheel (see Fig. 2 or Fig. 3 ).", [["infectious disease", "DISEASE", 14, 32], ["infectious disease spreading", "PROBLEM", 14, 42], ["infectious", "OBSERVATION", 14, 24], ["trace", "OBSERVATION", 76, 81]]], ["The intensity of the movement of reported infections is indicated by the brightness of the color traces.", [["infections", "DISEASE", 42, 52], ["reported infections", "PROBLEM", 33, 52], ["intensity", "OBSERVATION_MODIFIER", 4, 13], ["movement", "OBSERVATION_MODIFIER", 21, 29], ["infections", "OBSERVATION", 42, 52]]], ["Since historical data (0-235 cases per week per municipality) falls within a 0-255 range no scaling was necessary to stay within 8-bit range of the imaging analysis used.", [["historical data", "TEST", 6, 21], ["scaling", "PROBLEM", 92, 99], ["the imaging analysis", "TEST", 144, 164]]], ["Contrast was enhanced by stretching the histogram range up to 255 grey values in figures showing here in Photoshop CS5 to ensure that all pixel are visible when printing this article on paper.", [["stretching the histogram range", "TEST", 25, 55], ["grey values", "TEST", 66, 77], ["Photoshop CS5", "TEST", 105, 118]]], ["Red-colored no-data areas in the original output images were re-colored here in white for better visualization.", [["-data areas", "PROBLEM", 14, 25], ["the original output images", "TEST", 29, 55], ["colored", "OBSERVATION_MODIFIER", 4, 11]]], ["Of note, no data was dropped in the process and no over-stretching of the histogram occurred.", [["the histogram", "TEST", 70, 83]]], ["For better orientation country borders were added as overlay after image processing.MethodsMonte Carlo simulation and data analysis.", [["image processing", "TEST", 67, 83], ["data analysis", "TEST", 118, 131]]], ["The control data-set is a randomly generated array of time and location independent incidence values between 0 and 235 over the time-period analyzed.", [["The control data", "TEST", 0, 16]]], ["This control was performed in order to prove that optical flows of historically observed infectious disease spreads are clearly distinguishable from random spreading patterns.", [["This control", "TREATMENT", 0, 12], ["infectious disease spreads", "PROBLEM", 89, 115], ["infectious", "OBSERVATION", 89, 99]]], ["Three different sets of randomized data were generated with different constraints in each data-set.Methods\u2022 First constraint: 0-235 cases per week, per municipality.", [["randomized data", "TEST", 24, 39]]], ["(Observed case counts between 2008-2018) \u2022 Second constraint: 0-10 cases in 90% of the weeks and 11-235 cases in 10% of the weeks \u2022 Third constraint: Set only the winter weeks 0-14 per year per municipality to high case count , leave the rest at 0-10 cases Peak detection classified highest occurring peak of incidents as seasonal peak per year for the analysis of historical and control data.", [["Peak detection", "TEST", 257, 271], ["the analysis", "TEST", 349, 361]]], ["Data analysis was conducted by following a process (Fig. 6 ) that included MC control data from the earliest time point on.", [["Data analysis", "TEST", 0, 13], ["MC control data", "TEST", 75, 90]]], ["Case report data and municipality metadata was integrated into a master table from which heatmaps, distance data and incidence plots were generated.", [["distance data", "TEST", 99, 112], ["incidence plots", "PROBLEM", 117, 132]]], ["From the incidence plots optical flow plots were generated.", [["optical flow plots", "TEST", 25, 43], ["flow plots", "OBSERVATION", 33, 43]]]], "PMC7103119": [["IntroductionMany pathogens, including bacteria, viruses and parasites, are known to cause gastrointestinal infections in humans and animals.", [["gastrointestinal", "ANATOMY", 90, 106], ["gastrointestinal infections", "DISEASE", 90, 117], ["gastrointestinal", "ORGANISM_SUBDIVISION", 90, 106], ["humans", "ORGANISM", 121, 127], ["humans", "SPECIES", 121, 127], ["humans", "SPECIES", 121, 127], ["IntroductionMany pathogens", "PROBLEM", 0, 26], ["bacteria", "PROBLEM", 38, 46], ["viruses", "PROBLEM", 48, 55], ["parasites", "PROBLEM", 60, 69], ["gastrointestinal infections in humans", "PROBLEM", 90, 127], ["gastrointestinal", "ANATOMY", 90, 106], ["infections", "OBSERVATION", 107, 117]]], ["Diarrhoea caused by these pathogens is one of the principal reasons for high morbidity in humans in developed and developing countries, often resulting in mortality in underprivileged communities (Fletcher et al., 2013).", [["Diarrhoea", "DISEASE", 0, 9], ["humans", "ORGANISM", 90, 96], ["humans", "SPECIES", 90, 96], ["humans", "SPECIES", 90, 96], ["Diarrhoea", "PROBLEM", 0, 9], ["these pathogens", "PROBLEM", 20, 35], ["high morbidity", "PROBLEM", 72, 86], ["high", "OBSERVATION_MODIFIER", 72, 76], ["morbidity", "OBSERVATION", 77, 86]]], ["Among parasitic pathogens, Cryptosporidium and Giardia are frequently associated with diarrhoea and pose a considerable threat to human and animal health globally (Jex et al., 2011a, Thompson et al., 2008).Introduction", [["parasitic pathogens", "DISEASE", 6, 25], ["Cryptosporidium and Giardia", "DISEASE", 27, 54], ["diarrhoea", "DISEASE", 86, 95], ["Cryptosporidium", "ORGANISM", 27, 42], ["human", "ORGANISM", 130, 135], ["human", "SPECIES", 130, 135], ["human", "SPECIES", 130, 135], ["Among parasitic pathogens", "PROBLEM", 0, 25], ["Cryptosporidium", "PROBLEM", 27, 42], ["Giardia", "PROBLEM", 47, 54], ["diarrhoea", "PROBLEM", 86, 95], ["parasitic", "OBSERVATION_MODIFIER", 6, 15], ["pathogens", "OBSERVATION", 16, 25], ["Cryptosporidium", "OBSERVATION", 27, 42], ["Giardia", "OBSERVATION", 47, 54]]]], "PMC7162320": [], "b8ebfc9d742812e0451a90829bf6d68595abdac4": [["IntroductionRespiratory tract infections (RTIs) are a major cause of morbidity and mortality worldwide.", [["IntroductionRespiratory tract infections", "DISEASE", 0, 40], ["RTIs", "DISEASE", 42, 46], ["IntroductionRespiratory tract infections (RTIs)", "PROBLEM", 0, 47], ["morbidity", "PROBLEM", 69, 78], ["tract", "OBSERVATION_MODIFIER", 24, 29], ["infections", "OBSERVATION", 30, 40], ["morbidity", "OBSERVATION", 69, 78]]], ["Viral pathogens are the most common etiological agents of acute respiratory disease.", [["respiratory", "ANATOMY", 64, 75], ["Viral pathogens", "DISEASE", 0, 15], ["acute respiratory disease", "DISEASE", 58, 83], ["Viral pathogens", "PROBLEM", 0, 15], ["acute respiratory disease", "PROBLEM", 58, 83], ["pathogens", "OBSERVATION", 6, 15], ["most common", "OBSERVATION_MODIFIER", 24, 35], ["acute", "OBSERVATION_MODIFIER", 58, 63], ["respiratory disease", "OBSERVATION", 64, 83]]], ["The social and economic impact of viral respiratory disease is substantial, due to hospitalizations, medical costs, missed work, and school and day care absences.", [["respiratory", "ANATOMY", 40, 51], ["viral respiratory disease", "DISEASE", 34, 59], ["viral respiratory disease", "PROBLEM", 34, 59], ["viral", "OBSERVATION_MODIFIER", 34, 39], ["respiratory disease", "OBSERVATION", 40, 59]]], ["For instance, estimates show that viral respiratory tract illnesses (mostly common colds) cost US$40 billion annually in the United States alone [1] .IntroductionThere are over 200 different types of viruses which cause RTIs in humans.", [["respiratory tract", "ANATOMY", 40, 57], ["viral respiratory tract illnesses", "DISEASE", 34, 67], ["colds", "DISEASE", 83, 88], ["RTIs", "DISEASE", 220, 224], ["tract", "ORGANISM_SUBDIVISION", 52, 57], ["humans", "ORGANISM", 228, 234], ["humans", "SPECIES", 228, 234], ["humans", "SPECIES", 228, 234], ["viral respiratory tract illnesses", "PROBLEM", 34, 67], ["viruses", "PROBLEM", 200, 207], ["RTIs in humans", "PROBLEM", 220, 234], ["viral", "OBSERVATION_MODIFIER", 34, 39], ["respiratory tract", "OBSERVATION", 40, 57], ["viruses", "OBSERVATION", 200, 207], ["RTIs", "OBSERVATION", 220, 224]]], ["Human rhinoviruses (HRV) are the largest group of respiratory viruses, comprising over 150 serotypes [2] .", [["respiratory viruses", "DISEASE", 50, 69], ["Human rhinoviruses", "ORGANISM", 0, 18], ["Human", "SPECIES", 0, 5], ["Human rhinoviruses", "SPECIES", 0, 18], ["HRV", "SPECIES", 20, 23], ["Human rhinoviruses", "PROBLEM", 0, 18], ["respiratory viruses", "PROBLEM", 50, 69], ["largest", "OBSERVATION_MODIFIER", 33, 40], ["respiratory viruses", "OBSERVATION", 50, 69]]], ["In humans, the predominant illness caused by HRV is the acute upper RTI, also known as the common cold.", [["illness", "DISEASE", 27, 34], ["RTI", "DISEASE", 68, 71], ["humans", "ORGANISM", 3, 9], ["upper", "ORGANISM_SUBDIVISION", 62, 67], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["the acute upper RTI", "PROBLEM", 52, 71], ["predominant", "OBSERVATION_MODIFIER", 15, 26], ["illness", "OBSERVATION", 27, 34], ["acute", "OBSERVATION_MODIFIER", 56, 61], ["upper RTI", "ANATOMY", 62, 71]]], ["The second most common viruses infecting humans are the human enteroviruses (HEV), which are associated with clinical manifestations ranging from mild respiratory symptoms to serious conditions [2] .", [["respiratory", "ANATOMY", 151, 162], ["respiratory symptoms", "DISEASE", 151, 171], ["humans", "ORGANISM", 41, 47], ["human", "ORGANISM", 56, 61], ["enteroviruses", "ORGANISM", 62, 75], ["HEV", "ORGANISM", 77, 80], ["humans", "SPECIES", 41, 47], ["human", "SPECIES", 56, 61], ["humans", "SPECIES", 41, 47], ["human", "SPECIES", 56, 61], ["HEV", "SPECIES", 77, 80], ["the human enteroviruses", "PROBLEM", 52, 75], ["clinical manifestations", "PROBLEM", 109, 132], ["mild respiratory symptoms", "PROBLEM", 146, 171], ["serious conditions", "PROBLEM", 175, 193], ["most common", "OBSERVATION_MODIFIER", 11, 22], ["viruses", "OBSERVATION", 23, 30], ["enteroviruses", "OBSERVATION", 62, 75], ["mild", "OBSERVATION_MODIFIER", 146, 150], ["respiratory symptoms", "OBSERVATION", 151, 171]]], ["Influenza viruses, respiratory syncytial virus (RSV), and adenoviruses are also major causative agents of both upper and lower RTIs [3] [4] [5] .", [["Influenza viruses", "DISEASE", 0, 17], ["respiratory syncytial virus (RSV)", "DISEASE", 19, 52], ["RTIs", "DISEASE", 127, 131], ["Influenza viruses", "ORGANISM", 0, 17], ["respiratory syncytial virus", "ORGANISM", 19, 46], ["RSV", "ORGANISM", 48, 51], ["adenoviruses", "ORGANISM", 58, 70], ["upper", "ORGANISM_SUBDIVISION", 111, 116], ["Influenza", "SPECIES", 0, 9], ["respiratory syncytial virus", "SPECIES", 19, 46], ["Influenza viruses", "SPECIES", 0, 17], ["respiratory syncytial virus", "SPECIES", 19, 46], ["RSV", "SPECIES", 48, 51], ["Influenza viruses", "PROBLEM", 0, 17], ["respiratory syncytial virus (RSV)", "PROBLEM", 19, 52], ["adenoviruses", "PROBLEM", 58, 70], ["respiratory syncytial virus", "OBSERVATION", 19, 46], ["upper", "ANATOMY_MODIFIER", 111, 116]]], ["In addition, many other viruses or virus groups cause RTIs, e.g., parainfluenza viruses and coronaviruses can cause a broad spectrum of respiratory diseases, ranging from mild upper RTIs to pneumonia [6] .", [["respiratory", "ANATOMY", 136, 147], ["RTIs", "DISEASE", 54, 58], ["parainfluenza viruses", "DISEASE", 66, 87], ["coronaviruses", "DISEASE", 92, 105], ["respiratory diseases", "DISEASE", 136, 156], ["RTIs", "DISEASE", 182, 186], ["pneumonia", "DISEASE", 190, 199], ["parainfluenza viruses", "ORGANISM", 66, 87], ["coronaviruses", "ORGANISM", 92, 105], ["upper", "ORGANISM_SUBDIVISION", 176, 181], ["parainfluenza", "SPECIES", 66, 79], ["parainfluenza viruses", "SPECIES", 66, 87], ["many other viruses", "PROBLEM", 13, 31], ["virus groups", "PROBLEM", 35, 47], ["RTIs", "PROBLEM", 54, 58], ["parainfluenza viruses", "PROBLEM", 66, 87], ["coronaviruses", "PROBLEM", 92, 105], ["respiratory diseases", "PROBLEM", 136, 156], ["mild upper RTIs to pneumonia", "PROBLEM", 171, 199], ["viruses", "OBSERVATION", 24, 31], ["parainfluenza viruses", "OBSERVATION", 66, 87], ["broad", "OBSERVATION_MODIFIER", 118, 123], ["respiratory diseases", "OBSERVATION", 136, 156], ["mild", "OBSERVATION_MODIFIER", 171, 175], ["upper RTIs", "OBSERVATION_MODIFIER", 176, 186], ["pneumonia", "OBSERVATION", 190, 199]]], ["In recent years, with the rapid development of high-throughput molecular techniques, several new viruses associated with respiratory diseases, such as human bocavirus, human metapneumovirus, and the new coronaviruses HKU1 and NL63, have been identified as well [7] .IntroductionThe prevention of viral respiratory infections is an important challenge to public health.", [["respiratory", "ANATOMY", 121, 132], ["respiratory", "ANATOMY", 302, 313], ["respiratory diseases", "DISEASE", 121, 141], ["human metapneumovirus", "DISEASE", 168, 189], ["viral respiratory infections", "DISEASE", 296, 324], ["human", "ORGANISM", 151, 156], ["bocavirus", "GENE_OR_GENE_PRODUCT", 157, 166], ["human", "ORGANISM", 168, 173], ["metapneumovirus", "ORGANISM", 174, 189], ["coronaviruses", "ORGANISM", 203, 216], ["HKU1", "GENE_OR_GENE_PRODUCT", 217, 221], ["NL63", "GENE_OR_GENE_PRODUCT", 226, 230], ["human", "SPECIES", 151, 156], ["human", "SPECIES", 168, 173], ["metapneumovirus", "SPECIES", 174, 189], ["human", "SPECIES", 151, 156], ["human metapneumovirus", "SPECIES", 168, 189], ["high-throughput molecular techniques", "PROBLEM", 47, 83], ["several new viruses", "PROBLEM", 85, 104], ["respiratory diseases", "PROBLEM", 121, 141], ["human bocavirus", "PROBLEM", 151, 166], ["human metapneumovirus", "PROBLEM", 168, 189], ["the new coronaviruses HKU1", "PROBLEM", 195, 221], ["viral respiratory infections", "PROBLEM", 296, 324], ["high", "OBSERVATION_MODIFIER", 47, 51], ["new", "OBSERVATION_MODIFIER", 93, 96], ["viruses", "OBSERVATION", 97, 104], ["respiratory diseases", "OBSERVATION", 121, 141], ["metapneumovirus", "OBSERVATION", 174, 189], ["new", "OBSERVATION_MODIFIER", 199, 202], ["coronaviruses", "OBSERVATION", 203, 216], ["viral", "OBSERVATION_MODIFIER", 296, 301], ["respiratory infections", "OBSERVATION", 302, 324]]], ["Currently, the only effective antivirals and vaccines for the prevention and treatment of respiratory virus infections are available against influenza viruses and adenoviruses.", [["respiratory virus infections", "DISEASE", 90, 118], ["influenza viruses", "DISEASE", 141, 158], ["respiratory virus", "ORGANISM", 90, 107], ["influenza viruses", "ORGANISM", 141, 158], ["adenoviruses", "ORGANISM", 163, 175], ["effective antivirals", "TREATMENT", 20, 40], ["vaccines", "TREATMENT", 45, 53], ["the prevention", "TREATMENT", 58, 72], ["treatment", "TREATMENT", 77, 86], ["respiratory virus infections", "PROBLEM", 90, 118], ["influenza viruses", "PROBLEM", 141, 158], ["adenoviruses", "PROBLEM", 163, 175], ["respiratory virus", "OBSERVATION", 90, 107]]], ["For the viruses causing common cold (HRV, HEV), no effective therapies are available.", [["HEV", "SPECIES", 42, 45], ["the viruses", "PROBLEM", 4, 15], ["common cold (HRV", "PROBLEM", 24, 40], ["effective therapies", "TREATMENT", 51, 70], ["viruses", "OBSERVATION", 8, 15]]], ["Large varieties of etiologic agents and increasing antibiotic and antiviral resistance challenge the development of efficient therapies.", [["etiologic agents", "TREATMENT", 19, 35], ["increasing antibiotic", "TREATMENT", 40, 61], ["antiviral resistance challenge", "TREATMENT", 66, 96], ["efficient therapies", "TREATMENT", 116, 135], ["varieties", "OBSERVATION_MODIFIER", 6, 15], ["etiologic agents", "OBSERVATION", 19, 35], ["antiviral resistance", "OBSERVATION", 66, 86], ["efficient therapies", "OBSERVATION", 116, 135]]], ["Consequently, it is of importance to find alternative and safe ways to reduce the risk of these infections.", [["infections", "DISEASE", 96, 106], ["these infections", "PROBLEM", 90, 106], ["infections", "OBSERVATION", 96, 106]]], ["Even partially effective therapy in the treatment and prevention of viral RTIs such as the common cold could have an impact on reducing morbidity and economic losses due to this illness.IntroductionProbiotics are defined as live microorganisms that confer a health benefit on the host [8] .", [["RTIs", "DISEASE", 74, 78], ["the treatment", "TREATMENT", 36, 49], ["viral RTIs", "PROBLEM", 68, 78], ["reducing morbidity", "PROBLEM", 127, 145], ["economic losses", "PROBLEM", 150, 165], ["this illness", "PROBLEM", 173, 185], ["IntroductionProbiotics", "TREATMENT", 186, 208], ["partially", "OBSERVATION_MODIFIER", 5, 14], ["effective", "OBSERVATION_MODIFIER", 15, 24], ["therapy", "OBSERVATION", 25, 32], ["viral RTIs", "OBSERVATION", 68, 78]]], ["The most common types of microbes used as probiotics are lactobacilli and bifidobacteria, which are generally consumed as part of fermented foods, such as yoghurts or dietary supplements.", [["lactobacilli", "CHEMICAL", 57, 69], ["bifidobacteria", "CHEMICAL", 74, 88], ["lactobacilli", "SIMPLE_CHEMICAL", 57, 69], ["bifidobacteria", "SIMPLE_CHEMICAL", 74, 88], ["yoghurts", "SIMPLE_CHEMICAL", 155, 163], ["probiotics", "TREATMENT", 42, 52], ["lactobacilli", "PROBLEM", 57, 69], ["bifidobacteria", "TREATMENT", 74, 88], ["dietary supplements", "TREATMENT", 167, 186], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["microbes", "OBSERVATION", 25, 33]]], ["Criteria for probiotic bacteria include that the bacterial strain: (1) must be able to survive in the gastrointestinal tract and to proliferate in the gut; (2) should exert benefits to the host through growth and/or activity in the human body; (3) should be non-pathogenic and non-toxic; (4) provide protection against pathogenic microorganisms by means of multiple mechanisms; and (5) should be lacking transferable antibiotic resistance [9] .", [["gastrointestinal tract", "ANATOMY", 102, 124], ["gut", "ANATOMY", 151, 154], ["body", "ANATOMY", 238, 242], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 102, 124], ["gut", "ORGANISM_SUBDIVISION", 151, 154], ["human", "ORGANISM", 232, 237], ["body", "ORGANISM_SUBDIVISION", 238, 242], ["human", "SPECIES", 232, 237], ["human", "SPECIES", 232, 237], ["probiotic bacteria", "PROBLEM", 13, 31], ["the bacterial strain", "PROBLEM", 45, 65], ["non-pathogenic", "PROBLEM", 258, 272], ["pathogenic microorganisms", "PROBLEM", 319, 344], ["lacking transferable antibiotic resistance", "TREATMENT", 396, 438], ["gastrointestinal tract", "ANATOMY", 102, 124], ["gut", "ANATOMY", 151, 154], ["human body", "ANATOMY", 232, 242]]], ["Different bacterial strains of the same genus and species, verified also by genomic information, may exert completely different effects on the host.IntroductionThe most promising health effects of probiotics in human intervention studies include the amelioration of acute diarrhea in children, relief of children's milk allergy/atopic dermatitis, and relief of irritable bowel syndrome [10, 11] .", [["milk", "ANATOMY", 315, 319], ["bowel", "ANATOMY", 371, 376], ["diarrhea", "DISEASE", 272, 280], ["milk allergy", "DISEASE", 315, 327], ["atopic dermatitis", "DISEASE", 328, 345], ["irritable bowel syndrome", "DISEASE", 361, 385], ["human", "ORGANISM", 211, 216], ["children", "ORGANISM", 284, 292], ["children", "ORGANISM", 304, 312], ["milk", "ORGANISM_SUBDIVISION", 315, 319], ["bowel", "ORGAN", 371, 376], ["human", "SPECIES", 211, 216], ["children", "SPECIES", 284, 292], ["children", "SPECIES", 304, 312], ["milk", "SPECIES", 315, 319], ["human", "SPECIES", 211, 216], ["Different bacterial strains of the same genus", "PROBLEM", 0, 45], ["Introduction", "TREATMENT", 148, 160], ["probiotics in human intervention", "TREATMENT", 197, 229], ["acute diarrhea", "PROBLEM", 266, 280], ["milk allergy", "PROBLEM", 315, 327], ["atopic dermatitis", "PROBLEM", 328, 345], ["irritable bowel syndrome", "PROBLEM", 361, 385], ["bacterial strains", "OBSERVATION", 10, 27], ["acute", "OBSERVATION_MODIFIER", 266, 271], ["diarrhea", "OBSERVATION", 272, 280], ["atopic dermatitis", "OBSERVATION", 328, 345], ["irritable bowel", "ANATOMY", 361, 376]]], ["Probiotics are likely to have an impact through gut mucosa by balancing the local microbiota by inhibiting the growth of pathogenic microorganisms [12] , and by enhancing local and systemic immune responses [13] .", [["gut mucosa", "ANATOMY", 48, 58], ["gut mucosa", "MULTI-TISSUE_STRUCTURE", 48, 58], ["Probiotics", "TREATMENT", 0, 10], ["an impact through gut mucosa", "PROBLEM", 30, 58], ["pathogenic microorganisms", "PROBLEM", 121, 146], ["gut mucosa", "ANATOMY", 48, 58]]], ["They may also influence the composition and activity of microbiota in the intestinal contents.", [["intestinal", "ANATOMY", 74, 84], ["intestinal", "ORGAN", 74, 84], ["intestinal", "ANATOMY", 74, 84]]], ["Considering the beneficial effects of probiotics in virus infections, specific probiotics have been suggested to be effective in alleviating the duration and severity of acute rotavirus gastroenteritis [14] .", [["infections", "DISEASE", 58, 68], ["rotavirus gastroenteritis", "DISEASE", 176, 201], ["probiotics", "TREATMENT", 38, 48], ["virus infections", "PROBLEM", 52, 68], ["specific probiotics", "TREATMENT", 70, 89], ["acute rotavirus gastroenteritis", "PROBLEM", 170, 201], ["acute", "OBSERVATION_MODIFIER", 170, 175], ["rotavirus gastroenteritis", "OBSERVATION", 176, 201]]], ["In addition, increasing evidence shows that probiotics are beneficial in RTIs [15] , which, in most cases, are of viral origin.", [["RTIs", "DISEASE", 73, 77], ["probiotics", "TREATMENT", 44, 54], ["viral origin", "OBSERVATION", 114, 126]]], ["However, the mechanisms behind these effects are largely unknown.AimThe aim of this review is to present the current knowledge of the health effects of probiotics on RTIs in humans, with a focus on viral respiratory infections.", [["respiratory", "ANATOMY", 204, 215], ["RTIs", "DISEASE", 166, 170], ["viral respiratory infections", "DISEASE", 198, 226], ["humans", "ORGANISM", 174, 180], ["humans", "SPECIES", 174, 180], ["humans", "SPECIES", 174, 180], ["probiotics", "TREATMENT", 152, 162], ["viral respiratory infections", "PROBLEM", 198, 226], ["respiratory", "ANATOMY", 204, 215], ["infections", "OBSERVATION", 216, 226]]], ["In addition, possible antiviral mechanisms of probiotics are discussed in context with studies conducted in vitro and in animal models.MethodsA PubMed and Scopus database search was performed up to January 2014 to review the relevant literature investigating the effects of probiotics on respiratory virus infections in cell culture, animal models, and clinical trials.", [["cell", "ANATOMY", 320, 324], ["respiratory virus infections", "DISEASE", 288, 316], ["respiratory virus", "ORGANISM", 288, 305], ["cell", "CELL", 320, 324], ["antiviral mechanisms of probiotics", "TREATMENT", 22, 56], ["studies", "TEST", 87, 94], ["probiotics", "TREATMENT", 274, 284], ["respiratory virus infections", "PROBLEM", 288, 316], ["cell culture", "TEST", 320, 332], ["animal models", "TEST", 334, 347], ["possible", "UNCERTAINTY", 13, 21], ["antiviral", "OBSERVATION", 22, 31]]], ["The following search terms were used individually and in combination: ' probiotic' , ' Lactobacillus' , ' Bif idobacterium' , 'Lactococcus', 'respiratory infection', 'respiratory virus', and 'influenza virus'.Animal experimentsAnimal experiments provide insight on the clinical effects of probiotics against respiratory virus infections (Clinical trialsChildren Altogether, five clinical trials have been conducted in children using L. rhamnosus GG as a probiotic [42] [43] [44] [45] [46] .", [["respiratory", "ANATOMY", 142, 153], ["respiratory infection", "DISEASE", 142, 163], ["respiratory virus'", "DISEASE", 167, 185], ["influenza virus", "DISEASE", 192, 207], ["respiratory virus infections", "DISEASE", 308, 336], ["respiratory virus", "ORGANISM", 167, 184], ["influenza virus", "ORGANISM", 192, 207], ["respiratory virus", "ORGANISM", 308, 325], ["children", "ORGANISM", 418, 426], ["L. rhamnosus GG", "ORGANISM", 433, 448], ["[42] [43] [44] [45", "SIMPLE_CHEMICAL", 464, 482], ["influenza virus", "SPECIES", 192, 207], ["Children", "SPECIES", 353, 361], ["children", "SPECIES", 418, 426], ["L. rhamnosus", "SPECIES", 433, 445], ["L. rhamnosus", "SPECIES", 433, 445], ["probiotic' , ' Lactobacillus'", "TREATMENT", 72, 101], ["Bif idobacterium'", "PROBLEM", 106, 123], ["'Lactococcus'", "PROBLEM", 126, 139], ["'respiratory infection'", "PROBLEM", 141, 164], ["'respiratory virus'", "PROBLEM", 166, 185], ["'influenza virus'", "PROBLEM", 191, 208], ["probiotics", "TREATMENT", 289, 299], ["respiratory virus infections", "PROBLEM", 308, 336], ["respiratory", "ANATOMY", 142, 153], ["infection", "OBSERVATION", 154, 163], ["respiratory virus", "OBSERVATION", 167, 184], ["influenza virus", "OBSERVATION", 192, 207]]], ["In healthy children attending day care, L. rhamnosus GG reduced the number of children experiencing RTIs [42, 43] , the number of upper and lower RTIs [43] , and the number of antibiotic treatments or absences from day care [42] .", [["L. rhamnosus", "CHEMICAL", 40, 52], ["RTIs", "DISEASE", 100, 104], ["RTIs", "DISEASE", 146, 150], ["children", "ORGANISM", 11, 19], ["L. rhamnosus GG", "ORGANISM", 40, 55], ["children", "ORGANISM", 78, 86], ["upper", "ORGANISM_SUBDIVISION", 130, 135], ["children", "SPECIES", 11, 19], ["L. rhamnosus", "SPECIES", 40, 52], ["children", "SPECIES", 78, 86], ["L. rhamnosus", "SPECIES", 40, 52], ["antibiotic treatments", "TREATMENT", 176, 197], ["upper", "ANATOMY_MODIFIER", 130, 135]]], ["In another study, no differences were reported between the L. rhamnosus GG and the control groups in the number of antibiotic treatments or respiratory symptom episodes [47] .", [["respiratory", "ANATOMY", 140, 151], ["L. rhamnosus GG", "ORGANISM", 59, 74], ["L. rhamnosus", "SPECIES", 59, 71], ["L. rhamnosus", "SPECIES", 59, 71], ["another study", "TEST", 3, 16], ["the L. rhamnosus GG", "TREATMENT", 55, 74], ["antibiotic treatments", "TREATMENT", 115, 136], ["respiratory symptom episodes", "PROBLEM", 140, 168]]], ["However, in a subgroup with L. rhamnosus GG identification in feces, L. rhamnosus GG usage reduced the duration of RTIs.", [["L. rhamnosus", "CHEMICAL", 69, 81], ["GG", "CHEMICAL", 82, 84], ["RTIs", "DISEASE", 115, 119], ["L. rhamnosus GG", "ORGANISM", 28, 43], ["feces", "ORGANISM_SUBSTANCE", 62, 67], ["L. rhamnosus GG", "ORGANISM", 69, 84], ["L. rhamnosus", "SPECIES", 28, 40], ["L. rhamnosus", "SPECIES", 69, 81], ["L. rhamnosus", "SPECIES", 28, 40], ["L. rhamnosus", "SPECIES", 69, 81], ["RTIs", "PROBLEM", 115, 119], ["feces", "ANATOMY", 62, 67]]], ["In hospitalized children, L. rhamnosus GG reduced the risk of RTIs and duration of RTI episodes [42] .", [["L. rhamnosus", "CHEMICAL", 26, 38], ["RTIs", "DISEASE", 62, 66], ["RTI", "DISEASE", 83, 86], ["children", "ORGANISM", 16, 24], ["L. rhamnosus GG", "ORGANISM", 26, 41], ["children", "SPECIES", 16, 24], ["L. rhamnosus", "SPECIES", 26, 38], ["L. rhamnosus", "SPECIES", 26, 38], ["RTIs", "PROBLEM", 62, 66], ["RTI episodes", "PROBLEM", 83, 95]]], ["In preterm infants, L. rhamnosus GG reduced the incidence of RTIs [46] .", [["L. rhamnosus", "CHEMICAL", 20, 32], ["RTIs", "DISEASE", 61, 65], ["infants", "ORGANISM", 11, 18], ["L. rhamnosus GG", "ORGANISM", 20, 35], ["infants", "SPECIES", 11, 18], ["L. rhamnosus", "SPECIES", 20, 32], ["L. rhamnosus", "SPECIES", 20, 32], ["RTIs", "PROBLEM", 61, 65]]], ["In addition, a meta-analysis of four randomized controlled trials investigating the role of L. rhamnosus GG in the prevention of respiratory infections in children showed that L. rhamnosus GG has the potential to reduce the risk of upper RTIs, incidence of acute otitis media, and antibiotic use.", [["respiratory", "ANATOMY", 129, 140], ["L. rhamnosus GG", "CHEMICAL", 92, 107], ["respiratory infections", "DISEASE", 129, 151], ["L. rhamnosus", "CHEMICAL", 176, 188], ["GG", "CHEMICAL", 189, 191], ["RTIs", "DISEASE", 238, 242], ["otitis", "DISEASE", 263, 269], ["L. rhamnosus GG", "ORGANISM", 92, 107], ["children", "ORGANISM", 155, 163], ["L. rhamnosus GG", "ORGANISM", 176, 191], ["upper", "ORGANISM_SUBDIVISION", 232, 237], ["L. rhamnosus", "SPECIES", 92, 104], ["children", "SPECIES", 155, 163], ["L. rhamnosus", "SPECIES", 176, 188], ["L. rhamnosus", "SPECIES", 92, 104], ["L. rhamnosus", "SPECIES", 176, 188], ["a meta-analysis", "TEST", 13, 28], ["four randomized controlled trials", "TREATMENT", 32, 65], ["L. rhamnosus GG", "TREATMENT", 92, 107], ["respiratory infections", "PROBLEM", 129, 151], ["L. rhamnosus GG", "PROBLEM", 176, 191], ["upper RTIs", "PROBLEM", 232, 242], ["acute otitis media", "PROBLEM", 257, 275], ["antibiotic use", "TREATMENT", 281, 295], ["rhamnosus GG", "OBSERVATION", 95, 107], ["respiratory", "ANATOMY", 129, 140], ["infections", "OBSERVATION", 141, 151], ["rhamnosus GG", "OBSERVATION", 179, 191], ["upper RTIs", "ANATOMY", 232, 242], ["acute", "OBSERVATION_MODIFIER", 257, 262], ["otitis", "OBSERVATION", 263, 269]]], ["There were no significant differences between the L. rhamnosus GG and the control groups in the incidence of lower RTIs [48] .Clinical trialsThere are seven studies conducted with probiotic bacteria other than L. rhamnosus GG.", [["RTIs", "DISEASE", 115, 119], ["L. rhamnosus GG", "ORGANISM", 50, 65], ["L. rhamnosus GG", "ORGANISM", 210, 225], ["L. rhamnosus", "SPECIES", 50, 62], ["L. rhamnosus", "SPECIES", 210, 222], ["L. rhamnosus", "SPECIES", 50, 62], ["L. rhamnosus", "SPECIES", 210, 222], ["the L. rhamnosus GG", "TREATMENT", 46, 65], ["lower RTIs", "PROBLEM", 109, 119], ["Clinical trials", "TEST", 126, 141], ["seven studies", "TEST", 151, 164], ["probiotic bacteria", "PROBLEM", 180, 198], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37], ["rhamnosus GG", "OBSERVATION", 53, 65], ["lower RTIs", "ANATOMY", 109, 119], ["rhamnosus GG", "OBSERVATION", 213, 225]]], ["L. casei rhamnosus in children reduced the number of RTIs [49] .", [["L. casei rhamnosus", "CHEMICAL", 0, 18], ["RTIs", "DISEASE", 53, 57], ["L. casei rhamnosus", "ORGANISM", 0, 18], ["children", "ORGANISM", 22, 30], ["L. casei rhamnosus", "SPECIES", 0, 18], ["children", "SPECIES", 22, 30], ["L. casei rhamnosus", "SPECIES", 0, 18], ["casei rhamnosus", "OBSERVATION", 3, 18]]], ["Also, L. casei DN114001 reduced the incidence rate for upper RTIs43 and decreased the duration (days) and incidence of only lower RTIs, but not upper RTIs [50] .", [["DN114001", "CHEMICAL", 15, 23], ["RTIs", "DISEASE", 61, 65], ["RTIs", "DISEASE", 130, 134], ["RTIs", "DISEASE", 150, 154], ["L. casei DN114001", "ORGANISM", 6, 23], ["L. casei", "SPECIES", 6, 14], ["L. casei DN114001", "SPECIES", 6, 23], ["upper RTIs", "PROBLEM", 55, 65], ["lower RTIs", "PROBLEM", 124, 134], ["upper RTIs", "PROBLEM", 144, 154], ["lower", "ANATOMY_MODIFIER", 124, 129], ["RTIs", "OBSERVATION", 130, 134]]], ["L. fermentum CECT5716 with prebiotics in infants, however, reduced the incidence of both upper and lower RTIs [51] .", [["CECT5716", "CHEMICAL", 13, 21], ["RTIs", "DISEASE", 105, 109], ["L. fermentum CECT5716", "ORGANISM", 0, 21], ["infants", "ORGANISM", 41, 48], ["upper", "ORGANISM_SUBDIVISION", 89, 94], ["L. fermentum", "SPECIES", 0, 12], ["infants", "SPECIES", 41, 48], ["L. fermentum", "SPECIES", 0, 12], ["prebiotics", "TREATMENT", 27, 37], ["fermentum CECT5716", "OBSERVATION", 3, 21], ["reduced", "OBSERVATION_MODIFIER", 59, 66], ["both", "ANATOMY_MODIFIER", 84, 88], ["upper", "ANATOMY_MODIFIER", 89, 94], ["lower RTIs", "ANATOMY", 99, 109]]], ["The use of B. animalis ssp. lactis Bb12 in healthy newborns was able to reduce the number of RTIs as well, but was ineffective in reducing the occurrence of acute otitis media (AOM) or symptoms of otitis media [52] .", [["B. animalis ssp. lactis Bb12", "CHEMICAL", 11, 39], ["RTIs", "DISEASE", 93, 97], ["acute otitis media", "DISEASE", 157, 175], ["AOM", "DISEASE", 177, 180], ["otitis", "DISEASE", 197, 203], ["B. animalis ssp. lactis", "ORGANISM", 11, 34], ["Bb12", "ORGANISM", 35, 39], ["newborns", "ORGANISM", 51, 59], ["B. animalis", "SPECIES", 11, 22], ["ssp. lactis", "SPECIES", 23, 34], ["B. animalis ssp. lactis", "SPECIES", 11, 34], ["B. animalis", "TREATMENT", 11, 22], ["RTIs", "PROBLEM", 93, 97], ["acute otitis media", "PROBLEM", 157, 175], ["AOM", "PROBLEM", 177, 180], ["symptoms", "PROBLEM", 185, 193], ["otitis media", "PROBLEM", 197, 209], ["acute", "OBSERVATION_MODIFIER", 157, 162], ["otitis", "OBSERVATION", 163, 169]]], ["In healthy infants, treatment with L. reuteri SD112, but not with B. animalis ssp. lactis Bb12, resulted in fewer days of absence from day care due to illness, lower number of days with fever, and clinical visits.", [["illness", "DISEASE", 151, 158], ["fever", "DISEASE", 186, 191], ["infants", "ORGANISM", 11, 18], ["L. reuteri SD112", "ORGANISM", 35, 51], ["B. animalis ssp.", "ORGANISM", 66, 82], ["lactis Bb12", "ORGANISM", 83, 94], ["infants", "SPECIES", 11, 18], ["L. reuteri", "SPECIES", 35, 45], ["B. animalis ssp.", "SPECIES", 66, 82], ["lactis", "SPECIES", 83, 89], ["L. reuteri", "SPECIES", 35, 45], ["B. animalis ssp.", "SPECIES", 66, 82], ["lactis", "SPECIES", 83, 89], ["treatment", "TREATMENT", 20, 29], ["L. reuteri SD112", "TREATMENT", 35, 51], ["lactis Bb12", "TEST", 83, 94], ["illness", "PROBLEM", 151, 158], ["fever", "PROBLEM", 186, 191]]], ["Both strains were ineffective in reducing the incidence or duration of RTIs [53, 54] .", [["RTIs", "DISEASE", 71, 75], ["Both strains", "PROBLEM", 0, 12], ["RTIs", "PROBLEM", 71, 75], ["ineffective", "OBSERVATION_MODIFIER", 18, 29]]], ["In healthy children, L. casei CRL431 or L. reuteri DSM17938 did not reduce the incidence, number, or duration of acute RTIs or RTI episodes [55] .Clinical trialsThe effectiveness of several combinations of probiotics on RTIs has been investigated in four clinical trials.", [["CRL431", "CHEMICAL", 30, 36], ["L. reuteri DSM17938", "CHEMICAL", 40, 59], ["RTIs", "DISEASE", 119, 123], ["RTI", "DISEASE", 127, 130], ["RTIs", "DISEASE", 220, 224], ["children", "ORGANISM", 11, 19], ["L. casei CRL431", "ORGANISM", 21, 36], ["L. reuteri DSM17938", "ORGANISM", 40, 59], ["children", "SPECIES", 11, 19], ["L. casei", "SPECIES", 21, 29], ["L. reuteri", "SPECIES", 40, 50], ["L. casei", "SPECIES", 21, 29], ["L. reuteri DSM17938", "SPECIES", 40, 59], ["acute RTIs", "PROBLEM", 113, 123], ["RTI episodes", "PROBLEM", 127, 139], ["Clinical trials", "TEST", 146, 161], ["probiotics", "TREATMENT", 206, 216], ["RTIs", "TREATMENT", 220, 224]]], ["A combination of L. rhamnosus GG, L. rhamnosus Lc705, B. breve Bb99, and P. freudenreichii ssp. shermanii JS in otitis-prone children [56] or a combination of L. rhamnosus GG and B. animalis ssp. lactis Bb12 in healthy newborns [57] both reduced the occurrence of recurrent RTIs, but not the incidence of AOM.", [["otitis", "DISEASE", 112, 118], ["RTIs", "DISEASE", 274, 278], ["AOM", "DISEASE", 305, 308], ["L. rhamnosus GG", "ORGANISM", 17, 32], ["L. rhamnosus Lc705", "ORGANISM", 34, 52], ["B. breve Bb99", "ORGANISM", 54, 67], ["P. freudenreichii ssp", "ORGANISM", 73, 94], ["shermanii JS", "ORGANISM", 96, 108], ["children", "ORGANISM", 125, 133], ["L. rhamnosus GG", "ORGANISM", 159, 174], ["B. animalis ssp", "ORGANISM", 179, 194], ["lactis Bb12", "ORGANISM", 196, 207], ["newborns", "ORGANISM", 219, 227], ["AOM", "PATHOLOGICAL_FORMATION", 305, 308], ["L. rhamnosus", "SPECIES", 17, 29], ["L. rhamnosus", "SPECIES", 34, 46], ["B. breve", "SPECIES", 54, 62], ["P. freudenreichii ssp", "SPECIES", 73, 94], ["shermanii", "SPECIES", 96, 105], ["children", "SPECIES", 125, 133], ["L. rhamnosus", "SPECIES", 159, 171], ["B. animalis ssp", "SPECIES", 179, 194], ["lactis", "SPECIES", 196, 202], ["L. rhamnosus", "SPECIES", 17, 29], ["L. rhamnosus", "SPECIES", 34, 46], ["B. breve Bb99", "SPECIES", 54, 67], ["P. freudenreichii ssp", "SPECIES", 73, 94], ["L. rhamnosus", "SPECIES", 159, 171], ["B. animalis ssp", "SPECIES", 179, 194], ["lactis", "SPECIES", 196, 202], ["L. rhamnosus GG", "TREATMENT", 17, 32], ["P. freudenreichii ssp", "PROBLEM", 73, 94], ["otitis", "PROBLEM", 112, 118], ["L. rhamnosus GG", "PROBLEM", 159, 174], ["recurrent RTIs", "PROBLEM", 264, 278], ["AOM", "PROBLEM", 305, 308], ["L.", "OBSERVATION_MODIFIER", 17, 19], ["rhamnosus GG", "OBSERVATION", 20, 32], ["freudenreichii ssp", "OBSERVATION", 76, 94], ["otitis", "OBSERVATION", 112, 118], ["rhamnosus GG", "OBSERVATION", 162, 174], ["recurrent", "OBSERVATION_MODIFIER", 264, 273], ["RTIs", "OBSERVATION", 274, 278], ["AOM", "OBSERVATION", 305, 308]]], ["A combination of L. acidophilus and B. bifidum in healthy children reduced the duration of acute RTI symptoms, school absence, and the risk of upper RTI symptoms as well [58] .", [["RTI", "DISEASE", 97, 100], ["RTI", "DISEASE", 149, 152], ["L. acidophilus", "ORGANISM", 17, 31], ["B. bifidum", "ORGANISM", 36, 46], ["children", "ORGANISM", 58, 66], ["upper", "ORGANISM_SUBDIVISION", 143, 148], ["L. acidophilus", "SPECIES", 17, 31], ["B. bifidum", "SPECIES", 36, 46], ["children", "SPECIES", 58, 66], ["L. acidophilus", "SPECIES", 17, 31], ["B. bifidum", "SPECIES", 36, 46], ["L. acidophilus", "TREATMENT", 17, 31], ["acute RTI symptoms", "PROBLEM", 91, 109], ["upper RTI symptoms", "PROBLEM", 143, 161], ["L. acidophilus", "OBSERVATION", 17, 31], ["upper RTI", "ANATOMY", 143, 152]]], ["However, a combination of 12 bacteria including species of Lactobacillus, Bifidobacterium, Streptococcus, and Enterococcus was not able to reduce the number of RTIs [49] .Clinical trialsThe viral etiologies of RTIs were investigated in only five studies.", [["Lactobacillus", "CHEMICAL", 59, 72], ["Enterococcus", "CHEMICAL", 110, 122], ["RTIs", "DISEASE", 160, 164], ["RTIs", "DISEASE", 210, 214], ["Lactobacillus", "SIMPLE_CHEMICAL", 59, 72], ["12 bacteria", "PROBLEM", 26, 37], ["Lactobacillus", "PROBLEM", 59, 72], ["Bifidobacterium", "PROBLEM", 74, 89], ["Streptococcus", "PROBLEM", 91, 104], ["Enterococcus", "PROBLEM", 110, 122], ["RTIs", "PROBLEM", 160, 164], ["Clinical trials", "TEST", 171, 186], ["RTIs", "PROBLEM", 210, 214], ["five studies", "TEST", 241, 253], ["Lactobacillus", "ANATOMY", 59, 72], ["viral", "OBSERVATION_MODIFIER", 190, 195], ["RTIs", "OBSERVATION", 210, 214]]], ["In preterm infants, L. rhamnosus GG decreased the incidence of rhinovirus-induced episodes, but not rhinovirus load [46] .", [["L. rhamnosus", "CHEMICAL", 20, 32], ["GG", "CHEMICAL", 33, 35], ["rhinovirus", "DISEASE", 63, 73], ["infants", "ORGANISM", 11, 18], ["L. rhamnosus GG", "ORGANISM", 20, 35], ["rhinovirus", "ORGANISM", 63, 73], ["rhinovirus", "ORGANISM", 100, 110], ["infants", "SPECIES", 11, 18], ["L. rhamnosus", "SPECIES", 20, 32], ["L. rhamnosus", "SPECIES", 20, 32], ["L. rhamnosus GG", "PROBLEM", 20, 35], ["rhinovirus", "PROBLEM", 63, 73], ["induced episodes", "PROBLEM", 74, 90], ["rhinovirus load", "PROBLEM", 100, 115], ["rhinovirus", "OBSERVATION", 63, 73]]], ["In otitis-prone children, a combination of L. rhamnosus GG, L. rhamnosus Lc705, B. breve Bb99, and P. freudenreichii ssp. shermanii JS reduced human bocavirus load in the nasopharynx [59] , but not picornaviruses [60] .", [["nasopharynx", "ANATOMY", 171, 182], ["otitis", "DISEASE", 3, 9], ["children", "ORGANISM", 16, 24], ["L. rhamnosus GG", "ORGANISM", 43, 58], ["L. rhamnosus Lc705", "ORGANISM", 60, 78], ["B. breve Bb99", "ORGANISM", 80, 93], ["P. freudenreichii ssp", "ORGANISM", 99, 120], ["shermanii JS", "ORGANISM", 122, 134], ["human", "ORGANISM", 143, 148], ["bocavirus", "ORGANISM", 149, 158], ["nasopharynx", "ORGAN", 171, 182], ["children", "SPECIES", 16, 24], ["L. rhamnosus", "SPECIES", 43, 55], ["L. rhamnosus", "SPECIES", 60, 72], ["B. breve", "SPECIES", 80, 88], ["P. freudenreichii ssp", "SPECIES", 99, 120], ["shermanii", "SPECIES", 122, 131], ["human", "SPECIES", 143, 148], ["L. rhamnosus", "SPECIES", 43, 55], ["L. rhamnosus", "SPECIES", 60, 72], ["B. breve Bb99", "SPECIES", 80, 93], ["P. freudenreichii ssp", "SPECIES", 99, 120], ["human", "SPECIES", 143, 148], ["otitis", "PROBLEM", 3, 9], ["P. freudenreichii ssp", "PROBLEM", 99, 120], ["shermanii JS", "PROBLEM", 122, 134], ["human bocavirus load in the nasopharynx", "PROBLEM", 143, 182], ["picornaviruses", "PROBLEM", 198, 212], ["otitis", "OBSERVATION", 3, 9], ["rhamnosus GG", "OBSERVATION", 46, 58], ["freudenreichii ssp", "OBSERVATION", 102, 120], ["bocavirus load", "OBSERVATION", 149, 163], ["nasopharynx", "ANATOMY", 171, 182]]], ["In healthy children attending day care, L. rhamnosus GG was not able to decrease significantly respiratory viruses (HRV, HEV, influenza viruses, parainfluenza viruses, RSV, adenovirus, and human bocavirus) in the upper respiratory tract [47] .", [["upper respiratory tract", "ANATOMY", 213, 236], ["respiratory viruses", "DISEASE", 95, 114], ["influenza viruses", "DISEASE", 126, 143], ["parainfluenza viruses", "DISEASE", 145, 166], ["children", "ORGANISM", 11, 19], ["L. rhamnosus GG", "ORGANISM", 40, 55], ["influenza viruses", "ORGANISM", 126, 143], ["parainfluenza viruses", "ORGANISM", 145, 166], ["RSV", "ORGANISM", 168, 171], ["adenovirus", "ORGANISM", 173, 183], ["human", "ORGANISM", 189, 194], ["bocavirus", "ORGANISM", 195, 204], ["upper respiratory", "ORGANISM_SUBDIVISION", 213, 230], ["tract", "ORGANISM_SUBDIVISION", 231, 236], ["children", "SPECIES", 11, 19], ["L. rhamnosus", "SPECIES", 40, 52], ["parainfluenza", "SPECIES", 145, 158], ["human", "SPECIES", 189, 194], ["L. rhamnosus", "SPECIES", 40, 52], ["HEV", "SPECIES", 121, 124], ["RSV", "SPECIES", 168, 171], ["adenovirus", "SPECIES", 173, 183], ["human", "SPECIES", 189, 194], ["significantly respiratory viruses", "PROBLEM", 81, 114], ["HRV", "TEST", 116, 119], ["HEV", "PROBLEM", 121, 124], ["influenza viruses", "PROBLEM", 126, 143], ["parainfluenza viruses", "PROBLEM", 145, 166], ["RSV", "PROBLEM", 168, 171], ["adenovirus", "PROBLEM", 173, 183], ["human bocavirus", "TREATMENT", 189, 204], ["respiratory viruses", "OBSERVATION", 95, 114], ["upper", "ANATOMY_MODIFIER", 213, 218], ["respiratory tract", "ANATOMY", 219, 236]]], ["Healthy children receiving L. casei rhamnosus had significantly lower odds of viral infection diagnosed by a doctor and a significant difference in doctor-diagnosed RTI.", [["L. casei rhamnosus", "CHEMICAL", 27, 45], ["viral infection", "DISEASE", 78, 93], ["RTI", "DISEASE", 165, 168], ["children", "ORGANISM", 8, 16], ["L. casei rhamnosus", "ORGANISM", 27, 45], ["children", "SPECIES", 8, 16], ["L. casei rhamnosus", "SPECIES", 27, 45], ["L. casei rhamnosus", "SPECIES", 27, 45], ["L. casei rhamnosus", "TREATMENT", 27, 45], ["viral infection", "PROBLEM", 78, 93], ["viral infection", "OBSERVATION", 78, 93]]], ["However, specific viruses were not reported in that study [49] .AdultsProbiotics' effectiveness in RTIs has been addressed in 13 studies in healthy adults, in athletes, and in individuals under stressful conditions.", [["RTIs", "DISEASE", 99, 103], ["viruses", "OBSERVATION", 18, 25]]], ["In healthy adults, L. fermentum CETC5716 reduced the number of RTIs and increased antigen-specific IgA formation after influenza virus vaccination [61] .", [["CETC5716", "CHEMICAL", 32, 40], ["RTIs", "DISEASE", 63, 67], ["L. fermentum", "ORGANISM", 19, 31], ["CETC5716", "ORGANISM", 32, 40], ["antigen", "GENE_OR_GENE_PRODUCT", 82, 89], ["IgA", "GENE_OR_GENE_PRODUCT", 99, 102], ["influenza virus", "ORGANISM", 119, 134], ["IgA", "PROTEIN", 99, 102], ["L. fermentum", "SPECIES", 19, 31], ["influenza virus", "SPECIES", 119, 134], ["L. fermentum", "SPECIES", 19, 31], ["L. fermentum", "TREATMENT", 19, 31], ["RTIs", "PROBLEM", 63, 67], ["increased antigen", "PROBLEM", 72, 89], ["influenza virus vaccination", "TREATMENT", 119, 146], ["increased", "OBSERVATION_MODIFIER", 72, 81]]], ["In addition, a combination of L. gasseri PA16/8, B. longum SP07/3, and B. bifidum MF20/5 reduced the duration of RTI symptoms [62] , duration of RTI episodes [63, 64] , but not the severity of RTI symptoms [63, 64] .", [["RTI", "DISEASE", 113, 116], ["RTI", "DISEASE", 145, 148], ["RTI", "DISEASE", 193, 196], ["L. gasseri", "ORGANISM", 30, 40], ["PA16/8", "ORGANISM", 41, 47], ["B. longum", "ORGANISM", 49, 58], ["SP07", "ORGANISM", 59, 63], ["3", "ORGANISM", 64, 65], ["B. bifidum MF20/5", "ORGANISM", 71, 88], ["L. gasseri", "SPECIES", 30, 40], ["B. longum", "SPECIES", 49, 58], ["B. bifidum", "SPECIES", 71, 81], ["L. gasseri", "SPECIES", 30, 40], ["B. longum SP07/3", "SPECIES", 49, 65], ["B. bifidum MF20/5", "SPECIES", 71, 88], ["L. gasseri PA16/8", "TREATMENT", 30, 47], ["RTI symptoms", "PROBLEM", 113, 125], ["RTI episodes", "PROBLEM", 145, 157], ["RTI symptoms", "PROBLEM", 193, 205]]], ["None of these trials reported the effects of combinations on respiratory virus load, although their viral etiology was studied.", [["respiratory virus", "ORGANISM", 61, 78], ["respiratory virus load", "PROBLEM", 61, 83]]], ["B. animalis ssp. lactis Bl-04 reduced the risk of an upper RTI episode [65] .", [["Bl-04", "CHEMICAL", 24, 29], ["B. animalis ssp", "ORGANISM", 0, 15], ["lactis", "ORGANISM", 17, 23], ["Bl-04", "GENE_OR_GENE_PRODUCT", 24, 29], ["upper", "ORGANISM_SUBDIVISION", 53, 58], ["B. animalis", "SPECIES", 0, 11], ["lactis", "SPECIES", 17, 23], ["B. animalis ssp", "SPECIES", 0, 15], ["lactis Bl", "TEST", 17, 26], ["an upper RTI episode", "PROBLEM", 50, 70], ["04 reduced", "OBSERVATION_MODIFIER", 27, 37], ["upper RTI", "ANATOMY", 53, 62]]], ["A combination of L. rhamnosus GG and B. animalis ssp. lactis Bb12 reduced both the duration of upper RTI and the severity of RTI symptoms [66] .AdultsAltogether, seven trials have been conducted among athletes or stressed individuals, but they did not report studying the viral etiology.", [["RTI", "DISEASE", 101, 104], ["RTI", "DISEASE", 125, 128], ["L. rhamnosus GG", "ORGANISM", 17, 32], ["B. animalis ssp", "ORGANISM", 37, 52], ["lactis Bb12", "ORGANISM", 54, 65], ["upper", "ORGANISM_SUBDIVISION", 95, 100], ["L. rhamnosus", "SPECIES", 17, 29], ["B. animalis", "SPECIES", 37, 48], ["lactis", "SPECIES", 54, 60], ["L. rhamnosus", "SPECIES", 17, 29], ["B. animalis ssp", "SPECIES", 37, 52], ["lactis", "SPECIES", 54, 60], ["L. rhamnosus GG", "TREATMENT", 17, 32], ["B. animalis ssp", "PROBLEM", 37, 52], ["lactis", "TEST", 54, 60], ["upper RTI", "PROBLEM", 95, 104], ["RTI symptoms", "PROBLEM", 125, 137], ["L.", "OBSERVATION_MODIFIER", 17, 19], ["rhamnosus GG", "OBSERVATION", 20, 32], ["upper RTI", "OBSERVATION_MODIFIER", 95, 104]]], ["In male elite distance runners, L. fermentum VRI003 reduced the duration of RTI symptoms, but not the incidence of RTIs or the severity of symptoms [67] .", [["VRI003", "CHEMICAL", 45, 51], ["RTI", "DISEASE", 76, 79], ["RTIs", "DISEASE", 115, 119], ["L. fermentum VRI003", "ORGANISM", 32, 51], ["L. fermentum", "SPECIES", 32, 44], ["L. fermentum", "SPECIES", 32, 44], ["L. fermentum", "TREATMENT", 32, 44], ["RTI symptoms", "PROBLEM", 76, 88], ["RTIs", "PROBLEM", 115, 119], ["the severity of symptoms", "PROBLEM", 123, 147]]], ["In competitive cyclists, L. fermentum (PCC) had some decreasing effects on the symptoms of upper RTI in males, but not in females [68] .", [["RTI", "DISEASE", 97, 100], ["L. fermentum", "ORGANISM", 25, 37], ["upper", "ORGANISM_SUBDIVISION", 91, 96], ["L. fermentum", "SPECIES", 25, 37], ["L. fermentum", "SPECIES", 25, 37], ["the symptoms", "PROBLEM", 75, 87], ["upper RTI in males", "PROBLEM", 91, 109], ["L. fermentum", "ANATOMY", 25, 37], ["decreasing", "OBSERVATION_MODIFIER", 53, 63], ["upper RTI", "ANATOMY", 91, 100]]], ["In rugby union players [69] , a combination of L. gasseri, B. bifidum, and B. longum reduced the incidence of upper RTIs, but not the severity of symptoms.", [["RTIs", "DISEASE", 116, 120], ["L. gasseri", "ORGANISM", 47, 57], ["B. bifidum", "ORGANISM", 59, 69], ["B. longum", "ORGANISM", 75, 84], ["upper", "ORGANISM_SUBDIVISION", 110, 115], ["L. gasseri", "SPECIES", 47, 57], ["B. bifidum", "SPECIES", 59, 69], ["B. longum", "SPECIES", 75, 84], ["L. gasseri", "SPECIES", 47, 57], ["B. bifidum", "SPECIES", 59, 69], ["B. longum", "SPECIES", 75, 84], ["L. gasseri", "TREATMENT", 47, 57], ["B. bifidum", "PROBLEM", 59, 69], ["B. longum", "PROBLEM", 75, 84], ["upper RTIs", "PROBLEM", 110, 120], ["the severity of symptoms", "PROBLEM", 130, 154], ["gasseri", "ANATOMY", 50, 57], ["bifidum", "ANATOMY", 62, 69], ["upper RTIs", "ANATOMY", 110, 120]]], ["However, in marathon runners, L. rhamnosus GG did not decrease the number of RTI episodes or the severity or the duration of RTI symptoms [70] .", [["L. rhamnosus", "CHEMICAL", 30, 42], ["RTI", "DISEASE", 77, 80], ["RTI", "DISEASE", 125, 128], ["L. rhamnosus GG", "ORGANISM", 30, 45], ["L. rhamnosus", "SPECIES", 30, 42], ["L. rhamnosus", "SPECIES", 30, 42], ["RTI episodes", "PROBLEM", 77, 89], ["the severity", "PROBLEM", 93, 105], ["RTI symptoms", "PROBLEM", 125, 137]]], ["In addition, in commando trainers, L. casei DN114001 was ineffective in reducing the incidence of RTIs or RTI symptoms [62] [63] [64] 71] .", [["DN114001", "CHEMICAL", 44, 52], ["RTIs", "DISEASE", 98, 102], ["RTI", "DISEASE", 106, 109], ["L. casei", "ORGANISM", 35, 43], ["L. casei", "SPECIES", 35, 43], ["L. casei DN114001", "SPECIES", 35, 52], ["RTIs", "PROBLEM", 98, 102], ["RTI symptoms", "PROBLEM", 106, 118]]], ["Similarly, L. salivarius did not lower the number of RTI episodes or reduce the severity or the duration of RTI symptoms in trainers [72] .", [["RTI", "DISEASE", 53, 56], ["RTI", "DISEASE", 108, 111], ["L. salivarius", "ORGANISM", 11, 24], ["L. salivarius", "SPECIES", 11, 24], ["L. salivarius", "SPECIES", 11, 24], ["L. salivarius", "PROBLEM", 11, 24], ["RTI episodes", "PROBLEM", 53, 65], ["the severity", "PROBLEM", 76, 88], ["RTI symptoms", "PROBLEM", 108, 120], ["L.", "OBSERVATION_MODIFIER", 11, 13], ["salivarius", "OBSERVATION", 14, 24]]], ["However, in shift workers, L. casei DN114001 reduced the number of RTIs and increased the function of immune cell activity [73] .The elderlyOnly five studies have investigated the effects of probiotics on RTIs, but not on the occurrence of specific viruses, in the elderly.", [["immune cell", "ANATOMY", 102, 113], ["DN114001", "CHEMICAL", 36, 44], ["RTIs", "DISEASE", 67, 71], ["RTIs", "DISEASE", 205, 209], ["L. casei DN114001", "ORGANISM", 27, 44], ["immune cell", "CELL", 102, 113], ["L. casei", "SPECIES", 27, 35], ["L. casei", "SPECIES", 27, 35], ["RTIs", "PROBLEM", 67, 71], ["immune cell activity", "TEST", 102, 122], ["five studies", "TEST", 145, 157], ["probiotics", "TREATMENT", 191, 201], ["RTIs", "TREATMENT", 205, 209], ["specific viruses", "PROBLEM", 240, 256], ["immune cell activity", "OBSERVATION", 102, 122], ["viruses", "OBSERVATION", 249, 256]]], ["L. casei DN114001 decreased the duration of RTIs [74, 75] , but had no effect on the incidence of RTIs [74] .", [["L.", "CHEMICAL", 0, 2], ["DN114001", "CHEMICAL", 9, 17], ["RTIs", "DISEASE", 44, 48], ["RTIs", "DISEASE", 98, 102], ["L.", "SPECIES", 0, 2], ["casei", "SPECIES", 3, 8], ["L.", "SPECIES", 0, 2], ["RTIs", "PROBLEM", 98, 102]]], ["L. casei Shirota did not have an effect on the number of upper RTIs or the severity of upper RTI symptoms, but probiotics decreased the duration of upper RTIs [76] .", [["RTIs", "DISEASE", 63, 67], ["RTI", "DISEASE", 93, 96], ["RTIs", "DISEASE", 154, 158], ["L. casei", "ORGANISM", 0, 8], ["Shirota", "ORGANISM", 9, 16], ["upper", "ORGANISM_SUBDIVISION", 57, 62], ["upper", "ORGANISM_SUBDIVISION", 87, 92], ["upper", "ORGANISM_SUBDIVISION", 148, 153], ["L. casei", "SPECIES", 0, 8], ["L. casei", "SPECIES", 0, 8], ["upper RTIs", "PROBLEM", 57, 67], ["upper RTI symptoms", "PROBLEM", 87, 105], ["probiotics", "TREATMENT", 111, 121], ["casei Shirota", "OBSERVATION", 3, 16], ["upper RTIs", "ANATOMY", 57, 67], ["upper RTI", "ANATOMY", 87, 96]]], ["However, in another study, L. casei Shirota had no effect on the duration of RTI symptoms [77] .", [["Shirota", "CHEMICAL", 36, 43], ["RTI", "DISEASE", 77, 80], ["L. casei Shirota", "ORGANISM", 27, 43], ["L. casei", "SPECIES", 27, 35], ["L. casei", "SPECIES", 27, 35], ["another study", "TEST", 12, 25], ["RTI symptoms", "PROBLEM", 77, 89]]], ["A combination of L. rhamnosus GG, L. rhamnosus Lc705, B. breve Bb99, and P. freudenreichii ssp. shermanii JS was ineffective in lowering the number of RTIs and reducing the duration of RTI symptoms.", [["shermanii", "CHEMICAL", 96, 105], ["RTIs", "DISEASE", 151, 155], ["RTI", "DISEASE", 185, 188], ["L. rhamnosus GG", "ORGANISM", 17, 32], ["L. rhamnosus Lc705", "ORGANISM", 34, 52], ["B. breve Bb99", "ORGANISM", 54, 67], ["P. freudenreichii ssp", "ORGANISM", 73, 94], ["L. rhamnosus", "SPECIES", 17, 29], ["L. rhamnosus", "SPECIES", 34, 46], ["B. breve", "SPECIES", 54, 62], ["P. freudenreichii ssp", "SPECIES", 73, 94], ["shermanii", "SPECIES", 96, 105], ["L. rhamnosus", "SPECIES", 17, 29], ["L. rhamnosus", "SPECIES", 34, 46], ["B. breve Bb99", "SPECIES", 54, 67], ["P. freudenreichii ssp", "SPECIES", 73, 94], ["L. rhamnosus GG", "TREATMENT", 17, 32], ["P. freudenreichii ssp", "PROBLEM", 73, 94], ["RTIs", "PROBLEM", 151, 155], ["RTI symptoms", "PROBLEM", 185, 197], ["L.", "OBSERVATION_MODIFIER", 17, 19], ["rhamnosus GG", "OBSERVATION", 20, 32], ["freudenreichii ssp", "OBSERVATION", 76, 94], ["ineffective", "OBSERVATION_MODIFIER", 113, 124]]], ["However, the combination reduced the duration of RTI episodes [60] .The elderlyThe clinical trials in children, adults, and the elderly presented in this review are summarized in Table 2 .", [["RTI", "DISEASE", 49, 52], ["children", "ORGANISM", 102, 110], ["children", "SPECIES", 102, 110], ["RTI episodes", "PROBLEM", 49, 61]]], ["A variety of probiotic strains have been used in these clinical trials, most of them belonging to the genus Lactobacillus.", [["Lactobacillus", "SIMPLE_CHEMICAL", 108, 121], ["probiotic strains", "TREATMENT", 13, 30], ["genus Lactobacillus", "ANATOMY", 102, 121]]], ["In addition, various combinations of probiotics have been used.", [["probiotics", "TREATMENT", 37, 47]]], ["Of 33 studies, altogether, 28 studies reported that probiotics had beneficial effects in the outcome of RTIs and five showed no clear benefit.", [["RTIs", "DISEASE", 104, 108], ["33 studies", "TEST", 3, 13], ["28 studies", "TEST", 27, 37], ["probiotics", "TREATMENT", 52, 62]]], ["Only eight studies, however, reported investigating the viral etiology.", [["eight studies", "TEST", 5, 18], ["viral", "OBSERVATION", 56, 61]]], ["Of these, only one study showed a statistically significant reduction in the virus load in the probiotic group.", [["one study", "TEST", 15, 24], ["a statistically significant reduction", "PROBLEM", 32, 69], ["the virus load", "PROBLEM", 73, 87], ["significant", "OBSERVATION_MODIFIER", 48, 59], ["reduction", "OBSERVATION_MODIFIER", 60, 69], ["virus load", "OBSERVATION", 77, 87]]], ["A Cochrane systematic review by Hao et al. concluded that probiotics were better than placebo in terms of reducing the number of upper RTI episodes, the incidence of acute upper RTI episodes, and antibiotics used [15] .", [["RTI", "DISEASE", 135, 138], ["RTI", "DISEASE", 178, 181], ["upper", "ORGANISM_SUBDIVISION", 129, 134], ["probiotics", "TREATMENT", 58, 68], ["placebo", "TREATMENT", 86, 93], ["upper RTI episodes", "PROBLEM", 129, 147], ["acute upper RTI episodes", "PROBLEM", 166, 190], ["antibiotics", "TREATMENT", 196, 207], ["upper RTI", "ANATOMY", 129, 138], ["acute", "OBSERVATION_MODIFIER", 166, 171], ["upper RTI", "ANATOMY", 172, 181]]], ["Although clinical trials show that the use of specific probiotics and probiotic combinations are beneficial in RTIs, there are also studies that report no clear advantage.", [["RTIs", "DISEASE", 111, 115], ["specific probiotics", "TREATMENT", 46, 65], ["probiotic combinations", "TREATMENT", 70, 92]]], ["In addition, several viruses can cause respiratory illnesses, but only a few studies have investigated probiotics' effectiveness on viral agents.", [["respiratory", "ANATOMY", 39, 50], ["respiratory illnesses", "DISEASE", 39, 60], ["several viruses", "PROBLEM", 13, 28], ["respiratory illnesses", "PROBLEM", 39, 60], ["a few studies", "TEST", 71, 84], ["viral agents", "TREATMENT", 132, 144], ["several", "OBSERVATION_MODIFIER", 13, 20], ["viruses", "OBSERVATION", 21, 28], ["respiratory illnesses", "OBSERVATION", 39, 60]]], ["The lack of consistent evidence between probiotic strains/genera and even within strains may be due to variation in study designs and reported outcome measures, the length of intervention, study populations used (children vs. adults) or bacterial doses (10 6 -10 10 cfu), and matrices (milk, yoghurt, capsule) used.", [["milk", "ANATOMY", 286, 290], ["capsule", "ANATOMY", 301, 308], ["children", "ORGANISM", 213, 221], ["milk", "ORGANISM_SUBDIVISION", 286, 290], ["yoghurt", "ORGANISM_SUBDIVISION", 292, 299], ["capsule", "CANCER", 301, 308], ["children", "SPECIES", 213, 221], ["probiotic strains/genera", "PROBLEM", 40, 64], ["variation in study designs", "PROBLEM", 103, 129], ["intervention", "TREATMENT", 175, 187], ["study populations", "TREATMENT", 189, 206], ["bacterial doses", "TREATMENT", 237, 252], ["matrices (milk, yoghurt, capsule)", "TREATMENT", 276, 309]]], ["In addition, in the elderly, decreased immunity due to aging may partly explain the conflicting results [79] .Possible mechanisms of actions of probiotics in respiratory virus infectionsClinical and animal studies have demonstrated that specific probiotics have antiviral effects, but the underlying mechanisms are unclear.", [["respiratory virus infections", "DISEASE", 158, 186], ["respiratory virus", "ORGANISM", 158, 175], ["probiotics", "TREATMENT", 144, 154], ["respiratory virus infections", "PROBLEM", 158, 186], ["Clinical and animal studies", "TEST", 186, 213], ["antiviral effects", "TREATMENT", 262, 279], ["respiratory virus", "OBSERVATION", 158, 175], ["antiviral effects", "OBSERVATION", 262, 279]]], ["Additionally, the strain-to-strain variation may be relatively large concerning strain properties and efficacy.", [["the strain-to-strain variation", "PROBLEM", 14, 44], ["relatively", "OBSERVATION_MODIFIER", 52, 62], ["large", "OBSERVATION", 63, 68]]], ["Possible antiviral mechanisms of probiotics include: (1) hindering the adsorption and (2) cell internalization of the virus; (3) production of metabolites and substances with a direct antiviral effect; and 4) crosstalk (immunomodulation) with the cells in establishing the antiviral protection.", [["cell", "ANATOMY", 90, 94], ["cells", "ANATOMY", 247, 252], ["cell", "CELL", 90, 94], ["cells", "CELL", 247, 252], ["antiviral mechanisms of probiotics", "TREATMENT", 9, 43], ["the adsorption and (2) cell internalization", "TREATMENT", 67, 110], ["the virus", "PROBLEM", 114, 123], ["production of metabolites and substances", "PROBLEM", 129, 169], ["a direct antiviral effect", "PROBLEM", 175, 200], ["crosstalk (immunomodulation", "TREATMENT", 209, 236], ["the cells", "TREATMENT", 243, 252], ["the antiviral protection", "TREATMENT", 269, 293], ["antiviral", "OBSERVATION", 9, 18], ["antiviral protection", "OBSERVATION", 273, 293]]], ["The possible mechanisms of probiotics against respiratory viruses are presented in Fig. 1 .Antagonism to respiratory virusesThe respiratory tract is covered by mucosal epithelial surfaces, which are constantly exposed to numerous microorganisms and serve as primary ports of entry for respiratory viruses.", [["respiratory tract", "ANATOMY", 128, 145], ["mucosal epithelial surfaces", "ANATOMY", 160, 187], ["respiratory viruses", "DISEASE", 46, 65], ["respiratory viruses", "DISEASE", 105, 124], ["respiratory viruses", "DISEASE", 285, 304], ["respiratory tract", "ORGANISM_SUBDIVISION", 128, 145], ["mucosal epithelial surfaces", "TISSUE", 160, 187], ["probiotics", "TREATMENT", 27, 37], ["respiratory viruses", "PROBLEM", 46, 65], ["Antagonism to respiratory viruses", "PROBLEM", 91, 124], ["The respiratory tract", "PROBLEM", 124, 145], ["respiratory viruses", "PROBLEM", 285, 304], ["possible", "UNCERTAINTY", 4, 12], ["viruses", "OBSERVATION", 58, 65], ["respiratory viruses", "OBSERVATION", 105, 124], ["respiratory tract", "ANATOMY", 128, 145], ["mucosal epithelial surfaces", "OBSERVATION", 160, 187], ["numerous", "OBSERVATION_MODIFIER", 221, 229], ["microorganisms", "OBSERVATION", 230, 244], ["respiratory viruses", "OBSERVATION", 285, 304]]], ["Virus attachment to a host cell is the first essential step in the disease process, and, therefore, interruption of this attachment could be beneficial to the host.", [["cell", "ANATOMY", 27, 31], ["Virus", "ORGANISM", 0, 5], ["host cell", "CELL", 22, 31], ["Virus attachment", "PROBLEM", 0, 16], ["host cell", "OBSERVATION", 22, 31], ["step", "OBSERVATION_MODIFIER", 55, 59], ["disease", "OBSERVATION", 67, 74]]], ["Probiotic bacteria may bind directly to the virus and inhibit virus attachment to the host cell receptor.", [["cell", "ANATOMY", 91, 95], ["host cell receptor", "GENE_OR_GENE_PRODUCT", 86, 104], ["host cell receptor", "PROTEIN", 86, 104], ["Probiotic bacteria", "PROBLEM", 0, 18], ["the virus", "PROBLEM", 40, 49], ["host cell receptor", "OBSERVATION", 86, 104]]], ["For instance, there is evidence that specific strains of lactobacilli are able to bind and inactivate vesicular stomatitis virus (flu-like virus) in vitro [81] .", [["lactobacilli", "CHEMICAL", 57, 69], ["vesicular stomatitis", "DISEASE", 102, 122], ["lactobacilli", "SIMPLE_CHEMICAL", 57, 69], ["vesicular stomatitis virus", "ORGANISM", 102, 128], ["flu-like virus", "ORGANISM", 130, 144], ["vesicular stomatitis virus", "SPECIES", 102, 128], ["stomatitis virus", "SPECIES", 112, 128], ["specific strains of lactobacilli", "PROBLEM", 37, 69], ["vesicular stomatitis virus", "PROBLEM", 102, 128], ["vesicular stomatitis", "OBSERVATION", 102, 122]]], ["Probiotics may also show direct antimicrobial activity against pathogens by producing antimicrobial substances such as organic acids, hydrogen peroxide, biosurfactants, and bacteriocins [12] .", [["organic acids", "CHEMICAL", 119, 132], ["hydrogen peroxide", "CHEMICAL", 134, 151], ["hydrogen peroxide", "CHEMICAL", 134, 151], ["organic acids", "SIMPLE_CHEMICAL", 119, 132], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 134, 151], ["biosurfactants", "SIMPLE_CHEMICAL", 153, 167], ["Probiotics", "TREATMENT", 0, 10], ["pathogens", "PROBLEM", 63, 72], ["antimicrobial substances", "TREATMENT", 86, 110], ["organic acids", "TREATMENT", 119, 132], ["hydrogen peroxide", "TREATMENT", 134, 151], ["biosurfactants", "TREATMENT", 153, 167], ["bacteriocins", "TREATMENT", 173, 185]]], ["In experimental studies in epithelial cells and macrophages, metabolic products of specific lactobacilli and bifidobacteria prevented vesicular stomatitis virus infection in a strain-specific manner [81] .", [["epithelial cells", "ANATOMY", 27, 43], ["macrophages", "ANATOMY", 48, 59], ["vesicular", "ANATOMY", 134, 143], ["lactobacilli", "CHEMICAL", 92, 104], ["bifidobacteria", "CHEMICAL", 109, 123], ["vesicular stomatitis virus infection", "DISEASE", 134, 170], ["epithelial cells", "CELL", 27, 43], ["macrophages", "CELL", 48, 59], ["lactobacilli", "SIMPLE_CHEMICAL", 92, 104], ["bifidobacteria", "SIMPLE_CHEMICAL", 109, 123], ["vesicular stomatitis virus", "ORGANISM", 134, 160], ["epithelial cells", "CELL_TYPE", 27, 43], ["macrophages", "CELL_TYPE", 48, 59], ["stomatitis virus", "SPECIES", 144, 160], ["experimental studies", "TEST", 3, 23], ["epithelial cells", "PROBLEM", 27, 43], ["macrophages", "PROBLEM", 48, 59], ["specific lactobacilli", "PROBLEM", 83, 104], ["bifidobacteria", "PROBLEM", 109, 123], ["vesicular stomatitis virus infection", "PROBLEM", 134, 170], ["epithelial cells", "OBSERVATION", 27, 43], ["lactobacilli", "OBSERVATION_MODIFIER", 92, 104], ["vesicular stomatitis virus infection", "OBSERVATION", 134, 170]]], ["In addition, metabolites of bacteria in yoghurts showed antiviral activity, inhibiting influenza virus replication [82] .", [["yoghurts", "ANATOMY", 40, 48], ["yoghurts", "SIMPLE_CHEMICAL", 40, 48], ["influenza virus", "ORGANISM", 87, 102], ["influenza virus", "SPECIES", 87, 102], ["influenza virus", "SPECIES", 87, 102], ["bacteria in yoghurts", "PROBLEM", 28, 48], ["antiviral activity", "PROBLEM", 56, 74], ["inhibiting influenza virus replication", "PROBLEM", 76, 114], ["bacteria", "OBSERVATION", 28, 36], ["antiviral activity", "OBSERVATION", 56, 74]]], ["The induction of low-level synthesis of nitric oxide may also be involved in the protective actions of probiotics against viruses in the respiratory cells, as shown in alveolar macrophages in vitro [27, 83, 84] .", [["respiratory cells", "ANATOMY", 137, 154], ["alveolar macrophages", "ANATOMY", 168, 188], ["nitric oxide", "CHEMICAL", 40, 52], ["nitric oxide", "CHEMICAL", 40, 52], ["nitric oxide", "SIMPLE_CHEMICAL", 40, 52], ["respiratory cells", "CELL", 137, 154], ["alveolar macrophages", "CELL", 168, 188], ["respiratory cells", "CELL_TYPE", 137, 154], ["alveolar macrophages", "CELL_TYPE", 168, 188], ["low-level synthesis of nitric oxide", "TREATMENT", 17, 52], ["probiotics", "TREATMENT", 103, 113], ["viruses in the respiratory cells", "PROBLEM", 122, 154], ["respiratory cells", "ANATOMY", 137, 154], ["alveolar macrophages", "OBSERVATION", 168, 188]]], ["However, it should be noted that respiratory viruses infect cells with different mechanisms by using various receptors and, also, the antiviral effects of probiotics are strain-specific.Cell-mediated immunityThe induction of antiviral cytokines such as interferons (IFNs), as well as proinflammatory cytokines and chemokines, upon antigen recognition in epithelial cells or underlying effector cells [macrophages, dendritic cells (DCs), neutrophils] play a key role in virus infections by initiating cell-mediated viral elimination and adaptive immune responses.", [["cells", "ANATOMY", 60, 65], ["Cell", "ANATOMY", 186, 190], ["epithelial cells", "ANATOMY", 354, 370], ["effector cells", "ANATOMY", 385, 399], ["macrophages", "ANATOMY", 401, 412], ["dendritic cells", "ANATOMY", 414, 429], ["DCs", "ANATOMY", 431, 434], ["neutrophils", "ANATOMY", 437, 448], ["cell", "ANATOMY", 500, 504], ["respiratory viruses", "DISEASE", 33, 52], ["infections", "DISEASE", 475, 485], ["cells", "CELL", 60, 65], ["Cell", "CELL", 186, 190], ["interferons", "GENE_OR_GENE_PRODUCT", 253, 264], ["IFNs", "GENE_OR_GENE_PRODUCT", 266, 270], ["epithelial cells", "CELL", 354, 370], ["underlying effector cells", "CELL", 374, 399], ["macrophages", "CELL", 401, 412], ["dendritic cells", "CELL", 414, 429], ["DCs", "CELL", 431, 434], ["neutrophils", "CELL", 437, 448], ["cell", "CELL", 500, 504], ["antiviral cytokines", "PROTEIN", 225, 244], ["interferons", "PROTEIN", 253, 264], ["IFNs", "PROTEIN", 266, 270], ["proinflammatory cytokines", "PROTEIN", 284, 309], ["chemokines", "PROTEIN", 314, 324], ["epithelial cells", "CELL_TYPE", 354, 370], ["effector cells", "CELL_TYPE", 385, 399], ["macrophages", "CELL_TYPE", 401, 412], ["dendritic cells", "CELL_TYPE", 414, 429], ["DCs", "CELL_TYPE", 431, 434], ["neutrophils", "CELL_TYPE", 437, 448], ["respiratory viruses infect cells", "PROBLEM", 33, 65], ["the antiviral effects of probiotics", "TREATMENT", 130, 165], ["antiviral cytokines", "TREATMENT", 225, 244], ["interferons (IFNs)", "TREATMENT", 253, 271], ["proinflammatory cytokines", "TREATMENT", 284, 309], ["chemokines", "TREATMENT", 314, 324], ["antigen recognition", "TEST", 331, 350], ["epithelial cells", "PROBLEM", 354, 370], ["underlying effector cells", "PROBLEM", 374, 399], ["macrophages", "PROBLEM", 401, 412], ["dendritic cells", "PROBLEM", 414, 429], ["neutrophils", "PROBLEM", 437, 448], ["virus infections", "PROBLEM", 469, 485], ["cell-mediated viral elimination", "TREATMENT", 500, 531], ["respiratory", "ANATOMY", 33, 44], ["viruses", "OBSERVATION", 45, 52], ["epithelial cells", "OBSERVATION", 354, 370], ["effector cells", "OBSERVATION", 385, 399], ["dendritic cells", "OBSERVATION", 414, 429]]], ["Probiotics may mediate their antiviral effects against respiratory viruses possibly by eliciting systemic immune responses via gut or enhancing cellular immunity in the airways with increased activity of natural killer cells and macrophages.", [["gut", "ANATOMY", 127, 130], ["cellular", "ANATOMY", 144, 152], ["airways", "ANATOMY", 169, 176], ["natural killer cells", "ANATOMY", 204, 224], ["macrophages", "ANATOMY", 229, 240], ["respiratory viruses", "DISEASE", 55, 74], ["gut", "ORGANISM_SUBDIVISION", 127, 130], ["cellular", "CELL", 144, 152], ["airways", "MULTI-TISSUE_STRUCTURE", 169, 176], ["natural killer cells", "CELL", 204, 224], ["macrophages", "CELL", 229, 240], ["natural killer cells", "CELL_TYPE", 204, 224], ["macrophages", "CELL_TYPE", 229, 240], ["Probiotics", "TREATMENT", 0, 10], ["respiratory viruses", "PROBLEM", 55, 74], ["enhancing cellular immunity in the airways", "PROBLEM", 134, 176], ["enhancing", "OBSERVATION_MODIFIER", 134, 143], ["cellular immunity", "OBSERVATION", 144, 161], ["airways", "ANATOMY", 169, 176], ["increased", "OBSERVATION_MODIFIER", 182, 191], ["activity", "OBSERVATION_MODIFIER", 192, 200], ["natural killer cells", "OBSERVATION", 204, 224]]], ["In the gut epithelial cells and/or antigen-presenting cells, probiotics are recognized by toll-like receptors (TLRs) [85] [86] [87] [88] .", [["gut epithelial cells", "ANATOMY", 7, 27], ["antigen-presenting cells", "ANATOMY", 35, 59], ["gut epithelial cells", "CELL", 7, 27], ["cells", "CELL", 54, 59], ["probiotics", "SIMPLE_CHEMICAL", 61, 71], ["toll-like receptors", "GENE_OR_GENE_PRODUCT", 90, 109], ["gut epithelial cells", "CELL_TYPE", 7, 27], ["antigen-presenting cells", "CELL_TYPE", 35, 59], ["toll-like receptors", "PROTEIN", 90, 109], ["TLRs", "PROTEIN", 111, 115], ["probiotics", "TREATMENT", 61, 71], ["gut", "ANATOMY", 7, 10], ["epithelial cells", "OBSERVATION", 11, 27]]], ["Probiotics may, therefore, modulate cytokine expression patterns through epithelial cells [89] and through underlying professional antigen-presenting cells, such as macrophages and dendritic cells [90] [91] [92] [93] [94] [95] .Cell-mediated immunityMany experimental studies in vitro and in animals show that specific strains of probiotics are capable of providing protection against virus infections by stimulating antiviral, cytokine, and chemokine responses in the respiratory and gastrointestinal epithelial cells or immune cells.", [["epithelial cells", "ANATOMY", 73, 89], ["cells", "ANATOMY", 150, 155], ["macrophages", "ANATOMY", 165, 176], ["dendritic cells", "ANATOMY", 181, 196], ["Cell", "ANATOMY", 228, 232], ["respiratory", "ANATOMY", 469, 480], ["gastrointestinal epithelial cells", "ANATOMY", 485, 518], ["immune cells", "ANATOMY", 522, 534], ["infections", "DISEASE", 391, 401], ["epithelial cells", "CELL", 73, 89], ["antigen", "GENE_OR_GENE_PRODUCT", 131, 138], ["cells", "CELL", 150, 155], ["macrophages", "CELL", 165, 176], ["dendritic cells", "CELL", 181, 196], ["Cell", "CELL", 228, 232], ["gastrointestinal epithelial cells", "CELL", 485, 518], ["immune cells", "CELL", 522, 534], ["cytokine", "PROTEIN", 36, 44], ["epithelial cells", "CELL_TYPE", 73, 89], ["professional antigen-presenting cells", "CELL_TYPE", 118, 155], ["macrophages", "CELL_TYPE", 165, 176], ["dendritic cells", "CELL_TYPE", 181, 196], ["cytokine", "PROTEIN", 428, 436], ["chemokine", "PROTEIN", 442, 451], ["respiratory and gastrointestinal epithelial cells", "CELL_TYPE", 469, 518], ["immune cells", "CELL_TYPE", 522, 534], ["Probiotics", "TREATMENT", 0, 10], ["epithelial cells", "TEST", 73, 89], ["Many experimental studies", "TEST", 250, 275], ["probiotics", "TREATMENT", 330, 340], ["virus infections", "PROBLEM", 385, 401], ["stimulating antiviral", "TREATMENT", 405, 426], ["cytokine", "TREATMENT", 428, 436], ["chemokine responses", "TEST", 442, 461], ["the respiratory and gastrointestinal epithelial cells", "PROBLEM", 465, 518], ["immune cells", "PROBLEM", 522, 534], ["macrophages", "ANATOMY", 165, 176], ["dendritic cells", "OBSERVATION", 181, 196], ["respiratory", "ANATOMY", 469, 480], ["gastrointestinal epithelial", "ANATOMY", 485, 512], ["immune cells", "OBSERVATION", 522, 534]]], ["In murine DCs, L. acidophilus NCFM and L. acidophilus X37 induced the expression of viral defense genes (IFN-\u03b2, IL-12, IL-10) [96] .", [["DCs", "ANATOMY", 10, 13], ["X37", "CHEMICAL", 54, 57], ["murine", "ORGANISM", 3, 9], ["DCs", "CELL", 10, 13], ["L. acidophilus NCFM", "ORGANISM", 15, 34], ["L. acidophilus X37", "ORGANISM", 39, 57], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 105, 110], ["IL-12", "GENE_OR_GENE_PRODUCT", 112, 117], ["IL-10", "GENE_OR_GENE_PRODUCT", 119, 124], ["murine DCs", "CELL_TYPE", 3, 13], ["viral defense genes", "DNA", 84, 103], ["IFN-\u03b2, IL-12", "DNA", 105, 117], ["murine", "SPECIES", 3, 9], ["L. acidophilus", "SPECIES", 15, 29], ["L. acidophilus", "SPECIES", 39, 53], ["L. acidophilus", "SPECIES", 15, 29], ["L. acidophilus", "SPECIES", 39, 53], ["L. acidophilus NCFM", "TREATMENT", 15, 34], ["L. acidophilus", "TREATMENT", 39, 53], ["viral defense genes", "PROBLEM", 84, 103], ["IFN", "TEST", 105, 108], ["IL", "TEST", 112, 114], ["IL", "TEST", 119, 121], ["acidophilus", "OBSERVATION_MODIFIER", 18, 29], ["L. acidophilus", "ANATOMY", 39, 53], ["viral defense genes", "OBSERVATION", 84, 103]]], ["In human macrophages, L. rhamnosus Lc705 induced Table 1 summarizes the effects of probiotic bacteria on cell-mediated immunity upon respiratory virus challenge in animal models.Humoral immunityData from animal studies indicate that strains of lactobacilli and bifidobacteria provide protection against respiratory virus infections also by inducing the synthesis of virus-specific immunoglobulins in the respiratory secretions and in serum [25, 30, 39, 41] .", [["macrophages", "ANATOMY", 9, 20], ["cell", "ANATOMY", 105, 109], ["respiratory secretions", "ANATOMY", 404, 426], ["serum", "ANATOMY", 434, 439], ["lactobacilli", "CHEMICAL", 244, 256], ["bifidobacteria", "CHEMICAL", 261, 275], ["respiratory virus infections", "DISEASE", 303, 331], ["human", "ORGANISM", 3, 8], ["macrophages", "CELL", 9, 20], ["L. rhamnosus Lc705", "ORGANISM", 22, 40], ["Table 1", "GENE_OR_GENE_PRODUCT", 49, 56], ["cell", "CELL", 105, 109], ["respiratory virus", "ORGANISM", 133, 150], ["lactobacilli", "SIMPLE_CHEMICAL", 244, 256], ["bifidobacteria", "SIMPLE_CHEMICAL", 261, 275], ["respiratory virus", "ORGANISM", 303, 320], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 381, 396], ["serum", "ORGANISM_SUBSTANCE", 434, 439], ["human macrophages", "CELL_TYPE", 3, 20], ["immunoglobulins", "PROTEIN", 381, 396], ["human", "SPECIES", 3, 8], ["L. rhamnosus", "SPECIES", 22, 34], ["human", "SPECIES", 3, 8], ["L. rhamnosus", "SPECIES", 22, 34], ["respiratory virus", "SPECIES", 303, 320], ["probiotic bacteria", "PROBLEM", 83, 101], ["cell-mediated immunity", "TREATMENT", 105, 127], ["respiratory virus challenge", "TREATMENT", 133, 160], ["Humoral immunityData", "TREATMENT", 178, 198], ["animal studies", "TEST", 204, 218], ["lactobacilli", "TREATMENT", 244, 256], ["bifidobacteria", "TREATMENT", 261, 275], ["protection", "TREATMENT", 284, 294], ["respiratory virus infections", "PROBLEM", 303, 331], ["the synthesis of virus", "PROBLEM", 349, 371], ["specific immunoglobulins", "TEST", 372, 396], ["the respiratory secretions", "TEST", 400, 426], ["serum", "TEST", 434, 439], ["human macrophages", "ANATOMY", 3, 20], ["respiratory virus", "OBSERVATION", 133, 150], ["respiratory secretions", "ANATOMY", 404, 426]]], ["In addition, studies in healthy human subjects suggest that specific probiotics may enhance the immunogenicity of viral vaccines.", [["human", "ORGANISM", 32, 37], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["studies in healthy human subjects", "TEST", 13, 46], ["specific probiotics", "TREATMENT", 60, 79], ["viral vaccines", "TREATMENT", 114, 128]]], ["L. rhamnosus GG was effective in inducing protective immune response against the H3N2 strain in influenza virus vaccine [99] .", [["L. rhamnosus", "CHEMICAL", 0, 12], ["GG", "CHEMICAL", 13, 15], ["influenza virus", "DISEASE", 96, 111], ["L. rhamnosus GG", "ORGANISM", 0, 15], ["H3N2 strain", "ORGANISM", 81, 92], ["influenza virus", "ORGANISM", 96, 111], ["L. rhamnosus", "SPECIES", 0, 12], ["influenza virus vaccine", "SPECIES", 96, 119], ["L. rhamnosus", "SPECIES", 0, 12], ["L. rhamnosus GG", "TREATMENT", 0, 15], ["the H3N2 strain", "PROBLEM", 77, 92], ["influenza virus vaccine", "TREATMENT", 96, 119], ["rhamnosus GG", "OBSERVATION", 3, 15]]], ["Moreover, L. fermentum CECT5716 ingestion in adults resulted in lower influenzalike illness, increased proportion of NK cells in blood, significantly higher TNF-\u03b1, and increased anti-influenza-specific IgA and IgM after influenza vaccination [61] .", [["NK cells", "ANATOMY", 117, 125], ["blood", "ANATOMY", 129, 134], ["CECT5716", "CHEMICAL", 23, 31], ["influenzalike illness", "DISEASE", 70, 91], ["L. fermentum CECT5716", "ORGANISM", 10, 31], ["NK cells", "CELL", 117, 125], ["blood", "ORGANISM_SUBSTANCE", 129, 134], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 157, 162], ["IgA", "GENE_OR_GENE_PRODUCT", 202, 205], ["IgM", "GENE_OR_GENE_PRODUCT", 210, 213], ["NK cells", "CELL_TYPE", 117, 125], ["TNF-\u03b1", "PROTEIN", 157, 162], ["IgA", "PROTEIN", 202, 205], ["IgM", "PROTEIN", 210, 213], ["L. fermentum", "SPECIES", 10, 22], ["L. fermentum", "SPECIES", 10, 22], ["lower influenzalike illness", "PROBLEM", 64, 91], ["NK cells", "PROBLEM", 117, 125], ["blood", "TEST", 129, 134], ["TNF", "TEST", 157, 160], ["increased anti-influenza", "PROBLEM", 168, 192], ["specific IgA", "TEST", 193, 205], ["IgM", "TEST", 210, 213], ["influenza vaccination", "PROBLEM", 220, 241], ["fermentum CECT5716", "OBSERVATION", 13, 31], ["NK cells", "OBSERVATION", 117, 125], ["increased", "OBSERVATION_MODIFIER", 168, 177], ["anti-influenza", "OBSERVATION", 178, 192]]], ["The consumption of B. animalis ssp. lactis Bb12 or L. paracasei ssp. paracasei L. casei 431431 also showed significantly greater increase in influenza virus vaccine-specific IgG antibodies in plasma and secretory IgA in saliva [100] .", [["plasma", "ANATOMY", 192, 198], ["paracasei L. casei 431431", "CHEMICAL", 69, 94], ["B. animalis ssp", "ORGANISM", 19, 34], ["lactis Bb12", "ORGANISM", 36, 47], ["L. paracasei ssp", "ORGANISM", 51, 67], ["paracasei", "ORGANISM", 69, 78], ["L. casei 431431", "ORGANISM", 79, 94], ["influenza virus", "ORGANISM", 141, 156], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 174, 188], ["plasma", "ORGANISM_SUBSTANCE", 192, 198], ["IgA", "GENE_OR_GENE_PRODUCT", 213, 216], ["saliva", "ORGANISM_SUBSTANCE", 220, 226], ["IgG antibodies", "PROTEIN", 174, 188], ["secretory IgA", "PROTEIN", 203, 216], ["B. animalis", "SPECIES", 19, 30], ["lactis", "SPECIES", 36, 42], ["L. paracasei ssp", "SPECIES", 51, 67], ["paracasei L. casei", "SPECIES", 69, 87], ["influenza virus vaccine", "SPECIES", 141, 164], ["B. animalis ssp", "SPECIES", 19, 34], ["lactis", "SPECIES", 36, 42], ["L. paracasei ssp", "SPECIES", 51, 67], ["paracasei L. casei 431431", "SPECIES", 69, 94], ["influenza virus", "SPECIES", 141, 156], ["B. animalis ssp", "PROBLEM", 19, 34], ["lactis", "TEST", 36, 42], ["L. paracasei ssp", "PROBLEM", 51, 67], ["paracasei L. casei", "TEST", 69, 87], ["significantly greater increase", "PROBLEM", 107, 137], ["influenza virus vaccine", "TREATMENT", 141, 164], ["specific IgG antibodies", "TEST", 165, 188], ["plasma", "TEST", 192, 198], ["secretory IgA in saliva", "TEST", 203, 226], ["L.", "OBSERVATION_MODIFIER", 51, 53], ["paracasei ssp", "OBSERVATION", 54, 67], ["influenza virus", "OBSERVATION", 141, 156]]], ["In the elderly, the consumption of fermented yoghurt with L. casei DN-114 001 increased significantly influenza-specific antibody titers after influenza vaccination, especially against influenza B virus [101] .", [["L. casei DN-114 001", "CHEMICAL", 58, 77], ["influenza B", "DISEASE", 185, 196], ["yoghurt", "ORGANISM_SUBDIVISION", 45, 52], ["L. casei DN-114 001", "ORGANISM", 58, 77], ["influenza B virus", "ORGANISM", 185, 202], ["L. casei", "SPECIES", 58, 66], ["influenza B virus", "SPECIES", 185, 202], ["L. casei DN-114", "SPECIES", 58, 73], ["influenza B virus", "SPECIES", 185, 202], ["L. casei DN", "TEST", 58, 69], ["influenza", "PROBLEM", 102, 111], ["specific antibody titers", "TEST", 112, 136], ["influenza vaccination", "TREATMENT", 143, 164], ["influenza B virus", "PROBLEM", 185, 202]]], ["These studies suggest that orally ingested lactobacilli and bifidobacteria have an adjuvant-like effect on the humoral responses.SafetyProbiotics are frequently part of the normal gastrointestinal microbiota, and, therefore, probiotic therapy is generally considered as safe [102] .", [["gastrointestinal", "ANATOMY", 180, 196], ["lactobacilli", "CHEMICAL", 43, 55], ["bifidobacteria", "CHEMICAL", 60, 74], ["SafetyProbiotics", "CHEMICAL", 129, 145], ["lactobacilli", "SIMPLE_CHEMICAL", 43, 55], ["bifidobacteria", "SIMPLE_CHEMICAL", 60, 74], ["SafetyProbiotics", "SIMPLE_CHEMICAL", 129, 145], ["gastrointestinal microbiota", "PATHOLOGICAL_FORMATION", 180, 207], ["These studies", "TEST", 0, 13], ["orally ingested lactobacilli", "PROBLEM", 27, 55], ["bifidobacteria", "TREATMENT", 60, 74], ["an adjuvant", "TREATMENT", 80, 91], ["SafetyProbiotics", "TREATMENT", 129, 145], ["probiotic therapy", "TREATMENT", 225, 242], ["gastrointestinal microbiota", "ANATOMY", 180, 207]]], ["However, probiotic therapy has raised potential safety concerns, including systemic infections, toxic or metabolic effects on the gastrointestinal tract, and the transfer of antibiotic resistance in the gastrointestinal microbiota [103] .", [["gastrointestinal tract", "ANATOMY", 130, 152], ["gastrointestinal", "ANATOMY", 203, 219], ["infections", "DISEASE", 84, 94], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 130, 152], ["gastrointestinal", "ORGAN", 203, 219], ["probiotic therapy", "TREATMENT", 9, 26], ["systemic infections", "PROBLEM", 75, 94], ["toxic or metabolic effects on the gastrointestinal tract", "PROBLEM", 96, 152], ["antibiotic resistance", "TREATMENT", 174, 195], ["infections", "OBSERVATION", 84, 94], ["metabolic effects", "OBSERVATION", 105, 122], ["gastrointestinal tract", "ANATOMY", 130, 152], ["gastrointestinal", "ANATOMY", 203, 219]]], ["In rare cases, some studies have reported Lactobacillus septicemia in children [104] , in immunocompromised subjects [105] , and detrimental effects in subjects with hepatitis [106] .", [["septicemia", "DISEASE", 56, 66], ["hepatitis", "DISEASE", 166, 175], ["Lactobacillus septicemia", "ORGANISM", 42, 66], ["children", "ORGANISM", 70, 78], ["children", "SPECIES", 70, 78], ["some studies", "TEST", 15, 27], ["Lactobacillus septicemia", "PROBLEM", 42, 66], ["immunocompromised subjects", "PROBLEM", 90, 116], ["hepatitis", "PROBLEM", 166, 175], ["Lactobacillus septicemia", "OBSERVATION", 42, 66]]], ["However, the European Food Safety Authority (EFSA) has concluded that there are no specific safety concerns regarding Lactobacillus, Bifidobacterium, or Propionibacterium strains, as they have a long history of safe use in food [107] .", [["Lactobacillus", "CHEMICAL", 118, 131], ["Lactobacillus", "SIMPLE_CHEMICAL", 118, 131], ["Bifidobacterium", "SIMPLE_CHEMICAL", 133, 148], ["Propionibacterium strains", "ORGANISM", 153, 178], ["Lactobacillus", "TREATMENT", 118, 131], ["Bifidobacterium", "TREATMENT", 133, 148], ["Propionibacterium strains", "PROBLEM", 153, 178]]], ["In addition, for instance in Finland, increased consumption of probiotic products containing L. rhamnosus GG has not resulted in a significant increase in Lactobacillus bacteremia [108] and L. rhamnosus GG consumption is regarded as safe in immunocompromised human immunodeficiency virus (HIV)-infected patients [108] .", [["L. rhamnosus", "CHEMICAL", 93, 105], ["GG", "CHEMICAL", 106, 108], ["bacteremia", "DISEASE", 169, 179], ["GG", "CHEMICAL", 203, 205], ["immunocompromised human immunodeficiency virus (HIV)-infected", "DISEASE", 241, 302], ["L. rhamnosus GG", "ORGANISM", 93, 108], ["Lactobacillus", "SIMPLE_CHEMICAL", 155, 168], ["L. rhamnosus GG", "ORGANISM", 190, 205], ["immunocompromised", "ORGANISM", 241, 258], ["human immunodeficiency virus", "ORGANISM", 259, 287], ["HIV", "ORGANISM", 289, 292], ["patients", "ORGANISM", 303, 311], ["L. rhamnosus", "SPECIES", 93, 105], ["L. rhamnosus", "SPECIES", 190, 202], ["human immunodeficiency virus (HIV", "SPECIES", 259, 292], ["patients", "SPECIES", 303, 311], ["L. rhamnosus", "SPECIES", 93, 105], ["L. rhamnosus", "SPECIES", 190, 202], ["human immunodeficiency virus", "SPECIES", 259, 287], ["HIV", "SPECIES", 289, 292], ["probiotic products", "TREATMENT", 63, 81], ["L. rhamnosus GG", "TREATMENT", 93, 108], ["a significant increase", "PROBLEM", 129, 151], ["Lactobacillus bacteremia", "PROBLEM", 155, 179], ["L. rhamnosus GG consumption", "TREATMENT", 190, 217], ["immunocompromised human immunodeficiency virus", "PROBLEM", 241, 287], ["significant", "OBSERVATION_MODIFIER", 131, 142], ["increase", "OBSERVATION_MODIFIER", 143, 151], ["Lactobacillus bacteremia", "OBSERVATION", 155, 179]]], ["It should be taken into consideration that the safety of probiotics has not been as systematically investigated as in drugs, and the safety evaluation is partly based on long-term experience.Summary and conclusionsThe aim of this review was to summarize the current literature investigating the effects of probiotics in respiratory virus infections in cell models, in animal models, and in humans.Summary and conclusionsIn addition, possible antiviral mechanisms of probiotics in There are also contradictory data on probiotic use in the prevention of RTIs.", [["cell", "ANATOMY", 352, 356], ["respiratory virus infections", "DISEASE", 320, 348], ["RTIs", "DISEASE", 552, 556], ["respiratory virus", "ORGANISM", 320, 337], ["cell", "CELL", 352, 356], ["humans", "ORGANISM", 390, 396], ["humans", "SPECIES", 390, 396], ["respiratory virus", "SPECIES", 320, 337], ["humans", "SPECIES", 390, 396], ["probiotics", "TREATMENT", 57, 67], ["the safety evaluation", "TEST", 129, 150], ["probiotics", "TREATMENT", 306, 316], ["respiratory virus infections in cell models", "PROBLEM", 320, 363], ["antiviral mechanisms of probiotics", "TREATMENT", 442, 476], ["RTIs", "PROBLEM", 552, 556], ["respiratory virus", "OBSERVATION", 320, 337], ["cell models", "OBSERVATION", 352, 363], ["possible", "UNCERTAINTY", 433, 441], ["antiviral", "OBSERVATION_MODIFIER", 442, 451], ["RTIs", "OBSERVATION", 552, 556]]], ["The variability in the outcomes between clinical trials studying probiotics' role in RTIs may be explained by the use of different probiotic strains, bacterial dose, and matrices.", [["RTIs", "DISEASE", 85, 89], ["clinical trials studying probiotics", "TREATMENT", 40, 75], ["RTIs", "PROBLEM", 85, 89], ["different probiotic strains", "TREATMENT", 121, 148], ["bacterial dose", "TREATMENT", 150, 164], ["variability", "OBSERVATION_MODIFIER", 4, 15]]], ["In addition, it should be noted that the effects of probiotics are highly strain-specific and the adequate amount of bacteria transferred into the effector sites in the gut may be crucial.", [["effector sites", "ANATOMY", 147, 161], ["gut", "ANATOMY", 169, 172], ["gut", "ORGANISM_SUBDIVISION", 169, 172], ["probiotics", "TREATMENT", 52, 62], ["bacteria", "PROBLEM", 117, 125], ["adequate", "OBSERVATION_MODIFIER", 98, 106], ["amount", "OBSERVATION_MODIFIER", 107, 113], ["bacteria", "OBSERVATION", 117, 125], ["effector sites", "OBSERVATION", 147, 161], ["gut", "ANATOMY", 169, 172], ["may be", "UNCERTAINTY", 173, 179], ["crucial", "OBSERVATION", 180, 187]]], ["Due to the lack of confirmatory studies and varied data available, more randomized, double-blind, and placebocontrolled clinical trials in different age populations investigating probiotic dose response, comparing probiotic strains, and elucidating the mechanisms of effects are necessary.Summary and conclusionsAs many animal studies show that probiotic administration through the nose is able to reduce viral titers and relieve clinical symptoms, nasal bacteriotherapy for viral RTIs in humans could be worthy approach for consideration in the future.", [["nose", "ANATOMY", 382, 386], ["nasal", "ANATOMY", 449, 454], ["RTIs", "DISEASE", 481, 485], ["nose", "ORGANISM_SUBDIVISION", 382, 386], ["nasal", "ORGANISM_SUBDIVISION", 449, 454], ["humans", "ORGANISM", 489, 495], ["humans", "SPECIES", 489, 495], ["humans", "SPECIES", 489, 495], ["confirmatory studies", "TEST", 19, 39], ["varied data", "TEST", 44, 55], ["double-blind", "TREATMENT", 84, 96], ["placebocontrolled clinical trials", "TREATMENT", 102, 135], ["probiotic dose response", "TREATMENT", 179, 202], ["probiotic strains", "TREATMENT", 214, 231], ["many animal studies", "TEST", 315, 334], ["probiotic administration", "TREATMENT", 345, 369], ["viral titers", "PROBLEM", 405, 417], ["clinical symptoms", "PROBLEM", 430, 447], ["nasal bacteriotherapy", "TREATMENT", 449, 470], ["viral RTIs in humans", "PROBLEM", 475, 495]]], ["Probiotics' ability to enhance local and systemic innate immunity during virus infection in animal experiments is a likely, yet unverified, effect mechanism behind beneficial effects, and an interesting area of future research.", [["infection", "DISEASE", 79, 88], ["Probiotics", "TREATMENT", 0, 10], ["local and systemic innate immunity", "TREATMENT", 31, 65], ["virus infection", "PROBLEM", 73, 88]]], ["The inclusion of serological and immunological diagnostics, such as the identification of virus-specific immunoglobulins and cytokines, in clinical research would have clear benefits in providing valuable information on the effects of probiotics in respiratory virus infections.", [["respiratory virus infections", "DISEASE", 249, 277], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 105, 120], ["respiratory virus", "ORGANISM", 249, 266], ["immunoglobulins", "PROTEIN", 105, 120], ["cytokines", "PROTEIN", 125, 134], ["serological and immunological diagnostics", "TEST", 17, 58], ["virus", "PROBLEM", 90, 95], ["cytokines", "PROBLEM", 125, 134], ["probiotics", "TREATMENT", 235, 245], ["respiratory virus infections", "PROBLEM", 249, 277], ["respiratory virus", "OBSERVATION", 249, 266]]]], "PMC7281694": [["BackgroundHemophagocytic lymphohistiocytosis (HLH) is a rare, but aggressive and life-threatening syndrome, which is characterized by a hyperinflammatory immune response that initiates systemic inflammation, hypercytokinemia and multi-organ failure [1].", [["multi-organ", "ANATOMY", 229, 240], ["Hemophagocytic lymphohistiocytosis", "DISEASE", 10, 44], ["HLH", "DISEASE", 46, 49], ["inflammation", "DISEASE", 194, 206], ["hypercytokinemia", "DISEASE", 208, 224], ["multi-organ failure", "DISEASE", 229, 248], ["BackgroundHemophagocytic lymphohistiocytosis", "PROBLEM", 0, 44], ["HLH", "PROBLEM", 46, 49], ["aggressive and life-threatening syndrome", "PROBLEM", 66, 106], ["a hyperinflammatory immune response", "PROBLEM", 134, 169], ["systemic inflammation", "PROBLEM", 185, 206], ["hypercytokinemia", "PROBLEM", 208, 224], ["multi-organ failure", "PROBLEM", 229, 248], ["Hemophagocytic lymphohistiocytosis", "OBSERVATION", 10, 44], ["aggressive", "OBSERVATION_MODIFIER", 66, 76], ["systemic", "OBSERVATION_MODIFIER", 185, 193], ["inflammation", "OBSERVATION", 194, 206], ["multi-organ failure", "OBSERVATION", 229, 248]]], ["HLH is broadly divided into two distinct groups: Primary and secondary HLH.", [["HLH", "DISEASE", 0, 3], ["HLH", "DISEASE", 71, 74], ["HLH", "PROBLEM", 0, 3], ["secondary HLH", "PROBLEM", 61, 74], ["secondary", "OBSERVATION_MODIFIER", 61, 70], ["HLH", "OBSERVATION", 71, 74]]], ["In adults, secondary HLH is often triggered by certain types of infection, cancer and numerous autoimmune diseases; however, of the numerous infectious triggers associated with HLH, the consequences of Bartonella henselae (B. henselae) infection have been rarely reported [2, 3].", [["cancer", "ANATOMY", 75, 81], ["HLH", "DISEASE", 21, 24], ["infection", "DISEASE", 64, 73], ["cancer", "DISEASE", 75, 81], ["autoimmune diseases", "DISEASE", 95, 114], ["HLH", "DISEASE", 177, 180], ["Bartonella henselae", "DISEASE", 202, 221], ["B. henselae) infection", "DISEASE", 223, 245], ["cancer", "CANCER", 75, 81], ["Bartonella henselae", "ORGANISM", 202, 221], ["B. henselae", "ORGANISM", 223, 234], ["Bartonella henselae", "SPECIES", 202, 221], ["B. henselae", "SPECIES", 223, 234], ["Bartonella henselae", "SPECIES", 202, 221], ["B. henselae", "SPECIES", 223, 234], ["secondary HLH", "PROBLEM", 11, 24], ["infection", "PROBLEM", 64, 73], ["cancer", "PROBLEM", 75, 81], ["numerous autoimmune diseases", "PROBLEM", 86, 114], ["the numerous infectious triggers", "PROBLEM", 128, 160], ["HLH", "PROBLEM", 177, 180], ["Bartonella henselae (B. henselae) infection", "PROBLEM", 202, 245], ["HLH", "OBSERVATION", 21, 24], ["infection", "OBSERVATION", 64, 73], ["cancer", "OBSERVATION", 75, 81], ["numerous", "OBSERVATION_MODIFIER", 86, 94], ["autoimmune diseases", "OBSERVATION", 95, 114], ["numerous", "OBSERVATION_MODIFIER", 132, 140], ["infectious", "OBSERVATION", 141, 151]]], ["B. henselae is known to cause cat-scratch disease (CSD), a benign and self-limited condition, which presents in immunocompetent children.", [["B. henselae", "DISEASE", 0, 11], ["cat-scratch disease", "DISEASE", 30, 49], ["CSD", "DISEASE", 51, 54], ["B. henselae", "ORGANISM", 0, 11], ["children", "ORGANISM", 128, 136], ["B. henselae", "SPECIES", 0, 11], ["children", "SPECIES", 128, 136], ["B. henselae", "SPECIES", 0, 11], ["cat-scratch disease", "PROBLEM", 30, 49], ["a benign and self-limited condition", "PROBLEM", 57, 92], ["henselae", "OBSERVATION", 3, 11], ["known to cause", "UNCERTAINTY", 15, 29], ["scratch disease", "OBSERVATION", 34, 49], ["benign", "OBSERVATION_MODIFIER", 59, 65]]], ["However, the condition is hypothesized to worsen if the patients developed hemophagocytic syndrome.", [["hemophagocytic syndrome", "DISEASE", 75, 98], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["hemophagocytic syndrome", "PROBLEM", 75, 98], ["hemophagocytic syndrome", "OBSERVATION", 75, 98]]], ["Thus, the present case study reported on a case of HLH associated with disseminated B. henselae infection in a patient with both STXBP2 and IRF5 gene variants.Case presentationA 48-year-old female with a previous medical history of drug allergies was recently prescribed a traditional Chinese medicine (TCM), namely a Niuhuang Jiedu tablet, for their swollen gums.", [["HLH", "DISEASE", 51, 54], ["B. henselae infection", "DISEASE", 84, 105], ["drug allergies", "DISEASE", 232, 246], ["B. henselae", "ORGANISM", 84, 95], ["patient", "ORGANISM", 111, 118], ["STXBP2", "GENE_OR_GENE_PRODUCT", 129, 135], ["IRF5", "GENE_OR_GENE_PRODUCT", 140, 144], ["female", "ORGANISM", 190, 196], ["gums", "ORGANISM_SUBDIVISION", 359, 363], ["STXBP2 and IRF5 gene variants", "DNA", 129, 158], ["B. henselae", "SPECIES", 84, 95], ["patient", "SPECIES", 111, 118], ["B. henselae", "SPECIES", 84, 95], ["HLH", "PROBLEM", 51, 54], ["disseminated B. henselae infection", "PROBLEM", 71, 105], ["both STXBP2 and IRF5 gene variants", "PROBLEM", 124, 158], ["drug allergies", "PROBLEM", 232, 246], ["a traditional Chinese medicine", "TREATMENT", 271, 301], ["a Niuhuang Jiedu tablet", "TREATMENT", 316, 339], ["their swollen gums", "PROBLEM", 345, 363], ["disseminated", "OBSERVATION_MODIFIER", 71, 83], ["henselae", "OBSERVATION_MODIFIER", 87, 95], ["infection", "OBSERVATION", 96, 105], ["IRF5 gene variants", "OBSERVATION", 140, 158], ["gums", "ANATOMY", 359, 363]]], ["A painful and itchy purple patch of skin on the lips, genitals and hands occurred within 12 h of taking the drug.", [["skin", "ANATOMY", 36, 40], ["lips", "ANATOMY", 48, 52], ["genitals", "ANATOMY", 54, 62], ["skin", "ORGAN", 36, 40], ["lips", "ORGANISM_SUBDIVISION", 48, 52], ["genitals", "ORGANISM_SUBDIVISION", 54, 62], ["A painful and itchy purple patch of skin on the lips", "PROBLEM", 0, 52], ["the drug", "TREATMENT", 104, 112], ["painful", "OBSERVATION_MODIFIER", 2, 9], ["itchy", "OBSERVATION_MODIFIER", 14, 19], ["purple", "OBSERVATION_MODIFIER", 20, 26], ["patch", "OBSERVATION_MODIFIER", 27, 32], ["skin", "ANATOMY", 36, 40], ["lips", "ANATOMY", 48, 52], ["genitals", "ANATOMY", 54, 62], ["hands", "ANATOMY", 67, 72]]], ["Although the patient did not seek medical advice in time, the rash gradually subsided without any medical treatment.", [["rash", "DISEASE", 62, 66], ["patient", "ORGANISM", 13, 20], ["patient", "SPECIES", 13, 20], ["the rash", "PROBLEM", 58, 66], ["any medical treatment", "TREATMENT", 94, 115]]], ["On the seventh day after the allergic reaction, the patient presented with a 20-day history of intermittent fever, which was accompanied by another systemic rash, fatigue, anorexia and weight loss.", [["allergic reaction", "DISEASE", 29, 46], ["intermittent fever", "DISEASE", 95, 113], ["rash", "DISEASE", 157, 161], ["fatigue", "DISEASE", 163, 170], ["anorexia", "DISEASE", 172, 180], ["weight loss", "DISEASE", 185, 196], ["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["the allergic reaction", "PROBLEM", 25, 46], ["intermittent fever", "PROBLEM", 95, 113], ["another systemic rash", "PROBLEM", 140, 161], ["fatigue", "PROBLEM", 163, 170], ["anorexia", "PROBLEM", 172, 180], ["weight loss", "PROBLEM", 185, 196], ["allergic", "OBSERVATION", 29, 37], ["intermittent", "OBSERVATION_MODIFIER", 95, 107], ["fever", "OBSERVATION", 108, 113], ["systemic", "OBSERVATION_MODIFIER", 148, 156], ["rash", "OBSERVATION", 157, 161], ["anorexia", "OBSERVATION", 172, 180], ["weight loss", "OBSERVATION", 185, 196]]], ["The patient was subsequently admitted to our hospital for further evaluation and management.Case presentationOn admission, the patient has a temperature of 38.4 \u00b0C, a pulse rate of 120 beats/min, a respiratory rate of 22 breaths/min and a blood pressure of 68/36 mmHg; the patient was also unconscious.", [["respiratory", "ANATOMY", 198, 209], ["blood", "ANATOMY", 239, 244], ["patient", "ORGANISM", 4, 11], ["patient", "ORGANISM", 127, 134], ["blood", "ORGANISM_SUBSTANCE", 239, 244], ["patient", "ORGANISM", 273, 280], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 127, 134], ["patient", "SPECIES", 273, 280], ["further evaluation", "TEST", 58, 76], ["management", "TREATMENT", 81, 91], ["a temperature", "TEST", 139, 152], ["a pulse rate", "TEST", 165, 177], ["a respiratory rate", "TEST", 196, 214], ["a blood pressure", "TEST", 237, 253], ["unconscious", "PROBLEM", 290, 301]]], ["A physical examination revealed a palpable spleen located 3 cm below the costal margin, and an enlarged, painful and mobile lymph node in the right inguinal region.", [["palpable spleen", "ANATOMY", 34, 49], ["costal margin", "ANATOMY", 73, 86], ["lymph node", "ANATOMY", 124, 134], ["right inguinal region", "ANATOMY", 142, 163], ["spleen", "ORGAN", 43, 49], ["costal margin", "MULTI-TISSUE_STRUCTURE", 73, 86], ["lymph node", "MULTI-TISSUE_STRUCTURE", 124, 134], ["A physical examination", "TEST", 0, 22], ["an enlarged, painful and mobile lymph node", "PROBLEM", 92, 134], ["palpable", "OBSERVATION", 34, 42], ["spleen", "ANATOMY", 43, 49], ["3 cm", "OBSERVATION_MODIFIER", 58, 62], ["costal", "ANATOMY", 73, 79], ["margin", "ANATOMY_MODIFIER", 80, 86], ["enlarged", "OBSERVATION_MODIFIER", 95, 103], ["painful", "OBSERVATION_MODIFIER", 105, 112], ["mobile", "OBSERVATION_MODIFIER", 117, 123], ["lymph node", "OBSERVATION", 124, 134], ["right", "ANATOMY_MODIFIER", 142, 147], ["inguinal", "ANATOMY", 148, 156], ["region", "ANATOMY_MODIFIER", 157, 163]]], ["The chest and heart were normal.", [["chest", "ANATOMY", 4, 9], ["heart", "ANATOMY", 14, 19], ["chest", "ORGAN", 4, 9], ["heart", "ORGAN", 14, 19], ["chest", "ANATOMY", 4, 9], ["heart", "ANATOMY", 14, 19], ["normal", "OBSERVATION", 25, 31]]], ["Immediately, the emergency team performed anti-shock procedures and further tests.", [["anti-shock procedures", "TREATMENT", 42, 63], ["further tests", "TEST", 68, 81]]], ["The laboratory evaluation revealed that the patient had a total leukocyte count of 1850 \u00d7 106/L, alongside a diagnosis of anemia (hemoglobin, 79 g/L) and thrombocytopenia (platelet count, 2000 \u00d7 106/L).", [["leukocyte", "ANATOMY", 64, 73], ["platelet", "ANATOMY", 172, 180], ["anemia", "DISEASE", 122, 128], ["thrombocytopenia", "DISEASE", 154, 170], ["patient", "ORGANISM", 44, 51], ["leukocyte", "CELL", 64, 73], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 130, 140], ["platelet", "CELL", 172, 180], ["hemoglobin", "PROTEIN", 130, 140], ["patient", "SPECIES", 44, 51], ["The laboratory evaluation", "TEST", 0, 25], ["a total leukocyte count", "TEST", 56, 79], ["anemia", "PROBLEM", 122, 128], ["hemoglobin", "TEST", 130, 140], ["thrombocytopenia", "PROBLEM", 154, 170], ["platelet count", "TEST", 172, 186], ["anemia", "OBSERVATION", 122, 128], ["thrombocytopenia", "OBSERVATION", 154, 170]]], ["Liver function assays were subsequently performed, and the following levels were recorded: (i) Aminotransferase, 69.1 U/L; (ii) aspartate aminotransferase, 182 U/L; (iii) lactate dehydrogenase, 6194 U/L; bilirubin total/direct, 52.8/37.1 \u03bcmol/L; and (iv) ferritin, > 2000 ng/mL.", [["Liver", "ANATOMY", 0, 5], ["aspartate", "CHEMICAL", 128, 137], ["lactate", "CHEMICAL", 171, 178], ["bilirubin", "CHEMICAL", 204, 213], ["aspartate", "CHEMICAL", 128, 137], ["lactate", "CHEMICAL", 171, 178], ["bilirubin", "CHEMICAL", 204, 213], ["Liver", "ORGAN", 0, 5], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 128, 154], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 171, 192], ["bilirubin", "GENE_OR_GENE_PRODUCT", 204, 213], ["ferritin", "GENE_OR_GENE_PRODUCT", 255, 263], ["aspartate aminotransferase", "PROTEIN", 128, 154], ["lactate dehydrogenase", "PROTEIN", 171, 192], ["ferritin", "PROTEIN", 255, 263], ["Liver function assays", "TEST", 0, 21], ["the following levels", "TEST", 55, 75], ["Aminotransferase", "TEST", 95, 111], ["U/L", "TEST", 118, 121], ["aspartate aminotransferase", "TEST", 128, 154], ["U/L", "TEST", 160, 163], ["lactate dehydrogenase", "TEST", 171, 192], ["U/L", "TEST", 199, 202], ["bilirubin", "TEST", 204, 213], ["direct", "TEST", 220, 226], ["\u03bcmol", "TEST", 238, 242], ["ferritin", "TEST", 255, 263]]], ["The following parameters were also recorded: (i) Cholesterol, 2.51 mmol/L; (ii) triglycerides, 1.81 mmol/L; (iii) prothrombin time, 17.4 s; (iv) partial thromboplastin time, 56.8 s; and (v) fibrinogen, 0.77 g/L. Computed tomography scans revealed scattered, high-density patchy opacities in the bilateral lungs.Case presentationOn day 3 of hospitalization, the patient experienced shortness of breath and a very high fever (39.8 \u00b0C).", [["lungs", "ANATOMY", 305, 310], ["Cholesterol", "CHEMICAL", 49, 60], ["shortness of breath", "DISEASE", 381, 400], ["fever", "DISEASE", 417, 422], ["Cholesterol", "CHEMICAL", 49, 60], ["triglycerides", "CHEMICAL", 80, 93], ["Cholesterol", "SIMPLE_CHEMICAL", 49, 60], ["triglycerides", "SIMPLE_CHEMICAL", 80, 93], ["prothrombin", "GENE_OR_GENE_PRODUCT", 114, 125], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 153, 167], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 190, 200], ["lungs", "ORGAN", 305, 310], ["patient", "ORGANISM", 361, 368], ["prothrombin", "PROTEIN", 114, 125], ["fibrinogen", "PROTEIN", 190, 200], ["patient", "SPECIES", 361, 368], ["Cholesterol", "TEST", 49, 60], ["triglycerides", "TEST", 80, 93], ["mmol/L", "TEST", 100, 106], ["prothrombin time", "TEST", 114, 130], ["partial thromboplastin time", "TEST", 145, 172], ["fibrinogen", "TEST", 190, 200], ["Computed tomography scans", "TEST", 212, 237], ["scattered, high-density patchy opacities in the bilateral lungs", "PROBLEM", 247, 310], ["shortness of breath", "PROBLEM", 381, 400], ["a very high fever", "PROBLEM", 405, 422], ["scattered", "OBSERVATION_MODIFIER", 247, 256], ["high", "OBSERVATION_MODIFIER", 258, 262], ["-density", "OBSERVATION_MODIFIER", 262, 270], ["patchy", "OBSERVATION_MODIFIER", 271, 277], ["opacities", "OBSERVATION", 278, 287], ["bilateral", "ANATOMY_MODIFIER", 295, 304], ["lungs", "ANATOMY", 305, 310]]], ["An arterial blood gas test indicated pH of 7.55, PO2 of 57 mmHg, PCO2 of 36 mmHg and bicarbonate level of 31.6 mEq/L. Subsequently, the patient was intubated and connected to a mechanical ventilator.", [["arterial blood", "ANATOMY", 3, 17], ["bicarbonate", "CHEMICAL", 85, 96], ["bicarbonate", "CHEMICAL", 85, 96], ["arterial", "MULTI-TISSUE_STRUCTURE", 3, 11], ["blood", "ORGANISM_SUBSTANCE", 12, 17], ["bicarbonate", "SIMPLE_CHEMICAL", 85, 96], ["patient", "ORGANISM", 136, 143], ["patient", "SPECIES", 136, 143], ["An arterial blood gas test", "TEST", 0, 26], ["pH", "TEST", 37, 39], ["PO2", "TEST", 49, 52], ["mmHg", "TEST", 59, 63], ["PCO2", "TEST", 65, 69], ["mmHg", "TEST", 76, 80], ["bicarbonate level", "TEST", 85, 102], ["intubated", "TREATMENT", 148, 157], ["a mechanical ventilator", "TREATMENT", 175, 198], ["arterial", "ANATOMY", 3, 11], ["mechanical ventilator", "OBSERVATION", 177, 198]]], ["Due to the worsening clinical presentation, the ineffective treatment with broad-spectrum antimicrobials [cefoperazone-sulbactam (2000\u20131000 mg per day for 7 days) and azithromycin (250 mg per day for 2 days)], and continuing fever and cytopenia, HLH was suspected.", [["cefoperazone-sulbactam", "CHEMICAL", 106, 128], ["azithromycin", "CHEMICAL", 167, 179], ["fever", "DISEASE", 225, 230], ["cytopenia", "DISEASE", 235, 244], ["HLH", "DISEASE", 246, 249], ["cefoperazone", "CHEMICAL", 106, 118], ["sulbactam", "CHEMICAL", 119, 128], ["azithromycin", "CHEMICAL", 167, 179], ["cefoperazone-sulbactam", "SIMPLE_CHEMICAL", 106, 128], ["azithromycin", "SIMPLE_CHEMICAL", 167, 179], ["the worsening clinical presentation", "PROBLEM", 7, 42], ["the ineffective treatment", "TREATMENT", 44, 69], ["broad-spectrum antimicrobials", "TREATMENT", 75, 104], ["cefoperazone", "TREATMENT", 106, 118], ["sulbactam", "TREATMENT", 119, 128], ["azithromycin", "TREATMENT", 167, 179], ["continuing fever", "PROBLEM", 214, 230], ["cytopenia", "PROBLEM", 235, 244], ["HLH", "PROBLEM", 246, 249], ["worsening", "OBSERVATION_MODIFIER", 11, 20], ["cytopenia", "OBSERVATION", 235, 244]]], ["A bone marrow aspirate was subsequently performed, which confirmed hemophagocytic activity (Fig. 1).", [["bone marrow aspirate", "ANATOMY", 2, 22], ["hemophagocytic", "DISEASE", 67, 81], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 2, 13], ["A bone marrow aspirate", "TEST", 0, 22], ["hemophagocytic activity", "PROBLEM", 67, 90], ["bone", "ANATOMY", 2, 6], ["marrow", "ANATOMY", 7, 13], ["hemophagocytic activity", "OBSERVATION", 67, 90]]], ["Low natural killer (NK) cell activity (12.38%) and elevated serum soluble IL-2R\u03b1 (sCD25) levels (> 44,000 ng/L) also supported the diagnosis of HLH.Case presentationTo identify the cause of HLH, a series of targeted examinations were performed.", [["natural killer (NK) cell", "ANATOMY", 4, 28], ["serum", "ANATOMY", 60, 65], ["HLH", "DISEASE", 144, 147], ["HLH", "DISEASE", 190, 193], ["natural killer (NK) cell", "CELL", 4, 28], ["serum", "ORGANISM_SUBSTANCE", 60, 65], ["IL-2R\u03b1", "GENE_OR_GENE_PRODUCT", 74, 80], ["sCD25", "GENE_OR_GENE_PRODUCT", 82, 87], ["natural killer (NK) cell", "CELL_TYPE", 4, 28], ["sCD25", "PROTEIN", 82, 87], ["cell activity", "TEST", 24, 37], ["elevated serum soluble IL", "PROBLEM", 51, 76], ["levels", "TEST", 89, 95], ["HLH", "PROBLEM", 144, 147], ["HLH", "PROBLEM", 190, 193], ["a series of targeted examinations", "TEST", 195, 228], ["natural killer", "OBSERVATION", 4, 18], ["HLH", "OBSERVATION", 144, 147], ["HLH", "OBSERVATION", 190, 193]]], ["The patient had a negative T-SPOT test result.", [["patient", "ORGANISM", 4, 11], ["T-SPOT", "GENE_OR_GENE_PRODUCT", 27, 33], ["patient", "SPECIES", 4, 11]]], ["In addition, bacterial and fungal cultures were negative, and serology evaluations for Epstein\u2013Barr virus, human herpesvirus-6, cytomegalovirus, influenza A virus, hepatitis B and C, human immunodeficiency virus and mycoplasma pneumoniae antibodies all yielded negative results.", [["cultures", "ANATOMY", 34, 42], ["influenza A virus", "DISEASE", 145, 162], ["hepatitis B", "DISEASE", 164, 175], ["human immunodeficiency virus", "DISEASE", 183, 211], ["fungal cultures", "CELL", 27, 42], ["Epstein\u2013Barr virus", "ORGANISM", 87, 105], ["human herpesvirus-6", "ORGANISM", 107, 126], ["cytomegalovirus", "ORGANISM", 128, 143], ["influenza A virus", "ORGANISM", 145, 162], ["hepatitis B and C", "ORGANISM", 164, 181], ["human immunodeficiency virus", "ORGANISM", 183, 211], ["mycoplasma pneumoniae", "ORGANISM", 216, 237], ["mycoplasma pneumoniae antibodies", "PROTEIN", 216, 248], ["human herpesvirus-6", "SPECIES", 107, 126], ["influenza A virus", "SPECIES", 145, 162], ["human", "SPECIES", 183, 188], ["immunodeficiency virus", "SPECIES", 189, 211], ["mycoplasma pneumoniae", "SPECIES", 216, 237], ["Epstein\u2013Barr virus", "SPECIES", 87, 105], ["human herpesvirus-6", "SPECIES", 107, 126], ["influenza A virus", "SPECIES", 145, 162], ["hepatitis B", "SPECIES", 164, 175], ["human immunodeficiency virus", "SPECIES", 183, 211], ["mycoplasma pneumoniae", "SPECIES", 216, 237], ["bacterial and fungal cultures", "TEST", 13, 42], ["serology evaluations", "TEST", 62, 82], ["Epstein\u2013Barr virus", "PROBLEM", 87, 105], ["human herpesvirus", "TEST", 107, 124], ["cytomegalovirus", "PROBLEM", 128, 143], ["influenza A virus", "PROBLEM", 145, 162], ["hepatitis B and C", "PROBLEM", 164, 181], ["human immunodeficiency virus", "PROBLEM", 183, 211], ["mycoplasma pneumoniae antibodies", "TEST", 216, 248], ["bacterial", "OBSERVATION_MODIFIER", 13, 22], ["Barr virus", "OBSERVATION", 95, 105]]], ["However, an inguinal lymph node biopsy was performed, and the histopathologic examination revealed necrotizing granulomatous inflammation (Fig. 2).", [["inguinal lymph node", "ANATOMY", 12, 31], ["granulomatous", "ANATOMY", 111, 124], ["necrotizing granulomatous inflammation", "DISEASE", 99, 137], ["lymph node", "MULTI-TISSUE_STRUCTURE", 21, 31], ["an inguinal lymph node biopsy", "TEST", 9, 38], ["the histopathologic examination", "TEST", 58, 89], ["necrotizing granulomatous inflammation", "PROBLEM", 99, 137], ["inguinal", "ANATOMY", 12, 20], ["lymph node", "OBSERVATION", 21, 31], ["necrotizing", "OBSERVATION_MODIFIER", 99, 110], ["granulomatous", "OBSERVATION_MODIFIER", 111, 124], ["inflammation", "OBSERVATION", 125, 137]]], ["The immunohistochemical stains of the lymph node revealed positive reactions to CD3, CD20, CD68, CD30, MPO, CD15 and Ki-67, which excluded the possibility of lymphoma.", [["lymph node", "ANATOMY", 38, 48], ["lymphoma", "ANATOMY", 158, 166], ["lymphoma", "DISEASE", 158, 166], ["lymph node", "MULTI-TISSUE_STRUCTURE", 38, 48], ["CD3", "GENE_OR_GENE_PRODUCT", 80, 83], ["CD20", "GENE_OR_GENE_PRODUCT", 85, 89], ["CD68", "GENE_OR_GENE_PRODUCT", 91, 95], ["CD30", "GENE_OR_GENE_PRODUCT", 97, 101], ["MPO", "GENE_OR_GENE_PRODUCT", 103, 106], ["CD15", "GENE_OR_GENE_PRODUCT", 108, 112], ["Ki-67", "GENE_OR_GENE_PRODUCT", 117, 122], ["lymphoma", "CANCER", 158, 166], ["CD3", "PROTEIN", 80, 83], ["CD20", "PROTEIN", 85, 89], ["CD68", "PROTEIN", 91, 95], ["CD30", "PROTEIN", 97, 101], ["MPO", "PROTEIN", 103, 106], ["CD15", "PROTEIN", 108, 112], ["Ki-67", "PROTEIN", 117, 122], ["The immunohistochemical stains", "TEST", 0, 30], ["the lymph node", "TEST", 34, 48], ["positive reactions", "PROBLEM", 58, 76], ["CD3", "TEST", 80, 83], ["CD20", "TEST", 85, 89], ["CD68", "TEST", 91, 95], ["CD30", "TEST", 97, 101], ["MPO", "TEST", 103, 106], ["CD15", "TEST", 108, 112], ["Ki", "TEST", 117, 119], ["lymphoma", "PROBLEM", 158, 166], ["lymph node", "OBSERVATION", 38, 48], ["positive reactions", "OBSERVATION", 58, 76], ["excluded the possibility of", "UNCERTAINTY", 130, 157], ["lymphoma", "OBSERVATION", 158, 166]]], ["However, Warthin-Starry staining revealed negative results for the presence of organisms.", [["Warthin-Starry staining", "TEST", 9, 32], ["organisms", "PROBLEM", 79, 88]]], ["Therefore, metagenomic next-generation sequencing (mNGS) analysis of the lymph node was performed.", [["lymph node", "ANATOMY", 73, 83], ["lymph node", "MULTI-TISSUE_STRUCTURE", 73, 83], ["metagenomic next-generation sequencing (mNGS) analysis", "TEST", 11, 65], ["the lymph node", "TEST", 69, 83], ["lymph node", "OBSERVATION", 73, 83]]], ["DNA of samples were extracted from lymph node homogenates with a TIANamp Micro DNA Kit (DP316, TIANGEN BIOTECH) according to the manufacturer\u2019s recommendation.", [["samples", "ANATOMY", 7, 14], ["lymph node homogenates", "ANATOMY", 35, 57], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["lymph node homogenates", "ORGANISM_SUBSTANCE", 35, 57], ["DNA of samples", "TEST", 0, 14], ["lymph node homogenates", "TREATMENT", 35, 57], ["lymph node", "OBSERVATION", 35, 45]]], ["A total of 100 ng of the extracted DNA were subjected to processes of interruption, end repair, library construction, and sequencing.", [["DNA", "CELLULAR_COMPONENT", 35, 38], ["the extracted DNA", "TREATMENT", 21, 38], ["end repair", "TREATMENT", 84, 94], ["library construction", "TREATMENT", 96, 116], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["Sequencing were performed at BGISEQ-500 platform (Beijing Genomics Institute, Wuhan, China).", [["Sequencing", "TEST", 0, 10]]], ["A total of 44,544,787 single-end reads were generated from lymph node mNGS analysis.", [["lymph node", "ANATOMY", 59, 69], ["lymph node", "MULTI-TISSUE_STRUCTURE", 59, 69], ["lymph node mNGS analysis", "TEST", 59, 83], ["lymph node", "OBSERVATION", 59, 69]]], ["After filtering out the low-quality and human genome sequences (hg19), 32,259 microbial reads (0.07%) remained and were aligned to four Microbial Genome databases, consisting of 6350 bacteria, 1798 viruses, 1064 fungi and 234 parasites from the NCBI (https://ftp.ncbi.nlm.nih.gov/genomes/).", [["human", "ORGANISM", 40, 45], ["human genome sequences", "DNA", 40, 62], ["hg19", "DNA", 64, 68], ["Microbial Genome databases", "DNA", 136, 162], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["Microbial Genome databases", "TEST", 136, 162], ["6350 bacteria", "PROBLEM", 178, 191], ["fungi", "TEST", 212, 217], ["parasites", "TEST", 226, 235], ["the NCBI", "TEST", 241, 249]]], ["A total of 7182 reads were discovered to be aligned to the B. henselae reference genome, with a genome coverage of 13.94% (280,820/2,014,762) (Additional file 1: Fig. S1).", [["B. henselae", "ORGANISM", 59, 70], ["S1", "GENE_OR_GENE_PRODUCT", 167, 169], ["B. henselae reference genome", "DNA", 59, 87], ["S1", "PROTEIN", 167, 169], ["B. henselae", "SPECIES", 59, 70], ["B. henselae", "SPECIES", 59, 70], ["a genome coverage", "TEST", 94, 111]]], ["The other microbial sequences detected in the sample were mostly due to common laboratory contaminants or environmental microbes.", [["The other microbial sequences", "TEST", 0, 29], ["common laboratory contaminants", "PROBLEM", 72, 102]]], ["Subsequently, communication was made with the family of the patient.", [["patient", "ORGANISM", 60, 67], ["patient", "SPECIES", 60, 67]]], ["The patient\u2019s hometown is Susong in Anhui, a rural central region in China.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["rural", "ANATOMY_MODIFIER", 45, 50], ["central", "ANATOMY_MODIFIER", 51, 58], ["region", "ANATOMY_MODIFIER", 59, 65], ["China", "ANATOMY", 69, 74]]], ["Notably, the family reported that 4 days after the patient presented with the first allergic symptoms, the patient had been scratched on their right hand by a street cat.Case presentationUnder the impression that the patient had an HLH, she was administered with intravenous immunoglobulin (500 mg/kg per day) for 5 days, followed by methylprednisolone (10 mg/kg per day).", [["right hand", "ANATOMY", 143, 153], ["intravenous", "ANATOMY", 263, 274], ["allergic symptoms", "DISEASE", 84, 101], ["HLH", "DISEASE", 232, 235], ["methylprednisolone", "CHEMICAL", 334, 352], ["methylprednisolone", "CHEMICAL", 334, 352], ["patient", "ORGANISM", 51, 58], ["patient", "ORGANISM", 107, 114], ["hand", "ORGANISM_SUBDIVISION", 149, 153], ["cat", "ORGANISM_SUBDIVISION", 166, 169], ["patient", "ORGANISM", 217, 224], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 275, 289], ["methylprednisolone", "SIMPLE_CHEMICAL", 334, 352], ["immunoglobulin", "PROTEIN", 275, 289], ["patient", "SPECIES", 51, 58], ["patient", "SPECIES", 107, 114], ["patient", "SPECIES", 217, 224], ["the first allergic symptoms", "PROBLEM", 74, 101], ["an HLH", "PROBLEM", 229, 235], ["intravenous immunoglobulin", "TREATMENT", 263, 289], ["methylprednisolone", "TREATMENT", 334, 352], ["scratched", "OBSERVATION", 124, 133], ["right", "ANATOMY_MODIFIER", 143, 148], ["HLH", "OBSERVATION", 232, 235]]], ["The patient also continued to receive minocycline (100 mg per day) and rifampin combination therapy to treat the B. henselae infection for a month.", [["minocycline", "CHEMICAL", 38, 49], ["rifampin", "CHEMICAL", 71, 79], ["B. henselae infection", "DISEASE", 113, 134], ["minocycline", "CHEMICAL", 38, 49], ["rifampin", "CHEMICAL", 71, 79], ["patient", "ORGANISM", 4, 11], ["minocycline", "SIMPLE_CHEMICAL", 38, 49], ["rifampin", "SIMPLE_CHEMICAL", 71, 79], ["B. henselae", "ORGANISM", 113, 124], ["patient", "SPECIES", 4, 11], ["B. henselae", "SPECIES", 113, 124], ["B. henselae", "SPECIES", 113, 124], ["minocycline", "TREATMENT", 38, 49], ["rifampin combination therapy", "TREATMENT", 71, 99], ["the B. henselae infection", "PROBLEM", 109, 134], ["henselae infection", "OBSERVATION", 116, 134]]], ["Subsequently, both the fever and skin rashes subsided.", [["skin", "ANATOMY", 33, 37], ["fever", "DISEASE", 23, 28], ["skin rashes", "DISEASE", 33, 44], ["skin", "ORGAN", 33, 37], ["the fever", "PROBLEM", 19, 28], ["skin rashes", "PROBLEM", 33, 44], ["fever", "OBSERVATION", 23, 28], ["skin", "ANATOMY", 33, 37], ["rashes", "OBSERVATION", 38, 44]]], ["On the fifth day, the patient was successfully extubated and began to gradually regain consciousness; the liver function returned to normal levels and pancytopenia was reversed within 2 weeks.", [["liver", "ANATOMY", 106, 111], ["pancytopenia", "DISEASE", 151, 163], ["patient", "ORGANISM", 22, 29], ["liver", "ORGAN", 106, 111], ["patient", "SPECIES", 22, 29], ["the liver function", "TEST", 102, 120], ["pancytopenia", "PROBLEM", 151, 163], ["liver", "ANATOMY", 106, 111], ["pancytopenia", "OBSERVATION", 151, 163]]], ["The patient was successfully discharged from the intensive care unit and remained in good condition after 2 months of follow-up.Case presentationTo identify the genetic cause of HLH, whole exome sequencing (WES) was performed by a commercial service from BGI-Shenzhen (Shenzhen, China) as previously described [4].", [["HLH", "DISEASE", 178, 181], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["HLH", "PROBLEM", 178, 181], ["HLH", "OBSERVATION", 178, 181]]], ["In brief, whole blood was collected from the patient after obtaining written informed consent.", [["whole blood", "ANATOMY", 10, 21], ["blood", "ORGANISM_SUBSTANCE", 16, 21], ["patient", "ORGANISM", 45, 52], ["patient", "SPECIES", 45, 52]]], ["DNA was extracted from blood and 50 ng of the high-quality DNA of the patient was used to prepare library and exome capture using MGIEasy Exome Capture V5 Universal Reagent Kit.", [["blood", "ANATOMY", 23, 28], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["blood", "ORGANISM_SUBSTANCE", 23, 28], ["DNA", "CELLULAR_COMPONENT", 59, 62], ["patient", "ORGANISM", 70, 77], ["patient", "SPECIES", 70, 77], ["DNA", "PROBLEM", 0, 3], ["blood", "TEST", 23, 28], ["library and exome capture", "TREATMENT", 98, 123]]], ["High-throughput sequencing was then performed for each captured exome library on the BGISEQ-500 platform according to the manufacturer\u2019s instructions.", [["exome library", "DNA", 64, 77], ["BGISEQ", "DNA", 85, 91]]], ["After variants called by BGISEQ-500 basecalling software, all clean reads were aligned to the human reference genome (GRCh37/HG19) using BurrowsWheeler Aligner (BWA V0.7.12).", [["human", "ORGANISM", 94, 99], ["BGISEQ", "DNA", 25, 31], ["human reference genome", "DNA", 94, 116], ["GRCh37", "DNA", 118, 124], ["HG19", "DNA", 125, 129], ["human", "SPECIES", 94, 99], ["human", "SPECIES", 94, 99]]], ["The genomic variations, including SNPs and InDels, were detected using the HaplotypeCaller of GATK (v3.7.0), then annotated using SNPEff, 1000 Genomes Project (http://www.1000genomes.org/), Exome Variant Server (EVS; http://evs.gs.washington.edu/EVS/), the Exome Aggregation Consortium (ExAC; http://exac.broadinstitute.org; release 0.3) and the Combined Annotation-Dependent Depletion tool.", [["InDels", "GENE_OR_GENE_PRODUCT", 43, 49], ["SNPs", "DNA", 34, 38], ["InDels", "DNA", 43, 49], ["GATK", "DNA", 94, 98], ["The genomic variations", "PROBLEM", 0, 22], ["SNPs", "TEST", 34, 38], ["InDels", "TEST", 43, 49], ["SNPEff", "TREATMENT", 130, 136], ["ExAC", "TEST", 287, 291], ["Dependent Depletion tool", "PROBLEM", 366, 390], ["genomic variations", "OBSERVATION", 4, 22], ["Dependent Depletion", "OBSERVATION", 366, 385]]], ["In total, more than 100,000 annotated variants were identified, demonstrating a hetero/homo ratio of 1.33; these variants were subsequently filtered based on their frequency, location, functional consequences, inheritance pattern and most importantly, clinical phenotype.", [["a hetero/homo ratio", "TEST", 78, 97], ["inheritance pattern", "PROBLEM", 210, 229]]], ["The results revealed a heterozygous synonymous mutation (rs2303116; c.528C>T; p.", [["a heterozygous synonymous mutation", "PROBLEM", 21, 55], ["synonymous mutation", "OBSERVATION", 36, 55]]], ["Arg165Arg) in the STXBP2 gene, which was predicted to be deleterious by SIFT, Polyphen2 and PROVEAN.", [["Arg165Arg", "GENE_OR_GENE_PRODUCT", 0, 9], ["STXBP2", "GENE_OR_GENE_PRODUCT", 18, 24], ["STXBP2 gene", "DNA", 18, 29], ["Polyphen2", "TREATMENT", 78, 87], ["PROVEAN", "TREATMENT", 92, 99]]], ["In addition, the patient was also discovered to have a splice donor variant in the IRF5 gene (rs2004640; NM_032643.4: c.-12 + 2G>T), which was previously reported to be associated with systemic lupus erythematosus, rheumatoid arthritis and secondary HLH (OMIM 607218).", [["systemic lupus erythematosus", "DISEASE", 185, 213], ["rheumatoid arthritis", "DISEASE", 215, 235], ["HLH", "DISEASE", 250, 253], ["OMIM 607218", "CHEMICAL", 255, 266], ["patient", "ORGANISM", 17, 24], ["IRF5", "GENE_OR_GENE_PRODUCT", 83, 87], ["c.-12 + 2G>T", "GENE_OR_GENE_PRODUCT", 118, 130], ["IRF5 gene", "DNA", 83, 92], ["patient", "SPECIES", 17, 24], ["a splice donor variant", "PROBLEM", 53, 75], ["NM_", "TEST", 105, 108], ["c.", "TEST", 118, 120], ["systemic lupus erythematosus", "PROBLEM", 185, 213], ["rheumatoid arthritis", "PROBLEM", 215, 235], ["secondary HLH", "PROBLEM", 240, 253], ["splice donor variant", "OBSERVATION", 55, 75], ["IRF5", "ANATOMY", 83, 87], ["associated with", "UNCERTAINTY", 169, 184], ["systemic", "OBSERVATION_MODIFIER", 185, 193], ["lupus erythematosus", "OBSERVATION", 194, 213], ["rheumatoid arthritis", "OBSERVATION", 215, 235]]], ["Using Sanger sequencing, these two identified mutations were confirmed in the proband (as a heterozygous mutation) and the patient\u2019s healthy sister (as a heterozygous mutation).DiscussionIn the present case report, the patient presented with typical symptoms of hemophagocytosis syndrome, including fever, splenomegaly, pancytopenia, decreased NK cell activity, hypofibrinogenemia, hemophagocytosis, hyperbilirubinemia, and increased levels of ferritin, sCD25 and lactate dehydrogenase.", [["NK cell", "ANATOMY", 344, 351], ["hemophagocytosis syndrome", "DISEASE", 262, 287], ["fever", "DISEASE", 299, 304], ["splenomegaly", "DISEASE", 306, 318], ["pancytopenia", "DISEASE", 320, 332], ["decreased NK cell activity", "DISEASE", 334, 360], ["hypofibrinogenemia", "DISEASE", 362, 380], ["hemophagocytosis", "DISEASE", 382, 398], ["hyperbilirubinemia", "DISEASE", 400, 418], ["lactate", "CHEMICAL", 464, 471], ["lactate", "CHEMICAL", 464, 471], ["patient", "ORGANISM", 123, 130], ["patient", "ORGANISM", 219, 226], ["splenomegaly", "PATHOLOGICAL_FORMATION", 306, 318], ["NK cell", "CELL", 344, 351], ["ferritin", "GENE_OR_GENE_PRODUCT", 444, 452], ["sCD25", "GENE_OR_GENE_PRODUCT", 454, 459], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 464, 485], ["ferritin", "PROTEIN", 444, 452], ["sCD25", "PROTEIN", 454, 459], ["lactate dehydrogenase", "PROTEIN", 464, 485], ["patient", "SPECIES", 123, 130], ["patient", "SPECIES", 219, 226], ["Sanger sequencing", "TEST", 6, 23], ["a heterozygous mutation", "PROBLEM", 90, 113], ["a heterozygous mutation", "PROBLEM", 152, 175], ["typical symptoms", "PROBLEM", 242, 258], ["hemophagocytosis syndrome", "PROBLEM", 262, 287], ["fever", "PROBLEM", 299, 304], ["splenomegaly", "PROBLEM", 306, 318], ["pancytopenia", "PROBLEM", 320, 332], ["decreased NK cell activity", "PROBLEM", 334, 360], ["hypofibrinogenemia", "PROBLEM", 362, 380], ["hemophagocytosis", "PROBLEM", 382, 398], ["hyperbilirubinemia", "PROBLEM", 400, 418], ["increased levels of ferritin", "PROBLEM", 424, 452], ["sCD25", "PROBLEM", 454, 459], ["lactate dehydrogenase", "PROBLEM", 464, 485], ["hemophagocytosis syndrome", "OBSERVATION", 262, 287], ["splenomegaly", "OBSERVATION", 306, 318], ["pancytopenia", "OBSERVATION", 320, 332], ["decreased NK cell activity", "OBSERVATION", 334, 360], ["hypofibrinogenemia", "OBSERVATION", 362, 380], ["hemophagocytosis", "OBSERVATION", 382, 398], ["hyperbilirubinemia", "OBSERVATION", 400, 418], ["increased", "OBSERVATION_MODIFIER", 424, 433], ["levels", "OBSERVATION_MODIFIER", 434, 440], ["ferritin", "OBSERVATION", 444, 452]]], ["However, determining the cause of HLH remained difficult.", [["HLH", "DISEASE", 34, 37], ["HLH", "PROBLEM", 34, 37], ["HLH", "OBSERVATION", 34, 37]]], ["In adults, HLH is often caused by various infectious agents (Epstein-Barr virus, cytomegalovirus, parainfluenza virus, Mycobacterium tuberculosis and Mycoplasma pneumoniae), autoimmune diseases (adult onset Still\u2019s disease and systemic lupus erythematosus) or malignant conditions (lymphomas) [1].", [["lymphomas", "ANATOMY", 282, 291], ["HLH", "DISEASE", 11, 14], ["Epstein-Barr virus, cytomegalovirus, parainfluenza virus", "DISEASE", 61, 117], ["Mycobacterium tuberculosis", "DISEASE", 119, 145], ["Mycoplasma pneumoniae", "DISEASE", 150, 171], ["autoimmune diseases", "DISEASE", 174, 193], ["Still\u2019s disease", "DISEASE", 207, 222], ["systemic lupus erythematosus", "DISEASE", 227, 255], ["malignant conditions", "DISEASE", 260, 280], ["lymphomas", "DISEASE", 282, 291], ["Epstein-Barr virus", "ORGANISM", 61, 79], ["cytomegalovirus", "ORGANISM", 81, 96], ["parainfluenza virus", "ORGANISM", 98, 117], ["Mycobacterium tuberculosis", "ORGANISM", 119, 145], ["Mycoplasma pneumoniae", "ORGANISM", 150, 171], ["malignant conditions", "CANCER", 260, 280], ["lymphomas", "CANCER", 282, 291], ["parainfluenza virus", "SPECIES", 98, 117], ["Mycobacterium tuberculosis", "SPECIES", 119, 145], ["Mycoplasma pneumoniae", "SPECIES", 150, 171], ["Epstein-Barr virus", "SPECIES", 61, 79], ["parainfluenza virus", "SPECIES", 98, 117], ["Mycobacterium tuberculosis", "SPECIES", 119, 145], ["Mycoplasma pneumoniae", "SPECIES", 150, 171], ["HLH", "PROBLEM", 11, 14], ["various infectious agents", "PROBLEM", 34, 59], ["Barr virus", "PROBLEM", 69, 79], ["cytomegalovirus", "PROBLEM", 81, 96], ["parainfluenza virus", "PROBLEM", 98, 117], ["Mycobacterium tuberculosis", "PROBLEM", 119, 145], ["Mycoplasma pneumoniae", "PROBLEM", 150, 171], ["autoimmune diseases", "PROBLEM", 174, 193], ["disease", "PROBLEM", 215, 222], ["systemic lupus erythematosus", "PROBLEM", 227, 255], ["malignant conditions (lymphomas)", "PROBLEM", 260, 292], ["HLH", "OBSERVATION", 11, 14], ["parainfluenza virus", "OBSERVATION", 98, 117], ["Mycobacterium tuberculosis", "OBSERVATION", 119, 145], ["Mycoplasma pneumoniae", "OBSERVATION", 150, 171], ["autoimmune diseases", "OBSERVATION", 174, 193], ["systemic", "OBSERVATION_MODIFIER", 227, 235], ["lupus erythematosus", "OBSERVATION", 236, 255], ["malignant", "OBSERVATION_MODIFIER", 260, 269]]], ["Several medications, such as lamotrigine, can also promote HLH.", [["lamotrigine", "CHEMICAL", 29, 40], ["HLH", "DISEASE", 59, 62], ["lamotrigine", "CHEMICAL", 29, 40], ["lamotrigine", "SIMPLE_CHEMICAL", 29, 40], ["Several medications", "TREATMENT", 0, 19], ["lamotrigine", "TREATMENT", 29, 40], ["HLH", "PROBLEM", 59, 62], ["HLH", "OBSERVATION", 59, 62]]], ["It was suspected that the likely trigger for HLH in the patient was an allergic reaction to TCM that they had been prescribed; however, the medical history of the patient revealed that the rash associated with HLH began upon the allergic reaction to the drug subsiding, and the characteristics of these two rashes were different.", [["HLH", "DISEASE", 45, 48], ["allergic reaction", "DISEASE", 71, 88], ["rash", "DISEASE", 189, 193], ["HLH", "DISEASE", 210, 213], ["allergic reaction", "DISEASE", 229, 246], ["rashes", "DISEASE", 307, 313], ["patient", "ORGANISM", 56, 63], ["patient", "ORGANISM", 163, 170], ["rash", "PATHOLOGICAL_FORMATION", 189, 193], ["rashes", "PATHOLOGICAL_FORMATION", 307, 313], ["patient", "SPECIES", 56, 63], ["patient", "SPECIES", 163, 170], ["HLH", "PROBLEM", 45, 48], ["an allergic reaction", "PROBLEM", 68, 88], ["the rash", "PROBLEM", 185, 193], ["HLH", "PROBLEM", 210, 213], ["the allergic reaction", "PROBLEM", 225, 246], ["these two rashes", "PROBLEM", 297, 313], ["allergic", "OBSERVATION", 71, 79], ["rash", "OBSERVATION", 189, 193]]], ["Moreover, the patient had experienced several multi-localized specific drug allergic reactions previously, but they had never presented with secondary HLH before.DiscussionBoth clinical and laboratory evaluations did not provide any evidence to indicate an infection initially.", [["drug allergic reactions", "DISEASE", 71, 94], ["HLH", "DISEASE", 151, 154], ["infection", "DISEASE", 257, 266], ["patient", "ORGANISM", 14, 21], ["patient", "SPECIES", 14, 21], ["several multi-localized specific drug allergic reactions", "PROBLEM", 38, 94], ["secondary HLH", "PROBLEM", 141, 154], ["laboratory evaluations", "TEST", 190, 212], ["an infection", "PROBLEM", 254, 266], ["drug allergic reactions", "OBSERVATION", 71, 94], ["infection", "OBSERVATION", 257, 266]]], ["However, the lymph node biopsy provided an important clue for the etiological diagnosis, because the pathological findings prompted the consideration of the possibility of CDS.", [["lymph node", "ANATOMY", 13, 23], ["lymph node", "MULTI-TISSUE_STRUCTURE", 13, 23], ["biopsy", "MULTI-TISSUE_STRUCTURE", 24, 30], ["the lymph node biopsy", "TEST", 9, 30], ["CDS", "PROBLEM", 172, 175], ["lymph node", "OBSERVATION", 13, 23]]], ["The pathogen causing CDS is B. henselae, which is difficult to culture and is insensitively detected by anti-B. henselae IgM-ELISAs.", [["B. henselae", "DISEASE", 28, 39], ["B. henselae", "ORGANISM", 28, 39], ["anti-B. henselae", "ORGANISM", 104, 120], ["IgM", "GENE_OR_GENE_PRODUCT", 121, 124], ["IgM", "PROTEIN", 121, 124], ["B. henselae", "SPECIES", 28, 39], ["anti-B. henselae", "SPECIES", 104, 120], ["B. henselae", "SPECIES", 28, 39], ["anti-B. henselae", "SPECIES", 104, 120], ["B. henselae", "PROBLEM", 28, 39], ["culture", "TEST", 63, 70], ["henselae IgM", "TEST", 112, 124], ["henselae", "OBSERVATION", 31, 39]]], ["Recently, Parra et al. [5] developed a novel real-time PCR assay to detect Bartonella spp. with high sensitivity and specificity; however, a commercial PCR kit remains unavailable in numerous regions, including China. mNGS is an unbiased approach that can theoretically detect all pathogens in a clinical sample, and it is especially suitable for rare, novel and atypical etiologies of complicated infectious diseases.", [["infectious diseases", "DISEASE", 398, 417], ["Bartonella spp", "ORGANISM", 75, 89], ["PCR assay", "TEST", 55, 64], ["Bartonella spp", "PROBLEM", 75, 89], ["high sensitivity", "PROBLEM", 96, 112], ["a commercial PCR kit", "TEST", 139, 159], ["all pathogens", "PROBLEM", 277, 290], ["a clinical sample", "TEST", 294, 311], ["complicated infectious diseases", "PROBLEM", 386, 417], ["complicated", "OBSERVATION_MODIFIER", 386, 397], ["infectious", "OBSERVATION", 398, 408]]], ["For example, Cheng et al. [6] used mNGS to detect the pathogens present in seven patients with culture-negative infective endocarditis; the results revealed that the pathogens, including B. henselae, in all the samples could be detected by mNGS.", [["samples", "ANATOMY", 211, 218], ["infective endocarditis", "DISEASE", 112, 134], ["B. henselae", "DISEASE", 187, 198], ["patients", "ORGANISM", 81, 89], ["B. henselae", "ORGANISM", 187, 198], ["samples", "CANCER", 211, 218], ["mNGS", "PROTEIN", 240, 244], ["patients", "SPECIES", 81, 89], ["B. henselae", "SPECIES", 187, 198], ["B. henselae", "SPECIES", 187, 198], ["the pathogens", "PROBLEM", 50, 63], ["culture", "TEST", 95, 102], ["infective endocarditis", "PROBLEM", 112, 134], ["the pathogens", "PROBLEM", 162, 175], ["B. henselae", "PROBLEM", 187, 198], ["infective", "OBSERVATION_MODIFIER", 112, 121], ["endocarditis", "OBSERVATION", 122, 134], ["henselae", "OBSERVATION", 190, 198]]], ["In our patient, mNGS also served an important role in the final determination of the etiology, especially since Warthin-Starry staining produced negative results for the presence of organisms.", [["patient", "ORGANISM", 7, 14], ["mNGS", "CANCER", 16, 20], ["patient", "SPECIES", 7, 14], ["Warthin", "TEST", 112, 119], ["organisms", "PROBLEM", 182, 191]]], ["In general, histology is regarded as the gold standard in the diagnosis of B. henselae infection [7].", [["B. henselae infection", "DISEASE", 75, 96], ["B. henselae", "ORGANISM", 75, 86], ["B. henselae", "SPECIES", 75, 86], ["B. henselae", "SPECIES", 75, 86], ["B. henselae infection", "PROBLEM", 75, 96], ["henselae infection", "OBSERVATION", 78, 96]]], ["However, the results are often affected by several technical factors, such as possible sampling error, the quality of histopathology slides of biopsies and the subjective judgment of the tester [8].", [["biopsies", "CANCER", 143, 151], ["sampling error", "PROBLEM", 87, 101], ["biopsies", "TEST", 143, 151]]], ["Moreover, our patient received empirical antibiotics treatment before biopsy; although azithromycin for 2 days did not cure the patient, many of the bacteria in lymph nodes may have been killed off.", [["lymph nodes", "ANATOMY", 161, 172], ["azithromycin", "CHEMICAL", 87, 99], ["azithromycin", "CHEMICAL", 87, 99], ["patient", "ORGANISM", 14, 21], ["azithromycin", "SIMPLE_CHEMICAL", 87, 99], ["patient", "ORGANISM", 128, 135], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 161, 172], ["patient", "SPECIES", 14, 21], ["patient", "SPECIES", 128, 135], ["empirical antibiotics treatment", "TREATMENT", 31, 62], ["biopsy", "TEST", 70, 76], ["azithromycin", "TREATMENT", 87, 99], ["the bacteria in lymph nodes", "PROBLEM", 145, 172], ["bacteria", "OBSERVATION_MODIFIER", 149, 157], ["lymph nodes", "OBSERVATION", 161, 172]]], ["Therefore, the bacteria were scantily and sparsely distributed that might be overlooked during Warthin-Starry interpretation.", [["the bacteria", "PROBLEM", 11, 23], ["bacteria", "OBSERVATION", 15, 23]]], ["Fortunately, mNGS is less affected by prior antibiotic exposure, because it can detect trace amounts of nucleic acid.", [["nucleic acid", "CHEMICAL", 104, 116], ["nucleic acid", "SIMPLE_CHEMICAL", 104, 116], ["prior antibiotic exposure", "TREATMENT", 38, 63], ["trace amounts of nucleic acid", "PROBLEM", 87, 116], ["less affected", "OBSERVATION_MODIFIER", 21, 34], ["nucleic acid", "OBSERVATION", 104, 116]]], ["So, mNGS may be a useful adjunct in identification of the causative organisms in conventional test-negative infection.DiscussionThe majority of the infections caused by B. henselae are mild, rarely running a severe course.", [["infection", "DISEASE", 108, 117], ["infections", "DISEASE", 148, 158], ["B. henselae", "DISEASE", 169, 180], ["mNGS", "SIMPLE_CHEMICAL", 4, 8], ["B. henselae", "ORGANISM", 169, 180], ["B. henselae", "SPECIES", 169, 180], ["B. henselae", "SPECIES", 169, 180], ["the causative organisms", "PROBLEM", 54, 77], ["conventional test", "TEST", 81, 98], ["infection", "PROBLEM", 108, 117], ["the infections", "PROBLEM", 144, 158], ["B. henselae", "PROBLEM", 169, 180], ["negative", "OBSERVATION_MODIFIER", 99, 107], ["infection", "OBSERVATION", 108, 117], ["infections", "OBSERVATION", 148, 158], ["henselae", "OBSERVATION", 172, 180], ["mild", "OBSERVATION_MODIFIER", 185, 189], ["severe", "OBSERVATION_MODIFIER", 208, 214]]], ["To the best of our knowledge, fewer than 2 HLH cases associated with B. henselae infections have been reported to date, both of which occurred in immunocompromised patients [2, 3].", [["HLH", "DISEASE", 43, 46], ["B. henselae infections", "DISEASE", 69, 91], ["B. henselae", "ORGANISM", 69, 80], ["patients", "ORGANISM", 164, 172], ["B. henselae", "SPECIES", 69, 80], ["patients", "SPECIES", 164, 172], ["B. henselae", "SPECIES", 69, 80], ["B. henselae infections", "PROBLEM", 69, 91]]], ["However, this patient denied suffering from any previous immunodeficiency disease or using immunosuppressive agents.", [["immunodeficiency disease", "DISEASE", 57, 81], ["patient", "ORGANISM", 14, 21], ["patient", "SPECIES", 14, 21], ["any previous immunodeficiency disease", "PROBLEM", 44, 81], ["immunosuppressive agents", "TREATMENT", 91, 115]]], ["Although allergic or adverse reactions caused by TCM are not considered to be the cause of HLH, allergic episodes to drugs may have a negative impact on the immune system; it is well established that both macrophages and T lymphocytes can be activated during allergic reactions [9, 10].", [["immune system", "ANATOMY", 157, 170], ["macrophages", "ANATOMY", 205, 216], ["T lymphocytes", "ANATOMY", 221, 234], ["allergic", "DISEASE", 9, 17], ["HLH", "DISEASE", 91, 94], ["allergic episodes", "DISEASE", 96, 113], ["allergic reactions", "DISEASE", 259, 277], ["immune system", "ANATOMICAL_SYSTEM", 157, 170], ["macrophages", "CELL", 205, 216], ["T lymphocytes", "CELL", 221, 234], ["macrophages", "CELL_TYPE", 205, 216], ["T lymphocytes", "CELL_TYPE", 221, 234], ["allergic", "PROBLEM", 9, 17], ["adverse reactions", "PROBLEM", 21, 38], ["TCM", "PROBLEM", 49, 52], ["HLH", "PROBLEM", 91, 94], ["allergic episodes", "PROBLEM", 96, 113], ["drugs", "TREATMENT", 117, 122], ["allergic reactions", "PROBLEM", 259, 277], ["allergic", "OBSERVATION", 9, 17], ["HLH", "OBSERVATION", 91, 94], ["macrophages", "OBSERVATION", 205, 216]]], ["The pathophysiological mechanism of HLH has been found to be mainly due to the uncontrolled activation of cytotoxic T lymphocytes and macrophages, which subsequently induces the excessive production of cytokines [11].", [["cytotoxic T lymphocytes", "ANATOMY", 106, 129], ["macrophages", "ANATOMY", 134, 145], ["HLH", "DISEASE", 36, 39], ["cytotoxic T lymphocytes", "CELL", 106, 129], ["macrophages", "CELL", 134, 145], ["cytotoxic T lymphocytes", "CELL_TYPE", 106, 129], ["macrophages", "CELL_TYPE", 134, 145], ["cytokines", "PROTEIN", 202, 211], ["HLH", "PROBLEM", 36, 39], ["the uncontrolled activation of cytotoxic T lymphocytes", "PROBLEM", 75, 129], ["macrophages", "PROBLEM", 134, 145], ["the excessive production of cytokines", "PROBLEM", 174, 211], ["HLH", "OBSERVATION", 36, 39], ["cytotoxic T lymphocytes", "OBSERVATION", 106, 129], ["excessive", "OBSERVATION_MODIFIER", 178, 187], ["production", "OBSERVATION_MODIFIER", 188, 198]]], ["Unfortunately, the relationship between the immune system disorder caused by the allergic reaction and the occurrence of HLH in this patient was not verified in the present study.DiscussionThe pathogenesis of secondary HLH is not as understood as primary HLH.", [["immune system", "ANATOMY", 44, 57], ["immune system disorder", "DISEASE", 44, 66], ["allergic reaction", "DISEASE", 81, 98], ["HLH", "DISEASE", 121, 124], ["HLH", "DISEASE", 219, 222], ["HLH", "DISEASE", 255, 258], ["patient", "ORGANISM", 133, 140], ["patient", "SPECIES", 133, 140], ["the immune system disorder", "PROBLEM", 40, 66], ["the allergic reaction", "PROBLEM", 77, 98], ["HLH", "PROBLEM", 121, 124], ["the present study", "TEST", 161, 178], ["secondary HLH", "PROBLEM", 209, 222], ["primary HLH", "PROBLEM", 247, 258], ["allergic", "OBSERVATION", 81, 89], ["HLH", "OBSERVATION", 121, 124]]], ["Although the likelihood of identifying a gene mutation is highest in younger patients, our genetic testing revealed two gene variants, STXBP2 and IRF5, in this adult patient with secondary HLH.", [["HLH", "DISEASE", 189, 192], ["patients", "ORGANISM", 77, 85], ["STXBP2", "GENE_OR_GENE_PRODUCT", 135, 141], ["IRF5", "GENE_OR_GENE_PRODUCT", 146, 150], ["patient", "ORGANISM", 166, 173], ["STXBP2", "DNA", 135, 141], ["IRF5", "DNA", 146, 150], ["patients", "SPECIES", 77, 85], ["patient", "SPECIES", 166, 173], ["a gene mutation", "PROBLEM", 39, 54], ["our genetic testing", "TEST", 87, 106], ["two gene variants", "PROBLEM", 116, 133], ["STXBP2", "PROBLEM", 135, 141], ["IRF5", "PROBLEM", 146, 150], ["secondary HLH", "PROBLEM", 179, 192], ["gene variants", "OBSERVATION", 120, 133], ["HLH", "OBSERVATION", 189, 192]]], ["STXBP2 reportedly serves an important role in the cytotoxic granule exocytosis of NK/T cells and its variants have been proven to be responsible for the pathogenesis of an HLH subtype, familial HLH type 5 [12].", [["granule", "ANATOMY", 60, 67], ["NK/T cells", "ANATOMY", 82, 92], ["STXBP2", "CHEMICAL", 0, 6], ["HLH", "DISEASE", 172, 175], ["HLH", "DISEASE", 194, 197], ["STXBP2", "GENE_OR_GENE_PRODUCT", 0, 6], ["NK/T cells", "CELL", 82, 92], ["STXBP2", "PROTEIN", 0, 6], ["NK/T cells", "CELL_TYPE", 82, 92], ["the cytotoxic granule exocytosis", "TEST", 46, 78], ["NK/T cells", "PROBLEM", 82, 92], ["an HLH subtype", "PROBLEM", 169, 183], ["familial HLH type", "PROBLEM", 185, 202], ["cytotoxic granule exocytosis", "OBSERVATION", 50, 78], ["HLH", "OBSERVATION", 172, 175]]], ["A synonymous mutation (rs2303116; c.528C>T; p.", [["A synonymous mutation", "TEST", 0, 21], ["synonymous mutation", "OBSERVATION", 2, 21]]], ["Arg165Arg) in the STXBP2 gene, which does not alter the protein sequence, was detected in our patient, but it was predicted to be deleterious by gene function analysis.", [["Arg165Arg", "GENE_OR_GENE_PRODUCT", 0, 9], ["STXBP2", "GENE_OR_GENE_PRODUCT", 18, 24], ["patient", "ORGANISM", 94, 101], ["STXBP2 gene", "DNA", 18, 29], ["patient", "SPECIES", 94, 101], ["the protein sequence", "TEST", 52, 72], ["gene function analysis", "TEST", 145, 167]]], ["Moreover, this mutation has been reported to be associated with HLH in the Chinese Han population.", [["HLH", "DISEASE", 64, 67], ["this mutation", "PROBLEM", 10, 23], ["HLH", "PROBLEM", 64, 67]]], ["Yang et al. [13] found that the rs2303116 CT/TT genotype (OR 3.900; 95% CI 1.537\u20139.899; P = 0.009) was an independent risk factor for HLH pathogenesis by using multivariate logistic regression analysis.", [["HLH", "DISEASE", 134, 137], ["rs2303116", "GENE_OR_GENE_PRODUCT", 32, 41], ["CT/TT genotype", "TEST", 42, 56], ["CI", "TEST", 72, 74], ["P", "TEST", 88, 89], ["an independent risk factor", "PROBLEM", 103, 129], ["HLH pathogenesis", "PROBLEM", 134, 150], ["multivariate logistic regression analysis", "TEST", 160, 201]]], ["IRF5 serves as a master transcription factor for the activation of genes encoding proinflammatory cytokines [14].", [["IRF5", "GENE_OR_GENE_PRODUCT", 0, 4], ["IRF5", "PROTEIN", 0, 4], ["master transcription factor", "PROTEIN", 17, 44], ["proinflammatory cytokines", "PROTEIN", 82, 107]]], ["Polymorphisms in the IRF5 gene have been associated with the susceptibility to autoimmune diseases.", [["autoimmune diseases", "DISEASE", 79, 98], ["IRF5", "GENE_OR_GENE_PRODUCT", 21, 25], ["IRF5 gene", "DNA", 21, 30], ["Polymorphisms in the IRF5 gene", "PROBLEM", 0, 30], ["the susceptibility to autoimmune diseases", "PROBLEM", 57, 98], ["IRF5", "ANATOMY", 21, 25], ["autoimmune", "OBSERVATION", 79, 89]]], ["Recently, Yanagimachi et al. [15] genotyped three IRF5 single-nucleotide polymorphisms using TaqMan assays in 82 patients with HLH and 188 control subjects; the statistical analysis revealed a significant association between the GT/TT genotype at rs2004640 with secondary HLH susceptibility.", [["HLH", "DISEASE", 127, 130], ["HLH", "DISEASE", 272, 275], ["IRF5", "GENE_OR_GENE_PRODUCT", 50, 54], ["patients", "ORGANISM", 113, 121], ["GT", "GENE_OR_GENE_PRODUCT", 229, 231], ["IRF5", "PROTEIN", 50, 54], ["patients", "SPECIES", 113, 121], ["nucleotide polymorphisms", "TEST", 62, 86], ["TaqMan assays", "TEST", 93, 106], ["HLH", "PROBLEM", 127, 130], ["the statistical analysis", "TEST", 157, 181], ["the GT/TT genotype", "PROBLEM", 225, 243], ["secondary HLH susceptibility", "PROBLEM", 262, 290], ["significant", "OBSERVATION_MODIFIER", 193, 204], ["HLH susceptibility", "OBSERVATION", 272, 290]]], ["In addition, the prediction of the protein structure indicated that these mutations tended to cause partial defects in the protein function rather than the complete loss of the protein, and this partial loss of function may explain the later age of HLH onset in adults.", [["HLH", "DISEASE", 249, 252], ["these mutations", "PROBLEM", 68, 83], ["partial defects in the protein function", "PROBLEM", 100, 139], ["the complete loss of the protein", "PROBLEM", 152, 184], ["this partial loss of function", "PROBLEM", 190, 219], ["HLH onset", "PROBLEM", 249, 258], ["partial", "OBSERVATION_MODIFIER", 100, 107], ["defects", "OBSERVATION", 108, 115], ["protein function", "OBSERVATION", 123, 139], ["HLH", "OBSERVATION", 249, 252]]], ["Furthermore, it should be noted that the same genetic mutation was found in the patient\u2019s sister; however, the sister had never exhibited any HLH clinical symptoms.", [["HLH", "DISEASE", 142, 145], ["patient", "ORGANISM", 80, 87], ["patient", "SPECIES", 80, 87], ["the same genetic mutation", "PROBLEM", 37, 62], ["any HLH clinical symptoms", "PROBLEM", 138, 163]]], ["These indicate quite clearly that the occurrence of the secondary HLH may be the result of the interaction between the infectious trigger and the genetic defects, while WES is an invaluable tool for genetic diagnosis in both primary and secondary HLH patients.DiscussionThe main limitation of this current study was that we failed to conduct a genealogical analysis, because the patient\u2019s parents died a few years ago, while her sister was willing to take a testing for susceptibility genes by conventional PCR but refused further WES.", [["primary", "ANATOMY", 225, 232], ["HLH", "DISEASE", 66, 69], ["HLH", "DISEASE", 247, 250], ["patients", "ORGANISM", 251, 259], ["patient", "ORGANISM", 379, 386], ["susceptibility genes", "DNA", 470, 490], ["patients", "SPECIES", 251, 259], ["patient", "SPECIES", 379, 386], ["the secondary HLH", "PROBLEM", 52, 69], ["the infectious trigger", "PROBLEM", 115, 137], ["the genetic defects", "PROBLEM", 142, 161], ["this current study", "TEST", 293, 311], ["a genealogical analysis", "TEST", 342, 365], ["a testing", "TEST", 456, 465], ["susceptibility genes", "PROBLEM", 470, 490], ["conventional PCR", "TEST", 494, 510], ["secondary", "OBSERVATION_MODIFIER", 56, 65], ["HLH", "OBSERVATION", 66, 69], ["infectious", "OBSERVATION", 119, 129]]], ["This makes it difficult to identified novel genes and mutations associated with HLH in this study.", [["HLH", "DISEASE", 80, 83], ["novel genes and mutations", "PROBLEM", 38, 63], ["HLH", "PROBLEM", 80, 83], ["this study", "TEST", 87, 97]]], ["In addition, B. henselae infection was diagnosed by mNGS, but an elevation of anti-B. henselae by ELISA was not performed due to the lack of commercial kits.DiscussionIn conclusion, HLH is a rare and highly morbid condition in adults, therefore identifying the etiology of HLH is crucial.", [["B. henselae infection", "DISEASE", 13, 34], ["HLH", "DISEASE", 182, 185], ["HLH", "DISEASE", 273, 276], ["B. henselae", "ORGANISM", 13, 24], ["anti-B. henselae", "ORGANISM", 78, 94], ["B. henselae", "SPECIES", 13, 24], ["anti-B. henselae", "SPECIES", 78, 94], ["B. henselae", "SPECIES", 13, 24], ["anti-B. henselae", "SPECIES", 78, 94], ["B. henselae infection", "PROBLEM", 13, 34], ["an elevation of anti-B. henselae", "PROBLEM", 62, 94], ["ELISA", "TEST", 98, 103], ["HLH", "PROBLEM", 273, 276], ["henselae", "OBSERVATION_MODIFIER", 16, 24], ["infection", "OBSERVATION", 25, 34], ["elevation", "OBSERVATION_MODIFIER", 65, 74], ["HLH", "OBSERVATION", 273, 276]]], ["The present case study emphasized the importance of mNGS in obtaining an etiological diagnosis, which suggested that screening for B. henselae should be considered in patients with HLH, especially those with a pet at home.", [["B. henselae", "DISEASE", 131, 142], ["HLH", "DISEASE", 181, 184], ["B. henselae", "ORGANISM", 131, 142], ["patients", "ORGANISM", 167, 175], ["B. henselae", "SPECIES", 131, 142], ["patients", "SPECIES", 167, 175], ["B. henselae", "SPECIES", 131, 142], ["screening", "TEST", 117, 126], ["B. henselae", "PROBLEM", 131, 142], ["HLH", "PROBLEM", 181, 184]]], ["In addition, the genetic defects were discovered to not only be present in primary HLH, but also in secondary HLH, even in the elderly.", [["HLH", "DISEASE", 83, 86], ["HLH", "DISEASE", 110, 113], ["HLH", "CANCER", 83, 86], ["the genetic defects", "PROBLEM", 13, 32], ["primary HLH", "PROBLEM", 75, 86], ["secondary HLH", "PROBLEM", 100, 113], ["defects", "OBSERVATION", 25, 32], ["HLH", "OBSERVATION", 83, 86], ["HLH", "OBSERVATION", 110, 113]]]], "PMC7477734": [], "PMC7169834": [], "PMC7258754": [["Screening of passengers was also initiated at 12 major seaports and all minor ports in the country to identify crew and passengers travelling back from China and to undertake required measures for isolation if found symptomatic.", [["all minor ports", "TREATMENT", 68, 83], ["isolation", "TREATMENT", 197, 206], ["symptomatic", "PROBLEM", 216, 227]]], ["In addition, the GoI also initiated screening at all integrated checkposts from Nepal in the States of Uttar Pradesh (UP), Uttarakhand, West Bengal, Sikkim and Bihar.Material & MethodsIndividuals evacuated from China and Japan: The GoI evacuated Indian citizens residing in Wuhan and neighbouring cities in the Hubei province of China.", [["screening", "TEST", 36, 45]]], ["Two subsequent evacuations were undertaken on January 31 and February 1, 2020.", [["Two subsequent evacuations", "TEST", 0, 26]]], ["A total of 654 individuals (including 645 Indians residing in Wuhan, 7 Maldivian nationals and 2 members from the crew) were brought back in dedicated aircrafts.", [["individuals", "ORGANISM", 15, 26]]], ["Similar operations were conducted to evacuate 112 individuals from Wuhan (including 76 Indians and 36 people from Madagascar, Maldives, Myanmar, South Africa and the USA) and 124 from Diamond Princess ship, Japan (including 119 Indians and 5 people from Nepal, Peru, South Africa and Sri Lanka) on February 27, 2020.", [["people", "SPECIES", 102, 108], ["people", "SPECIES", 242, 248], ["Similar operations", "TREATMENT", 0, 18]]], ["The facilities were managed by the Army and Indo-Tibetan Border Police.Material & MethodsInclusion criteria for testing for COVID-19: The following inclusion criteria were followed for considering samples for COVID-19 testing: (i) Symptomatic (fever, sore throat, running nose, dyspnoea, etc.)/asymptomatic individuals returned from Wuhan, China, after 15 January 2020; (ii) Only symptomatic individuals returned from rest of China, which was subsequently expanded to include Hong Kong, Japan, South Korea, Singapore, Iran and Italy, were also included; (iii) Close contacts of confirmed positive cases of COVID-19 infection; and (iv) All individuals evacuated from Wuhan, China, and Diamond Princess ship, Japan, in four different operations.Material & MethodsInclusion criteria for laboratory testing are evolving in India, given the increased number of cases of COVID-19 being reported from different countries10.Material & MethodsSample collection and transport: For all suspected cases with symptoms and/or travel history, nasopharyngeal and/or oropharyngeal swabs were collected in viral transport medium.", [["nasopharyngeal", "ANATOMY", 1028, 1042], ["oropharyngeal swabs", "ANATOMY", 1050, 1069], ["Indo", "CHEMICAL", 44, 48], ["fever", "DISEASE", 244, 249], ["sore throat", "DISEASE", 251, 262], ["dyspnoea", "DISEASE", 278, 286], ["infection", "DISEASE", 615, 624], ["nose", "ORGANISM_SUBDIVISION", 272, 276], ["nasopharyngeal", "CANCER", 1028, 1042], ["oropharyngeal swabs", "ORGANISM_SUBSTANCE", 1050, 1069], ["COVID-19", "SPECIES", 606, 614], ["testing", "TEST", 112, 119], ["COVID", "TEST", 124, 129], ["samples", "TEST", 197, 204], ["COVID", "TEST", 209, 214], ["Symptomatic", "PROBLEM", 231, 242], ["fever", "PROBLEM", 244, 249], ["sore throat", "PROBLEM", 251, 262], ["running nose", "PROBLEM", 264, 276], ["dyspnoea", "PROBLEM", 278, 286], ["asymptomatic individuals", "PROBLEM", 294, 318], ["symptomatic individuals", "PROBLEM", 380, 403], ["COVID-19 infection", "PROBLEM", 606, 624], ["Material & MethodsInclusion criteria", "TEST", 743, 779], ["laboratory testing", "TEST", 784, 802], ["COVID", "TEST", 865, 870], ["Material & MethodsSample collection", "PROBLEM", 916, 951], ["symptoms", "PROBLEM", 996, 1004], ["nasopharyngeal and/or oropharyngeal swabs", "PROBLEM", 1028, 1069], ["viral transport medium", "TREATMENT", 1088, 1110], ["infection", "OBSERVATION", 615, 624], ["increased", "OBSERVATION_MODIFIER", 836, 845], ["nasopharyngeal", "ANATOMY", 1028, 1042], ["oropharyngeal swabs", "ANATOMY", 1050, 1069]]], ["Samples were sent to testing laboratories at 4\u00b0C with ice packs within 24 h of collection.", [["Samples", "TEST", 0, 7], ["testing laboratories", "TEST", 21, 41], ["ice packs", "TREATMENT", 54, 63], ["collection", "PROBLEM", 79, 89]]], ["Special provision was made with the national and international courier agencies to facilitate uninterrupted sample transport from field to laboratories and for quality control purpose.Material & MethodsFor a subset of the individuals, blood samples were collected in serum separator and EDTA (ethylenediaminetetraacetic acid) tubes for serum and plasma, respectively.", [["blood samples", "ANATOMY", 235, 248], ["serum", "ANATOMY", 267, 272], ["serum", "ANATOMY", 336, 341], ["plasma", "ANATOMY", 346, 352], ["ethylenediaminetetraacetic acid", "CHEMICAL", 293, 324], ["EDTA", "CHEMICAL", 287, 291], ["ethylenediaminetetraacetic acid", "CHEMICAL", 293, 324], ["blood samples", "ORGANISM_SUBSTANCE", 235, 248], ["serum", "ORGANISM_SUBSTANCE", 267, 272], ["EDTA", "SIMPLE_CHEMICAL", 287, 291], ["ethylenediaminetetraacetic acid", "SIMPLE_CHEMICAL", 293, 324], ["serum", "ORGANISM_SUBSTANCE", 336, 341], ["plasma", "ORGANISM_SUBSTANCE", 346, 352], ["blood samples", "TEST", 235, 248], ["serum separator", "TEST", 267, 282], ["EDTA (ethylenediaminetetraacetic acid) tubes", "TREATMENT", 287, 331], ["serum and plasma", "TEST", 336, 352]]], ["Stool and urine samples were also collected from the laboratory-confirmed positive cases.", [["Stool", "ANATOMY", 0, 5], ["urine samples", "ANATOMY", 10, 23], ["Stool", "ORGANISM_SUBSTANCE", 0, 5], ["urine samples", "ORGANISM_SUBSTANCE", 10, 23], ["Stool and urine samples", "TEST", 0, 23], ["urine", "ANATOMY", 10, 15], ["positive cases", "OBSERVATION", 74, 88]]], ["Since SARS-CoV-2 is a new virus and diagnostic tests are evolving rapidly, it was considered critical to have various types of clinical samples for standardization and validation of new tests.", [["SARS-CoV-2", "ORGANISM", 6, 16], ["SARS-CoV", "SPECIES", 6, 14], ["SARS", "PROBLEM", 6, 10], ["a new virus", "PROBLEM", 20, 31], ["diagnostic tests", "TEST", 36, 52], ["clinical samples", "TEST", 127, 143], ["new tests", "TEST", 182, 191], ["new", "OBSERVATION_MODIFIER", 22, 25], ["virus", "OBSERVATION", 26, 31]]], ["However, owing to very low positivity rates of SARS-CoV-2 infection, it was subsequently decided to collect blood samples from only laboratory-confirmed positive cases and review the strategy later.Material & MethodsDiagnostic assays for SARS-CoV-2: Following release of the first sequence results of the SARS-CoV-2 virus by China7, candidate diagnostic real-time reverse transcription-polymerase chain reaction (rRT-PCR) assays were designed and made available in the public domain for researchers12.", [["blood samples", "ANATOMY", 108, 121], ["SARS-CoV-2 infection", "DISEASE", 47, 67], ["SARS", "DISEASE", 305, 309], ["SARS-CoV-2", "ORGANISM", 47, 57], ["blood samples", "ORGANISM_SUBSTANCE", 108, 121], ["SARS-CoV-2 virus", "ORGANISM", 305, 321], ["CoV-2 virus", "SPECIES", 310, 321], ["SARS-CoV-2", "SPECIES", 47, 57], ["SARS-CoV", "SPECIES", 238, 246], ["SARS-CoV-2 virus", "SPECIES", 305, 321], ["very low positivity rates", "PROBLEM", 18, 43], ["SARS", "PROBLEM", 47, 51], ["CoV-2 infection", "PROBLEM", 52, 67], ["blood samples", "TEST", 108, 121], ["Material & MethodsDiagnostic assays", "TEST", 198, 233], ["SARS", "PROBLEM", 238, 242], ["the SARS", "TEST", 301, 309], ["CoV", "TEST", 310, 313], ["polymerase chain reaction", "PROBLEM", 386, 411], ["SARS", "OBSERVATION", 47, 51], ["infection", "OBSERVATION", 58, 67]]], ["The first-line screening assay targeted the SARS-CoV-2-specific E gene.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 44, 54], ["E", "GENE_OR_GENE_PRODUCT", 64, 65], ["SARS-CoV-2-specific E gene", "DNA", 44, 70], ["SARS-CoV", "SPECIES", 44, 52], ["The first-line screening assay", "TEST", 0, 30], ["the SARS", "TEST", 40, 48], ["CoV", "TEST", 49, 52]]], ["Confirmatory assays targeted the 'RdRp gene', 'N gene' and 'ORF-1b'.", [["ORF-1b", "GENE_OR_GENE_PRODUCT", 60, 66], ["RdRp gene", "DNA", 34, 43], ["N gene", "DNA", 47, 53], ["ORF", "DNA", 60, 63], ["Confirmatory assays", "TEST", 0, 19], ["the 'RdRp gene', 'N gene'", "TREATMENT", 29, 54]]], ["Positive control materials for these assays were obtained from Charit\u00e9, Berlin, via EVAg13.", [["these assays", "TEST", 31, 43]]], ["Known copy numbers of in vitro transcribed RNA standard were used as the positive controls for the rRT-PCR assays.", [["rRT", "DNA", 99, 102], ["the rRT", "TEST", 95, 102], ["PCR assays", "TEST", 103, 113], ["numbers", "OBSERVATION_MODIFIER", 11, 18]]], ["Detection of RNAse P gene was used as an internal positive control to monitor sample quality, RNA extraction and detection of PCR inhibitors.", [["sample", "ANATOMY", 78, 84], ["RNAse P", "GENE_OR_GENE_PRODUCT", 13, 20], ["RNAse P gene", "DNA", 13, 25], ["RNAse P gene", "TREATMENT", 13, 25], ["an internal positive control", "TREATMENT", 38, 66], ["RNA extraction", "TREATMENT", 94, 108], ["PCR inhibitors", "TREATMENT", 126, 140]]], ["The Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV), Pune, which is the apex laboratory for viral diagnosis and research in India, optimized the conventional and real-time PCR assays targeting different genomic regions of SARS-CoV-2 and initiated testing of suspected cases.Material & MethodsLaboratory organization for SARS-CoV-2 testing in India: The Department of Health Research (DHR)/ICMR initiated establishment of a network of public health laboratories to enhance capacity for diagnosis and detection of viruses of public health importance in the Indian setting in 2013.", [["SARS", "DISEASE", 253, 257], ["SARS-CoV-2", "ORGANISM", 253, 263], ["genomic regions", "DNA", 234, 249], ["SARS-CoV", "SPECIES", 253, 261], ["PCR assays", "TEST", 203, 213], ["SARS", "TEST", 253, 257], ["CoV", "TEST", 258, 261], ["SARS", "PROBLEM", 351, 355], ["CoV", "TEST", 356, 359], ["apex", "ANATOMY_MODIFIER", 103, 107]]], ["Over the years, this network has been expanded, and currently, a total of 106 VRDLs have been established throughout the country (Fig. 1).", [["VRDLs", "CANCER", 78, 83], ["expanded", "OBSERVATION_MODIFIER", 38, 46]]], ["Detection of viral pathogens using serological methods and molecular diagnostic tools is the major focus of the VRDLs.", [["VRDLs", "CANCER", 112, 117], ["viral pathogens", "PROBLEM", 13, 28], ["serological methods", "TEST", 35, 54], ["molecular diagnostic tools", "TEST", 59, 85], ["the VRDLs", "PROBLEM", 108, 117], ["viral pathogens", "OBSERVATION", 13, 28]]], ["In addition, a subset of these also have capabilities to perform cell culture and virus cultivation.", [["cell", "ANATOMY", 65, 69], ["cell", "CELL", 65, 69], ["cell culture", "TEST", 65, 77], ["virus cultivation", "TREATMENT", 82, 99]]], ["All established VRDLs are equipped to perform testing for viral aetiologies at least under Biosafety Level 2 (BSL-2) conditions.", [["VRDLs", "ANATOMY", 16, 21], ["VRDLs", "CANCER", 16, 21], ["testing", "TEST", 46, 53], ["viral aetiologies", "PROBLEM", 58, 75], ["Biosafety Level", "TEST", 91, 106], ["BSL", "TEST", 110, 113]]], ["Further, 10 VRDLs are in various stages of operationalization of a BSL-3 facility for detection of high-risk pathogens14.Material & MethodsThe NIV, Pune, functions as the resource centre for the VRDL network and is responsible for providing technical training for performing molecular and serological assays for virological diagnosis.", [["VRDLs", "CANCER", 12, 17], ["VRDL network", "MULTI-TISSUE_STRUCTURE", 195, 207], ["high-risk pathogens", "PROBLEM", 99, 118], ["technical training", "TREATMENT", 241, 259], ["serological assays", "TEST", 289, 307], ["virological diagnosis", "TEST", 312, 333]]], ["It also performs the important task of standardizing assay procedures for the network as well as quality control and quality assurance activities.Material & MethodsVRDLs as State nodal centres for coordination of sample collection and shipment: In the last week of January 2020, the DHR/ICMR provided directives on sample collection and transport to all the 106 VRDLs currently under the network.", [["standardizing assay procedures", "TREATMENT", 39, 69], ["sample collection", "TEST", 213, 230], ["the DHR", "TEST", 279, 286], ["sample collection", "TEST", 315, 332]]], ["Video conferences were held with VRDLs where the directives were explained and issues regarding sample collection and shipment were discussed.", [["VRDLs", "TREATMENT", 33, 38], ["sample collection", "TEST", 96, 113], ["shipment", "TREATMENT", 118, 126]]], ["From each State or Union Territory, one VRDL was designated as the nodal centre for coordination of collection and shipment of samples to testing laboratories.", [["nodal centre", "ANATOMY", 67, 79], ["VRDL", "CANCER", 40, 44], ["testing laboratories", "TEST", 138, 158], ["Union Territory", "OBSERVATION", 19, 34]]], ["The role of the nodal centre was to enable timely and proper transport of the collected samples from the VRDLs to the designated testing laboratory.Material & MethodsThe National Centre for Disease Control (NCDC), Ministry of Health and Family Welfare, Integrated Disease Surveillance Programme (IDSP) and State public health departments were informed regarding the nodal centres and assigned testing laboratories for the respective States.", [["nodal centre", "ANATOMY", 16, 28], ["samples", "ANATOMY", 88, 95], ["nodal centre", "MULTI-TISSUE_STRUCTURE", 16, 28], ["testing laboratories", "TEST", 393, 413]]], ["Flow diagram depicting the complete process from sample collection in the field, transportation, testing and reporting of results is shown in Figure 2.Material & MethodsAll the laboratories were supplied with the primers, probes, PCR reagents, positive and negative controls and standard operating procedure (SOP) for the real-time RT-PCR (rRT-PCR) assay by NIV, Pune.", [["Flow diagram", "TEST", 0, 12], ["sample collection", "TEST", 49, 66], ["transportation, testing", "TEST", 81, 104], ["All the laboratories", "TEST", 169, 189], ["the primers", "TEST", 209, 220], ["PCR reagents", "TEST", 230, 242], ["standard operating procedure", "TREATMENT", 279, 307], ["complete", "OBSERVATION_MODIFIER", 27, 35], ["process", "OBSERVATION", 36, 43]]], ["A stringent inventory control was maintained at NIV and VRDLs based on the upsurge in number of cases and evolution of the disease.Material & MethodsExpansion of testing capabilities and selection of testing laboratories for SARS-CoV-2: Following the increase in the load of screening samples from suspected cases with symptoms and travel history to China or asymptomatic persons with travel history to Wuhan after January 15, 2020, it was decided that strategically located VRDLs needed to start testing for SARS-CoV-2 in addition to the apex laboratory at NIV, Pune.", [["SARS", "DISEASE", 225, 229], ["SARS", "DISEASE", 509, 513], ["VRDLs", "CANCER", 475, 480], ["persons", "SPECIES", 372, 379], ["SARS-CoV", "SPECIES", 225, 233], ["SARS-CoV", "SPECIES", 509, 517], ["A stringent inventory control", "TREATMENT", 0, 29], ["NIV", "TREATMENT", 48, 51], ["VRDLs", "TREATMENT", 56, 61], ["the disease", "PROBLEM", 119, 130], ["testing capabilities", "TEST", 162, 182], ["selection of testing laboratories", "TEST", 187, 220], ["SARS", "PROBLEM", 225, 229], ["screening samples", "TEST", 275, 292], ["symptoms", "PROBLEM", 319, 327], ["testing", "TEST", 497, 504], ["SARS", "PROBLEM", 509, 513], ["CoV", "TEST", 514, 517], ["disease", "OBSERVATION", 123, 130], ["apex", "ANATOMY_MODIFIER", 539, 543]]], ["VRDLs were chosen based on their location in cities with international airports receiving travellers from China, the capability of the VRDLs to perform real-time PCR assays and their involvement in the ongoing testing for influenza viruses within the network.", [["influenza viruses", "DISEASE", 222, 239], ["VRDLs", "TREATMENT", 0, 5], ["real-time PCR assays", "TEST", 152, 172], ["the ongoing testing", "TEST", 198, 217], ["influenza viruses", "PROBLEM", 222, 239]]], ["A total of 13 VRDLs across 11 States were selected for SARS-CoV-2 testing.", [["VRDLs", "CANCER", 14, 19], ["SARS-CoV", "SPECIES", 55, 63], ["SARS", "TEST", 55, 59], ["CoV-2 testing", "TEST", 60, 73]]], ["After February 29, 2020, based on the upsurge in the number of suspect cases, primarily due to outbreaks reported from countries other than China (Iran, South Korea, Italy and Japan), the number of testing laboratories was scaled up to a total of 31 laboratories.", [["outbreaks", "PROBLEM", 95, 104], ["testing laboratories", "TEST", 198, 218]]], ["It is eventually proposed to involve all 106 VRDLs in COVID-19 testing or sample collection and transportation.", [["sample", "ANATOMY", 74, 80], ["COVID", "TEST", 54, 59], ["sample collection", "TEST", 74, 91]]], ["The distribution of COVID-19 testing (operational and new) laboratories in India is depicted in Figure 3.Material & MethodsBefore initiating testing of clinical specimens from suspected cases of SARS-CoV-2, each VRDL shared results from the rRT-PCR runs performed with positive and negative controls with the apex laboratory (NIV, Pune).", [["specimens", "ANATOMY", 161, 170], ["SARS", "DISEASE", 195, 199], ["specimens", "CANCER", 161, 170], ["rRT", "DNA", 241, 244], ["SARS-CoV", "SPECIES", 195, 203], ["COVID", "TEST", 20, 25], ["clinical specimens", "TEST", 152, 170], ["SARS", "PROBLEM", 195, 199], ["CoV", "TEST", 200, 203], ["the rRT", "TEST", 237, 244], ["PCR runs", "TEST", 245, 253], ["apex", "ANATOMY_MODIFIER", 309, 313]]], ["After satisfactory performance of the laboratories, independent testing was initiated in the designated catchment areas.", [["the laboratories", "TEST", 34, 50], ["independent testing", "TEST", 52, 71]]], ["Frontline screening rRT-PCR test targeting SARS-CoV-2-specific E gene was performed.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 43, 53], ["E", "GENE_OR_GENE_PRODUCT", 63, 64], ["rRT", "DNA", 20, 23], ["SARS-CoV-2", "DNA", 43, 53], ["E gene", "DNA", 63, 69], ["SARS-CoV", "SPECIES", 43, 51], ["Frontline screening rRT", "TEST", 0, 23], ["PCR test", "TEST", 24, 32], ["SARS", "TEST", 43, 47], ["CoV", "TEST", 48, 51]]], ["Initial support was also provided to NCDC, New Delhi, for initiation of SARS-CoV-2 testing.", [["SARS", "DISEASE", 72, 76], ["SARS", "TEST", 72, 76], ["CoV-2 testing", "TEST", 77, 90]]], ["Thereafter, NCDC, Delhi, initiated independent testing; however, results were shared with ICMR on a daily basis.Material & MethodsFigure 4 depicts the organization of laboratories for SARS-CoV-2 diagnosis and their respective roles.Material & MethodsQuality control for SARS-CoV-2 testing at VRDLs: NIV, Pune, coordinated the quality control activities for SARS-CoV-2 testing VRDLs.", [["SARS", "DISEASE", 184, 188], ["SARS", "DISEASE", 357, 361], ["SARS-CoV", "SPECIES", 184, 192], ["SARS-CoV", "SPECIES", 270, 278], ["SARS-CoV", "SPECIES", 357, 365], ["independent testing", "TEST", 35, 54], ["Material & MethodsFigure", "TREATMENT", 112, 136], ["SARS", "TEST", 184, 188], ["CoV", "TEST", 189, 192], ["Material & MethodsQuality control", "TREATMENT", 232, 265], ["SARS", "PROBLEM", 270, 274], ["CoV", "TEST", 275, 278], ["NIV", "TREATMENT", 299, 302], ["SARS", "PROBLEM", 357, 361], ["CoV", "TEST", 362, 365]]], ["The laboratories shared first 10 negatives, all positive and equivocal samples for SARS-CoV-2 to NIV, Pune, for confirmation.", [["samples", "ANATOMY", 71, 78], ["SARS", "DISEASE", 83, 87], ["SARS-CoV", "SPECIES", 83, 91], ["The laboratories", "TEST", 0, 16], ["SARS", "TEST", 83, 87], ["CoV", "TEST", 88, 91], ["NIV", "TREATMENT", 97, 100], ["confirmation", "TEST", 112, 124]]], ["Samples tested positive at VRDLs were subjected to confirmatory tests at NIV, Pune.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["confirmatory tests", "TEST", 51, 69], ["NIV", "TREATMENT", 73, 76]]], ["The final result for any SARS-CoV-2-positive samples was released only after confirmation at the apex laboratory.", [["samples", "ANATOMY", 45, 52], ["SARS", "DISEASE", 25, 29], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 25, 35], ["SARS-CoV", "SPECIES", 25, 33], ["any SARS", "TEST", 21, 29], ["CoV", "TEST", 30, 33], ["apex", "ANATOMY_MODIFIER", 97, 101]]], ["Ten negative samples from VRDLs were also randomly picked up and subjected to next-generation sequencing (NGS).Demographic profile of individuals screened for COVID-19 ::: ::: ResultsEvacuees from China and Japan quarantined at army and border police camps: Of the 654 evacuees from Wuhan, 29.2 per cent (191/654) were female and 70.5 per cent (461/654) were male.", [["samples", "ANATOMY", 13, 20], ["VRDLs", "ANATOMY", 26, 31], ["VRDLs", "CANCER", 26, 31], ["VRDLs", "TEST", 26, 31], ["Demographic profile", "TEST", 111, 130], ["COVID", "TEST", 159, 164]]], ["The mean age of the evacuees was 23.5 yr (median: 22 yr; range: 1-72 yr); 77.2 per cent (492/637) of the evacuees for whom information about age was available were \u226425 yr of age.Demographic profile of individuals screened for COVID-19 ::: ::: ResultsThe second batch of quarantined individuals at these two camps arrived on February 27, 2020 which included a total of 236 evacuees from China and from the cruise ship Diamond Princess off the coast of Japan.", [["Demographic profile", "TEST", 178, 197], ["COVID", "TEST", 226, 231], ["quarantined individuals", "PROBLEM", 270, 293]]], ["All these were also tested negative.Demographic profile of individuals screened for COVID-19 ::: ::: ResultsIndividuals tested for SARS-CoV-2 other than evacuees who were quarantined: Of the 1,369 individuals other than evacuees who were tested, all demographic details were available for a total of 1,263 (843 male, 420 female) individuals.", [["SARS-CoV-2", "ORGANISM", 131, 141], ["individuals", "ORGANISM", 329, 340], ["SARS-CoV", "SPECIES", 131, 139], ["Demographic profile", "TEST", 36, 55], ["COVID", "TEST", 84, 89], ["ResultsIndividuals", "TEST", 101, 119], ["SARS", "TEST", 131, 135], ["CoV", "TEST", 136, 139]]], ["The mean age of the individuals who underwent testing was 25.9 yr (median: 27 yr; range: eight months-76 yr).", [["individuals", "ORGANISM", 20, 31], ["testing", "TEST", 46, 53]]], ["A little more than half of these individuals were in the 25-50 yr age group (54.2%).Demographic profile of individuals screened for COVID-19 ::: ::: ResultsSamples from three suspected cases with symptoms of acute respiratory illness were tested positive for SARS-CoV-2 at NIV, Pune.", [["respiratory", "ANATOMY", 214, 225], ["acute respiratory illness", "DISEASE", 208, 233], ["individuals", "ORGANISM", 33, 44], ["SARS-CoV", "SPECIES", 259, 267], ["Demographic profile", "TEST", 84, 103], ["COVID", "TEST", 132, 137], ["symptoms", "PROBLEM", 196, 204], ["acute respiratory illness", "PROBLEM", 208, 233], ["SARS", "PROBLEM", 259, 263], ["CoV", "TEST", 264, 267], ["NIV", "TREATMENT", 273, 276], ["little", "OBSERVATION_MODIFIER", 2, 8], ["acute", "OBSERVATION_MODIFIER", 208, 213], ["respiratory", "ANATOMY", 214, 225], ["illness", "OBSERVATION", 226, 233]]], ["A total of 67 samples from 64 individuals with contact history with the three confirmed cases who developed respiratory symptoms were also tested for SARS-CoV-2.", [["samples", "ANATOMY", 14, 21], ["respiratory", "ANATOMY", 108, 119], ["respiratory symptoms", "DISEASE", 108, 128], ["samples", "CANCER", 14, 21], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 150, 160], ["SARS-CoV", "SPECIES", 150, 158], ["respiratory symptoms", "PROBLEM", 108, 128], ["SARS", "PROBLEM", 150, 154], ["CoV", "TEST", 155, 158]]], ["All the samples from the 64 contacts were negative for SARS-CoV-2.Demographic profile of individuals screened for COVID-19 ::: ::: ResultsSymptomatology and travel history of individuals screened for COVID-19 infection outside the quarantine camps: Of the total 1263 individuals, 19 per cent (n=240) did not report any specific symptoms for inclusion for COVID-19 testing.", [["samples", "ANATOMY", 8, 15], ["infection", "DISEASE", 209, 218], ["samples", "CANCER", 8, 15], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 55, 65], ["SARS-CoV", "SPECIES", 55, 63], ["All the samples", "TEST", 0, 15], ["SARS", "PROBLEM", 55, 59], ["CoV", "TEST", 60, 63], ["Demographic profile", "TEST", 66, 85], ["COVID", "TEST", 114, 119], ["COVID", "TEST", 200, 205], ["any specific symptoms", "PROBLEM", 315, 336], ["COVID", "TEST", 355, 360], ["infection", "OBSERVATION", 209, 218]]], ["Among those reported as symptomatic, complete details of clinical history were accessed for 292 individuals.", [["symptomatic", "PROBLEM", 24, 35]]], ["The presence of cough was the most common symptom reported in 49.7 per cent (n=145).", [["cough", "DISEASE", 16, 21], ["cough", "PROBLEM", 16, 21], ["cough", "OBSERVATION", 16, 21]]], ["Sore throat was reported by 21.2 per cent (n=62), whereas 34.6 per cent of the individuals (n=101) were febrile at the time of presentation; 17.1 per cent (n=50) of all symptomatic individuals presented with nasal discharge and rhinitis.", [["nasal", "ANATOMY", 208, 213], ["Sore throat", "DISEASE", 0, 11], ["febrile", "DISEASE", 104, 111], ["rhinitis", "DISEASE", 228, 236], ["individuals", "ORGANISM", 79, 90], ["individuals", "ORGANISM", 181, 192], ["nasal", "ORGANISM_SUBDIVISION", 208, 213], ["Sore throat", "PROBLEM", 0, 11], ["febrile", "PROBLEM", 104, 111], ["all symptomatic individuals", "PROBLEM", 165, 192], ["nasal discharge", "PROBLEM", 208, 223], ["rhinitis", "PROBLEM", 228, 236], ["throat", "ANATOMY", 5, 11], ["nasal", "ANATOMY", 208, 213], ["rhinitis", "OBSERVATION", 228, 236]]], ["Diarrhoea was a presenting symptom for only 1.4 per cent (4/292) of all symptomatic patients with available clinical history.", [["Diarrhoea", "DISEASE", 0, 9], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["Diarrhoea", "PROBLEM", 0, 9], ["a presenting symptom", "PROBLEM", 14, 34]]], ["The remaining 158 (12.5%) individuals did not have any pertinent overseas travel history.Demographic profile of individuals screened for COVID-19 ::: ::: ResultsQuality control for ongoing testing: For quality control purposes, all testing VRDLs performing the E gene screening assay shared the first 10 negative samples and all positive or equivocal/borderline testing samples with ICMR-NIV, Pune, for reconfirmation.", [["samples", "ANATOMY", 313, 320], ["samples", "ANATOMY", 370, 377], ["individuals", "ORGANISM", 26, 37], ["VRDLs", "DNA", 240, 245], ["E gene", "DNA", 261, 267], ["Demographic profile", "TEST", 89, 108], ["COVID", "TEST", 137, 142], ["ongoing testing", "TEST", 181, 196], ["all testing VRDLs", "TEST", 228, 245], ["the E gene screening assay", "TEST", 257, 283], ["ICMR", "TEST", 383, 387], ["NIV", "TREATMENT", 388, 391], ["reconfirmation", "TEST", 403, 417]]], ["Eleven negative samples further subjected to NGS revealed negative results for SARS-CoV-2 but tested positive for other viruses: influenza A (2) and rhinovirus (3).Demographic profile of individuals screened for COVID-19 ::: ::: ResultsA total of 126 samples which tested negative by the E gene rRT-PCR screening assay at the 13 testing VRDLs were shared with NIV, Pune, till February 29, 2020, and these were all confirmed negative.", [["samples", "ANATOMY", 16, 23], ["samples", "ANATOMY", 251, 258], ["influenza A", "DISEASE", 129, 140], ["SARS-CoV-2", "ORGANISM", 79, 89], ["influenza A", "ORGANISM", 129, 140], ["rhinovirus", "ORGANISM", 149, 159], ["samples", "CANCER", 251, 258], ["E gene rRT", "DNA", 288, 298], ["SARS-CoV", "SPECIES", 79, 87], ["NGS", "TEST", 45, 48], ["SARS", "PROBLEM", 79, 83], ["CoV", "TEST", 84, 87], ["influenza A", "PROBLEM", 129, 140], ["rhinovirus", "PROBLEM", 149, 159], ["Demographic profile", "TEST", 164, 183], ["COVID", "TEST", 212, 217], ["PCR screening assay", "TEST", 299, 318], ["NIV", "TREATMENT", 360, 363], ["negative", "OBSERVATION", 424, 432]]], ["The concordance for the negative samples was, therefore, 100 per cent.Demographic profile of individuals screened for COVID-19 ::: ::: ResultsThe VRDLs also shared 13 samples which were borderline positives and showed amplification at late Ct values (range: 33-37 cycles) for confirmation.", [["samples", "ANATOMY", 33, 40], ["VRDLs", "ANATOMY", 146, 151], ["samples", "ANATOMY", 167, 174], ["VRDLs", "CANCER", 146, 151], ["Demographic profile", "TEST", 70, 89], ["COVID", "TEST", 118, 123], ["The VRDLs", "TEST", 142, 151], ["borderline positives", "PROBLEM", 186, 206], ["amplification", "TEST", 218, 231], ["confirmation", "TEST", 276, 288]]], ["These included seven follow up samples collected from the three laboratory-confirmed positive cases which were also tested positive for the E gene at the testing VRDL.", [["samples", "ANATOMY", 31, 38], ["E", "GENE_OR_GENE_PRODUCT", 140, 141], ["E gene", "DNA", 140, 146], ["follow up samples", "TEST", 21, 38], ["positive cases", "PROBLEM", 85, 99]]], ["Testing results were concordant for five of seven follow up samples.", [["samples", "ANATOMY", 60, 67]]], ["The remaining six samples which showed borderline positivity with the screening qPCR at the testing VRDLs were found to be negative with the confirmatory qPCR assays performed at NIV, Pune.Demographic profile of individuals screened for COVID-19 ::: ::: ResultsInventory control: Inventory control posed several challenges.", [["samples", "ANATOMY", 18, 25], ["VRDLs", "CANCER", 100, 105], ["The remaining six samples", "TEST", 0, 25], ["borderline positivity", "PROBLEM", 39, 60], ["the screening qPCR", "TEST", 66, 84], ["the testing VRDLs", "TEST", 88, 105], ["the confirmatory qPCR assays", "TEST", 137, 165], ["Demographic profile", "TEST", 189, 208], ["COVID", "TEST", 237, 242], ["Inventory control", "TREATMENT", 280, 297], ["borderline", "OBSERVATION_MODIFIER", 39, 49], ["positivity", "OBSERVATION", 50, 60]]], ["Since nature of spread of the disease was unknown, testing reagents were stockpiled for only 5000 tests initially.", [["the disease", "PROBLEM", 26, 37], ["testing reagents", "TEST", 51, 67], ["spread", "OBSERVATION_MODIFIER", 16, 22], ["disease", "OBSERVATION", 30, 37]]], ["NIV initiated testing from January 21, 2020.", [["NIV", "CHEMICAL", 0, 3], ["NIV", "TREATMENT", 0, 3]]], ["However, in view of upsurge in global cases and deaths, the testing capacity was upscaled to another 13 laboratories and inventory at NIV was scaled up to 25,000 tests by February 1, 2020.", [["deaths", "DISEASE", 48, 54], ["the testing capacity", "TEST", 56, 76], ["inventory at NIV", "TREATMENT", 121, 137]]], ["Following further upsurge in global cases and deaths by February 25, 2020, the inventory was upscaled to 70,000 tests.", [["deaths", "DISEASE", 46, 52], ["the inventory", "TEST", 75, 88]]], ["Daily situational analysis of inventory at the apex and testing laboratories was undertaken to ensure optimum supplies and avoid exhaustion of reagents at the apex and testing laboratories.DiscussionGlobal epidemics due to emerging/re-emerging infectious diseases have become common over the past two decades, with the major reason being increased trade and travel, leading to movement of people across borders.", [["infectious diseases", "DISEASE", 244, 263], ["people", "ORGANISM", 389, 395], ["people", "SPECIES", 389, 395], ["testing laboratories", "TEST", 56, 76], ["optimum supplies", "TREATMENT", 102, 118], ["testing laboratories", "TEST", 168, 188], ["emerging infectious diseases", "PROBLEM", 235, 263], ["apex", "ANATOMY_MODIFIER", 47, 51], ["apex", "ANATOMY_MODIFIER", 159, 163], ["infectious", "OBSERVATION", 244, 254], ["increased", "OBSERVATION", 338, 347]]], ["A recent example is the epidemic of SARS-CoV-2 in Hubei province of China which has spread to more than 70 countries within a two-month time.", [["SARS", "DISEASE", 36, 40], ["SARS-CoV-2", "ORGANISM", 36, 46], ["SARS-CoV", "SPECIES", 36, 44], ["SARS", "PROBLEM", 36, 40]]], ["During the initial period, virus sequences were unknown, there were no known sources for acquiring positive controls and the virus isolates were not available.", [["virus sequences", "TEST", 27, 42], ["acquiring positive controls", "PROBLEM", 89, 116], ["the virus isolates", "TEST", 121, 139]]], ["In view of this, the challenge to develop diagnostics for a new disease with a pandemic potential initially seemed unsurmountable.", [["a new disease", "PROBLEM", 58, 71], ["new", "OBSERVATION_MODIFIER", 60, 63], ["disease", "OBSERVATION", 64, 71]]], ["However, once the virus sequences were made available in public domain and source of positive controls and probes could be identified, India immediately established a network of testing laboratories for the new SARS-CoV-2 virus very swiftly.", [["SARS", "DISEASE", 211, 215], ["SARS-CoV-2 virus", "ORGANISM", 211, 227], ["CoV-2 virus", "SPECIES", 216, 227], ["SARS-CoV-2 virus", "SPECIES", 211, 227], ["the virus sequences", "TEST", 14, 33], ["positive controls and probes", "PROBLEM", 85, 113], ["testing laboratories", "TEST", 178, 198], ["the new SARS", "TEST", 203, 215], ["CoV", "TEST", 216, 219]]], ["Starting with availability of validated diagnosis at the ICMR-NIV, Pune, testing capacity was further upscaled to another 13 DHR/ICMR VRDLs.", [["NIV", "TREATMENT", 62, 65], ["testing capacity", "TEST", 73, 89]]], ["The apex laboratory standardized the testing protocols within one week, and the VRDLs initiated testing within two weeks of release of laboratory protocols by the WHO.", [["the testing protocols", "TEST", 33, 54], ["the VRDLs", "TEST", 76, 85], ["laboratory protocols", "TREATMENT", 135, 155], ["apex", "ANATOMY_MODIFIER", 4, 8]]], ["In addition, 35 laboratories fully equipped in terms of availability of adequate infrastructure and trained staff for SARS-CoV-2 testing were kept on a standby.", [["SARS", "DISEASE", 118, 122], ["SARS", "TEST", 118, 122], ["CoV-2 testing", "TEST", 123, 136], ["a standby", "TREATMENT", 150, 159]]], ["An impressive model wherein the VRDLs have closely worked with the field surveillance programme of GoI (IDSP) has been operationalized during this public health crisis.", [["VRDLs", "CANCER", 32, 37], ["impressive", "OBSERVATION_MODIFIER", 3, 13]]], ["Kerala, Karnataka, Telangana, Rajasthan and Uttar Pradesh clearly leveraged the capacity of existing VRDLs.", [["VRDLs", "CANCER", 101, 106]]], ["The sample transport mechanisms from IDSP to VRDLs at these places were also good.", [["sample", "ANATOMY", 4, 10], ["IDSP to VRDLs", "TREATMENT", 37, 50], ["good", "OBSERVATION_MODIFIER", 77, 81]]], ["The number of tests conducted by VRDLs in these States depicted the effective screening of suspect cases implemented at nearby airports, IDSP and State health programmes.", [["tests", "TEST", 14, 19]]], ["Liasoning between VRDLs and IDSP needs to be further strengthened in such areas.DiscussionQuality control programme implemented by NIV, Pune, for the VRDLs revealed 100 per cent concordance between the testing at VRDLs and NIV for negative samples.", [["samples", "ANATOMY", 240, 247], ["VRDLs", "TREATMENT", 18, 23], ["the VRDLs", "TEST", 146, 155], ["the testing", "TEST", 198, 209], ["NIV", "TREATMENT", 223, 226]]], ["For borderline positive samples (Ct values between 33 and 35 cycles), concordance was low.", [["samples", "ANATOMY", 24, 31], ["borderline positive samples", "PROBLEM", 4, 31], ["Ct values", "TEST", 33, 42], ["concordance", "TEST", 70, 81], ["positive", "OBSERVATION", 15, 23], ["low", "OBSERVATION_MODIFIER", 86, 89]]], ["This emphasized the need to continue reconfirmation of all positive samples at NIV, Pune.", [["samples", "ANATOMY", 68, 75], ["all positive samples at NIV", "TREATMENT", 55, 82]]], ["This has also indicated that E gene screening assay may not be sufficient to declare positivity.", [["E", "GENE_OR_GENE_PRODUCT", 29, 30], ["E gene", "DNA", 29, 35], ["E gene screening assay", "TEST", 29, 51]]], ["Further confirmatory tests as currently done by NIV, Pune, are required for confirming true positivity.", [["Further confirmatory tests", "TEST", 0, 26], ["NIV", "TREATMENT", 48, 51], ["true positivity", "PROBLEM", 87, 102]]], ["To enhance the robustness of testing, it is essential to equip the SARS-CoV-2 testing VRDLs with additional confirmatory assays.DiscussionInventory control posed challenges at every step.", [["VRDLs", "CANCER", 86, 91], ["testing", "TEST", 29, 36], ["the SARS", "TEST", 63, 71], ["CoV", "TEST", 72, 75], ["additional confirmatory assays", "TEST", 97, 127]]], ["Thoughtful optimization of inventory was undertaken.", [["inventory", "PROBLEM", 27, 36]]], ["Planning of availability of tests at a given point was done in such a way that the excess tests could be used for routine surveillance in case the situation of COVID-19 does not worsen in India.DiscussionThe threat of a potential pandemic due to SARS-CoV-2 has brought out the strength of the judiciously established network of VRDLs in India and also the capability of this network to rapidly adapt in times of any public health emergency, with appropriate quality checks.", [["SARS", "DISEASE", 246, 250], ["COVID-19", "CHEMICAL", 160, 168], ["SARS-CoV-2", "ORGANISM", 246, 256], ["VRDLs", "CANCER", 328, 333], ["SARS-CoV", "SPECIES", 246, 254], ["tests", "TEST", 28, 33], ["the excess tests", "TEST", 79, 95], ["routine surveillance", "TEST", 114, 134], ["COVID", "TEST", 160, 165], ["SARS", "PROBLEM", 246, 250]]], ["This already operational platform was able to switch gears to provide countrywide diagnosis for SARS-CoV-2 within a month after discovery of this novel virus.", [["SARS", "DISEASE", 96, 100], ["SARS-CoV", "SPECIES", 96, 104], ["SARS", "PROBLEM", 96, 100], ["this novel virus", "PROBLEM", 141, 157]]], ["VRDLs offer a robust platform for early detection of emerging/re-emerging viral infections in all parts of India, facilitating early containment and prevention of larger epidemics.", [["viral infections", "DISEASE", 74, 90], ["viral infections", "PROBLEM", 74, 90], ["larger epidemics", "PROBLEM", 163, 179], ["viral infections", "OBSERVATION", 74, 90], ["early containment", "OBSERVATION", 127, 144], ["larger", "OBSERVATION_MODIFIER", 163, 169], ["epidemics", "OBSERVATION", 170, 179]]]], "PMC7402623": [["The abrupt outbreak of the Coronavirus Disease 2019 (COVID-19) pandemic produced unprecedented societal impacts in China.", [["COVID-19", "CHEMICAL", 53, 61], ["Coronavirus Disease 2019 (COVID-19", "SPECIES", 27, 61], ["the Coronavirus Disease", "PROBLEM", 23, 46], ["COVID", "TEST", 53, 58], ["pandemic", "PROBLEM", 63, 71], ["abrupt", "OBSERVATION_MODIFIER", 4, 10], ["outbreak", "OBSERVATION_MODIFIER", 11, 19], ["Coronavirus Disease", "OBSERVATION", 27, 46], ["unprecedented", "OBSERVATION_MODIFIER", 81, 94], ["societal", "OBSERVATION_MODIFIER", 95, 103], ["impacts", "OBSERVATION_MODIFIER", 104, 111]]], ["To curb the virus spread among humans, a preventive lockdown was first implemented on January 23 in Wuhan, Hubei.", [["humans", "ORGANISM", 31, 37], ["humans", "SPECIES", 31, 37], ["humans", "SPECIES", 31, 37], ["virus", "OBSERVATION", 12, 17]]], ["During the lockdown period, emissions from the traffic sector were drastically reduced.", [["reduced", "OBSERVATION_MODIFIER", 79, 86]]], ["Such a shutdown serves as a natural experiment to evaluate air quality responses to a dramatic emissions reduction and to assess the interplay between emission, atmospheric chemistry, and meteorological conditions.", [["a dramatic emissions reduction", "TREATMENT", 84, 114], ["atmospheric chemistry", "TEST", 161, 182]]], ["Here, we synthesize multiple-year satellite retrieved atmospheric compositions, national ground station measurements of major pollutants, meteorology from reanalysis data, and a suite of state-of-the-art online atmospheric chemistry model simulations to assess the atmospheric influence of the COVID-19 outbreak in China and to reveal its implications for air pollution control strategies.", [["reanalysis data", "TEST", 155, 170], ["the COVID", "TEST", 290, 299], ["air pollution control strategies", "TREATMENT", 356, 388], ["multiple", "OBSERVATION_MODIFIER", 20, 28]]]]}